Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
715500.0
|
2021-10-12 00:00:00 UTC
|
Health Care Sector Update for 10/12/2021: DCPH,CVAC,GSK,INMD,BCDA
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-10-12-2021%3A-dcphcvacgskinmdbcda-2021-10-12
|
nan
|
nan
|
Health care stocks were set to finish moderately lower this afternoon, with the NYSE Health Care Index falling 0.4% while the SPDR Health Care Select Sector ETF (XLV) also was down 0.5%.
The Nasdaq Biotechnology index, however, was climbing 0.1% in late trade.
In company news, Deciphera Pharmaceuticals (DCPH) climbed 6.6% after Tuesday saying Swiss regulators have approved its Qinlock lead drug candidate for the treatment of adult patients with advanced gastrointestinal stromal tumor who were previously treated with three or more kinase inhibitors.
CureVac (CVAC) dropped 5.1% after saying it was withdrawing its first-generation COVID-19 vaccine candidate from regulatory review by the European Medicines Agency and will instead focus its efforts on a second-generation mRNA vaccine candidate through a partnership with GlaxoSmithKline (GSK).
To the upside, InMode (INMD) rose 8.6% after the medical device company said it is expecting to report non-GAAP Q3 net income in a range of $0.53 to $0.54 per share on between $93.5 million to $94 million in revenue, blowing past the Capital IQ consensus expecting a $0.32 per share adjusted profit on $74.9 million in revenue for the three months ended Sept. 30. It also raised its FY21 revenue forecast above Street views.
BioCardia (BCDA) climbed 4% after the regenerative medicines company Tuesday said it received a US patent for its technology enhancing control for interventional catheter-based therapies.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Deciphera Pharmaceuticals (DCPH) climbed 6.6% after Tuesday saying Swiss regulators have approved its Qinlock lead drug candidate for the treatment of adult patients with advanced gastrointestinal stromal tumor who were previously treated with three or more kinase inhibitors. CureVac (CVAC) dropped 5.1% after saying it was withdrawing its first-generation COVID-19 vaccine candidate from regulatory review by the European Medicines Agency and will instead focus its efforts on a second-generation mRNA vaccine candidate through a partnership with GlaxoSmithKline (GSK). BioCardia (BCDA) climbed 4% after the regenerative medicines company Tuesday said it received a US patent for its technology enhancing control for interventional catheter-based therapies.
|
In company news, Deciphera Pharmaceuticals (DCPH) climbed 6.6% after Tuesday saying Swiss regulators have approved its Qinlock lead drug candidate for the treatment of adult patients with advanced gastrointestinal stromal tumor who were previously treated with three or more kinase inhibitors. Health care stocks were set to finish moderately lower this afternoon, with the NYSE Health Care Index falling 0.4% while the SPDR Health Care Select Sector ETF (XLV) also was down 0.5%. CureVac (CVAC) dropped 5.1% after saying it was withdrawing its first-generation COVID-19 vaccine candidate from regulatory review by the European Medicines Agency and will instead focus its efforts on a second-generation mRNA vaccine candidate through a partnership with GlaxoSmithKline (GSK).
|
In company news, Deciphera Pharmaceuticals (DCPH) climbed 6.6% after Tuesday saying Swiss regulators have approved its Qinlock lead drug candidate for the treatment of adult patients with advanced gastrointestinal stromal tumor who were previously treated with three or more kinase inhibitors. Health care stocks were set to finish moderately lower this afternoon, with the NYSE Health Care Index falling 0.4% while the SPDR Health Care Select Sector ETF (XLV) also was down 0.5%. To the upside, InMode (INMD) rose 8.6% after the medical device company said it is expecting to report non-GAAP Q3 net income in a range of $0.53 to $0.54 per share on between $93.5 million to $94 million in revenue, blowing past the Capital IQ consensus expecting a $0.32 per share adjusted profit on $74.9 million in revenue for the three months ended Sept. 30.
|
In company news, Deciphera Pharmaceuticals (DCPH) climbed 6.6% after Tuesday saying Swiss regulators have approved its Qinlock lead drug candidate for the treatment of adult patients with advanced gastrointestinal stromal tumor who were previously treated with three or more kinase inhibitors. Health care stocks were set to finish moderately lower this afternoon, with the NYSE Health Care Index falling 0.4% while the SPDR Health Care Select Sector ETF (XLV) also was down 0.5%. The Nasdaq Biotechnology index, however, was climbing 0.1% in late trade.
|
a48e8881-6b4e-4941-a597-71e8330c365d
|
715501.0
|
2021-10-12 00:00:00 UTC
|
Deciphera Pharma Reports Approval Of QINLOCK In Switzerland - Quick Facts
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharma-reports-approval-of-qinlock-in-switzerland-quick-facts-2021-10-12
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.
"The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The company anticipates a potential approval from the European Commission for QINLOCK in the fourth quarter of the current year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. "The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The company anticipates a potential approval from the European Commission for QINLOCK in the fourth quarter of the current year.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. "The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. "The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. "The approval in Switzerland is our seventh approval worldwide and the first in Europe," said Steve Hoerter, CEO of Deciphera. The company anticipates a potential approval from the European Commission for QINLOCK in the fourth quarter of the current year.
|
086a072f-072d-41f4-911f-ecc4451d028d
|
715502.0
|
2021-10-10 00:00:00 UTC
|
Have Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Insiders Been Selling Their Stock?
|
DCPH
|
https://www.nasdaq.com/articles/have-deciphera-pharmaceuticals-inc.-nasdaq%3Adcph-insiders-been-selling-their-stock-2021-10
|
nan
|
nan
|
Investors may wish to note that the Executive VP & Chief Medical Officer of Deciphera Pharmaceuticals, Inc., Matthew Sherman, recently netted US$88k from selling stock, receiving an average price of US$33.17. It wasn't a huge sale, but it did reduce their holding by 14%. This does not instill confidence.
Deciphera Pharmaceuticals Insider Transactions Over The Last Year
Notably, that recent sale by Matthew Sherman is the biggest insider sale of Deciphera Pharmaceuticals shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$32.32. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
Insiders in Deciphera Pharmaceuticals didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
NasdaqGS:DCPH Insider Trading Volume October 10th 2021
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Deciphera Pharmaceuticals insiders own 0.7% of the company, worth about US$12m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Deciphera Pharmaceuticals Insiders?
An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted 3 warning signs for Deciphera Pharmaceuticals you should know about.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NasdaqGS:DCPH Insider Trading Volume October 10th 2021 For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Investors may wish to note that the Executive VP & Chief Medical Officer of Deciphera Pharmaceuticals, Inc., Matthew Sherman, recently netted US$88k from selling stock, receiving an average price of US$33.17. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company.
|
NasdaqGS:DCPH Insider Trading Volume October 10th 2021 For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Investors may wish to note that the Executive VP & Chief Medical Officer of Deciphera Pharmaceuticals, Inc., Matthew Sherman, recently netted US$88k from selling stock, receiving an average price of US$33.17. Deciphera Pharmaceuticals Insider Transactions Over The Last Year Notably, that recent sale by Matthew Sherman is the biggest insider sale of Deciphera Pharmaceuticals shares that we've seen in the last year.
|
NasdaqGS:DCPH Insider Trading Volume October 10th 2021 For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Deciphera Pharmaceuticals Insider Transactions Over The Last Year Notably, that recent sale by Matthew Sherman is the biggest insider sale of Deciphera Pharmaceuticals shares that we've seen in the last year. Insiders in Deciphera Pharmaceuticals didn't buy any shares in the last year.
|
NasdaqGS:DCPH Insider Trading Volume October 10th 2021 For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Deciphera Pharmaceuticals Insider Transactions Over The Last Year Notably, that recent sale by Matthew Sherman is the biggest insider sale of Deciphera Pharmaceuticals shares that we've seen in the last year. Insiders in Deciphera Pharmaceuticals didn't buy any shares in the last year.
|
df702378-7352-4bff-a40d-d485b7587f6e
|
715503.0
|
2021-10-08 00:00:00 UTC
|
December 17th Options Now Available For Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/december-17th-options-now-available-for-deciphera-pharmaceuticals-dcph-2021-10-08
|
nan
|
nan
|
Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options become available today, for the December 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 70 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $30.00 strike price has a current bid of $4.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $26.00 (before broker commissions). To an investor already interested in purchasing shares of DCPH, that could represent an attractive alternative to paying $32.00/share today.
Because the $30.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 13.33% return on the cash commitment, or 69.48% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $2.40. If an investor was to purchase shares of DCPH stock at the current price level of $32.00/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $40.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 32.50% if the stock gets called away at the December 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DCPH shares really soar, which is why looking at the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DCPH's trailing twelve month trading history, with the $40.00 strike highlighted in red:
Considering the fact that the $40.00 strike represents an approximate 25% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 82%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 7.50% boost of extra return to the investor, or 39.08% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 132%, while the implied volatility in the call contract example is 127%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $32.00) to be 50%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Of course, a lot of upside could potentially be left on the table if DCPH shares really soar, which is why looking at the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DCPH's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 25% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options become available today, for the December 17th expiration.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 25% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options become available today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 25% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options become available today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
|
At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new December 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing DCPH's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 25% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options become available today, for the December 17th expiration.
|
19c281c9-cbf2-4d90-a572-8155edb3de1c
|
715504.0
|
2021-10-04 00:00:00 UTC
|
Analysts Forecast 19% Upside For ESML
|
DCPH
|
https://www.nasdaq.com/articles/analysts-forecast-19-upside-for-esml-2021-10-04
|
nan
|
nan
|
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (Symbol: ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.27 per unit.
With ESML trading at a recent price near $39.66 per unit, that means that analysts see 19.20% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of ESML's underlying holdings with notable upside to their analyst target prices are Vroom Inc (Symbol: VRM), Apellis Pharmaceuticals Inc (Symbol: APLS), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Although VRM has traded at a recent price of $21.75/share, the average analyst target is 131.26% higher at $50.30/share. Similarly, APLS has 99.46% upside from the recent share price of $33.59 if the average analyst target price of $67.00/share is reached, and analysts on average are expecting DCPH to reach a target price of $66.75/share, which is 94.78% above the recent price of $34.27. Below is a twelve month price history chart comparing the stock performance of VRM, APLS, and DCPH:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares ESG Aware MSCI USA Small-Cap ETF ESML $39.66 $47.27 19.20%
Vroom Inc VRM $21.75 $50.30 131.26%
Apellis Pharmaceuticals Inc APLS $33.59 $67.00 99.46%
Deciphera Pharmaceuticals Inc DCPH $34.27 $66.75 94.78%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
iShares ESG Aware MSCI USA Small-Cap ETF ESML $39.66 $47.27 19.20% Vroom Inc VRM $21.75 $50.30 131.26% Apellis Pharmaceuticals Inc APLS $33.59 $67.00 99.46% Deciphera Pharmaceuticals Inc DCPH $34.27 $66.75 94.78% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of ESML's underlying holdings with notable upside to their analyst target prices are Vroom Inc (Symbol: VRM), Apellis Pharmaceuticals Inc (Symbol: APLS), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Similarly, APLS has 99.46% upside from the recent share price of $33.59 if the average analyst target price of $67.00/share is reached, and analysts on average are expecting DCPH to reach a target price of $66.75/share, which is 94.78% above the recent price of $34.27.
|
Three of ESML's underlying holdings with notable upside to their analyst target prices are Vroom Inc (Symbol: VRM), Apellis Pharmaceuticals Inc (Symbol: APLS), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). iShares ESG Aware MSCI USA Small-Cap ETF ESML $39.66 $47.27 19.20% Vroom Inc VRM $21.75 $50.30 131.26% Apellis Pharmaceuticals Inc APLS $33.59 $67.00 99.46% Deciphera Pharmaceuticals Inc DCPH $34.27 $66.75 94.78% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Similarly, APLS has 99.46% upside from the recent share price of $33.59 if the average analyst target price of $67.00/share is reached, and analysts on average are expecting DCPH to reach a target price of $66.75/share, which is 94.78% above the recent price of $34.27.
|
Similarly, APLS has 99.46% upside from the recent share price of $33.59 if the average analyst target price of $67.00/share is reached, and analysts on average are expecting DCPH to reach a target price of $66.75/share, which is 94.78% above the recent price of $34.27. Three of ESML's underlying holdings with notable upside to their analyst target prices are Vroom Inc (Symbol: VRM), Apellis Pharmaceuticals Inc (Symbol: APLS), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Below is a twelve month price history chart comparing the stock performance of VRM, APLS, and DCPH: Below is a summary table of the current analyst target prices discussed above:
|
iShares ESG Aware MSCI USA Small-Cap ETF ESML $39.66 $47.27 19.20% Vroom Inc VRM $21.75 $50.30 131.26% Apellis Pharmaceuticals Inc APLS $33.59 $67.00 99.46% Deciphera Pharmaceuticals Inc DCPH $34.27 $66.75 94.78% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of ESML's underlying holdings with notable upside to their analyst target prices are Vroom Inc (Symbol: VRM), Apellis Pharmaceuticals Inc (Symbol: APLS), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Similarly, APLS has 99.46% upside from the recent share price of $33.59 if the average analyst target price of $67.00/share is reached, and analysts on average are expecting DCPH to reach a target price of $66.75/share, which is 94.78% above the recent price of $34.27.
|
5a34528b-af22-45cd-83d2-202c50669570
|
715505.0
|
2021-09-17 00:00:00 UTC
|
CHMP Adopts Positive Opinion For Deciphera's Qinlock To Treat Gastrointestinal Stromal Tumor
|
DCPH
|
https://www.nasdaq.com/articles/chmp-adopts-positive-opinion-for-decipheras-qinlock-to-treat-gastrointestinal-stromal
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.
The European Commission decision is anticipated by the fourth quarter of 2021.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.
|
cf48db6e-b9b4-4368-96f8-9605d81cde42
|
715506.0
|
2021-08-04 00:00:00 UTC
|
Deciphera Pharmaceuticals, inc (DCPH) Q2 2021 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc-dcph-q2-2021-earnings-call-transcript-2021-08-04
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, inc (NASDAQ: DCPH)
Q2 2021 Earnings Call
Aug 3, 2021, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone, and welcome to Deciphera Pharmaceuticals Second Quarter 2021 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Robinson, Vice President of Investor Relations. Jen?
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 7, 2021
Jen Robinson -- Vice President of Investor Relations
Thank you, operator. Welcome, and thank you for joining us today to discuss Deciphera second quarter 2021 financial results. I am Jen Robinson, Vice President, Investor Relations at Deciphera. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management, made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include our expectations for our preclinical and clinical programs, our commercialization of QINLOCK and 2021 guidance. Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent quarterly report on Form 10-Q, as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements.
Following this call, a replay will be made available on the Company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steven L. Hoerter -- President and Chief Executive Officer
Thank you, Jen. During the first half of 2021, we continue to execute on our strategic priorities across the Company, positioning us for a catalyst-rich second half of the year that will set the stage for the Company's next phase of growth. As our Chief Commercial Officer, Dan Martin, will outline on today's call, our US commercial organization has rapidly established QINLOCK as the standard of care in fourth-line GIST, which has created a strong foundation for our future expansion into the second-line setting. In addition, we continue to publish key data updates from QINLOCK studies, which underscore the broad clinical benefit this best-in-class medicine provides in GIST.
Outside of the United States, we are making excellent progress with launches now underway in China and Hong Kong. As a reminder, an estimated 30,000 new patients are diagnosed with GIST in China each year, and we look forward to supporting our partner, Zai Lab, as they launch QINLOCK in this important territory. In Europe, where our marketing authorization application is under review, we are building out an experienced commercial organization that is preparing for the expected approval by the European Medicines Agency in the fourth quarter of this year. This focused team will be well positioned to quickly deliver QINLOCK to patients in early launch markets once the EMA approval is secured.
Our next priority for QINLOCK is moving this medicine into earlier lines of therapy for GIST. We have seen the significant difference QINLOCK has been able to make in the lives of patients with fourth-line GIST and are eager to bring that life-changing impact to patients in earlier lines of treatment. We continue to expect to announce top line results from the ongoing Phase 3 INTRIGUE study in second-line GIST in the fourth quarter of this year.
In addition to QINLOCK, we remain focused on advancing our growing pipeline of novel kinase inhibitors. In June, we treated the first patient in our Phase 1 study of DCC-3116. This Phase 1 study is investigating the safety and tolerability of our first-in-class switch-control ULK kinase inhibitor, first as monotherapy in patients with solid tumors expressing a mutant RAS or RAF gene and then in combination with a MEK inhibitor. We believe we have a leading position in the development of regulators of autophagy for cancer, an approach that holds tremendous potential to help a very large group of patients.
As Matt Sherman, our Chief Medical Officer, will discuss in more detail, we were pleased to announce today an exclusive licensing agreement with Sprint Bioscience for a research-stage program targeting VPS34, another important kinase in the autophagy pathway. This research program is complementary to DCC-3116 and builds on our expertise in the science for regulating autophagy and cancer.
We are also pleased with the progress we are making with our later-stage clinical development programs. At the upcoming ESMO Congress, we look forward to presenting new data from the Phase 1/2 study of vimseltinib in patients with tenosynovial giant cell tumor, in addition to data from the platinum-resistant ovarian cancer cohort from the Phase 1b/2 of rebastinib in combination with paclitaxel. We plan to finalize pivotal development studies for both programs in the second half of the year.
I'll now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss the US QINLOCK commercial results from Q2. Dan?
Daniel C. Martin -- Senior Vice President, Chief Commercial Officer
Thank you, Steve. In Q2, the commercial team continued to execute against our core launch objectives. Since our approval in May of last year, we have established QINLOCK as the clear standard of care in our initial fourth-line indication and have rapidly penetrated the fourth-line market opportunity. Importantly, we have also built broad clinical experience of positive product perceptions among both academic and community GIST prescribers in advance of our planned launch into the significantly larger second-line opportunity.
In Q2, we achieved $22 million in total net product revenue globally, including $20.7 million in the US. QINLOCK performance metrics remain extremely positive as we continue to capitalize on the opportunity for QINLOCK to provide significant clinical benefit in the fourth-line setting. Despite lingering physician access challenges created by the pandemic, our sales and marketing teams continue to achieve high levels of prescriber reach and share of voice. QINLOCK awareness and familiarity among targeted GIST treaters remain extremely high. And prescribers from both academic and community settings continue to cite strong QINLOCK performance across all key product attributes.
In Q2, we continued to expand our prescriber footprint. Since launch, over 450 physicians representing more than 400 institutions have prescribed QINLOCK. As expected, while academic physicians made up the majority of our earliest adopters, most of our new prescriber growth is now coming from the community setting. We are pleased with our progress within community practices, not only as it relates to our current fourth-line launch, but also as it relates to our planned second-line launch, as we expect community prescribers to play an even larger role in earlier lines of therapy. Overall, we believe our success to date across both academic and community settings reflects QINLOCK's highly differentiated clinical profile and proven patient benefit in this historically difficult to treat disease.
Regarding duration of therapy, the real-world persistency that we see for patients who have received QINLOCK continues to be similar to what we saw in the INVICTUS study, consistent with our pre-launch expectations. As we have shared previously, we expect the average time on therapy to eventually be longer than the median, based on experience from our clinical trials, in which some patients remained on therapy for extended periods. We continue to monitor the impact that the COVID pandemic is having in oncology broadly and GIST specifically. Recent data from IQVIA show that the pandemic's negative impact on diagnosis visits has persisted into 2021. IQVIA now estimates that this has negatively impacted total oncology prescriptions by 21% through the first half of the year.
Regarding GIST patient volume, claims data continue to show an approximate 10% decline in new patient starts in earlier lines of therapy over the past year. Assessing the impact of COVID is challenging, particularly given that we lack a pre-pandemic baseline for comparison. However, taken together, these data suggest that COVID may be having an impact on the volume of GIST patients progressing to fourth-line treatment.
One of our core objectives is to optimize patient access to QINLOCK, and we were very pleased to see excellent payer coverage continued during the quarter with policies aligned to our FDA label.
Regarding the percentage of patients receiving free drug under our patient assistance program, or PAP, we saw an increased trend in Q2 versus prior quarters. For the quarter, the PAP percentage was at the high end of our estimated range of 20% to 30%. This trend appears to be driven by increased patient affordability challenges that result from the Medicare Part D drug benefit design. It's important to keep in mind that Medicare patients who receive free drug under a company's patient assistance program must remain within that program through the end of the calendar year. Therefore, although projecting PAP in future quarters is challenging, we expect to see higher PAP levels persist in Q3 and Q4, potentially exceeding our estimated range.
As we look ahead, preparations are underway for our planned second-line launch, pending FDA approval. We are extremely optimistic about the significant potential for QINLOCK in the second-line setting, driven by a larger estimated patient population and anticipated longer duration of therapy. Our enthusiasm regarding QINLOCK's potential to positively impact a broader population of GIST patients is widely shared by GIST treaters, underscoring the recognized need for an improved second-line treatment option. In market research, GIST thought leaders and community oncologists have consistently shared their desire to use QINLOCK in the second-line, pending FDA approval.
To date, QINLOCK has had a profound impact on the treatment of patients with GIST, and we believe the success we have seen in our initial fourth-line indication provides a strong foundation for QINLOCK in the future. We look forward to building on that foundation and to helping even more patients of GIST by expanding into the second-line setting, pending positive data from INTRIGUE later this year and subsequent approval.
I will now turn the call over to Matt to discuss the progress of our clinical programs. Matt?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thank you, Dan. This quarter was marked by impressive progress expanding our pipeline of exciting novel kinase inhibitors. I'd like to start today by discussing our newest clinical program, DCC-3116, which we believe to be a first-in-class ULK kinase inhibitor in development for the treatment of mutant, RAS and RAF cancers. In June, we achieved an important milestone dosing the first patient in the Phase 1 first-in-human study. DCC-3116 is designed to inhibit autophagy, an important process in which sales recycle components to generate energy. Autophagy is often upregulated in cancer cells due to stressed damage caused by anticancer treatments.
DCC-3116 is designed to suppress autophagy by inhibiting the ULK kinase, the initiating factor in the autophagy pathway. The clinical development plan for DCC-3116 will focus on documented RAS and RAF cancer mutations, which utilize autophagy for tumor growth and survival. Assuming positive results in the dose-escalation phase, expansion cohorts in combination with trametinib, a commercially available MEK inhibitor are currently planned in multiple tumor types.
We are continuing to explore other combination partners for DCC-3116 pre-clinically, and we expect to evaluate it in combination with other inhibitors with the RAS MAP kinase signaling pathway beyond MEK. Our research team has generated additional exciting preclinical data with DCC-3116 in combination with approved targeted oncology agents in multiple tumor types, demonstrating potentially broad applicability of targeting autophagy to ULK inhibition. We look forward to sharing some important works at an upcoming medical meeting.
Our enthusiasm for the potential of autophagy as an important targetable pathway in oncology does not end with DCC-3116. As Steve mentioned, we in-licensed the exclusive rights to a research-stage program targeting VPS34. The VPS34 program complements our robust internal research programs in growing pipeline and enhances our efforts to explore the potential for regulating antophagen cancer. Together, Deciphera's ULK and VPS34 programs represent a comprehensive approach to addressing the clinical role of autophagy in cancer with the potential to benefit a very large number of patients.
Moving on to our other programs, we were excited to present data from both the QINLOCK and rebastinib clinical studies at this year's ASCO annual meeting. For QINLOCK, we presented an exploratory analysis of our INVICTUS Phase 3 study showing that dose escalation for QINLOCK 150 milligrams BID after progression on 150 milligrams QD can offer substantial additional clinical benefit with a tolerable safety profile. These data were published in the peer review journal, The Oncologist, just last week. As the body of data supporting QINLOCK's efficacy and safety continues to grow, we are pleased with this potential to offer clinically meaningful benefits for GIST patients in multiple settings of the disease.
For the ongoing INTRIGUE Phase 3 study comparing QINLOCK to sunitinib in patients with second-line GIST, we remain optimistic that the top line data expected in the fourth quarter this year will demonstrate significant clinical benefit for these patients. We believe that the exceptional results of the INVICTUS Phase 3 study showing a median PFS of 6.3 months with fourth-line plus GIST patients receiving QINLOCK, as well as the Phase 1 data strongly support the likelihood of success in INTRIGUE.
Plan for the fourth quarter, we are excited to initiate the Phase 1b/2 of QINLOCK in combination with binimetinib, a commercially available MEK inhibitor to address one of the potential resistant mechanism of post-imatinib GIST. As we stated before, the goal of this new study is to see whether we can deepen and prolonged initial responses by combining broad KIT inhibition with QINLOCK with inhibition of the MAP kinase pathway using a MEK inhibitor for patients with post-imatinib GIST.
We have also been studying rebastinib, our selective TIE2 inhibitor in two Phase 1b/2 studies utilizing a Simon two-stage design in combination with paclitaxel and in combination with carboplatin. For the carboplatin study, we presented preliminary data from the dose-escalation phase at ESMO last year and have been evaluating the combination of three tumor-specific expansion cohorts. While we have seen additional clinical activity in the carboplatinum expansion and a tolerable safety profile, we have not seen the level of clinical activity that we believe is necessary to continue in development this time and have decided to focus our resources for rebastinib, paclitaxel combination.
We continue to generate informative data in the paclitaxel study, and we look forward to sharing updated data from the platinum-resistant ovarian cancer cohort at the ESMO Congress in September. The data will include updated safety and efficacy data on the full cohort of patients in the second stage, including progression-free survival, which we believe is the key indicator of clinical activity in this difficult to treat patient population. Based on the published literature, single-agent paclitaxel and platinum-resistant ovarian cancer is expected to be approximately three to four months. We look forward to presenting these updated results at ESMO next month. We plan to finalize pivotal development plans for rebastinib in combination with paclitaxel in the second half of this year.
Finally, we are excited to share updated data for vimseltinib, which we believe to be the best-in-class inhibitor of CSF1R for the treatment of tenosynovial giant cell tumor at this year's ESMO Congress in September, along with guidance on our pivotal development plans for this program. At ESMO, we expect to present updated safety and efficacy data from the ongoing Phase 1/2 study in approximately 50 TGCT patients. We look forward to the continued progress of these programs, each of which has the potential to make a meaningful difference in the lives of patients and fulfill current unmet medical needs.
I will now turn the call over to Tucker Kelly, our Chief Financial Officer, to review the financial results. Tucker?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Thanks, Matt. I'd like to review the highlights from our second quarter financial results. Total revenue for the second quarter was $23.6 million, which includes $22 million in net product revenue of QINLOCK. Net product revenues for the second quarter of 2021 includes US sales of QINLOCK of $20.7 million and ex-US sales of QINLOCK of $1.3 million. The gross-to-net adjustment in the second quarter was significantly below our annualized estimate of 15% and we expect it to be more in line with our 15% estimate in future quarters. Collaboration revenue in the quarter was $1.5 million, which includes commercial supply and royalty revenue under our agreement with Zai Lab for Greater China.
Cost of sales for the three months ended June 30, 2021, was $1.3 million, which included $400,000 in cost of net product revenue for QINLOCK product sales and $900,000 in cost of collaboration efforts. As we have said previously, we expect the cost of net product sales in the US will remain immaterial through at least this year and would not expect cost of sales to be significant until the initial pre-launch inventory is depleted and additional inventory is manufactured and sold.
Total operating expenses were $94.1 million in the second quarter of 2021, compared to total operating expenses of $76 million in the same period in 2020.
Research and development expenses in the second quarter were $60 million, compared to $46.1 million in the same period in 2020.
Selling, general and administrative expenses in the second quarter were $32.8 million, compared to $29.9 million in the same period in 2020.
We continue to expect that our operating expenses will increase modestly this year as we invest in the development of our clinical pipeline, executing on the commercialization of QINLOCK in the US and prepare for potential commercial launch in Europe.
We ended the second quarter in a strong financial position and remain well capitalized with cash, cash equivalents and marketable securities of approximately $451 million, which we expect to be sufficient to fund our operations into the first half of 2023.
With that, I'll now turn the call back over to Steve.
Steven L. Hoerter -- President and Chief Executive Officer
Thank you, Tucker. We continue to make important progress across our strategic priorities in 2021. While our focus has been on establishing QINLOCK as the standard of care in fourth-line GIST around the world, we are excited as we prepare to report the top line results from the INTRIGUE study in Q4 of this year. If successful, these study results will enable filings around the world and dramatically expand the potential for QINLOCK to benefit patients with GIST.
Our progress in this most recent quarter has demonstrated the strength of our pipeline beyond QINLOCK. We have successfully initiated the Phase 1 study of DCC-3116 and we look forward to sharing new data and finalizing pivotal development plans for vimseltinib and rebastinib later this year.
Operator, I'd now like to open the call for Q&A.
Questions and Answers:
Operator
And thank you. [Operator Instructions] And our first question comes from Jessica Fye from J.P. Morgan. Your line is now open.
Daniel Wolle -- J.P. Morgan -- Analyst
Hi. This is Daniel for Jessica Fye. Thanks for taking our question. In your prepared remarks, you have described the impact of COVID on new patient starts, as well as free drug use. Do you have any new insight on whether COVID has an impact on duration of therapy? And how that make you kind of evolved over the last year and into second -- first half of 2021? That's my first question.
Second question is, the addressable fourth-line market seems smaller than we had previously anticipated. As we approach INTRIGUE data readout and think about the second-line opportunity, what gives you the confidence that the same will not be true for the second-line opportunity?
And last question is, maybe can you set the stage for us that the Phase 1b/2 study of rebastinib in platinum-resistant ovarian cancer settings in terms of what we can see patient number wise, as well as number of scans? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
Okay, Daniel. It's Steve. Thanks for all the questions. So we'll try and take these somewhat in order. Maybe what I'll do first is take your second question, which relates to the performance in the fourth-line and then I'll ask Dan to talk a little bit about the COVID impact to the extent he can add some additional color and then I'll ask Matt to take the platinum-resistant ovarian cancer cohort question, the data that's coming up here next month at ESMO, which we're excited about.
So, first, with respect to your question on the fourth-line opportunity, I think I'll just start by reiterating what I said and Dan said in the prepared remarks, which is that, we're really pleased with the launch performance in the US to date and how this sets the stage, as you pointed out, for the second-line INTRUIGUE study, which is due to readout in quarter four. So, we think having established the drug as the standard of care in this fourth-line indication with -- largely with community docs now, as Dan outlined in his prepared remarks, with a large fraction of new prescribers coming from the community, really sets the stage now for us to move into the second-line with the readout of the INTRIGUE study later this year and then filings that would flow from that.
I think with respect to the demand dynamics that we see in the fourth-line, the underlying drivers of demand in this fourth-line indication remain the same as we talked about on the quarter one call. So, we noted on that call that the next big leg up in growth we thought was going to be coming from the second-line indication. And that's really driven by two factors. One is just the larger number of patients that we see in the second-line. And as you know, we estimate the treatment eligible number of patients in the second-line in the US of being at about 2,000 patients. And the second driver in the second-line, we believe, is going to be related to duration of treatment. So, those are the two factors really to look to as we think about the second-line opportunity, pending the INTRIGUE readout.
Dan, would you like to take the COVID question? And then, Matt, just as a reminder, the platinum-resistant ovarian cancer cohort question for ESMO.
Daniel C. Martin -- Senior Vice President, Chief Commercial Officer
Yeah, absolutely. Thanks for the question, Daniel. So, just to clarify, we did note that we continue to track the impact of COVID and try to assess what impact it's having on oncology broadly and GIST specifically. And what I mentioned, just to make sure I'm clarifying is that, some of the data that we look at points to potential impact to new patient starts in earlier lines of therapy over the last year of approximately 10%.
I think you asked about PAP. We haven't spoken specifically to COVID-impact on PAP. PAP was increased in Q2 as we talked about at the high end of our range. And because of the way PAP works, where patients who enter that program have to remain in the program for the balance of the calendar year, we expect that higher levels of PAP may persist into Q3 and Q4, potentially above the estimated range that we've provided, but didn't -- I didn't tie that into COVID specifically.
And then lastly, are we able to discern any impact of COVID on duration? And the short answer to that is no, we have not. We continue to be really pleased with the persistency that we're seeing in patients who received QINLOCK from launch. As we noted, it's developed as we expected and looks a lot like what we saw in the INVICTUS study.
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
And hi, Daniel, this is Matt. Let me pickup the question about the rebastinib data in platinum-resistant ovarian cancer that we plan to update at next month's ESMO meeting. As you remember, it was a year ago that we presented the first part of the two-stage Simon design and the expansion cohort for platinum-resistant ovarian cancer at the ESMO meeting one year ago. And at that time, we had 24 evaluable patients and we reported nine of the 24 having a response or an objective response rate of 38%. And that was early in the study. So we now have completed full enrollment in the expansion cohort and we have 33 evaluable patients. And now not only an update on the objective response rate, but we'll also be able to provide the progression-free survival in this cohort of patients. So, we look forward to providing that data next month.
Daniel Wolle -- J.P. Morgan -- Analyst
Thank you very much.
Operator
And thank you. And our next question comes from Chris Raymond from Piper Sandler. Your line is now open.
Christopher Raymond -- Piper Sandler -- Analyst
Hey, thanks. I wanted to just explore maybe what I think I heard from Dan to the last question. Dan, I think you had mentioned last quarter that fourth-line GIST was already well penetrated, which I think inferred no quarter-on-quarter growth. But US growth, as my math goes, it looks like it was 7% on the revenue line. And I think I heard you say there were some patient starts in earlier lines of therapy. So maybe can you just clarify, is that what's driving the growth there? Or is there some other -- and I think I also heard you guys talk about a gross to net benefit. Can you maybe break out what's driving that growth, if it's not increased penetration in the fourth-line?
And then the second question is on intra-patient dose escalation data at ASCO. Last time we did a check, which was pre-ASCO, we didn't really see any indication of docs doing that. Maybe can you just broadly talk about how -- if you are seeing any anecdotal use employment of that? Is the data resonating with docs? Just sort of any color sort of on that data you could provide? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
Hey, Chris. It's Steve. Thanks for the question. Dan, would you like to take both of Chris' questions there?
Daniel C. Martin -- Senior Vice President, Chief Commercial Officer
Yeah, sure. Absolutely. Thanks, Chris. I appreciate the question. So, with respect to the performance and the 7% quarter-over-quarter, when we think about the story for this quarter, we think about it in terms of demand and then things that impact PAP and gross to net. And that's how we try to sort of lay out the story of the quarter.
As it relates to demand, things are basically unchanged, consistent with what we've communicated previously, which is that all of our data sources continue to suggest that QINLOCK is highly penetrated in the fourth-line opportunity. And because of this higher share, that's why we've said, as you noted, that we expect the opportunity for demand growth to be limited until our planned second-line launch. We did benefit quarter-over-quarter from lower gross to net, as Tucker mentioned. That was a component as well. And then importantly, the PAP piece, we saw, particularly as we exited the quarter a bit of an increase in that PAP percentage, and we attribute that to the Medicare Part D drug benefit design and how patients now that they're in that program, they need to stay in that program. That's how the program works. And that's why we spoke to expecting potentially higher PAP in Q3 and Q4 as well. So, I think those are the major brush strokes.
And then for IPDE, it's a good question. So, as Matt said, we're really pleased that we continue to grow the sort of the base of data for QINLOCK broadly. But you're right, so far, as we said on prior calls, we have not seen a lot of use of IPDE. We see some. By the way, as always, I should mention that we don't promote this data, given that it's an off-label regimen. And so, we do see some payer coverage currently is a bit inconsistent. Some claims get paid for, some don't. And so, it is rather minimal at this time. So, pretty consistent with what it sounds like you're seeing in your survey.
Christopher Raymond -- Piper Sandler -- Analyst
Okay. Can I ask a follow-up on that? I mean, you guys did take a -- almost 5% price increase I think before the quarter began. Was there some impact from that that we should be thinking about as we model?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah, Chris, it's Steve. That's right. We did take a 4.9% price increase as of July 1. So that's the price increase that we've taken, which is really in line with what we've seen with other oral oncolytics. So that, as Dan just outlined, there were a variety of different factors, of course, that contribute to overall performance. And Dan just spoke to a couple of them that we thought we wanted to highlight for quarter two, but there are a whole variety of factors, including price that play into the balance of the year.
Christopher Raymond -- Piper Sandler -- Analyst
Okay. Thanks.
Operator
And thank you. And our next question comes from Eun Yang from Jefferies. Your line is now open.
Eun Yang -- Jefferies & Company -- Analyst
Thank you. So, based on -- Steve, based on your comments and the clinical data that we've seen to date, do you think it's fair to say that in the US, at least, the second-line GIST opportunity would be about 4 times greater than fourth-line?
And second question is for Matt, so in Phase 3 INTRIGUE trial, you guys are allowing certain dose reduction in the event of a toxic effect. So, can you comment on what percent of patients on certain group had dose reduction and how they may compare to Pfizer's Phase 3 study for CR [Phonetic] in second-line?
And the last question is to Tucker, are you planning to -- at some point, are you planning to breakout royalty revenue from Zai Lab from the collaboration revenues? Thank you.
Steven L. Hoerter -- President and Chief Executive Officer
Hi, Eun, it's Steve. Thanks for the question. So before I turn it over to Matt and then Tucker, let me take your first question. And really it's just to reiterate what I said to the question from Daniel earlier in the call earlier in the Q&A, which is the way that we think about the second-line opportunity relative to the fourth-line opportunity is really driven by those two factors that we've talked about very consistently. One is about the epidemiology, so the number of patients that we see in the second-line and we believe there are about 2,000 new patients that are treatment eligible in the US each year. And then the second component of that is really going to be about duration, duration of treatment, how long patients are staying on therapy. We think those are going to be the two biggest differences and drivers relative to the fourth-line opportunity.
Matt, would you like to take the question about INTRIGUE?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. Hi, Eun, it's Matt. So, yes, we have our ongoing Phase 3 study comparing ripretinib QINLOCK to sunitinib in the second-line setting in this head-to-head comparison. As you know, we fully enrolled the study as of the end of last year. We remain blinded to the data, not only to the treatment of Simon, but to how patients have done on the study in terms of dose reductions or other modifications per treatment arm. So, once we have the top line results, which we are planning to have this in the fourth quarter this year, we'll be able to make those comparisons compared to the indication -- the labeled indication of sunitinib in that setting.
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Great. And Eun, it's Tucker. I'll answer your last question on the collaboration revenue. So, at the moment, we don't have any intention to breakout the various components of collaboration revenue, which include the clinical or commercial supply that we have with Zai, as well as now here in Q2, the initial royalty payments. And then in other quarters, we had milestone payments. So, it's all at the moment related to the Zai collaboration, but we haven't broken out the various components other than at times where we have to say a large milestone payment, but this quarter does include both commercial supply and initial royalty payments.
Eun Yang -- Jefferies & Company -- Analyst
Thank you.
Operator
And thank you. And our next question comes from Michael Smith from Guggenheim Securities. Your line is now open.
Charles Zhu -- Guggenheim Securities -- Analyst
Hey. Good afternoon, everybody. This is Charles Zhu on for Michael. I guess, one commercial question first before I shift over to the pipeline, but how much line of sight do you have into the number of second-line patients currently present at the accounts where you have a commercial presence off of your fourth line-label? And given the overlap in your experience thus far in fourth-line, I guess, how should we think about the potential launch trajectory and market opportunity, assuming INTRIGUE is successful? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Thanks, Charles. It's a great question. Dan, would you like to take that?
Daniel C. Martin -- Senior Vice President, Chief Commercial Officer
Yeah, absolutely. Thanks for the question. So, we've been really -- I've been really pleased with our ability to reach treating -- GIST treaters despite the ongoing challenges of the pandemic, it's tough to launch a drug in the pandemic, of course, but the team really did a great job pivoting GIST prior to launch and finding ways to leverage both remote virtual, but also in-person interactions when possible. And as a result of that, we've been able to reach the vast majority of our targets. And those targets aren't just current fourth-line treaters, we target GIST treaters broadly because it's hard to know which one is going to have a fourth-line patient and when. So, we've reached quite a number of GIST treaters. We do also work to identify and be mindful of where patients in earlier lines are out there so that when they do progress to fourth-line, we are able to capitalize.
So, we have -- we feel like we've got a really good feel for the GIST market now being out there as long as we have. And then we think it sets up great for a second-line launch. I mean, one of the things that we are really excited about is the progress we have made in the community setting. I noted in my prepared remarks that the majority of our new prescribers are now coming from the community. And we think that's great because they are likely to play an even larger role when we get to second-line. So, we think the progress we've had in the fourth-line has been great and right in line with our expectations, and we've got a nice foundation set for our successful second-line launch pending approval.
Charles Zhu -- Guggenheim Securities -- Analyst
Makes sense. And maybe one for Matt, I think. So, looking at autophagy, there is a lot of literature out there that describes how autophagy can play a role in their immunization [Phonetic] in addition to its mechanism [Phonetic] alongside the RAF, MEK, ERK pathway. I guess, how would you characterize your interest on that front in terms of clinical study? And are there any sort of particular, I guess, valuable biomarkers that could indicate an increased tumor reliance on autophagy to a big immune system? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
Hey, Charles. It's a great question. Matt, why don't you go ahead, please?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Yeah. Hi, Charles. So, yeah, thanks for the question. It's really interesting, and I can spend a minute talking about some of the near findings of both the role in autophagy in immune surveillance. First, we're very excited about the initiation of our Phase 1 study of 3116, our ULK kinase inhibitor that we announced last month to have a first-in-human study underway now. And we'll be progressing with a single agent for safety of 3116 followed by combination -- initially targeting combination with mutant RAS and RAF cancer, so targeting the MAP kinase pathway for the initial combination study.
Well, I think you referred to in your question is some recent published data, it's also very exciting by showing that in the subset of non-small cell lung cancer patients who have a comutation of a RAS mutation plus the LKB1 mutation. This occurs in about 20% of non-small cell lung cancer patients. They are highly resistant to PD-1, PD-L1 checkpoint blockade. So, in comparison to the 30% or greater response rates that PD-1 agents can provide to non-small cell lung cancer patients, if they co-mutate or carry the KB1 mutation as well, they have less than 10% response rate. The study of recent publish showing that by inhibiting the ULK kinase in tumor cells in that population, it can restore immunoresponsiveness and allow for responsiveness to checkpoint inhibitors such as a PD-1, PD-L1 pathway. So, that provides potential opportunities for us in the future in terms of combination studies.
Charles Zhu -- Guggenheim Securities -- Analyst
Got it. Thanks for taking the questions.
Operator
And thank you. And our next question comes from Robyn Karnauskas from Truist Securities. Your line is now open.
Srikripa Devarakonda -- Truist Securities -- Analyst
Hey, guys. Thank you so much for taking my questions. This is Kripa on for Robyn. So, I had a question about the ex-US expansion opportunities, both in fourth-line and eventually in second-line GIST, your EMA approval is still on track for fourth quarter and you talked about launch in China and Hong Kong. First, can we -- can you talk to us about any potential impact of COVID on the commercial preparedness in EU, especially given how different the situation seems to be among the different countries?
And then looking beyond regions where you either have approval or where you expect approval, any color on expansion strategy? Are there other geographies where you think it will be easy to penetrate and would be meaningful markets? Thank you.
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Thanks, Kripa. It's Steve. Thanks for the great question about our progress outside of the US. So, let me try and address the questions that you posed. First, as you all know, we, of course, have the approval in the US, the approval in Canada, as well as Australia. And now we've added to that the Zai approval and their territory in Greater China and China and Hong Kong specifically. And we expect that we will see additional territories come online, additional approvals that will come both from the Zai territory and also, as you noted, from outside of the Zai territory, specifically our EU approval, which we expect in quarter four of this year.
So, we've made really good progress in terms of starting to build our organization in Europe to address the opportunity there. And our focus is, as I've mentioned before on prior calls, really on the early access markets. So, as you may know, in certain markets, we have the opportunity to price freely. In others, it requires a negotiation on price and on reimbursement. And so, as a result, market access can take some time, particularly in Southern Europe, where it can take substantially longer in some cases. But we are making very good progress, not only in attracting the right talent, building the team, but also getting the work done as we prepare for that potential approval in Europe at the end of this year. And then we'll build in relevant territories across the EU as we get market access, so that will very much be a staged approach to both the build, as well as to the launch as we get market access and have the opportunity to deliver on revenue.
So, with respect to expansion strategy, there really are two key areas of expansion strategy for QINLOCK and the first, as we've talked about previously is about moving the drug into an earlier line of treatment. That's the basis for the INTRIGUE study, which we've spent a lot of time talking about. And the second, as you addressed is about geographic expansion. So, our focus as a Company, in addition to, of course, the US launch here for fourth-line and looking to the second-line launch is really about Europe and that really is where our focus is. So we're trying to go where the largest market opportunity is to try to capture that ourselves, in other territories as we've already demonstrated in Australia and in Canada, we'll work through distributors to access those markets.
Srikripa Devarakonda -- Truist Securities -- Analyst
Great. Thank you very much. If I can ask one more question, this is more to do with, as you treated multiple patients now, you have a couple of quarters, not sure how much analysis you are doing but a mutational background of patients that are being treated with QINLOCK. Is it comparable to INVICTUS trial? Are you seeing any differences in the mutational background of responders in particular?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. So, it's a really good question. And unfortunately, we don't have good access to that sort of data from patients who are being treated in a commercial setting. What we would expect based on the size of the INVICTUS study and where we enrolled those patients is that, the commercial experience is consistent with what we saw in INVICTUS, where we saw very broad activity of the drug irrespective of mutational background. And I think Dan's comments earlier about persistency and duration of treatment tracking pretty closely to INVICTUS and that is something we have access to. I think that suggests to us that in the real world setting that we're seeing a very similar patient population to what we treated in INVICTUS and the drug is behaving very similarly.
Srikripa Devarakonda -- Truist Securities -- Analyst
Great. Thank you so much.
Operator
And thank you. And our next question comes from Reni Benjamin from JMP Securities. Your line is now open.
Reni Benjamin -- JMP Securities -- Analyst
Hey. Good afternoon, guys. Thanks for taking the questions. I guess, maybe just with the rebastinib program, you mentioned you're not moving forward with carboplatinum. Can you talk a little bit about what led to that decision? Was it more on the efficacy side, more on the safety side? And as we think about sort of the new data that we're going to get or updated data we're going to get at ESMO, given that it's only -- whatever it is, seven more patients than what we've seen before, maybe nine more patients than what we've seen before, is it fair to say that, you know what, you have a pretty good idea as to the efficacy and safety here and there likely is a path forward or will you be going through the same sort of decision-making process as to whether or not you want to move that program forward?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Thanks, Reni for the question about the rebastinib program. And as I noted, we're excited to share the data from the PROC cohort coming up here next month at ESMO. Matt, would you like to address the question that Reni asked with respect to carbo versus paclitaxel and the safety profile of the drug relative to activity?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. So, hi, Reni, it's Matt. So yeah, just to go back, so as you know, rebastinibs are potent selected inhibitor, the TIE2 kinase. And TIE2 is expressed on endothelial cells and as well as androgenic macrophages. And inhibition of TIE2 can block those macrophages, as well as tumor angiogenesis. We did preclinical studies a while back and we noticed that paclitaxel in these tumor models could promote angiogenesis and increase the number of TIE2 expressing macrophages within the tumor cell. So, that's on the basis we're using rebastinib in combination with paclitaxel and show that we could have this antitumor response. We move that forward into the phase -- in the combination Phase 1/2 trial.
In addition, because carboplatinum is also a very common backbone therapy in oncology, we decided to extend that observation into a clinical trial in combination with carboplatin. But as we announced today, the activity we saw there while the combination was safe, we did see activity in these cohorts of patients, it do not meet the level of evidence for us to proceed into further development, and we've discontinued the carboplatinum trial.
In regard to what we plan to present at ESMO next month, as I said earlier, we have the full enrollment of the expansion cohort of the platinum-resistant ovarian cancer patients and not only updating the objective response rate, but still looking at the progression-free survival for these patients. Now that they've been on for quite an extended period of time, will be very informative to inform us moving forward in this indication.
Reni Benjamin -- JMP Securities -- Analyst
And as we think about the finalization of the pivotal programs at the end of this year, how should we be thinking about the timing as to when those pivotal programs might initiate? And would you need to meet with the FDA ahead of that for some -- for the regulatory buy-in of the structure of the pivotal programs before starting?
Steven L. Hoerter -- President and Chief Executive Officer
Hi, Reni, it's Steve. It's a really good question. So, I think there are really two pieces of information for us to consider moving into a pivotal study. One, as we've just talked about, is getting the data presented and evaluating the data and understanding how the drug performs in the relevant indication, and you're exactly right. The second is to make sure that we have good regulatory input as we think about a potential design of a pivotal study for the program. So those would be the two key steps. So, we're looking forward to getting the data out there, as Matt referenced, coming up next month. And then we'll be in a position, as we've noted here in the second half, to start to talk about what a pivotal program could look like.
Reni Benjamin -- JMP Securities -- Analyst
Got it. And then a final question for the new asset, VPS34, can you talk a little bit about, I guess -- is there -- what the overlap -- biological overlap might be with ULK or how the two molecules at one point may find themselves in a combination study, if that works biologically? And, I guess, separately, did you guys utilize the switch control kind of kinase inhibitor platform that you have to try to find drugs that might target VPS34, or was this sort of something that came out of the blue or from your own BD development pathways?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Thanks for the question, Reni. So let me start off, and then I'll turn it over to Matt, just to talk about the two ways that we're targeting autophagy and how they're differentiated. But first, let me just say that we're really excited to announce today the licensing of this research-stage program targeting VPS34 from Sprint. And this really builds upon, not only our interest, but also our expertise in targeting this pathway for the potential treatment of cancer. And as you referenced, we have a first-in-class program targeting ULK, which we're excited now to have that Phase 1 study underway and to be actively enrolling patients. And as we have been evaluating the pathway, looking for potential additional targets to pursue, VPS34 certainly was a target that we've been tracking. And so, we're excited to have brought a program in, which would advance substantially in the internal work that we might have otherwise done.
But Matt, why don't you talk a little bit, if you would, about the difference between targeting ULK versus VPS34?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
[Technical Issues] Hey, Steve, did I lose you? You guys didn't hear that.
Jen Robinson -- Vice President of Investor Relations
No. I think, Matt, we're having a hard time hearing you.
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Okay. Can I continue?
Jen Robinson -- Vice President of Investor Relations
Yes. If you can start from the beginning. I would start from the beginning and Reni, thank you for your question, so its ULK versus VPS34.
Reni Benjamin -- JMP Securities -- Analyst
Correct. And I didn't hear anything. I -- it like completely cut off, Matt, I'm sorry.
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Okay. No, I'm sorry. Can you hear me now, Reni?
Reni Benjamin -- JMP Securities -- Analyst
Yes, totally.
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Okay. Yes. So let me just go back and add my excitement about the VPS34 opportunity that we recently in-licensed from Sprint Bioscience. And as Steve was saying, this will allow us to build a leadership position in the use of treatment of cancer with autophagy inhibitors. While we've indicated before that the ULK kinase is the initiating factor for autophagy, VPS34 works at a different node, is involved in endosome vesicular trafficking of recycling cargo within these autophagosomes for regenerating energy. We have regenerating of energy that becomes a survival mechanism for tumor cells and distressed with the treatment with anti-cancer therapy.
And I was also noting that the recently published work by a group in the Luxembourg Institute of Health along with the Karolinska Institutet show that VPS34 inhibition could restore immune cold tumors to inflamed tumors with increases in chemokines and tumor T cells and killer NK cells, sensitizing these tumors to checkpoint inhibition with PD-1, PD-L1 blockers. So, taken together, this really can provide a great opportunity for patients who otherwise have tumors that are not responsive to checkpoint blockade.
Reni Benjamin -- JMP Securities -- Analyst
Got it. Thank you, guys, very much for taking the questions.
Operator
Thank you. And our next question comes from Peter Lawson from Barclays. Your line is now open.
Peter Lawson -- Barclays -- Analyst
Hi. Thanks for taking the question. Just on the Phase 3 INTRIGUE in 4Q, just the level of detail that we're seeing in the release of data and do we get kind of subgroup analysis? And just your thoughts on how the control arm could be behaving?
Steven L. Hoerter -- President and Chief Executive Officer
Hi, Peter, it's Steve. Thanks for the question. So, in terms of what you expect from the top line, I think probably the best guidance is to think about what we previously presented as top line from the INVICTUS study when we reported that out. So I imagine it will be a relatively fulsome top line, providing the key information to investors about the study. I wouldn't expect that readout of top line, however, to have subgroup analyses and a deeper analysis that would likely take some time. So I think that's the best way to think about what to expect from top line results.
In terms of the study itself, we're really pleased with the fact that we've, of course, gotten to full enrollment last year. The study conduct has been great, and we're looking forward to get into the top line report out. As you know, we're blinded to the study. So we don't have visibility to how things are progressing arm by arm. We know, in aggregate, of course, how events are accumulating, which is how we're able to provide guidance on when the study may report out. But as I said, we don't have any other color because we don't have any additional insight into specifics on the study given that we are blinded.
Peter Lawson -- Barclays -- Analyst
Okay. And then, just as we think about ESMO, so rebastinib in ovarian, what's the bar for you to move forward with that?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. So I think as Matt mentioned in his prepared remarks, and Matt, feel free to amplify that, if you'd like. We would expect that single agent paclitaxel will deliver a progression-free survival on this patient population of somewhere in the order of three to four months. So we haven't guided to a specific bar, Peter, but I think what we would need to see is something that's substantially different from what we would expect to see with single agent paclitaxel.
Peter Lawson -- Barclays -- Analyst
Perfect. Thank you. And then just final question, just on TGCT at ESMO kind of what should we expect to see at the level of detail around that initial efficacy data?
Steven L. Hoerter -- President and Chief Executive Officer
Sure. Matt, would you like to provide some additional detail on what to expect there? I know you covered some of this in -- I think, in your prepared remarks.
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. No, thanks. And thanks, Peter, for the question. So, as we noted, vimseltinib is our selective and potent inhibitor of the CSF1 receptor and now in development for treating the patients with TGCT. And we've had very rapid enrollment into the Phase 1/2 study. So -- just as a reminder, the study was designed with both an escalation phase into expansion cohorts. The first expansion cohort in treatment-naive patients, and second one previously treated patients. So now we fully enrolled the expansion cohort with 32 TGCT patients, as well as fully enrolling the treatment-naive patient cohort with 40 patients, and we'll be able to report ASCI data on approximately 50 patients from both the escalation and expansion phases at the ESMO meeting next month. And just as a note, this 50 patients is more than double the 22 patients that we were able to report on at CTOS last year.
Peter Lawson -- Barclays -- Analyst
Perfect. Thank you so much.
Operator
And thank you. And our next question comes from Arlinda Lee from Canaccord. Your line is now open.
Arlinda Lee -- Canaccord Genuity -- Analyst
Great. Thanks for taking my questions. I had a couple, can you -- sorry, so on vimseltinib at ESMO, the 50 patients are going to include both the CSF1-naive and experienced. And then, can you maybe clarify a little bit on the INTRIGUE second-line? You mentioned that you have just the aggregate information at this point. Can you maybe talk about what proportion of patients do you think have exon 13/14 mutation? And then maybe what your assumptions are for efficacy? I think you -- with sutent being in the 5.5 to 7-month expectations, I'm wondering what your assumptions are. Thank you.
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Hi, Arlinda, it's Steve. So let me take the second part of your question, and then I'll ask Matt just to address the vimseltinib question. So first, with respect to INTRIGUE, we are blinded to the study. So we don't have visibility to things such as mutation status or profile of the patients that are being enrolled in the study. Now that isn't something that we have visibility to.
And with respect to our assumptions about how ripretinib may perform in the study is really driven by what we've seen in the Phase 1 study with ripretinib where we saw an impressive PFS rate in the cohort of second-line patients. In terms of what to expect from sutent in that same study? We anchor, of course, to what's in the label for sutent, which was about 5.5 months. So we've -- we expect that sutent would perform in the six-month range in terms of PFS. So that's how we think about the efficacy part of the story potentially coming from INTRIGUE.
Matt, would you like to take the vimseltinib question with respect to ESMO?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. So just to go back for the escalation phase of the study, we did not limit it to treatment-naive patients, so it was a mix of both treatment -- pre-treated patients with a CSF1 inhibitor or treatment-naive patients. And that's the 32-patient cohort that we'll be able to report on to our efficacy. In addition to that, we enrolled a treatment-naive cohort of 40 patients, and that will also be part of the efficacy valuable data set that we'll present at ESMO. The treatment -- the previously treated patients cohort is still enrolling, and we're going to have an update on enrollment efficacy at this time from that group of patients.
Arlinda Lee -- Canaccord Genuity -- Analyst
Okay, great. Thank you very much.
Operator
And thank you for that question. I'm showing no further questions. I would now like to turn the call back over to Steve Hoerter, President and CEO, for closing remarks.
Steven L. Hoerter -- President and Chief Executive Officer
Great. Thank you. Thanks, everybody, for joining us on today's call, and thank you for your continued interest and support of Deciphera. We look forward to keeping you updated on our continuing progress for the balance of 2021. Hope you all have a great evening. Thank you.
Operator
[Operator Closing Remarks]
Duration: 59 minutes
Call participants:
Jen Robinson -- Vice President of Investor Relations
Steven L. Hoerter -- President and Chief Executive Officer
Daniel C. Martin -- Senior Vice President, Chief Commercial Officer
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Daniel Wolle -- J.P. Morgan -- Analyst
Christopher Raymond -- Piper Sandler -- Analyst
Eun Yang -- Jefferies & Company -- Analyst
Charles Zhu -- Guggenheim Securities -- Analyst
Srikripa Devarakonda -- Truist Securities -- Analyst
Reni Benjamin -- JMP Securities -- Analyst
Peter Lawson -- Barclays -- Analyst
Arlinda Lee -- Canaccord Genuity -- Analyst
More DCPH analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q2 2021 Earnings Call Aug 3, 2021, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 59 minutes Call participants: Jen Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President and Chief Executive Officer Daniel C. Martin -- Senior Vice President, Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Daniel Wolle -- J.P. Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies & Company -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Srikripa Devarakonda -- Truist Securities -- Analyst Reni Benjamin -- JMP Securities -- Analyst Peter Lawson -- Barclays -- Analyst Arlinda Lee -- Canaccord Genuity -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. As Matt Sherman, our Chief Medical Officer, will discuss in more detail, we were pleased to announce today an exclusive licensing agreement with Sprint Bioscience for a research-stage program targeting VPS34, another important kinase in the autophagy pathway.
|
Operator [Operator Closing Remarks] Duration: 59 minutes Call participants: Jen Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President and Chief Executive Officer Daniel C. Martin -- Senior Vice President, Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Daniel Wolle -- J.P. Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies & Company -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Srikripa Devarakonda -- Truist Securities -- Analyst Reni Benjamin -- JMP Securities -- Analyst Peter Lawson -- Barclays -- Analyst Arlinda Lee -- Canaccord Genuity -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q2 2021 Earnings Call Aug 3, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 59 minutes Call participants: Jen Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President and Chief Executive Officer Daniel C. Martin -- Senior Vice President, Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Daniel Wolle -- J.P. Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies & Company -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Srikripa Devarakonda -- Truist Securities -- Analyst Reni Benjamin -- JMP Securities -- Analyst Peter Lawson -- Barclays -- Analyst Arlinda Lee -- Canaccord Genuity -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q2 2021 Earnings Call Aug 3, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 59 minutes Call participants: Jen Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President and Chief Executive Officer Daniel C. Martin -- Senior Vice President, Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Daniel Wolle -- J.P. Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies & Company -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Srikripa Devarakonda -- Truist Securities -- Analyst Reni Benjamin -- JMP Securities -- Analyst Peter Lawson -- Barclays -- Analyst Arlinda Lee -- Canaccord Genuity -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q2 2021 Earnings Call Aug 3, 2021, 4:30 p.m. For the ongoing INTRIGUE Phase 3 study comparing QINLOCK to sunitinib in patients with second-line GIST, we remain optimistic that the top line data expected in the fourth quarter this year will demonstrate significant clinical benefit for these patients.
|
0fac2c70-46b5-4cee-ba56-2a2f52a0fc1c
|
715507.0
|
2021-07-27 00:00:00 UTC
|
2 Beaten-Down Biotech Stocks That Could Bounce Back
|
DCPH
|
https://www.nasdaq.com/articles/2-beaten-down-biotech-stocks-that-could-bounce-back-2021-07-27
|
nan
|
nan
|
Biotech stock investing is full of ups and downs. Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs.
Shares of ChemoCentryx were soaring in 2020 until an FDA advisory committee vote pulled the rug out from under its stock price in May. As a result, shares of the biotech have lost around 77% of their value this year.
Image source: Getty Images.
Deciphera's first drug earned approval last year, but sales so far have been a disappointment. After giving up around 41% of its value this year, an upcoming clinical trial readout could allow shares of this biotech to bounce right back.
ChemoCentryx
This company doesn't have a steady source of revenue at the moment but that could change before the end of the year. On or before Oct. 7, the FDA will announce a long-awaited approval decision regarding a new drug application for ChemoCentryx's lead candidate, avacopan, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
Shares of ChemoCentryx were beaten down in May, when an FDA advisory panel voted 10-8 on whether avacopan's apparent benefits outweighed its potential safety concerns. The company has since submitted an amendment to the new drug application under review to address its shortcomings.
The FDA's willingness to incorporate the amendments is a positive signal because the agency doesn't do it very often. When major amendments are included, the agency ends up approving the new drug in question more often than not.
Avacopan is an oral drug that limits the activation of destructive white blood cells by blocking the C5a receptor. Overactive C5a receptor activity leads to ANCA-associated vasculitis, but standard treatment with steroids like prednisone broadly suppresses immune system activity and causes lots of unintended side effects.
As a tolerable alternative to traditional steroids, avacopan could generate more than $1 billion for ChemoCentryx within a few years of its initial launch.
Image source: Getty Images.
Deciphera Pharmaceuticals
This company currently markets Qinlock, a new treatment for gastrointestinal stromal tumors (GIST) a type of cancer that usually originates in the stomach and small intestine. The FDA approved Qinlock in 2020 for relapsing GIST patients who have already failed three different courses of therapy.
Sales of Qinlock have been disappointing in the limited fourth-line setting, which is keeping Deciphera Pharmaceuticals' stock price a lot lower than it could be. Before the year's finished, though, hope for a label expansion could push shares of this biotech stock into the clouds again.
In the fourth quarter, Deciphera will read out results from a head-to-head trial with Sutent, which is currently the standard for GIST patients who relapse after their first line of treatment. Sales of Qinlock are on pace to reach just $80 million this year, but successful expansion to the second-line setting could make it a blockbuster drug that adds more than $1 billion to Deciphera's top line year after year.
Beyond Qinlock, Deciphera Pharmaceuticals already has three more cancer drug candidates in clinical-stage testing. More revenue from a second-line indication for Qinlock would allow this company to develop the rest of its pipeline at a faster pace.
Time to buy?
Investors want to tread lightly with ChemoCentryx even though avacopan could produce blockbuster sales as a targeted treatment for ANCA-associated vasculitis and additional autoimmune disorders. The FDA's willingness to incorporate new information into the ongoing review process is encouraging, but the company shouldn't be in this position in the first place.
Throughout development, the FDA told ChemoCentryx its phase 3 trial design wouldn't be sufficient. Investors have no reason to be surprised if the FDA sends the company a complete response letter instead of a green light to market avacopan.
Deciphera Pharmaceuticals' market cap has fallen down to just $1.9 billion at recent prices. That seems really cheap for a company with several clinical-stage candidates when you consider it's already proven itself capable of shepherding new cancer drugs through the FDA's review process.
10 stocks we like better than Deciphera Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 7, 2021
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. On or before Oct. 7, the FDA will announce a long-awaited approval decision regarding a new drug application for ChemoCentryx's lead candidate, avacopan, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Shares of ChemoCentryx were beaten down in May, when an FDA advisory panel voted 10-8 on whether avacopan's apparent benefits outweighed its potential safety concerns.
|
Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. On or before Oct. 7, the FDA will announce a long-awaited approval decision regarding a new drug application for ChemoCentryx's lead candidate, avacopan, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Overactive C5a receptor activity leads to ANCA-associated vasculitis, but standard treatment with steroids like prednisone broadly suppresses immune system activity and causes lots of unintended side effects.
|
Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. Sales of Qinlock have been disappointing in the limited fourth-line setting, which is keeping Deciphera Pharmaceuticals' stock price a lot lower than it could be. Sales of Qinlock are on pace to reach just $80 million this year, but successful expansion to the second-line setting could make it a blockbuster drug that adds more than $1 billion to Deciphera's top line year after year.
|
Anyone who's been watching ChemoCentryx (NASDAQ: CCXI) and Deciphera Pharmaceuticals (NASDAQ: DCPH) lately can tell you all about the downs. ChemoCentryx This company doesn't have a steady source of revenue at the moment but that could change before the end of the year. Sales of Qinlock are on pace to reach just $80 million this year, but successful expansion to the second-line setting could make it a blockbuster drug that adds more than $1 billion to Deciphera's top line year after year.
|
a31cac9a-abeb-4919-8685-02b07b3ec0c9
|
715508.0
|
2021-07-21 00:00:00 UTC
|
3 Biotech Stocks That Could Double Soon
|
DCPH
|
https://www.nasdaq.com/articles/3-biotech-stocks-that-could-double-soon-2021-07-21
|
nan
|
nan
|
If you're looking for stocks that can double your money or better, the biotechnology industry is a pretty good place to start. Hardly a week goes by where clinical trial results or FDA decisions don't send at least one biotech stock rocketing higher.
Wall Street analysts following these biotechs have high expectations for the drugs they're developing and in one case already marketing. In fact, all three have price targets that suggest more than 100% upside once the rest of the stock market comes to the same conclusions.
Image source: Getty Images.
Blindly investing in stocks with promising price targets isn't a great investing strategy. That said, hidden gems do get uncovered from time to time. Read on to find out more about three risky biotech stocks that could pay out huge rewards in the foreseeable future.
Allakos
Allakos (NASDAQ: ALLK) is a clinical-stage biotech that's developing new drugs to treat severe autoimmune diseases. The company's lead candidate, lirentelimab is a potential first-in-class antibody that depletes eosinophils and inhibits mast cells. These are white blood cells that fight infections and play a key role in allergic reactions.
Recently revealed clinical trial results inspired Patrick Trucchio from H.C. Wainwright to pin a $230 price target on Allakos that suggests the stock could run 189% higher. During the phase 2 Enigma trial, patients with severe autoimmune disorders of the stomach and small intestine called eosinophilic gastritis and eosinophilic duodenitis received one of two dosages of lirentelimab or a placebo. Results showed an average eosinophil reduction of 86%, compared with a 9% increase for the placebo group.
Knocking down eosinophil production with Allakos lead candidate improved symptom scores by 48% while the placebo group only improved by 22%. This should translate to meaningful improvements for patients suffering from eosinophil-driven inflammation of their digestive tract and eventually blockbuster sales for Allakos.
Affimed
Affimed (NASDAQ: AFMD) is developing new drugs that help patients' immune systems fight cancer. The company's lead candidate, AFM13 is an experimental treatment for patients with peripheral T-cell lymphoma (PTCL) that targets CD30 positive cancer cells. Affimed's candidate also brings circulating natural killer cells (NK) into contact with tumor cells by selectively binding to CD16A while avoiding CD16B.
Targeting CD16 proteins to engage NK cells is nothing new, but Affimed is the first to avoid CD16B. So far the results are compelling. Affimed's unique approach shrank tumors for four out of four evaluable patients treated with NK cells and AFMD13.
BMO Capital analyst Do Kim recently raised his price target on Affimed to $15, implying 134% upside potential. Investors could realize that potential before the end of 2021 if the next readout with AFM13 falls in line with the first.
Image source: Getty Images.
Deciphera
In 2020, Deciphera (NASDAQ: DCPH) launched its first drug, Qinlock after the FDA gave it a green light but sales so far have been fairly disappointing. That's because the FDA only approved it to treat patients with gastrointestinal stromal tumors (GIST) who relapse after trying all three currently available targeted therapies.
Credit Suisse analyst Brad Canino has a bold $78 price target on Deciphera because he believes Qinlock's about to become a lot more popular. In the fourth quarter, the company expects to report topline results from a pivotal study that could convince the FDA to bump Qinlock up to a second-line indication.
During the study that led to Qinlock's approval in the fourth-line setting, the drug reduced patients' risk of death by an outstanding 64% compared to the placebo group. I'll be shocked if investigators don't uncover a meaningful benefit for patients in the second-line setting as well.
Looking out
Before making a huge bet on Allakos, it's important to realize efficacy is less than half the picture when it comes to new antiinflammatory drugs meant for long-term use. Patients received just four monthly infusions during the Enigma trial, so there's still a lot we don't know about lirentelimab's long-term safety profile.
Results from the first four evaluable patients treated with Affimed's lead candidate were highly encouraging but investors probably want to tread lightly with this stock. New cancer drug candidates that look amazing for just a few patients have a tendency to disappoint once more data rolls in.
Disappointing first-quarter sales have pushed Deciphera's shares into bargain territory for a commercial-stage biotech with a pipeline full of wholly owned cancer therapy candidates. Potential expansion to treat second-line GIST patients would be icing on the cake making this a pretty good biotech stock to buy right now.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 7, 2021
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera In 2020, Deciphera (NASDAQ: DCPH) launched its first drug, Qinlock after the FDA gave it a green light but sales so far have been fairly disappointing. Recently revealed clinical trial results inspired Patrick Trucchio from H.C. Wainwright to pin a $230 price target on Allakos that suggests the stock could run 189% higher. In the fourth quarter, the company expects to report topline results from a pivotal study that could convince the FDA to bump Qinlock up to a second-line indication.
|
Deciphera In 2020, Deciphera (NASDAQ: DCPH) launched its first drug, Qinlock after the FDA gave it a green light but sales so far have been fairly disappointing. Recently revealed clinical trial results inspired Patrick Trucchio from H.C. Wainwright to pin a $230 price target on Allakos that suggests the stock could run 189% higher. Affimed Affimed (NASDAQ: AFMD) is developing new drugs that help patients' immune systems fight cancer.
|
Deciphera In 2020, Deciphera (NASDAQ: DCPH) launched its first drug, Qinlock after the FDA gave it a green light but sales so far have been fairly disappointing. Results from the first four evaluable patients treated with Affimed's lead candidate were highly encouraging but investors probably want to tread lightly with this stock. Potential expansion to treat second-line GIST patients would be icing on the cake making this a pretty good biotech stock to buy right now.
|
Deciphera In 2020, Deciphera (NASDAQ: DCPH) launched its first drug, Qinlock after the FDA gave it a green light but sales so far have been fairly disappointing. During the study that led to Qinlock's approval in the fourth-line setting, the drug reduced patients' risk of death by an outstanding 64% compared to the placebo group. Potential expansion to treat second-line GIST patients would be icing on the cake making this a pretty good biotech stock to buy right now.
|
fe9cfecd-88a2-42b0-9de5-6dc9f078a735
|
715509.0
|
2021-06-19 00:00:00 UTC
|
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
|
DCPH
|
https://www.nasdaq.com/articles/companies-like-deciphera-pharmaceuticals-nasdaq%3Adcph-are-in-a-position-to-invest-in-growth
|
nan
|
nan
|
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.
So should Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.
Does Deciphera Pharmaceuticals Have A Long Cash Runway?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at March 2021, Deciphera Pharmaceuticals had cash of US$502m and no debt. In the last year, its cash burn was US$232m. That means it had a cash runway of about 2.2 years as of March 2021. Notably, analysts forecast that Deciphera Pharmaceuticals will break even (at a free cash flow level) in about 3 years. That means unless the company reduces its cash burn quickly, it may well look to raise more cash. You can see how its cash balance has changed over time in the image below.
NasdaqGS:DCPH Debt to Equity History June 19th 2021
How Well Is Deciphera Pharmaceuticals Growing?
At first glance it's a bit worrying to see that Deciphera Pharmaceuticals actually boosted its cash burn by 15%, year on year. Given that its operating revenue increased 168% in that time, it seems the company has reason to think its expenditure is working well to drive growth. If revenue is maintained once spending on growth decreases, that could well pay off! It seems to be growing nicely. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.
Can Deciphera Pharmaceuticals Raise More Cash Easily?
We are certainly impressed with the progress Deciphera Pharmaceuticals has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
Deciphera Pharmaceuticals has a market capitalisation of US$2.2b and burnt through US$232m last year, which is 11% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.
How Risky Is Deciphera Pharmaceuticals' Cash Burn Situation?
As you can probably tell by now, we're not too worried about Deciphera Pharmaceuticals' cash burn. For example, we think its revenue growth suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. One real positive is that analysts are forecasting that the company will reach breakeven. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 2 warning signs for Deciphera Pharmaceuticals that potential shareholders should take into account before putting money into a stock.
Of course Deciphera Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
So should Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders be worried about its cash burn? NasdaqGS:DCPH Debt to Equity History June 19th 2021 How Well Is Deciphera Pharmaceuticals Growing? We are certainly impressed with the progress Deciphera Pharmaceuticals has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth.
|
So should Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders be worried about its cash burn? NasdaqGS:DCPH Debt to Equity History June 19th 2021 How Well Is Deciphera Pharmaceuticals Growing? How Risky Is Deciphera Pharmaceuticals' Cash Burn Situation?
|
So should Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders be worried about its cash burn? NasdaqGS:DCPH Debt to Equity History June 19th 2021 How Well Is Deciphera Pharmaceuticals Growing? We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.
|
So should Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders be worried about its cash burn? NasdaqGS:DCPH Debt to Equity History June 19th 2021 How Well Is Deciphera Pharmaceuticals Growing? In the last year, its cash burn was US$232m.
|
4819348d-c53f-468e-bccb-228482144a6d
|
715510.0
|
2021-05-18 00:00:00 UTC
|
Peek Under The Hood: ESGV Has 11% Upside
|
DCPH
|
https://www.nasdaq.com/articles/peek-under-the-hood%3A-esgv-has-11-upside-2021-05-18
|
nan
|
nan
|
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard ESG U.S. Stock ETF (Symbol: ESGV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $84.82 per unit.
With ESGV trading at a recent price near $76.62 per unit, that means that analysts see 10.71% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of ESGV's underlying holdings with notable upside to their analyst target prices are Insmed Inc (Symbol: INSM), Epizyme Inc. (Symbol: EPZM), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Although INSM has traded at a recent price of $26.04/share, the average analyst target is 107.92% higher at $54.14/share. Similarly, EPZM has 105.33% upside from the recent share price of $9.01 if the average analyst target price of $18.50/share is reached, and analysts on average are expecting DCPH to reach a target price of $70.86/share, which is 105.26% above the recent price of $34.52. Below is a twelve month price history chart comparing the stock performance of INSM, EPZM, and DCPH:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Vanguard ESG U.S. Stock ETF ESGV $76.62 $84.82 10.71%
Insmed Inc INSM $26.04 $54.14 107.92%
Epizyme Inc. EPZM $9.01 $18.50 105.33%
Deciphera Pharmaceuticals Inc DCPH $34.52 $70.86 105.26%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Vanguard ESG U.S. Stock ETF ESGV $76.62 $84.82 10.71% Insmed Inc INSM $26.04 $54.14 107.92% Epizyme Inc. EPZM $9.01 $18.50 105.33% Deciphera Pharmaceuticals Inc DCPH $34.52 $70.86 105.26% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of ESGV's underlying holdings with notable upside to their analyst target prices are Insmed Inc (Symbol: INSM), Epizyme Inc. (Symbol: EPZM), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Similarly, EPZM has 105.33% upside from the recent share price of $9.01 if the average analyst target price of $18.50/share is reached, and analysts on average are expecting DCPH to reach a target price of $70.86/share, which is 105.26% above the recent price of $34.52.
|
Three of ESGV's underlying holdings with notable upside to their analyst target prices are Insmed Inc (Symbol: INSM), Epizyme Inc. (Symbol: EPZM), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Similarly, EPZM has 105.33% upside from the recent share price of $9.01 if the average analyst target price of $18.50/share is reached, and analysts on average are expecting DCPH to reach a target price of $70.86/share, which is 105.26% above the recent price of $34.52. Vanguard ESG U.S. Stock ETF ESGV $76.62 $84.82 10.71% Insmed Inc INSM $26.04 $54.14 107.92% Epizyme Inc. EPZM $9.01 $18.50 105.33% Deciphera Pharmaceuticals Inc DCPH $34.52 $70.86 105.26% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now?
|
Similarly, EPZM has 105.33% upside from the recent share price of $9.01 if the average analyst target price of $18.50/share is reached, and analysts on average are expecting DCPH to reach a target price of $70.86/share, which is 105.26% above the recent price of $34.52. Three of ESGV's underlying holdings with notable upside to their analyst target prices are Insmed Inc (Symbol: INSM), Epizyme Inc. (Symbol: EPZM), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Below is a twelve month price history chart comparing the stock performance of INSM, EPZM, and DCPH: Below is a summary table of the current analyst target prices discussed above:
|
Vanguard ESG U.S. Stock ETF ESGV $76.62 $84.82 10.71% Insmed Inc INSM $26.04 $54.14 107.92% Epizyme Inc. EPZM $9.01 $18.50 105.33% Deciphera Pharmaceuticals Inc DCPH $34.52 $70.86 105.26% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of ESGV's underlying holdings with notable upside to their analyst target prices are Insmed Inc (Symbol: INSM), Epizyme Inc. (Symbol: EPZM), and Deciphera Pharmaceuticals Inc (Symbol: DCPH). Similarly, EPZM has 105.33% upside from the recent share price of $9.01 if the average analyst target price of $18.50/share is reached, and analysts on average are expecting DCPH to reach a target price of $70.86/share, which is 105.26% above the recent price of $34.52.
|
ad50def3-7c4f-4eb8-a503-685ace70605e
|
715511.0
|
2021-05-13 00:00:00 UTC
|
Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?
|
DCPH
|
https://www.nasdaq.com/articles/near-a-2-year-low-is-deciphera-pharmaceuticals-a-buy-2021-05-13
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company, which went public with an IPO in 2017, got a big bump late in 2019 on positive phase 3 trials for its lead drug, Qinlock (ripretinib).
The company's stock has fallen significantly since then, but this might provide a good buying opportunity for investors. Deciphera stock is down more than 39% this year and more than 37% over the past 12 months.
IMAGE SOURCE: GETTY IMAGES.
The company concentrates on oncology therapies that are known as kinase inhibitors. Enzymes called kinases help regulate cellular functions and the communication of cells with their environments. When they are dysregulated (go awry), kinases can lead to diseases, including cancer and various inflammatory or autoimmune diseases. Deciphera's therapies are designed to slow the growth of cancer cells by targeting the "switch-pocket mechanism" (where a kind of "on-off system" is located) to inhibit kinases.
Qinlock is just getting started
The company reported $42.1 million in revenue for 2020, up from $25 million in 2019. Qinlock (ripretinib) was responsible for most of that revenue, including $38 million in the U.S. and $1.5 million in international sales. The drug gained FDA approval last May to treat advanced gastrointestinal stromal tumors (GIST) as a fourth-line treatment (for patients who have already had three or more treatments for GIST). The cancer is fairly rare -- according to the American Cancer Society, about 4,000 to 6,000 people in the U.S. are diagnosed with it each year. Most GIST cases begin in the stomach or small intestine, though they can occur anywhere in the gastrointestinal tract.
The company built on those numbers in the first quarter of 2021, with Qinlock responsible for $19.9 million in revenue, up from $19.5 million in the prior quarter. Deciphera has the drug in trials to expand its usage as a second-line treatment for GIST. It also got approval in China as a fourth-line treatment for GIST and is awaiting approval as a fourth-line treatment for GIST from the European Medicines Agency, an OK the company said it expects by the fourth quarter.
But there's a lot riding on Qinlock
Deciphera is growing revenue, but it's still a long way from making a profit. In the first quarter, the company had a net loss of $61.2 million. It has $201.6 million in cash, which isn't a huge cushion. The company is very reliant on the continued growth in sales of Qinlock, the only drug it has so far managed to take through late-stage clinical trials. Deciphera will likely need to raise funds for research and development, and the drop in share price won't help that.
Deciphera is also developing three other cancer therapies. It is testing vimseltinib in a phase 1/2 study for tenosynovial giant cell tumor (TGCT), a rare group of cancers than can cause severe joint pain. These cancers are not benign and do not metastasize to other areas of the body, though their growth can cause damage to surrounding tissue. The usual course of treatment for TGCT is surgery, but the condition frequently recurs, showing a potential need for vimseltinib.
Rebastinib, another Deciphera therapy, is in various early studies as a standalone treatment for multiple solid tumors, as well as in combination with chemotherapy to treat solid tumors.
The other drug in the company's pipeline, DCC-3116, is planned to enter phase 1 trials in the second quarter. It will be studied both as a single agent and combined with trametinib (a mitogen-activated protein kinase) to treat metastatic tumors with a mutant RAS or RAF gene that commonly shows up in melanomas, as well as in pancreatic, colorectal, lung, bile duct, and thyroid cancers.
Playing the long game
Deciphera is successfully making the jump from a clinical-stage biopharmaceutical company to one that is earning revenue. Though it is hard to see Qinlock as a blockbuster drug, because GIST is so rare, Quinlock does have the potential to help fund the rest of the company's pipeline -- and a blockbuster drug could come out of that mix. That pipeline and the company's focus on rare cancers means it's frequently mentioned as a potential takeover target, which could also be very rewarding for investors.
I have concerns about the biotech stock's cash position, and this is certainly a stock that carries a bit of risk. However, at its current price near a two-year low, and coming off improving numbers in the first quarter, I can see this stock rewarding investors this year. The recent approval of Quinlock in China and its pending approval in Europe mean the company should easily grow revenue this year.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 24, 2021
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. Deciphera's therapies are designed to slow the growth of cancer cells by targeting the "switch-pocket mechanism" (where a kind of "on-off system" is located) to inhibit kinases. It is testing vimseltinib in a phase 1/2 study for tenosynovial giant cell tumor (TGCT), a rare group of cancers than can cause severe joint pain.
|
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company, which went public with an IPO in 2017, got a big bump late in 2019 on positive phase 3 trials for its lead drug, Qinlock (ripretinib). It also got approval in China as a fourth-line treatment for GIST and is awaiting approval as a fourth-line treatment for GIST from the European Medicines Agency, an OK the company said it expects by the fourth quarter.
|
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company built on those numbers in the first quarter of 2021, with Qinlock responsible for $19.9 million in revenue, up from $19.5 million in the prior quarter. It also got approval in China as a fourth-line treatment for GIST and is awaiting approval as a fourth-line treatment for GIST from the European Medicines Agency, an OK the company said it expects by the fourth quarter.
|
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The drug gained FDA approval last May to treat advanced gastrointestinal stromal tumors (GIST) as a fourth-line treatment (for patients who have already had three or more treatments for GIST). * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them!
|
22cd3bd3-9ee7-443a-828f-a8b41702232c
|
715512.0
|
2021-02-14 00:00:00 UTC
|
Analysts Are Betting On Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) With A Big Upgrade This Week
|
DCPH
|
https://www.nasdaq.com/articles/analysts-are-betting-on-deciphera-pharmaceuticals-inc.-nasdaq%3Adcph-with-a-big-upgrade-this
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.
After the upgrade, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$121m in 2021. If met, this would reflect a major 188% improvement in sales compared to the last 12 months. Losses are expected to be contained, narrowing 11% from last year to US$4.23. However, before this estimates update, the consensus had been expecting revenues of US$102m and US$4.38 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
NasdaqGS:DCPH Earnings and Revenue Growth February 14th 2021
Despite these upgrades, the analysts have not made any major changes to their price target of US$73.27, implying that their latest estimates don't have a long term impact on what they think the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Deciphera Pharmaceuticals, with the most bullish analyst valuing it at US$84.00 and the most bearish at US$61.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Deciphera Pharmaceuticals' past performance and to peers in the same industry. It's clear from the latest estimates that Deciphera Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 188% revenue growth noticeably faster than its historical growth of 68% over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 20% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Deciphera Pharmaceuticals is expected to grow much faster than its industry.
The Bottom Line
The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Deciphera Pharmaceuticals is moving incrementally towards profitability. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Deciphera Pharmaceuticals.
Better yet, Deciphera Pharmaceuticals is expected to break-even soon - within the next few years - according to analyst forecasts, which would be a momentous event for shareholders. For more information, you can click through to our free platform to learn more about these forecasts.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. NasdaqGS:DCPH Earnings and Revenue Growth February 14th 2021 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.27, implying that their latest estimates don't have a long term impact on what they think the stock is worth. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. NasdaqGS:DCPH Earnings and Revenue Growth February 14th 2021 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.27, implying that their latest estimates don't have a long term impact on what they think the stock is worth. It's clear from the latest estimates that Deciphera Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 188% revenue growth noticeably faster than its historical growth of 68% over the past year.
|
NasdaqGS:DCPH Earnings and Revenue Growth February 14th 2021 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.27, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. NasdaqGS:DCPH Earnings and Revenue Growth February 14th 2021 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.27, implying that their latest estimates don't have a long term impact on what they think the stock is worth. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.
|
28c15d06-dd59-4af1-bd10-e6522dcbac27
|
715513.0
|
2021-02-11 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-nasdaq%3Adcph-reported-earnings-last-week-and-analysts-are
|
nan
|
nan
|
Last week, you might have seen that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its full-year result to the market. The early response was not positive, with shares down 3.7% to US$49.73 in the past week. The business exceeded revenue expectations with sales of US$42m coming in 2.4% ahead of forecasts. Statutory losses were US$4.78 a share, in line with what the analysts predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
NasdaqGS:DCPH Earnings and Revenue Growth February 12th 2021
After the latest results, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$113.4m in 2021. If met, this would reflect a substantial 170% improvement in sales compared to the last 12 months. Losses are supposed to decline, shrinking 12% from last year to US$4.23. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$98.6m and losses of US$4.45 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.
There was no major change to the consensus price target of US$73.27, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Deciphera Pharmaceuticals analyst has a price target of US$91.00 per share, while the most pessimistic values it at US$61.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Deciphera Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 170% revenue growth noticeably faster than its historical growth of 68% over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 21% next year. Factoring in the forecast acceleration in revenue, it's pretty clear that Deciphera Pharmaceuticals is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Deciphera Pharmaceuticals going out to 2025, and you can see them free on our platform here.
And what about risks? Every company has them, and we've spotted 2 warning signs for Deciphera Pharmaceuticals you should know about.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Last week, you might have seen that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its full-year result to the market. NasdaqGS:DCPH Earnings and Revenue Growth February 12th 2021 After the latest results, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$113.4m in 2021. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business.
|
NasdaqGS:DCPH Earnings and Revenue Growth February 12th 2021 After the latest results, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$113.4m in 2021. Last week, you might have seen that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its full-year result to the market. There was no major change to the consensus price target of US$73.27, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook.
|
NasdaqGS:DCPH Earnings and Revenue Growth February 12th 2021 After the latest results, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$113.4m in 2021. Last week, you might have seen that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its full-year result to the market. There was no major change to the consensus price target of US$73.27, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook.
|
Last week, you might have seen that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its full-year result to the market. NasdaqGS:DCPH Earnings and Revenue Growth February 12th 2021 After the latest results, the ten analysts covering Deciphera Pharmaceuticals are now predicting revenues of US$113.4m in 2021. There was no major change to the consensus price target of US$73.27, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook.
|
b69ced9b-d6d6-4bf6-a635-e775afdeb81b
|
715514.0
|
2021-02-09 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-q4-2020-earnings-call-transcript-2021-02-10
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Q4 2020 Earnings Call
Feb 9, 2021, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone, and welcome to Deciphera Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call. [Operator Instructions]
At this time, I'd like to turn the call over to Jen Robinson, Vice President, Investor Relations. Jen?
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 20, 2020
Jen Robinson -- Vice President, Investor Relations
Welcome, and thank you for joining us today to discuss Deciphera's fourth quarter and full year 2020 financial results. I'm Jen Robinson, Vice President, Investor Relations at Deciphera. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include our expectations for our preclinical and clinical programs, our commercialization of QINLOCK and 2021 guidance.
Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent annual report on Form 10-K as well as our other SEC documents. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steven L. Hoerter -- President and Chief Executive Officer
Thank you, Jen. Good afternoon, everyone, and thank you for joining us on today's call. The fourth quarter caps a landmark year for Deciphera, in which we launched our first medicine, QINLOCK, reported encouraging data from the product candidates in our pipeline and filed the IND for a new product candidate entering the clinic this year. This progress would have been impressive in any year, but I'm particularly proud of our team for accomplishing all this in the midst of the ongoing COVID-19 pandemic. The team here at Deciphera adapted quickly and as a result of their hard work, dedication and patient focus, we achieved the ambitious goals we outlined at the beginning of 2020. This work positions us well for 2021 as we seek to expand the opportunity with QINLOCK and set the stage for our next wave of growth.
For QINLOCK, we have three specific priorities in 2021. First, we are continuing to execute on the successful launch of QINLOCK for the treatment of patients with fourth-line gastrointestinal stromal tumors or GIST in the United States. QINLOCK has the potential to change the treatment of advanced GIST, and we have made great progress in delivering this important new medicine to eligible patients in the fourth-line setting. Dan Martin, our Chief Commercial Officer, will share the commercial highlights from the fourth quarter in a few minutes.
Second, we are committed to expanding the geographic reach for QINLOCK, and we are rapidly advancing our efforts on this front. This past summer, we received regulatory approval for QINLOCK in Canada and Australia and selected distribution partners who are responsible for commercializing QINLOCK in these territories. In China, our partner, Zai Lab, filed the NDA for QINLOCK last summer and have guided to a potential approval in the first half of this year.
And finally, we received validation from the European Medicines Agency, or EMA, for the marketing authorization application for QINLOCK in fourth-line GIST, setting us up for a potential EMA approval in the second half of 2021. As we continue our efforts to bring QINLOCK to patients in Europe and around the world, we are very excited to announce today the appointment of Margarida Duarte, Senior Vice President, Head of International. Margarida joins us from Alnylam Pharmaceuticals, where she most recently was Vice President of Commercial, for Canada, Europe, Middle East and Africa.
She was responsible for a number of important successful new product launches at Alnylam and brings to Deciphera over 15 years of experience in the global pharmaceutical industry with expertise in commercializing innovative products in the EU and internationally. I know that her deep commercial and operational expertise will be an incredible asset to Deciphera. And I look forward to working with Margarida as we continue our mission to deliver important new medicines to patients. The third focus for QINLOCK is expanding into earlier line of therapy in GIST. In particular, we see significant opportunity for QINLOCK to offer benefit to patients in the larger second line GIST population.
In the fourth quarter, we completed enrollment in our pivotal Phase III INTRIGUE study in the second line and are on track for a top line data readout in the second half of this year. Behind QINLOCK, we have a robust maturing pipeline of fully owned programs. During the course of this year, we expect the potential of this pipeline to come into sharper focus. On the call today, Matt Sherman, our Chief Medical Officer, will highlight recent progress from the bemcentinib and rebastinib programs which have both demonstrated strong initial clinical data in their respective potential indications. We expect to share additional data for both programs throughout the year as well as updates on potential pivotal development plans.
Matt will also provide more details around the newest addition to our clinical pipeline, DCC-3116, including the Phase I study design and the preclinical data package that supports the potential for 3116. As a novel potential first-in-class ULK kinase inhibitor, we believe DCC-3116 has the potential to benefit the large group of patients with mutant RAS and RAS cancers.
I'll now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss the results for the second full quarter of QINLOCK's commercial sales. Dan?
Daniel C. Martin -- Chief Commercial Officer
Thank you, Steve. Good afternoon. Today, I'm pleased to report the results of our second full quarter of QINLOCK sales and to provide some color regarding our expectations as we look ahead. We continue to be extremely pleased with the QINLOCK launch and with our rapid penetration of the fourth-line opportunity. In Q4, we achieved $19.5 million in total net product revenue including $18.5 million in the U.S., which equates to 26% quarter-over-quarter growth and brings total launch-to-date U.S. net product revenue to $38 million. Prior to the U.S. launch of QINLOCK, we identified two primary goals.
The first was to rapidly establish QINLOCK as the clear standard of care in fourth-line GIST. The second was to leverage our approved indication to build a strong foundation for a potential second line launch by establishing a broad and diverse prescriber base and by achieving positive product perceptions among QINLOCK users. Based on our strong launch results and multiple key performance metrics, we believe we have made tremendous progress toward these goals since launch. Our recent market research indicates that during Q4, our sales and marketing teams achieved the highest prescriber reach and product share of voice among all companies in the GIST market.
In addition, this research showed that despite the challenges of the pandemic, we have rapidly increased awareness of QINLOCK over the last two quarters. In fact, among physicians treating late-line GIST patients, awareness of QINLOCK was similar to that of established products that have been approved for the treatment of GIST for many years. Our commercialization efforts resulted in rapid uptake by a broad and diverse prescriber base. We estimate that from launch through Q4, over 350 prescribers from more than 300 institutions have prescribed QINLOCK. During Q4, as expected, slightly more than half of both new and total prescribers came from the community setting.
Conversely, slightly more than half of total patients treated during the quarter came from the academic setting, which highlights the fact that the number of patients per physician is higher in the academic setting, consistent with our prelaunch understanding. To date, nearly all of our highest priority accounts and physicians, irrespective of practice setting, have either prescribed QINLOCK or have identified patients for future QINLOCK treatment when those patients progress to the fourth-line. And importantly, our merge research indicates that prescribers have had very favorable experiences with QINLOCK, with users citing both positive product perceptions and high fourth-line patient share.
Additionally, our market access team continued to deliver broad patient access to QINLOCK in Q4. Payer coverage for QINLOCK has remained very strong with policies aligned to our FDA label. As expected, the percentage of patients that received free drug under our Patient Assistance Program, or PAP, was slightly higher in Q4 due to the increased affordability challenges that commonly impact Medicare patients late in the year, but fell within our 20% to 30% estimated range. As previously communicated, our PAP percentage in Q1 may be impacted by the Medicare Part D benefit reset that occurs at the beginning of the year, which requires patients to pay for their deductible and their portion of the coverage gap before reaching the catastrophic coverage tier.
We continue to expect our PAP percentage to be in the 20% to 30% range on average over the course of the year. Looking forward, we anticipate that our next phase of significant growth will come with our expansion into second-line GIST, pending positive data from Intrigue and subsequent approval. Until then, we anticipate that future quarter-over-quarter growth will moderate and be determined largely by how patient persistency develops in the real-world setting. In the near term, our focus will be on working with existing academic and community prescribers to optimize identification of appropriate patients for QINLOCK, while continuing our efforts to gradually expand our prescriber footprint.
Finally, as we look ahead to the entry readout later this year and to a potential second-line approval, we remain extremely optimistic about the potential for QINLOCK to continue to transform the treatment of GIST. We believe high awareness of QINLOCK and positive product perceptions, coupled with a broad prescriber base across both academic and community settings, has established a strong foundation for a successful launch in the second-line setting pending approval.
Feedback from just GIST treaters, including just thought leaders, continues to give us confidence that QINLOCK has the potential to establish a new standard of care in second-line GIST. Given the larger patient population in second-line GIST and what we expect to be increased persistency, a second-line approval represents a truly transformative opportunity for QINLOCK and most importantly, for patients with GIST.
I will now turn the call over to Matt to discuss the progress of our clinical programs. Matt?
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Thank you, Dan. We continue to make great strides across our growing pipeline of novel switch control kinase inhibitors. Let me start with QINLOCK. At the end of last year, we completed enrollment in our Phase III INTRIGUE study investigating QINLOCK in patients with second-line GIST and remain confident in the likelihood of success in this pivotal study. The preclinical profile of QINLOCK demonstrates that as broadly inhibits kit mutations that drive the disease across all lines of therapy. In addition, we have a strong clinical data package, not only with the exceptional results from the Phase III in FICA study in fourth-line plus patients, but also the compelling results in the Phase I study, showing that clinical efficacy continues to improve in patients with second-line through fourth line plus GIST.
We believe that QINLOCK may provide significant benefit to just patients in the second-line setting and look forward to reporting top line data from the INTRIGUE study, which we project to read out in the second half of this year. Turning to vimseltinib, our potent selective inhibitor of CSF1R in development for the treatment of tenosynovial giant cell tumor, or TGCT. Patients with TGCT experienced significant disease burden and commonly report multiple symptoms, including pain, limited function, swelling and stiffness. The only approved systemic therapy for patients with TGCT is pexidartinib, which has a boxed warning and is subject to a REMS program due to hepatotoxicity, an adverse event that was thought to be an off-target effect.
We believe that vimseltinib has the potential to be best-in-class and to fulfill the unmet medical need for an effective and well tolerated treatment for patients with TGCT. At the Connective Tissue Oncology Society meeting last year, we presented encouraging preliminary results from the ongoing Phase I/II study of vimseltinib in patients with TGCT. The trial is progressing well and we look forward to sharing additional data updates from the study and are planning to finalize and unveil our pivotal development plans later this year. Turning to rebastinib, our potentially first-in-class potent and selective inhibitor of the TIE2 kinase.
We are very encouraged by the initial clinical data we presented last year from both the endometrial and platinum-resistant ovarian cancer cohorts in our Phase Ib/II study in combination with paclitaxel. We have reached full enrollments for these cohorts and are continuing to enroll patients into Stage I of the carcinosarcoma and inflammatory breast cancer cohorts. In the other Phase Ib/II study in combination with carboplatin, enrollment in Part two stage I of the platinum-sensitive ovarian cancer cohort has been completed, and efficacy and safety evaluation is ongoing. For endometrial cancer, there are limited treatment options after paclitaxel and carboplatinum in the first-line setting and pembrolizumab and lenvatinib in the second-line setting.
Beyond second line, treatment is very heterogeneous. In generally office patients, a progression-free survival benefit of only three to four months with objective response rates of just 10% to 20%. At ASCO last year, we presented encouraging data in 21 patients from the Phase Ib/II study, where we saw a confirmed and unconfirmed response rate of 39% and the clinical benefit rate at eight weeks of 72%. Although the patients enrolled in this study had received prior paclitaxel therapy and nearly 60% have received more than three lines of prior treatment. For the platinum-resistant ovarian cancer cohort, we presented data at ESMO last year.
Similar to endometrial cancer, treatment of later line platinum-resistant disease is very heterogeneous and generally office patients with progression-free survival benefit for three to four months with objective response rates of 15% to 25%. In our study, the combination of rebastinib with paclitaxel had a confirmed and unconfirmed response rate of 38% and the clinical benefit rate at eight weeks of 88%. Nearly 80% of these patients had received four or more prior anti-cancer regimens. We're encouraged by both the safety and efficacy profile of the combination in this heavily pretreated population. Our focus with this program is to continue driving forward as quickly and prudently as we can and assuming continued positive data, we expect to finalize a potential pivotal development plan for rebastinib in combination with paclitaxel in the second half of this year.
With enrollment completed in the endometrial and platinum-resistant ovarian cancer cohorts, we are looking forward to providing data updates in these indications later this year. Finally, we continue to be extremely excited about DCC-3116, our potential first-in-class ULK kinase inhibitor designed to treat cancer patients in combination with RAS and MAP kinase signaling pathway inhibition, particularly in patients with RAS or BRAF mutations. I am pleased to announce that we have received FDA clearance for the DCC-3116 IND, and we expect to begin our first-in-human study in the second quarter of this year. The mechanism of action, the DCC-3116 combined with the emerging preclinical data supports broad development in combination with MAP kinase inhibitors.
The ULK complex is the initiating factor in the autophagy pathway, a key survival pathway. Mutant RAS and RAF cancers are reported to have high basal levels of autophagy, which these cancers use to maintain nutrient supply and regulate cancer cell metabolism and survival. Cellular studies in mutant RAS and RAF cancers have also demonstrated that treatment with MAP kinase pathway inhibitors can also induce autophagy as a compensatory survival mechanism. As we have previously shared, the preclinical data supports this approach showing the synergistic anti proliferative and anti-tumor activity of DCC-3116 in combination with the inhibition of RAS, MAP kinase signaling in mutant RAS and RAF cancers.
This provides us with a number of development opportunities for DCC-3116 in combination with a RAS, MAP kinase signaling pathway inhibitor such as MEK inhibitors, ERK inhibitors or KRAS G12C inhibitors that could potentially establish a new treatment paradigm in RAS and RAF mutant cancers. More than 30% of all human cancers are driven by mutations of RAS and RAF genes, yet these cancers continue to be underserved. We are excited to initiate our Phase I study in the second quarter of this year, which will evaluate 3116 alone and in combination with trametinib approved MEK inhibitor in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.
After the safety and tolerability of 3116 as a single agent is determined, the first cohort of the combination dose escalation will open for enrollment. The dose expansion phase will be initiated after the recommended Phase II dose of the combination is determined and will include cohorts for patients with pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer and melanoma harboring mutation and the RAS and RAF pathway. We are strongly encouraged by the progress across each of the programs in our pipeline and believe 2021 will be an important year in the development of these assets as we look to making a meaningful difference in the treatment of patients with cancer.
I will now turn the call over to Tucker Kelly, our Chief Financial Officer, to review the financial results. Tucker?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Thanks, Matt. I'd like to review the highlights for our fourth quarter and full year 2020 financial results. Total revenue for the fourth quarter was $19.5 million, which includes $18.5 million in U.S. net product sales. Consistent with the third quarter, the gross to net adjustment in the fourth quarter was slightly lower than our annualized estimate of 15%. Total revenue for the full year was $42.1 million, comprised of net product sales of $39.5 million, including $38 million in U.S. net product sales as well as approximately $2.6 million in collaboration revenue.
Cost of sales for the three and 12 months ending December 31, 2020, was immaterial, as the majority of the manufacturing costs related to QINLOCK sales were incurred prior to FDA approval and thus were reported as R&D expands. Until the initial prolonged inventory is depleted and additional inventory is manufactured and sold, cost of sales will not be significant, and we expect the cost of sales will remain immaterial in 2021. Total operating expenses were $82.5 million in the fourth quarter of 2020 compared to total operating expenses of $70.4 million in the same period in 2019. For the full year 2020, total operating expenses were $313.3 million compared to total operating expenses of $225.7 million in 2019.
Research and development expenses in the fourth quarter were $52.3 million compared to $46.6 million in the same period in 2019. For the full year 2020, R&D expenses were $199 million compared to $157.6 million in 2019. Selling, general and administrative expenses in the fourth quarter were $30.1 million compared to $23.7 million in the same period in 2019. And for the full year 2020, SG&A expenses were $114.1 million compared with $68.1 million in 2019.
We continue to expect that our operating expenses will increase in 2021 as compared to 2020 as we invest in the development of our clinical pipeline, continue to execute on the commercial launch of QINLOCK in the U.S. and prepare for a potential commercial launch in Europe. We ended the fourth quarter in a strong financial position and remained well capitalized with cash, cash equivalents and marketable securities of approximately $561 million, which we expect to be sufficient to fund our operations into the second half of 2022.
And with that, I'll now turn the call back over to Steve.
Steven L. Hoerter -- President and Chief Executive Officer
Thank you, Tucker. I'm extremely proud of what our team accomplished in 2020, and we expect 2021 to be a year with significant milestones. We look forward to building upon the momentum of the QINLOCK launch by solidifying its position among GIST prescribers and patients in the U.S. while also taking the regulatory and commercial steps necessary to bring hemlock to patients with advanced GIST around the world. On the clinical development front, we expect the readout of the pivotal Phase III INTRIGUE study to potentially expand QINLOCK into the larger second-line GIST population.
And we expect significant clinical updates on two programs that could support advancement into registration enabling studies. Finally, we look forward to initiating the first-in-human study for a potential first-in-class product candidate addressing one of the largest unmet needs in oncology. We believe 2021 will be another exciting year in our company's journey to bring important new medicines to patients.
Operator, I'd now like to open the call for Q&A.
Questions and Answers:
Operator
Thank you. [Operator Instructions] Our first question will come from the line of Jessica Fye from JPMorgan. You may begin.
Jessica Fye -- JPMorgan -- Analyst
Hi guys, good afternoon. Thanks so much for taking my question. I was hoping you could elaborate a little bit on the comment you made about future quarter-to-quarter growth moderating and being determined by patient persistency. Is that moderating growth you alluded to the result of substantially penetrating the incident fourth-line GIST opportunity? Where do you think you are in terms of penetration of this setting?
Steven L. Hoerter -- President and Chief Executive Officer
Jess, it's Steve. Just before I turn it over to Dan, who can provide some color. I think as we said in the prepared remarks, we're really pleased with how the launch has gone so far and that we've really rapidly established QINLOCK as the standard of care in the fourth-line setting. And as Dan noted in his prepared remarks, we do expect growth to moderate going forward. But Dan, would you like to provide some more color on that?
Daniel C. Martin -- Chief Commercial Officer
Sure. Absolutely. Thanks Jess, for the questions. Yes, a couple of questions there. So if I don't quite hit on everything, just let me know. So when we talk about the phrase growth will moderate, like Steve said, we've just been extremely pleased with the performance of the team, the ability to rapidly penetrate the fourth-line patient population despite the challenges of the pandemic. And as Steve mentioned, it is clear that we have established QINLOCK as the clear standard of care in fourth line just across both academic and community settings.
And therefore, while we achieved 26% quarter-over-quarter in Q4, we would expect quarter-over-quarter growth to slow. And the point about, well, to slow until we achieve the second line expansion pending approval. And the point that we made about the persistency is that we're about seven plus months, I guess, two quarters into launch. And so as we've mentioned previously, on previous calls, that data is still maturing. So we'll be bringing -- we plan to bring forward some additional color on persistency as we move forward. But that will be really important to see how that develops in the real-world setting.
A number -- any number of things could impact how persistency develops in the real-world setting, including efficacy, tolerability, patient mix is important, both by line of therapy and by performance status. And then there's also non clinical considerations such as the cumulative, emotional, financial and administrative burdens on the patient during their cancer journey. So these are the things that we'll look to see how they play out and impact persistency over time in the real-world setting.
Jessica Fye -- JPMorgan -- Analyst
Got it. Thanks for that. And maybe just one more. If you could elaborate on the -- you have helpful data about sort of the number of prescribers and the mix there. I'm curious how many prescribers have written QINLOCK to more than one patient?
Daniel C. Martin -- Chief Commercial Officer
Yes. It's a good question. I don't have that figure off the top of my head. There's certainly a good portion that have written for more than one patient, but there is a significant number of our prescribers who have only written for one because they've only had one. Keep in mind that, as we've described, these patients are rare, in general, late-line GIST patients and particularly outside of the academic setting they're extremely rare and very sort of diffuse and thinly dispersed. So a significant portion of our prescriber base would have only prescribed one because that's how many patients they've had so far.
Jessica Fye -- JPMorgan -- Analyst
Got it. Thank you.
Operator
Thank you. Our next question will come from the line of Chris Raymond from Piper Sandler. Your line is open.
Allison Bratzel -- Piper Sandler -- Analyst
Hi. This is Allison Bratzel on for Chris this afternoon. Thanks for taking the question. So one, just on earlier-line use. I guess, just some of our just survey work has indicated that, that most cannot use is on label in fourth-line plus patients, but there is some detectable use in earlier-line patients, particularly among docs in the academic setting.
So just wondering if you have any color on, that dynamic now that, you're a couple of quarters into launch. So just -- could you talk to that and if some earlier line use could be contributing to growth, throughout 2021?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Thanks for the question, Allison. I'll ask Dan to take that. Dan?
Daniel C. Martin -- Chief Commercial Officer
Yeah. Thank you, Allison. It's a good question. And we did see the survey that you guys did. And generally speaking, we thought it was relatively, consistent thematically with what we've said before and what we saw in Q4. We've said before that, while it's challenging to assess with certainty, the use by line of therapy, when we sort of triangulate with the available data sources we have. We feel strongly that the significant majority of use that we've seen is in, the fourth-line setting consistent with label.
And there has been some earlier line use, but again, significant majority in the fourth-line. And we've said before that, it's tough to know, what the future holds. What we do know is that, there's, a lot of things that drive, use in the real world setting, of course. There's availability of data. We can't promote, of course, to any of that earlier line data. I probably should have started wit my typical disclaimer, that we always -- all of our promotion, all of our commercial efforts are targeted toward our labeled indication.
And so, what's in the label, what's in payer policies, what's in guidelines. And to this point, most of all of that is aligned pretty consistently to our approved indications. So, hard to say, but that's why we've provided the color we have around significantly penetrating the fourth-line opportunity rapidly. And that we think, as a result of that, growth is likely to moderate quarter-over-quarter moving forward, until we reach the second-line setting pending approval.
Allison Bratzel -- Piper Sandler -- Analyst
That makes sense. And maybe just one more, a follow-up from -- I think last quarter, you had indicated that, there might be a little bit of the BID dosing, especially based on the data you had last year, at ESMO, showing inter patient dose escalation is supportive of treatment past progression.
So just hoping, you could talk to any updates on those trends? And maybe where or how you're thinking about that strategically in terms of getting that data, perhaps added to the label or NCCN guidelines? And how that plays into the longer-term QINLOCK GIST strategy? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
So maybe, what I'll do first, Allison, to just comment on, the BID data and then, ask Dan to talk a little bit about, what we actually see in the marketplace. And what sort of things would need to happen for that sort of use to be more common, despite the fact that, of course we can't promote to it.
So, as you referenced at ESMO last year, we reported data from the Phase I study. And in the Phase I study, physicians had the opportunity to dose escalate patients to 150 BID upon progression. And as we shared at ESMO last year, the data that we see in PFS2, so the second Progression-Free Survival Interval is really quite compelling relative to the PFS1 the patients experienced on the study.
In the INVICTUS study, so the study that served as the basis for our approval, a similar approach was allowed where physicians were able to dose escalate their patients to 150 BID. And we're still analyzing those data, but we anticipate being able to present those in the context of a medical meeting at some point in the future.
So we think this is a meaningful finding. We don't view either, set of data as being label enabling. And maybe, Dan, do you want to comment just on what we're seeing commercially. And what sort of factors would play into the ability of physicians to use this, despite the fact that we can't promote to it.
Daniel C. Martin -- Chief Commercial Officer
Yeah, absolutely, thank you. Steve. It's a good question. And we've -- we continue to see -- or I should say, we continue to see in Q4, what we've spoken to before, which is we have seen some BID dosing, but it's been a small portion of the overall use, a large majority of our uses of the 150 QD labeled indication.
And the same drivers really impact a off-labeled dose that drive an off-labeled data use. Number one, we don't promote the BID data. We're limited, of course, to promoting our labeled dose, and then, guidelines and payer policies, which, to this point, continue to be aligned with our labeled dose. So it's not a surprise to us, given those considerations that the large majority of use is consistent with the 150 QD.
Allison Bratzel -- Piper Sandler -- Analyst
Got it. Thank you.
Operator
And our next question will come from Michael Schmidt from Guggenheim. Your line is open.
Michael Schmidt -- Guggenheim -- Analyst
Hey, guys. Good afternoon. Thanks for taking my questions. I had a pipeline question about DCC-3116. I may have missed it, but could you remind us what the patient population will be in the initial Phase I study? Is it all commerce? Or will they be already selected for certain RAS, RAF mutations?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Hi, Michael, it's Steve. Thanks for the question. Matt, would you like to take that?
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Yes. Hi, thanks for the question. Yes. So in the first-in-human study for DCC-3116, which is our novel first-in-class gene inhibitor. The survey was conducted as a two-part study. So the first part will be a dose escalation part of this study. And that will be in all-comer solid tumors, but they will be selected for a mutation in the RAS, BRAF pathway. And that will be followed by the second part of the study. We'll be selecting homogeneous patients with specific tumors, pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer and melanoma. And those patients will also be RAS or BRAF mutation positive.
Michael Schmidt -- Guggenheim -- Analyst
Understood. And then mechanistically, is this a drug that might have single agent activity? Or should we really think about this as a combination drug with other RAS pathway inhibitors?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. Michael.
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Yeah. So we believe that this drug would be best developed in combination with other signaling pathway inhibitors and initially targeting the RAS, MAP kinase pathway.
Michael Schmidt -- Guggenheim -- Analyst
Okay. That makes sense. Thanks so much and congrats on progress.
Operator
Thank you. Our next question will come from the line of Eun Yang from Jefferies. You may begin.
Eun Yang -- Jefferies -- Analyst
Thank you. So, regarding ripretinib, aside from GIST, you have orphan drug designations for other solid tumors like GBM and astrocytoma. And in Phase I expansion, cohort you have or have you been enrolling multiple tumor types. So can you give us an update on other solid tumors aside from GIST?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah, Eun, it's Steve. Thanks for the question. And your question goes back to the Phase I study. And we provided an update on this on the Q3 call, where we talked about the variety of expansion cohorts and what the status of those were. And so at that time, as we discussed, we had completed enrollment and a number of the cohorts, the melanoma cohort at that stage was still enrolling, and that's data that we will continue to evaluate. But our focus going forward continues to be on exploring the potential for ripretinib or QINLOCK to benefit patients in GIST.
Eun Yang -- Jefferies -- Analyst
Okay. So I guess, so we are not going to be expecting data from the non-GIST tumors anytime soon, correct?
Steven L. Hoerter -- President and Chief Executive Officer
That's right, Eun. Exactly right.
Eun Yang -- Jefferies -- Analyst
Okay.
Steven L. Hoerter -- President and Chief Executive Officer
Our focus is on GIST. We'll continue to follow the data that we've collected from the Phase I expansion cohort, specifically in melanoma and we'll update folks on when the time is right. But the focus for development going forward is in GIST.
Eun Yang -- Jefferies -- Analyst
Thank you. And then in terms of a second-line GIST, so certain is going to go generic in the US and EU this year and next. So, is there an example or examples that you can share with us where generic drugs did not impact new superior drug in cancer settings?
Steven L. Hoerter -- President and Chief Executive Officer
Yes. Thanks for the question. So it's Steve. I'll take that. And then, Dan, if you have any additional color, you'd like to add, please feel free to jump in. So as you know, the INTRIGUE study is a head-to-head study. So it's QINLOCK versus sunitinib. And as we've discussed previously, we would expect that sunitinib in that study would demonstrate a PFS in the range of 5.5 to six months. And we believe that you would need to demonstrate a two to three-month improvement over that for the outcome to be clinically meaningful.
So in other words, QINLOCK would need to demonstrate a two to three-month improvement over sunitinib for that to be viewed as clinically meaningful. Given that this would be a head-to-head study versus the current standard of care, we don't believe that the fact that sunitinib could be going generic, it would have any meaningful impact on physician's willingness and interest in using a better treatment option for their patients with GIST. Dan, you have anything else that you'd add to that?
Daniel C. Martin -- Chief Commercial Officer
I would just add that when we think about the different stakeholders, from physicians, as Steve mentioned, to payers and patients. Like Steve said, for physicians, but I would also add for payers, historically speaking, the gold standard has been in assessing different product alternatives has been head-to-head comparison in a large randomized Phase III trial. And so if INTRIGUE is positive, which to our knowledge would be the first and only positive Phase III head-to-head study in GIST. We believe that puts us in a really good position.
And then from a patient perspective, we will continue to do what we always do, which is everything we're permitted to do with -- in line with relevant laws and regulations to prevent costs from being a barrier patient access to QINLOCK. So overall, we're very confident that irrespective of generic suiting that pending INTRIGUE, QINLOCK really has a great opportunity to again, transform the standard of care.
Eun Yang -- Jefferies -- Analyst
Thank you. And then I have a last question, a quick question to Tucker. So do you anticipate approval in China? Would you actually book that approval milestone at once since -- first of the second quarter of this year for Zai?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Sure. Yes. Thanks for the question. So I think what we've heard from Zai and their public disclosures, they are expecting a potential regulatory decision in the first half. We have not provided any breakdown of the additional clinical or pre-approval milestones that we have under the collaboration agreement. But in the past, certainly, when we have had milestones that have hit, we typically booked those in the quarter in which they were achieved.
Eun Yang -- Jefferies -- Analyst
Thank you.
Operator
Our next question will come from the line of Andrew Berens from SVB Leerink. You may begin.
Andrew Berens -- SVB Leerink -- Analyst
Hi. Thanks. Congrats on the quarter. I also have a question on your comments regarding the persistency going forward. Since there's nothing approved in the fifth line, are you seeing patients come off of therapy because they're going on something else? Or are they dying? Or are patients staying on therapy beyond progression? Then I have a follow-up on the old inhibitor.
Steven L. Hoerter -- President and Chief Executive Officer
Yes. Thanks, Andy. Dan, do you want to take that?
Daniel C. Martin -- Chief Commercial Officer
Sure. Thanks, Andy. So as we said recently, it's just a little early to be able to provide color on what we're seeing with persistency. I think we've been, what just over two months -- sorry, two quarters now. And so the data that we have to evaluate that is still maturing. And we've said, we understand how important that is to everyone's models and certainly intend to bring some -- bring forward some additional color when we have it.
So as you know, I've started talking a bit more in terms of persistency of late as opposed to average duration of therapy because persistency, as you know, is the percentage of patients that remain on therapy over time. And with any product, some patients come off early and some patients stay on for an extended period. So we'll just have to see how all that shakes out in the real-world setting, given the factors I mentioned before, including mix by line of therapy and patient performance status and some non-clinical considerations, all of that. So more to come as we feel like we -- that data is sort of sufficiently ready for prime time.
Andrew Berens -- SVB Leerink -- Analyst
Okay. But aside from the BID option, are some patients staying on longer even after they progress?
Daniel C. Martin -- Chief Commercial Officer
That's hard to know because what we see from our side is just whether or not the patient is getting the product. What we don't see from our side when there is a physician determination of progression. So that's just really hard for me to answer. And like I said, we'll bring forward additional color on how long patients are staying on therapy as that data matures.
Andrew Berens -- SVB Leerink -- Analyst
Okay. And then on the ULK inhibitor, I was just wondering, are there any concerns about the impact of the drug in the CNS, where autophagy is an important part of amino acid homeostasis, I know you guys had a special investor, but I just don't remember whether the drug crosses the blood-brain barrier, and if that's a concern or not?
Steven L. Hoerter -- President and Chief Executive Officer
Yes. Thanks, Andy. It's a great question. Matt, do you want to take that?
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Yes. Thanks, Andy, for the question. So yes, no, we don't -- we do not have concerns. So the drug was designed to be a potent selective inhibitor of ULK kynase but to avoid CNS exposure. So we look forward to beginning of the Phase I study.
Andrew Berens -- SVB Leerink -- Analyst
Okay. Thanks a lot. Appreciate it.
Operator
And our next question comes from the line of Peter Lawson from Barclays. You may begin.
Peter Lawson -- Barclays -- Analyst
Thank you. Thanks for taking the question. Maybe a question for Dan. Just any sense of kind of off-label use or the degree of off-label use in GIST?
Daniel C. Martin -- Chief Commercial Officer
Sure. Thanks. You mean with QINLOCK or generally?
Peter Lawson -- Barclays -- Analyst
With QINLOCK, please.
Daniel C. Martin -- Chief Commercial Officer
Yes. So as we've shared previously, the data that is available to assess use by line of therapy is limited. It's got challenges with it. So we do our best to triangulate that and estimate that. But it's definitely imperfect data. And what we've said is that a significant majority of the use, we believe we're confident is fourth line, consistent with our indication, which is, of course, the only way we promote QINLOCK. We've said that there has been some earlier line use, but the significant majority has been fourth line, consistent with our indication.
Peter Lawson -- Barclays -- Analyst
Got you. And then the ULK inhibitor, so 3116, when could we see the initial data from that? So I guess that's for Matt.
Steven L. Hoerter -- President and Chief Executive Officer
Yes. Peter, it's Steve. So I'll take that. It's a good question. So as Matt mentioned a little bit earlier and as we've talked about previously, we don't expect to see monotherapy activity with the ULK inhibitors. So really, what we're trying to drive to as quickly as we can as we get into the combination portion of the study that Matt described in his prepared remarks. So we don't have specific guidance as to when we might be able to report data it certainly won't be this year in 2021. But as we have visibility to what the potential timing might be, we'll, of course, update investors at that time.
Peter Lawson -- Barclays -- Analyst
Great. Thank you so much. Thanks for taking the questions.
Operator
Thank you. Our next question on the call will be from the line of Ren Benjamin of JMP Securities. You may begin.
Ren Benjamin -- JMP Securities -- Analyst
Hey, good afternoon, guys. Thanks for taking the questions and congratulations on the quarter. Maybe just in terms of market penetration, can you maybe just give us a sense, do you have an idea as to how much of the fourth-line market you guys have penetrated? I guess I'm trying to get a sense of was it so rapid that it was pretty steep and we're kind of -- the future growth moderating is more because we're getting closer to plateau? Or we came up, sort of, steep, but then we still got a decent way to go, at least in fourth-line? And then I just have a follow-up.
Steven L. Hoerter -- President and Chief Executive Officer
Yes, Ren, it's a good question. Dan, do you want to take that?
Daniel C. Martin -- Chief Commercial Officer
Sure. Thanks, Ren. I think you're -- the first interpretation is consistent with what we intend to communicate. So the team has just done a fabulous job executing despite the pandemic, and as a result, it's rapidly penetrated the fourth line patient opportunity. By any measure, we're pretty -- it's pretty clear that we've established QINLOCK as the clear standard in the fourth line now across both academic and community settings. And so that's why, given that, that's why we've communicated that we anticipate quarter-over-quarter growth to moderate until we're able to reach that next phase of significant growth being the second-line setting pending approval.
Ren Benjamin -- JMP Securities -- Analyst
Got it. That makes sense. And just -- I know I've asked this before, I just want to know if there's any new thinking behind the European launch. From my notes, it's a staggered launch. It's likely going to be your end weighted in terms of hiring the sales force and the like. Is that still the case, Steve? Or is there more of an active BD effort going on? Have things changed in your thinking as the application has been validated?
Steven L. Hoerter -- President and Chief Executive Officer
Yeah. So it's a great question, Ren. So as you point out, the MAA has been validated by EMA that occurred last year. And so we're targeting the second half of this year. That's when we believe that the European Medicines Agency could take action on the application. We also announced today that we've now hired Margarida Duarte, Senior Vice President, International -- Head of International. And she is going to now be taking on the role of building the nimble organization that we're hiring in Europe to be ready for a potential launch across that territory. I think it's important to note, and you alluded to this, Ren, that the launch will, of course, be staggered just by virtue of the fact that we have to wait for pricing and reimbursement negotiations to be completed in each and every country where we anticipate launching or introducing the drug.
So the territory where we would expect to be launching first is likely to be Germany where we don't have to go through pricing and reimbursement negotiation at least initially. But then for the rest of the territories, if you take Southern Europe, for example, Spain and Italy, we would expect the hiring associated with those territories as well as the launch to come at some point later, it could be 12 months to 18 months after approval, just depending on the pace of those negotiations with the authorities.
Ren Benjamin -- JMP Securities -- Analyst
Got it. And if you let me sneak one in for Tucker. The inventory -- we keep talking about COGS and how it's immaterial until the inventory is used up. When do you think that inventory will be used up? And can you just remind us what the COGS should go to?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Yeah. Thanks, Ren, for the question. So we haven't provided any long-term guidance on what we think the cost of goods will be for QINLOCK. What we have said is what we competed today, which is for the moment, it remains material. And that we think for the balance of the year of 2021, that it should remain at a very low level. So not this year. And stay tuned, we'll try and update you as we get more understanding about when we'll have a larger cost of goods for the product.
Ren Benjamin -- JMP Securities -- Analyst
Perfect. Thank you very much.
Operator
Thank you. And our last question will come from the line of Robyn Karnauskas with Truist. You may begin.
Robyn Karnauskas -- Truist Securities -- Analyst
Hi, guys. Hi, guys. Thanks again for taking the question and congratulations on the -- all the hard work on the launch. So two questions. This one, first one maybe a silly one. So as you continue to touch more doctors in the community setting, in the academic setting and you talked to them about the treatment of GIST, have you got any supportive or anecdotal data points that support, suit in second-line PFS of around five to six months. So is it supportive? Just anything anecdotal would be helpful as you're talking to doctors.
And the second question on 3116. So Amgen, obviously, their KRAS could be approved very shortly. And there's a lot of oncology designs -- have been adaptive trial designs quickly -- quick path to market, quickly being able to see what kind of combinations work best. Have you thought about exploring any -- an adaptive trial design for 3116, given the space is very competitive, and there could be certain combinations that work best? Thanks.
Steven L. Hoerter -- President and Chief Executive Officer
Yes. Thanks, Robyn. It's Steve. So let me take the first question, and then I'll ask Matt, if you'd like to take the second question about 3116. And then your question about combinations are adaptive trial designs going forward. So first, with respect to what we would expect to see from Sutent, nothing has really changed on that front. So as you know, in the label, the PFS for Sutent in the second-line is at 5.6 months.
And we -- when we were designing INTRIGUE spent a lot of time with investigators and thought leaders trying to understand what the best estimate was to use for Sutent's PFS in the second-line setting. And all of those thought leaders and investigators all coalesce around six months as being the right estimate to use. So we haven't learned anything new on that front, certainly not from anecdotal conversations with individual physicians that change our view that six months is the right estimate to use, and that was the basis for our design than of the INTRIGUE study. So Matt, do you want to take the second part of that question about 3116?
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Yes. So thanks, Robyn. It's a really good question. And so first, to start off, we're going to combine 3116 with an inhibitor, trametinib and the MAP kinase pathway. And we look forward to evaluating the data, and we'll be able to make a determination whether or not most move fast -- move forward to registration. And certainly using a novel adaptive design gives companies the ability to just expand the current cohorts of patients perhaps as they see a high level of activity, and that's the data that could be go forward to regulatory authorities. But in addition to, there may be other combination partners that 3116 can be combined with, and we've started to generate some of that data as well, too. So it could go beyond the MAP kinase pathway in combination.
Robyn Karnauskas -- Truist Securities -- Analyst
Got it. All right. Thank you.
Operator
Thank you. And I'm not showing any further questions at this time. So I'd turn the call back over to Steve to give any closing remarks.
Steven L. Hoerter -- President and Chief Executive Officer
Great. Thanks, Victor. Thanks to all of you for joining us on this afternoon's call and for your continued support of Deciphera. We look forward to keeping you all updated on our continued progress, not only with the Qinlock launch, but also as the balance of our development programs really come into focus this year and we provide some meaningful further data updates. Hope you'll have a great evening. Thanks again.
Operator
[Operator Closing Remarks]
Duration: 54 minutes
Call participants:
Jen Robinson -- Vice President, Investor Relations
Steven L. Hoerter -- President and Chief Executive Officer
Daniel C. Martin -- Chief Commercial Officer
Matthew L. Sherman, M.D. -- Executive Vice President, Chief Medical Officer
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Jessica Fye -- JPMorgan -- Analyst
Allison Bratzel -- Piper Sandler -- Analyst
Michael Schmidt -- Guggenheim -- Analyst
Eun Yang -- Jefferies -- Analyst
Andrew Berens -- SVB Leerink -- Analyst
Peter Lawson -- Barclays -- Analyst
Ren Benjamin -- JMP Securities -- Analyst
Robyn Karnauskas -- Truist Securities -- Analyst
More DCPH analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Allison Bratzel -- Piper Sandler -- Analyst Michael Schmidt -- Guggenheim -- Analyst Eun Yang -- Jefferies -- Analyst Andrew Berens -- SVB Leerink -- Analyst Peter Lawson -- Barclays -- Analyst Ren Benjamin -- JMP Securities -- Analyst Robyn Karnauskas -- Truist Securities -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. On the call today, Matt Sherman, our Chief Medical Officer, will highlight recent progress from the bemcentinib and rebastinib programs which have both demonstrated strong initial clinical data in their respective potential indications.
|
-- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Allison Bratzel -- Piper Sandler -- Analyst Michael Schmidt -- Guggenheim -- Analyst Eun Yang -- Jefferies -- Analyst Andrew Berens -- SVB Leerink -- Analyst Peter Lawson -- Barclays -- Analyst Ren Benjamin -- JMP Securities -- Analyst Robyn Karnauskas -- Truist Securities -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
-- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Allison Bratzel -- Piper Sandler -- Analyst Michael Schmidt -- Guggenheim -- Analyst Eun Yang -- Jefferies -- Analyst Andrew Berens -- SVB Leerink -- Analyst Peter Lawson -- Barclays -- Analyst Ren Benjamin -- JMP Securities -- Analyst Robyn Karnauskas -- Truist Securities -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
-- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Allison Bratzel -- Piper Sandler -- Analyst Michael Schmidt -- Guggenheim -- Analyst Eun Yang -- Jefferies -- Analyst Andrew Berens -- SVB Leerink -- Analyst Peter Lawson -- Barclays -- Analyst Ren Benjamin -- JMP Securities -- Analyst Robyn Karnauskas -- Truist Securities -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
0f954af4-e930-4a7b-9a66-db1972d6f1c1
|
715515.0
|
2021-01-22 00:00:00 UTC
|
Deciphera Pharmaceuticals Enters Oversold Territory (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-enters-oversold-territory-dcph-2021-01-22
|
nan
|
nan
|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Friday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $46.434 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 63.3. A bullish investor could look at DCPH's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DCPH shares:
Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.63.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Friday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $46.434 per share. A bullish investor could look at DCPH's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DCPH shares: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.63.
|
A bullish investor could look at DCPH's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DCPH shares: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.63. In trading on Friday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $46.434 per share.
|
In trading on Friday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $46.434 per share. A bullish investor could look at DCPH's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DCPH shares: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.63.
|
In trading on Friday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $46.434 per share. A bullish investor could look at DCPH's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of DCPH shares: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.63.
|
69fe7e51-a5e3-4b4c-abe3-4de2bcc593e4
|
715516.0
|
2021-01-06 00:00:00 UTC
|
DCPH Crosses Below Key Moving Average Level
|
DCPH
|
https://www.nasdaq.com/articles/dcph-crosses-below-key-moving-average-level-2021-01-06
|
nan
|
nan
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $53.48, changing hands as low as $52.13 per share. Deciphera Pharmaceuticals Inc shares are currently trading down about 1.7% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $52.78.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $53.48, changing hands as low as $52.13 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $52.78. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $53.48, changing hands as low as $52.13 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $52.78. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $53.48, changing hands as low as $52.13 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $52.78. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $53.48, changing hands as low as $52.13 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $33.10 per share, with $71.11 as the 52 week high point — that compares with a last trade of $52.78. Deciphera Pharmaceuticals Inc shares are currently trading down about 1.7% on the day.
|
173c601a-f634-478c-a677-9ce9891c4ce2
|
715517.0
|
2020-11-09 00:00:00 UTC
|
Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 17%
|
DCPH
|
https://www.nasdaq.com/articles/growth-investors%3A-industry-analysts-just-upgraded-their-deciphera-pharmaceuticals-inc.
|
nan
|
nan
|
Shareholders in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that Deciphera Pharmaceuticals will make substantially more sales than they'd previously expected. The market may be pricing in some blue sky too, with the share price gaining 12% to US$64.88 in the last 7 days. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.
After this upgrade, Deciphera Pharmaceuticals' eight analysts are now forecasting revenues of US$115m in 2021. This would be a sizeable 409% improvement in sales compared to the last 12 months. Losses are forecast to narrow 5.8% to US$4.70 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$99m and losses of US$4.84 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.
NasdaqGS:DCPH Earnings and Revenue Growth November 10th 2020
Despite these upgrades, the analysts have not made any major changes to their price target of US$73.50, implying that their latest estimates don't have a long term impact on what they think the stock is worth. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Deciphera Pharmaceuticals analyst has a price target of US$91.00 per share, while the most pessimistic values it at US$52.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Deciphera Pharmaceuticals shareholders.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Deciphera Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with revenues forecast to grow 409%, well above its historical decline of 9.6% a year over the past year. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 21% per year. So it looks like Deciphera Pharmaceuticals is expected to grow faster than its competitors, at least for a while.
The Bottom Line
The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting Deciphera Pharmaceuticals is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Deciphera Pharmaceuticals.
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Deciphera Pharmaceuticals going out to 2024, and you can see them free on our platform here..
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NasdaqGS:DCPH Earnings and Revenue Growth November 10th 2020 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.50, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Shareholders in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that Deciphera Pharmaceuticals will make substantially more sales than they'd previously expected.
|
Shareholders in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. NasdaqGS:DCPH Earnings and Revenue Growth November 10th 2020 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.50, implying that their latest estimates don't have a long term impact on what they think the stock is worth. The Bottom Line The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting Deciphera Pharmaceuticals is moving incrementally towards profitability.
|
NasdaqGS:DCPH Earnings and Revenue Growth November 10th 2020 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.50, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Shareholders in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Deciphera Pharmaceuticals shareholders.
|
Shareholders in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. NasdaqGS:DCPH Earnings and Revenue Growth November 10th 2020 Despite these upgrades, the analysts have not made any major changes to their price target of US$73.50, implying that their latest estimates don't have a long term impact on what they think the stock is worth. After this upgrade, Deciphera Pharmaceuticals' eight analysts are now forecasting revenues of US$115m in 2021.
|
eaa8fd5f-da09-41ee-a572-003a30e321b6
|
715518.0
|
2020-11-06 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2020 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-q3-2020-earnings-call-transcript-2020-11-07
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Q3 2020 Earnings Call
Nov 6, 2020, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone and welcome to the Deciphera Pharmaceuticals Third Quarter 2020 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Robinson, Vice President, Investor Relations. Jen?
Jen Robinson -- Investor Relation
Thank you, operator. Welcome. And thank you for joining us today to discuss the Cyprus third quarter 2020 financial results. I'm Ken Robinson, Vice President Investor Relations at decipher. With me this afternoon to discuss the financial results and provide a general corporate update our Steve herder, President and Chief Executive Officer, Dan Martin, Chief Commercial Officer, Matt Sherman, Chief Medical Officer, and Tucker Kelley Chief Financial Officer. Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward looking statements, reflecting the current beliefs and expectations of management may pursuant to the Safe Harbor provisions of the private securities litigation Reform Act of 1995. Examples of forward looking statements made during this conference call include our expectations for our preclinical and clinical programs, our commercialization of Kinloch and 2020 guidance. forward looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. And we cannot assure you that our expectations will be achieved. such risks and uncertainties include those set forth and our most recent quarterly report on form 10 Q, as well as our other SEC filings. We assume no obligation to update or revise any forward looking statements. Following this call a replay will be available on the company's website www.cypress.com.
With that, I will now turn the call over to Steve herder, President and Chief Executive Officer of decipher Steve.
Steve Hoerter -- President and Chief Executive Officer
Thank you, Jen. Good afternoon, everyone. And thank you for joining us on today's call. This year has been an incredibly exciting one for decipher, a year in which we received regulatory approval for and launched our first medicine, Ken lock, and also made significant progress advancing our pipeline of new product candidates that we were able to accomplish so much this year, in spite of the challenges of a pandemic, is a testament to the dedication and hard work of the team here at decipher, and the investigators we work with around the world. We are well positioned for a strong finish to 2020 and eager to continue our mission in 2021. The third quarter marks the first full quarter of results from our ongoing launch of Ken lock and the United States can lock which was approved by the FDA in May of this year, was designed to address the broad spectrum of mutations that are one of the hallmarks of gastrointestinal stromal tumor. Or just in a moment Dan Martin, our chief Commercial Officer will share with you highlights from the launch and outline how we have been successful in establishing Ken lock as the standard of care in our approved indication. We are focused on exploring the full potential of can walk to benefit people with just and on today's call Matt Sherman, our chief medical officer will review recent data updates from the ken lock Development Program, which reinforced the potential best in class profile of Ken lock in this disease. Our near term focus for further clinical development remains in the second line treatment setting and we are on track to complete target enrollment by the end of this year in the phase three intrigued study in which we are comparing Ken lock to sunitinib in the second line. We believe can lock has the potential to play an even broader role in the treatment adjust. And we look forward to sharing with you our vision for further clinical development in the coming months. One of our goals this year was to expand access to Ken lock for people with just outside the United States. To that end, we announced today that we recently submitted a marketing authorization application or ma to the European Medicines Agency. The submission was validated by the AMA last month, which signals the beginning of the formal review process. We look forward to working with the AMA to bring this potential in treatment options for patients in the European Union union. We also announced today that we intend to establish a direct commercial presence and key markets in Europe to commercialize can unlock If approved, this nimble organization will be positioned for future expansion as we've developed and seek approval for additional decypher medicines in the coming years. And Europe, we believe the commercial opportunity and just as concentrated in the five largest markets, France, Germany, Italy, Spain and the UK. Within these countries the treatment of patients with just as often centralized at tertiary treatment centers, which we believe allows us to build an efficient and targeted commercial infrastructure.
As we lay out the building blocks in Europe, we continue to make strides for the commercialization of Ken Locke and other areas of the world as well. Over the summer, we received approvals for Ken mark and both Canada and Australia. I'm pleased to announce that we have recently entered into exclusive distribution agreements and both of these territories and in China, our partner Zeid lab, filed the new drug application for Ken lock in July, targeting a potential approval next year. We look forward to working with our partners around the world to bring Ken lots of patients with advanced chess. Finally, we continue to advance multiple clinical stage programs that have the potential to be future approved medicines. Earlier this year, we presented initial compelling data with Sebastien it in combination with Paclitaxel in patients with heavily pretreated endometrial and ovarian cancers. And later this month, we are excited to present additional clinical data with TCC 3014 in Tennessee synovial giant cell tumor. As our clinical stage pipeline comes into focus, our novel Switch Control kinase inhibitor discovery platform continues to provide opportunities for future growth.
I'll now turn the call over to Dan Martin, our chief Commercial Officer to discuss the exciting results for the first full quarter of Ken lock commercial sales. Dan.
Dan Martin -- Chief Credit Office
Thank you, Steve. Good afternoon. Today I'm pleased to share results from our first full quarter of Kinloch sales. In q3, we achieve us net product revenue of $14.7 million, bringing total US net product revenue for the first four and a half months of launch to 19 point 5 million. While it is important to remember that it is still early in our launch, we continue to be very pleased with the way the launch has progressed, several important factors contributed to our q3 results.
First, we have continued to see strong prescriber demand for kinlaw in addition to robust month over month sales growth. insights from our recent launch tracking surveys, show strong product awareness message recall, product perceptions and intense prescribe among physicians who have fourth line just patients. Further, a large majority of these conditions indicate they now view Kinloch as the standard of care treatment for these patients. Importantly, these metrics tend to be strongest among physicians who report being detailed by our sales team, underscoring the importance of physician reach and access in this promotionally sensitive disease area. Second, we saw continued new prescriber growth across both academic and community settings. Thanks to the tireless work of our commercial team to navigate the unprecedented and ongoing challenges of COVID-19 the number of new Kinloch prescribers more than doubled during q3 since launch more than 250 just treaters representing more than 200 unique institutions have prescribed kinlaw As expected, while just treaters within academic institutions comprise the majority of our early adopters, our data suggest new prescriber growth is shifting toward the community setting while new academic prescribers grew by more than 80% in q3, new community prescribers grew by nearly 150%. During the quarter, more than 50% of both kinnelon prescribers and Kim mock treated patients came from community accounts. Third, our market access team continued to deliver broad patient access to keylock in q3. We have been very pleased with our progress in security payer coverage for kin lock in patients with fourth line just we've also been very pleased with the performance of our channel partners and our Patient Support Center. Finally, the percentage of patients in q3 that received free drug under our patient Assistance Program, or pap was at the low end of our estimate of approximately 20 to 30%. However, we anticipate that the past percentage may be somewhat higher in q4, as it's not uncommon for patients to experience increased affordability challenges late in the year. Additionally, the fat percentage may be higher. In q1 of next year, given that the Medicare Part D benefit resets on January 1, requiring patients to pay for their deductible and their portion of the coverage gap before reaching the catastrophic coverage tier. Before turning the call over to Matt, I would like to highlight factors that may impact our results over the next several quarters. As I mentioned previously, we expect the majority of our future new prescriber growth to come from the community setting, we're fourth line just patients are much more widely dispersed and physician awareness and knowledge of just is much lower when compared to the academic setting. Analysis of claims data indicates that community oncologists who treat fourth line just patients may see only one such patient every 12 to 18 months. Thus, while we're very pleased with the results we have seen in both academic and community institutions today, we recognize that future growth and product awareness and new patients start that's maybe more challenging, and come more slowly as we work to further penetrate the community setting. And this dynamic may be particularly challenging given the hurdles to physician access created by COVID-19, which we expect to continue as the pandemic persists and potentially intensifies over the next several quarters.
I will now turn the call over to Matt to discuss the progress of our clinical programs. Matt.
Matt Sherman -- Chief Marketing Officer
Thank you. Dan. Kinloch serves as a great example of how we have effectively and efficiently discovered, developed and now commercialized a product generated from our research platform. Well, dance team has been focused on helping fourth line just patient access Kinloch in the US. Our clinical and medical affairs teams have continued to generate and publish additional data and Kinloch in our pipeline programs. as Steve mentioned earlier, our strategic priorities to maximize the potential of Ken lock in Jeff's and to generate additional clinical data for this program. And for our other development product candidates to reach key value inflection points on the way to potential registrational studies and regulatory approval. For Kinloch, were keenly focused on the completion of the ongoing phase three and treat study. In second lines, yes, the study is on track to reach for enrollment by year end, and we expect to be able to provide additional guidance or any new primary endpoint at that time. We remain confident in the likelihood of successful entry. Based on the strong data we have seen in the phase one and phase three studies. To demonstrate the broad clinical activity in patients with just at the recent esmo virtual Congress, we presented new data and to many oral presentations related to kimata that continue to demonstrate the strong clinical benefit for second line through fourth line plus just patients. The first mini oral presentation provided longer term follow up results from the Invictus study and fourth line shifts that reinforce the exceptional progression free survival and overall survival benefit observed at the time of the initial database lock. The updated data provided an additional nine months of follow up and demonstrated the treatment Kinloch continue to provide clinically meaningful benefit with a PFS maintained at 6.3 months. And importantly, the median OS benefit improved from an initial 15.1 months to an overall survival, there's now not been reached. In addition, the updated safety findings were consistent with the previous primary analysis results, demonstrating that Kinloch was generally well tolerated.
The second menu presentation as well provided exciting data from the ongoing Phase One study came up in patients with second line to a fourth line plus just who just escalated to 150 milligrams twice daily. And the phase one study, patients were permitted to dose escalate to Kinloch 150 milligrams twice daily after disease progression a 150 milligrams once daily. These data show that across all three patient groups treatment with 150 milligrams twice daily provided an additional clinically meaningful PFS benefit. Comparison of tea is reported in these two distinct periods demonstrated that Kim was similarly well tolerated. Feedback from key opinion leaders on these data has been very positive. And we believe these data have the potential to impact clinical practice. At the upcoming connective tissue oncology society or see TAs virtual meeting, we will be presenting new kinds of data from the Becker's trial. These days include an oral presentation discussing the extensive heterogeneity of care and pdgfr Alpha mutations, as well as opposed to discussing Kinloch demonstrated activity across all kit and pdgfra Alpha mutations in patients in the interactive study.
Kinloch was specifically designed as a drug that can broadly inhibit kit and pdgfr Alpha mutated kindnesses, making it particularly suited to address just a disease that is characterized by a broad spectrum of mutations in these kinds of We have also explored Kinloch utility and the treatment of additional non just indications in the ongoing Phase One study, including systemic mastocytosis or SM, we have decided with input from our lead investigators not to invest in further studies in SM at this time. While we have seen clinical activity in SM and the safety and tolerability we're consistent with what we've reported and just given the overall landscape and the strength of the opportunities we have with Kinloch and just and with our other product candidates, we believe it is best to focus our resources in areas in which we're able to have the greatest impact. As we continue to advance our development activities across the portfolio. We are very excited about the potential for both DCC 3014 are potent and selective inhibitors CSF one are investing in a potent selective type two inhibitor.
We're developing DCC 3014 for the treatment of tennis elbow, giant cell tumor or TGC t, which has significant morbidity for these patients, and is driven by a genetic translocation in certain cells within the tumor, causing an overproduction of CSF one, the login for the CSF one receptor. The only approved systemic therapy for patients with TGC tea is Pepsi darnit, a small molecule inhibitor and CSF one arm which is subject to a rems program due to Cata toxicity and adverse event that has got to be an off target effect. We believe that the PCC 3040 has the potential to be a best in class CSF one receptor inhibitor, and to fulfill the unmet medical need for an effective and well tolerated treatment for patients with tg CT and an oral presentation that see talks later this month. We are excited to present results from more than 22 gct patients across multiple dose levels and dose cohorts from the dose escalation portion of the phase one study. In addition, we are on track to select a recommended phase two dose and to initiate the expansion cohort the phase one to study in TGC t patients turning to adaptive our potent selective type two inhibitor, which is currently being studied in combination with chemotherapy, choose a target primarily expressed and affiliate sales and type two expressing macrophages or testes and plays an important role in angiogenesis as part of the NGO poets anti to signaling axis.
We were very pleased with the recent data presented at ASCO and asthma from the two phase one v two studies in combination with tackle taxall and with Carbo platinum. In particular, we presented data showing strong preliminary activity in patients with endometrial and platinum resistant ovarian cancer. In part two of the tackle of taxable combination study, data presented at the asmall virtual Congress 2020 and platinum resistant ovarian cancer demonstrated encouraging efficacy within the objective response rate. 38% confirmed an unconfirmed and the clinical benefit rate of 88% of eight weeks and heavily pretreated patients. All patients receive prior platinum and taxane based therapy 90% of patients received death facism at 62% received the PARP inhibitor and 31% received immunotherapy.
In addition to these data, we presented compelling data from the individual cohort at the ASCO 2020. Virtual program showing promising preliminary anti tumor activity in favorable tolerability with an objective response rate of 39% confirmed it unconfirmed, and the clinical benefit rate is 72% at eight weeks, also in heavily pretreated patients. We look forward to providing updated results from these ongoing phase one v two studies, as well as additional guidance on our clinical and regulatory plans for basnet. Finally, we continue to be excited about the prospects for DC state 3116. Our potential first in class oak kinase inhibitor designed to treat meeting wrasse cancers.
We're aiming to submit the ind in the fourth quarter of this year, but this event may shift to the first quarter of 2021. We're making great progress, of course, each of our programs in our pipeline, and we believe that this is just the beginning of making a meaningful difference in the treatment of patients with cancer and rare diseases. I will now turn the call over to Tucker Kelly, our chief financial officer to review the financial results. Tucker. Thanks, Matt. I'd like to review the highlights from our third quarter 2020 financial results, which includes our first complete quarter of Kinloch product sales. total revenue for the quarter was 15 point 5 million, which includes 15 point 2 million of net product sales pinlock and 300,000 of collaboration revenue. NET product revenue included 14 point 7 million in US product sales, as well as approximately 500,000. In product sales of Kinloch outside the US under early access programs. The gross net adjustment in q3 was slightly lower than our prior guidance of approximately 15%. I would note that this adjustment is likely to increase in q4 and q1 as we improve anticipated Medicare Part D rebates required for existing Kinloch treated patients who re enter the coverage gap in January. cost of sales for the three months ended September 30 2020 was immaterial, as the majority of the manufacturing costs related to Kinloch, sales were incurred prior to FDA approval, and thus were recorded as r&d expense. cost of sales will not be significant until the initial pre launch inventory is depleted, and additional inventory is manufactured and sold in the third quarter of 2020. Our total operating expenses excluding cost of sales were 79 million compared to total operating expenses of 76 million in the second quarter. Research and Development expenses were approximately 49 million and selling general and administrative expenses were approximately 30 million for the third quarter of 2020. We expect our operating expenses will increase modestly in the coming quarters as we continue to invest in the development of our clinical pipeline, the commercial launch of Kinloch in the US and prepare for potential commercial launch in Europe. We ended the third quarter in a strong financial position and remain well capitalized and in the quarter with cash cash equivalents and marketable securities of approximately 584 million, which we expect will be sufficient to fund our operations into the second half of 2022.
With that, I'll now turn the call back over to Steve.
Steve Hoerter -- President and Chief Executive Officer
Thank you, Tucker. I'm extremely proud with what our team has accomplished. so far. This year, we have delivered on our promise to bring an important new medicine to patients with cancer with the approval and successful initial launch of Ken lock in the United States, and are now working to bring this novel product to patients with advanced just around the world. Meanwhile, we continue to advance the rest of our pipeline based on our novel Switch Control kinase inhibitor platform. And we look forward to presenting updated data on GCC 3014 at the seat house meeting later this month.
Operator, I'd now like to open the call for q&a.
Questions and Answers:
Operator
First question comes from the line of Jessica fi with JP Morgan.
Jessica Fye -- J P Morgan -- Analyst
Hey, guys, good afternoon. Congrats on the quarter. I'mcurious if you can give a little more color about the Kinloch dynamics. For example, is it possible to find the average number of patients one can lock in the quarter? And how many were on therapy as a quarter run?
Steve Hoerter -- President and Chief Executive Officer
Yeah, hi, Jess. Let's see. Thanks. Can you hear your voice? And thanks for the question. I'm gonna scan Martin, who's on the call to address your question then. Hey, Jess, thanks for the question. It's a good one. So really, I think we're just going to remain focused on what we think are the key themes. This quarter, we've been really pleased to see the continued strong demand, not only in terms of the numbers themselves, the revenue numbers themselves, but also any number of measures from our various launch tracking surveys. The new prescriber growth that we saw as well as broad access, we've been really pleased with how payor policies have come into place for for Kinloch in the fourth line. And in terms of you know, specific metrics, you know, our goal is on these calls to provide color that's relevant to convey our launch progress and expectations moving forward. And we'll definitely continue to assess what information to share on future calls to help convey those insights. But we're not sharing specific patient numbers at this time.
Jessica Fye -- J P Morgan -- Analyst
Okay, maybe if you can be Can I answer that? I'm curious with the you know, rapid uptake you're seeing in the community? What percent of can last use you estimate is in fourth line versus potentially earlier lines of therapy?
Steve Hoerter -- President and Chief Executive Officer
Yeah, thank you. Another good question. You know, before launch, we've done quite a bit of claims analytics to help us estimate just that. And that, and before launch, before we had experienced selling our first product in that market, we thought that overall about 30%, of just treatment across all lines of therapy occurs in the academic setting, with about 70%, you know, broadly distributed throughout the much larger just in terms of number of physicians and institutions, community setting. At the time, we also thought that that was that tended to flip a bit with maybe 60% of lateline for offline or later, patients being treated in the academic setting. But interestingly, even then, our analytics would suggest that, you know, 40% or so of have very lateline patients receive care in the community. And what we're seeing, go Well, before I come in and what we're seeing, I think one other important thought was or one other important Question was with a new product that is highly efficacious and has a, you know, a favorable tolerability profile. Would more community treaters hold on to those late stage patients as opposed to maintaining the same referral patterns they had, you know, historically. And so, while we are still early days, and we don't have answers to all those questions, what we yet what we are seeing is slightly more than that, you know, 40% that we expected to occur in, in the community setting for lateline. Just we're seeing slightly more than 50% thus far, which we are encouraged to see. But like I said, in my prepared remarks, I think it's really important. One thing we want to highlight is we've said this on prior calls, although the majority of our early adopters were in the academic setting, and we've seen some nice growth in early days in the community setting, we expect moving forward, just because of the nature of the structure of the market, that future growth will need to increasingly come from the community setting. And that's a setting where patients are much more widely dispersed. As I mentioned, in my prepared remarks, you know, a lot of patients, excuse me, a lot of prescribers in the community setting may treat only one patient every 12 to 18 months with lateline. Jest. And so given that the lower awareness and lower knowledge, you know, we're cognizant of the fact that continued growth, which will depend on our ability to continue to penetrate not setting the community setting, maybe more challenging, it comes somewhat more slowly, particularly in light of the ongoing challenges of the pandemic, which I think we all know, is likely to persist and perhaps even intensify in the coming quarters. So that's how we're thinking about sort of source of business. You know, just overall and for Ken lock, as we look at.
Jessica Fye -- J P Morgan -- Analyst
Got it. Thank you. And if I can sneak in one more for Steve, in prepared remarks, I think you alluded to a broader potential for Ken lock in just and it kind of sounded like you weren't solely talking about second line. So can you elaborate on what you meant there?
Dan Martin -- Chief Credit Office
Yeah, thanks, Jess. It's a good question. And we're very committed with Ken lock to fully exploring the potential of the drug and just even beyond where we're at now currently standard of care on the fourth line, as Dan was describing, and also beyond the entry study, in the second line setting, we know we have a very active drug in this disease. And we think there may well be other places where we could explore the drugs utility. We're not ready to share details about that vision. And that strategy will do that over the course of the coming months. But we are fully committed to conducting further clinical study of this drug and just
Jessica Fye -- J P Morgan -- Analyst
Got it. Thank you.
Operator
Our next question comes from the line of Chris Raymond with Piper Sandler. Your line is open
Chris Raymond -- Piper Sandler -- Analyst
Hey, good afternoon. This is Alison Brasil. On for Chris. Thanks for taking the question. So first, one on McCulloch dynamics. I think last quarter, you've called that a slight revenue benefit. From Kinloch inventory belt. So just hoping you could provide any color on whether there is any inventory impact this quarter, or even just directionally help us understand how the magnitude or direction of any inventory impact and q3 compares to q2 and maybe a similar question on a new patient or new commercial patient adds from the the expanded access program and and how that played into the the q3 revenue number.
Dan Martin -- Chief Credit Office
Thanks for the questions. Alison, Celeste and Martin to take both of us. Yes, thanks, Alison. Good questions. So the first one related to inventory build inventory build was not a significant contributor to our q2 revenue performance. And then on the EAP front, as we've shared previously, there were a number of patients who converted from our EAP program to commercial product at the time of approval, and our q3 revenues did include continue to include a modest contribution from those patients, but we haven't provided specific numbers. But yes, q3 did include a modest contribution from those patients who were still in therapy.
Chris Raymond -- Piper Sandler -- Analyst
Okay, thanks. And maybe just one more on the some of the data you had as mo specifically the data on repetitive from the phase one, the interpatient dose escalation that was really supportive of treating patients patients progression and up dosing them to the to the big dose. And really the later line patients seen a nice benefit on PFS, too. So just hoping you could maybe talk to how that compares with with an early launch experience and and your messaging for Kinloch
Steve Hoerter -- President and Chief Executive Officer
And basically how willing are physicians to treat past progression in those later life, not just patients? damage looks like that. Sure, absolutely. So good question. Yes. We mentioned that data a number of times. I think that's really interesting data. We've also said previously, though, that you know, how a drug gets used, and the commercial setting is impacted by a number of factors. And as it relates to the big dosing, you know, first of all, I want to underscore that we are entirely focused on launching Kinloch in the fourth line, you know, in in consistent with our label, and that goes for indication, it goes for our recommended dose in our label. But we've seen a small number of prescriptions for b iD, but the vast majority has been the 150. Qd. And, you know, when I'd say a lot of things contribute to how a drug gets used in the commercial setting, you know, one of them that's really important is payer policies. And, you know, we've been really pleased to see the payer coverage come along really nicely for kin lock up, but those policies have very much been consistent with label, including those from the dentist perspective. So while certainly interesting data and certainly rk well tell us there's interest in it. From a commercial point of view, it's been a pretty modest contribution to revenues today.
Chris Raymond -- Piper Sandler -- Analyst
Got it. Thank you.
Operator
Our next question comes from the line of Peter Lawson with Barclays. Your line is open.
Peter Lawson -- Barclays -- Analyst
Hi, guys. This is a lead on for Peter. Congrats, them great quarter and interview taking the questions. Just had a couple of questions here. I was wondering if you could provide any sort of details on the Kinloch usage this quarter? Are you seeing any potential off label use in earlier lines of just? And then? And then a question on the upcoming data for for GGC, TG ctfc toss? wondering if you could set expectations as to what you would be consideringto be positive results from that study?
Steve Hoerter -- President and Chief Executive Officer
For religion adopt that see, thanks very much for the question. So maybe what I'll do is take the TGC question first, and then ask Dan, to take the first question that you have. So with respect to 3014, as Matt mentioned in his prepared remarks, but we're looking forward to having additional data from the phase one in just over 20 patients be presented in an oral presentation at the connective tissue oncology society conference here coming up in a couple of weeks. As you know, this phase one study is a dose escalation study. So what you can expect to see is data from a variety of different dose cohorts to doses and schedules of 3014. in patients with TGC T. What we do know is that our drug 3014 is very potent and very selective against the target. This is a disease as you know, that's driven by a genetic translocation results in overproduction of the the ligand for the receptor. So based on the biology, and based on our knowledge of the mechanism, we would expect to see 3014 have activity in this patient population, as we previously reported at CES last year. So we're looking forward to presenting the data here coming up in a couple of weeks.
And as Matt mentioned, where we remain on track to get to a recommended phase two dose, and also to open the expansion cohort. Dan, would you like to take Well, these question related to off level use? Sure, absolutely. So as I similar as I mentioned a moment ago, you know, we of course, are not out promoting anything other than our label indication. And the payer policies that we're seeing come online, have very consistently been aligned with our labeled indication. It is difficult we've shared before, it's difficult to estimate the proportion of patients who may be receiving can lock in earlier lines of therapy, frankly, because the data sources are imperfect. But what we are seeing in the data that we have is that a significant majority of Kinloch patients have been fourth line or fourth line plus, on the you know, that's not surprising to us again, because, again, the point about payer policies being consistent with label and then again, You know, we're not out promoting that that data. So you know, the large majority consistent with the fourth line indication.
Peter Lawson -- Barclays -- Analyst
Got it. Thanks for taking the questions.
Operator
Our next question comes from the line of Yun Yang with Jeffries, your line is open.
Eun Yang -- Jefferies -- Anlyst
Thank you. So the first question is enough for ages three intrigue, data data timeline. So based on what you saw in phase one in second line for the practice a PFS and certain SR compare Fs, when do you think you would expect to see the data once you finish the enrollment by end of this year?
Jen Robinson -- Investor Relation
Yeah, University. Thanks very much for the question. That's a great question. as Matt mentioned in his prepared remarks, we're looking forward to getting to completion of enrollment and intrigued here by the end of the year. And when we get to a completion of enrollment in the study, our intention at that time is to be able to share more detail about the timeline for the study carried out. As you know, from our phase one experience, in the second line cohort, we we've seen a very robust PFS, and that patient population that we've studied have close to 11 months of PFS. And when you look at the Sutent labeled one would expect to PFS in the range of five and a half months to six months. So it's premature for us at this stage to talk about when we think the study will read out. But certainly as we get to full enrollment here before the end of the year, which is our target will then be in a position to share more grades.
Eun Yang -- Jefferies -- Anlyst
And then as you move into second line with the in trade study. So once it's approved in second line, do you expect to use the report and even fourth line will be dramatically reduced? Or do you think there is a there is a potential that in some patients who practice Could it be recycled in the fourth line?
Jen Robinson -- Investor Relation
So you're gonna see it, I'll ask Dan, to address that here in a second. You know, his beautiful team and Dan have done a ton of market research and speak to clinicians all the time about their view of recruitment and Ken lock in the treatment of this disease as the treatment paradigm evolves. And then I think what's also relevant here, in a way are the data that we presented it as Mo, where we just escalated patients to 150 D ID and saw additional meaningful benefit by treating patients beyond after progression with a higher dose of the drug. So it seems clear that we're pregnant has the potential of least to be a real backbone of treatment for patients and for patients to receive prolonged benefit from the drug in that context. But Dan, maybe you want to comment further about how you see the market evolving in a world of a positive intrigue readout and how physicians may evolve the treatment approach and paradigm. Sure, absolutely. So you know, what we hear from our caol is certainly real interest in seeing Kinloch, get to that second line setting. They all tell us that that's where they see, you know, the principal use for Kinloch, and they're really excited to see the results of intrigue as a result, as you expect. Um, you know, there's there, when we look through the claims data, when we talk to our Cowell's, we don't see a dramatic amount of retreatment. In the space, as you know, there's some data for madness, with retreatment. But, you know, we just we haven't seen a ton of that. And so it remains to be seen whether or not retina komak would be looked at as a valuable option and retreatments setting. As we said before, there's a lot of there's a lot of things that go into how a drug will be used, obviously data that gets generated out things appearing guidelines, payer policies and the like. So it's still a bit early for us to have a good sense for that. But definitely what rk will tell us as they're looking forward to potentially having Kinloch available in the second one,
Eun Yang -- Jefferies -- Anlyst
The last question is on the market, the commercial strategy. So, you know, Steve, on your prepared remarks, you are preparing to launch in a list of major European countries. But emerging markets are like really a big opportunity for new therapies. So I want to ask you outside the US and, you know, major European countries and zylab territories, what are your plans for commercial strategy for pregnant? Thank you.
Steve Hoerter -- President and Chief Executive Officer
Thank you. That's a good question. So as you know, you referenced that we have our collaboration with Zai in Greater China that NDA has been filed Then there's the potential for action on that application next year. And of course, we also announced today that we're working through a couple of distributors in other territories, so specialized therapeutics in Australia and other Pacific Rim countries. And then we also announced our distribution agreement with medicine for Canada and Israel, beyond those territories. However, you know, our approach to commercial point of view would be to take a similar approach that is to work through distributors, in key territories and enrolled will start to make our way around the world, you know, with Ken lock in terms of making sure that patients have access to it in a commercial setting upon approval. And that is something that we're committed to so we're looking forward to continuing to identify partners in the right priority territories as we seek to make the drug available further.
Eun Yang -- Jefferies -- Anlyst
Thank you.
Operator
Next question comes from the line of Michael Schmidt with Guggenheim Your line is open.
Michael Smith -- Guggenheim -- Analyst
Hey, guys, this is Charles Xu on from Michael Schmidt. Thanks for taking the question and congrats on the strong quarter, a couple on DCC. For the tg CCT, I fully understand that you and others have highlighted the market opportunity for TGC t as an annual 1300 patients or so at least for the diffuse type with a much larger prevalence given its long, long lethal on that front. However, what's your sense of how many patients are truly candidates for pharmaceutical intervention relative to the current role and potential cure rates of a sir surgery even repeat surgery and or radiation?
Steve Hoerter -- President and Chief Executive Officer
I Charles it Steve, thanks for the question. With respect to 3014. As you know that the target indication for us for 3014 and tg CT is for patients that are not amenable to surgery. And we know that as a reference, there are about 1300 new patients in the US each year with a diffuse form of the disease. And these are patients with a high recurrence rate who generally at some point in the course of their disease, I think the estimates are between 30 and 50% of those those patients have recurrence. But at some point those those patients as we understand that run out of surgical options to manage their disease, and then would become candidates for a systemic therapy. So that is the population we're targeting. We also know that their patients with a localized form of the disease that are also not amenable to surgery, for whatever reason, and then also would be candidates for drug therapy for systemic therapy.
Michael Smith -- Guggenheim -- Analyst
Got it makes sense. And Iand I guess also based on the research you've done so far around taxi, darknet and other off label drugs, such as a magnet for this disease, what's your sense around a potential treatment duration in these patients? And is it possible to convert these patients, I guess, from previously unimaginable to serve surgery into eligible patients for potentially curative surgery?
Steve Hoerter -- President and Chief Executive Officer
Yes, it's a good question with respect to the potential for new adjunctive treatment in this disease contexts. And there who knows there may well be a role for CSF one or inhibition in such patients to shrink tumors to make them potentially resectable. Whereas perhaps prior to treatment that might not have been resectable. So that I think remains an open question. You know, this is a disease category, where there just haven't been systemic treatments until the approval of exodar. nib last year. And what we continue to hear from physicians is that they have concerns about using pecs in their patients and in fact, patients have concerns about about using packs as a result of the blackbox warning for hepatic toxicity and the rems that is associated with that. So we believe there remains a significant medical need for a drug that is effective and well tolerated in the treatment of this disease. And I think part of our task assuming continued success is going to be to to ensure that we're able to access access patients at the right time and their disease course for a systemic treatment like ours.
Michael Smith -- Guggenheim -- Analyst
Got it makes sense. Thanks for taking the questions and congrats again on the strong quarter.
Operator
Our next question comes from the line of Ren Benjamin JMP securities, your line is open.
Reni Benjamin -- JMP securities -- Analyst
Sorry about that. Congratulations, guys on a great quarter. Thanks for taking the questions. Can you provide us maybe a little bit more color on the commercial plans in the EU? I maybe I missed it. But how many people are we talking about? Are there is there going to be a centralized of Salesforce just any sort of idea as to how that how that build out will occur. They occurred just based on by country by country approval, any sort of color there.
Steve Hoerter -- President and Chief Executive Officer
Yeah, I ran, it sees I'd be happy to take your question about Europe. As I mentioned in the prepared remarks, we think the majority of the opportunity is in the five largest markets as you'd expect. And we don't have any reason to believe that the the prevalence of just or the incidence of just in Europe, as a percent of population is any different than what we see in the US. So based on that, we think across the five largest markets, they're probably between four and 6000 patients with just that are diagnosed each year. So as we think about our bills in Europe, it will very much be a staggered bill based on market access. So as you know, when each of these markets are generally single payer markets, and so depending on the country, a manufacturer like us would have to go through pricing and reimbursement negotiations. And sometimes that can take a matter of a few months. And sometimes that can take as long as a year. So depending upon, you know how long that process takes to get to a price and ticket to reimbursement in the system, that would then be the trigger for us to consider a bill related to that country. As I also mentioned in the prepared remarks around, you know, we our estimate is that these patients tend to be treated centrally at tertiary centers. So there's probably an opportunity here as we look at it for us to build more of a hub model across Europe where we'd have the majority of our headcount sitting at a regional center, within a field based personnel in key markets. And so I'm sure as we get to a potential approval in Europe, which is, you know, the filing is now gone in, it's been validated. So we think that the earliest potential action on the application could be by the end of next year. So as we get closer, I'm sure we'll be sharing some more detail about how we used to build and what we see in terms of numbers. But it's certainly going to be a staggered build. And we'll of course, continue to be thoughtful about what the size of that organization ends up looking like to access the opportunity
Reni Benjamin -- JMP securities -- Analyst
Got it? And then I think it was Matt, he might have mentioned that, you know, the the FM opportunity is, is you guys are no longer investing in that. Can you talk a little bit, I guess about, you know, was it was it because enrollment was kind of tough for you, we're not seeing the kind of efficacy that you were you were hoping for? And ultimately, you know, will we see based on the patients that you have enrolled, you know, what the data look like? Or it really doesn't make any sense to, you know, to that photograph?
Steve Hoerter -- President and Chief Executive Officer
Yeah, thanks for the question ran. And as we've been saying for a number of months, now, even well, over a year, our real focus of development for Ken lock over pregnant is in jest. And as Matt Novick and his prepared remarks, we have seen modest clinical activity in the fewer than 20 patients that we treated in that SM cohort. But we didn't see sufficient activity to warrant further development in this disease. And that's particularly given the context of the evolving treatment landscape in SM and frankly, the compelling investment opportunities that we see in other parts of the portfolio, not only and can lock over pregnant, but also in our other clinical stage assets as those start to really come into focus. And so as a result, we've decided to focus our investment resources, but people in dollars in other areas for now, I'm sure in the when the time is right at some sage will publish the data from the SM cohort. I don't have any specific details I can share with you at this time. Right. Got it. And then just one final one regarding behind the 43116. I think I heard it right that it was shifted to the first quarter anything, you know, is just you guys are gonna have enough to focus on right now or did anything kind of pop up that's making you have to make that shift. Now we remain really excited about 3116. You know, this is targeting the initiating factor and a tapa G, which is thought to play a role in breast cancer. So really large patient populations and significant tumor types like lung and bladder cancer. So we remain really excited about about the program, the team has been working cold hard to advance us to file the end. This is a goal that we have for the end of the year. That was our initial milestone. And as Matt indicated, this is a goal that we have for the end of the year. That was our initial milestone. And as Matt indicated that there's a possibility that this shifts into quarter one, but this is really just a function of of timing being an end of year sort of a goal. But we've remained really excited about the program and very focused on it.
Reni Benjamin -- JMP securities -- Analyst
Terrific, thanks for taking The questions and Congrats.
Steve Hoerter -- President and Chief Executive Officer
Thank you.
Operator
Thank you. And our last question comes from the line of our Linda Lee with Canaccord genuity. Your line is open.
Linda Lee -- Canaccord genuity -- Analyst
Hey, good afternoon, folks that it's Ben Shin for Linda and congrats on the great quarter. Many of my questions have already been answered, I kind of have a high level question for, for you for the benefit of us outsiders, can you can you walk us through how on a day to day basis for getting more penetration in the community setting? And how is it different in the pandemic environment? And what extent can you communicate the potential for earlier lines of treatment? Since you guys are already there? Can you kill two birds with one stone as it were? I have a couple of problems. Yeah, thanks for the question that I'll ask Dan Martin, to take that first part of your question that we'll come back to your follow us
Steve Hoerter -- President and Chief Executive Officer
Thank you. Good question. So the really the crux of our effort to penetrate the community setting is just being incredibly, highly targeted, and leveraging our analytics strength to identify where the physicians were most likely to have a late line. fourth line, just patient. As I mentioned, before, you know, patients are much more widely dispersed, as much more diffuse in the community setting. And so making sure that you are spending your sales marketing efforts in the right place is critically important. And so, of course, in addition to communicating all the things that we do, you know, irrespective of setting, communicating the best in class profile, communicating the fact that it's the only approved agent, for the fourth line, etc, you know, really making sure that we are laser targeted in our efforts is critically important. Now, as relates to COVID-19, this is an ongoing challenge, I think it is for just about every company, it's an ongoing challenge, because of any number of reasons. patient, you know, the data continues to show that, you know, broadly, patient numbers remain somewhat depressed and oncology. And, you know, there's a lot going on at these provider institutions. You know, the one of the things that is a challenge is virtual fatigue, I think a lot of people can appreciate the sort of virtual fatigue that that happens. And so, you know, we continue to invest in in training and resources for our field force to make sure that they are having the most robust and engaging conversations with physicians about about Kinloch and about their on label patients. So, you know, there's no magic bullet, no magic potion here. A lot of it is just, you know, continuing to work every day, and the team has done a fabulous job, a fabulous job navigating that. But, you know, as we think about moving further and further into the community setting and, and with the ongoing pandemic, which may, you know, intensify in the coming quarters, you know, it is something that we are cognizant of and think that, you know, continued growth in those new patients starts maybe a bit more challenging and come a bit more slowly. So, I hope that answers your question. I missed the second part of your question. And I wasn't sure if that was a commercial one or not the second line, what,yeah, what what came to what extent can you communicate? Or may you communicate to potential for earlier lines? Since you guys are already there and not having to go back? When you say rd there, you mean, at the physician with the physician, the hysician level?
Dan Martin -- Chief Credit Office
Yeah. Okay. Sure. So, the answer is we can't not promotionally the data on second line. You know, the K wells are obviously already aware of that data from the publications and such, really excited about it, and really looking forward to retrieve results. And the potential movement of kin lock up and, you know, order of therapy, but from a promotion perspective, we we stick to the labeled indication.
Linda Lee -- Canaccord genuity -- Analyst
Gotcha. Okay, that makes sense. And maybe a question for Tucker. Can you give us some color? When the accrued pre launch inventory? We'll be working through it.
Steve Hoerter -- President and Chief Executive Officer
Okay. Can't run.Without me. Sure. So.Yeah, absolutely.If you notice, we did have a little bit when you'll see the financial results in the earnings release, and then the cue that there was a little bit of cogs expense in this quarter, but it'll be a number of quarters before we work off the pre launch inventory as we've already expenses, r&d. Okay, that's very helpful. Well, I think you guys mentioned something was already material changes in pair mix for the quarter. I'm sorry if I missed the question or the statement. I can take that as Dan net No, no material change that we've seen.
Linda Lee -- Canaccord genuity -- Analyst
Okay, great. Thanks very much, and congrats on the quarter.
Operator
Thank you. And I'm not showing any further questions. So I'll now turn the call back over to Steve quarter for closing remarks.
Steve Hoerter -- President and Chief Executive Officer
Great. Thank you, Bridget. I appreciate that. And thanks to everybody on the call for joining us on the call today and for your continued support. We're looking forward to keeping you all updated on our continued progress with Ken Locke as well as with the balance of our development programs. Have a great evening, everyone.
Operator
[Operator Closing Remarks]
Duration: 56 minutes
Call participants:
Jen Robinson -- Investor Relation
Steve Hoerter -- President and Chief Executive Officer
Dan Martin -- Chief Credit Office
Matt Sherman -- Chief Marketing Officer
Jessica Fye -- J P Morgan -- Analyst
Chris Raymond -- Piper Sandler -- Analyst
Peter Lawson -- Barclays -- Analyst
Eun Yang -- Jefferies -- Anlyst
Michael Smith -- Guggenheim -- Analyst
Reni Benjamin -- JMP securities -- Analyst
Linda Lee -- Canaccord genuity -- Analyst
More DCPH analysis
All earnings call transcripts
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2020
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2020 Earnings Call Nov 6, 2020, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Investor Relation Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Credit Office Matt Sherman -- Chief Marketing Officer Jessica Fye -- J P Morgan -- Analyst Chris Raymond -- Piper Sandler -- Analyst Peter Lawson -- Barclays -- Analyst Eun Yang -- Jefferies -- Anlyst Michael Smith -- Guggenheim -- Analyst Reni Benjamin -- JMP securities -- Analyst Linda Lee -- Canaccord genuity -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. I'm pleased to announce that we have recently entered into exclusive distribution agreements and both of these territories and in China, our partner Zeid lab, filed the new drug application for Ken lock in July, targeting a potential approval next year.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Investor Relation Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Credit Office Matt Sherman -- Chief Marketing Officer Jessica Fye -- J P Morgan -- Analyst Chris Raymond -- Piper Sandler -- Analyst Peter Lawson -- Barclays -- Analyst Eun Yang -- Jefferies -- Anlyst Michael Smith -- Guggenheim -- Analyst Reni Benjamin -- JMP securities -- Analyst Linda Lee -- Canaccord genuity -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2020 Earnings Call Nov 6, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update our Steve herder, President and Chief Executive Officer, Dan Martin, Chief Commercial Officer, Matt Sherman, Chief Medical Officer, and Tucker Kelley Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Investor Relation Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Credit Office Matt Sherman -- Chief Marketing Officer Jessica Fye -- J P Morgan -- Analyst Chris Raymond -- Piper Sandler -- Analyst Peter Lawson -- Barclays -- Analyst Eun Yang -- Jefferies -- Anlyst Michael Smith -- Guggenheim -- Analyst Reni Benjamin -- JMP securities -- Analyst Linda Lee -- Canaccord genuity -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2020 Earnings Call Nov 6, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update our Steve herder, President and Chief Executive Officer, Dan Martin, Chief Commercial Officer, Matt Sherman, Chief Medical Officer, and Tucker Kelley Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Investor Relation Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Credit Office Matt Sherman -- Chief Marketing Officer Jessica Fye -- J P Morgan -- Analyst Chris Raymond -- Piper Sandler -- Analyst Peter Lawson -- Barclays -- Analyst Eun Yang -- Jefferies -- Anlyst Michael Smith -- Guggenheim -- Analyst Reni Benjamin -- JMP securities -- Analyst Linda Lee -- Canaccord genuity -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2020 Earnings Call Nov 6, 2020, 4:30 p.m. I'll now turn the call over to Dan Martin, our chief Commercial Officer to discuss the exciting results for the first full quarter of Ken lock commercial sales.
|
85cb2334-7ee6-4a5e-854f-20cb7aae2ca6
|
715519.0
|
2020-08-05 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-q2-2020-earnings-call-transcript-2020-08-05
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Q2 2020 Earnings Call
Aug 4, 2020, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone, and welcome to the Deciphera Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Robinson, Vice President, Investor Relations. Jen?
Jen Robinson -- Vice President, Investor Relations
Thank you, Michelle. Welcome and thank you for joining us today to discuss Deciphera's second quarter 2020 financial results. I am Jen Robinson, Vice President, Investor Relations at Deciphera. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include our expectations for our preclinical and clinical programs, our commercialization of QINLOCK and 2020 guidance. Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include the potential impact of COVID-19, the execution of clinical trials, the timing of study data, and those set forth in our most recent quarterly report on Form 10-Q as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steven L. Hoerter -- President & Chief Executive Officer
Thank you, Jen. Good afternoon, everyone and thank you for joining us on today's call. Deciphers mission has always been focused on discovering, developing and delivering important new medicines for the treatment of cancer. And in the second quarter, we were proud to announce FDA approval of our first product QINLOCK for the treatment of patients with fourth-line GIST.
QINLOCK was designed and purpose built for the treatment of this disease and is the only approved drug in the post-imatinib setting that offers a clinically meaningful overall survival benefit for GIST patients. The FDA approval and launch of QINLOCK is an important milestone for the thousands of people in the United States facing a GIST diagnosis, and also serves as validation of Deciphers novel approach to designing switch control kinase inhibitors. FDA's approval of the QINLOCK NDA came approximately three months ahead of its PDUFA date, and was reviewed under the FDA's real time oncology review pilot program with priority review. The QINLOCK NDA was also part of Project ORBIS, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among participating international health authorities.
As a part of this initiative, we recently announced the approval of QINLOCK, both by Health Canada and by the Australian Therapeutic Goods Administration. Additionally, as we look to further expand access to QINLOCK outside of the United States, we intend to file a marketing authorization application with the European Medicines Agency in the fourth quarter of this year. Finally, last month, we were excited to announce along with our partner the Zai Lab, that the China National Medical Products Administration or NMPA has accepted the NDA for QINLOCK. And earlier today, Zai announced that the QINLOCK NDA has received priority review. Prior to receiving FDA approval, our commercial and medical affairs teams had been working diligently to lay the groundwork and optimize readiness for the commercial launch, because of their dedication and hard work, we were able to ensure that QINLOCK was commercially available through our limited specialty pharmacy network within one week of approval.
During the call today, Dan Martin, our Chief Commercial Officer will share our initial insights into the commercial launch. While we are still in the early days of the launch, we are very pleased with our progress so far, and believe that QINLOCK has the potential to transform the treatment of GIST in the post-imatinib setting. Beyond QINLOCK, we continue to advance our pipeline of novel switch control kinase inhibitors. And Matt Sherman, our Chief Medical Officer will discuss in further detail the progress we've made across our portfolio of product candidates, including our plans to declare a recommended Phase 2 dose for DCC-3014 in tenosynovial giant cell tumor and to present additional data from our Phase 1 study in patients with TGCT later this year.
I'll now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss the exciting results for the first partial quarter of our QINLOCK commercial launch. Dan?
Daniel C. Martin -- Chief Commercial Officer
Thank you, Steve. Good afternoon. Today I'm pleased to share results from Deciphers first partial quarter as a commercial stage company, as well as initial insights regarding the QINLOCK launch. It's important to recall that QINLOCK was approved on May 15th. Therefore, the commercial results and early launch insights I will share counting just 31 selling days over a period of approximately six weeks.
We are very pleased with the results of our first partial quarter of launch. Q2 net product revenue for QINLOCK was $4.8 million. Several important factors contributed to this result. But first, it's strong prescriber demand for QINLOCK. Recent feedback from our sales team, market research and interactions with key opinion leaders, we believe that strong demand was a result of high unmet need in advanced GIST, rapid growth and awareness of QINLOCK. GIST triggers positive perceptions of the QINLOCK clinical profile and FDA label, and the focus and determination of our customer facing teams despite the challenging selling environment presented by COVID-19.
Second, we were very pleased to see significant prescriber breadth and diversity. In this initial six week launch period, there were more than 100 unique QINLOCK prescribers representing more than 90 unique institutions. Approximately 50% of prescribers and 40% of QINLOCK treated patients were from community accounts consistent with our understanding of where GIST patients received treatment. And nearly 80% of these prescribing institutions had no prior experience with QINLOCK on participation in clinical trials or our expanded access program.
Third, I am pleased to share that our market access team has rapidly achieved broad patient access to QINLOCK. Our extensive launch preparations enabled us to deliver our first patient shipment of QINLOCK within days of approval. Additionally, our payer focused efforts have led to broad coverage across both Medicare and commercial payers, including adoption of favorable coverage policies that are consistent with label.
In addition to strong demand, encouraging prescriber breadth and broad patient access, our Q2 results benefited from several additional factors. First, our Q2 revenue included a modest contribution from patients who switch to commercial drug from our expanded access program in the US The US portion our expanded access program was closed in May upon FDA approval of QINLOCK. In addition, as with any oral oncology launch, our Q2 product revenue included the impact of initial inventory build within our network of specialty pharmacies and specialty distributors. Inventory held by our channel partners was in line with our base on hand targets. And we expect this inventory impact to diminish in subsequent quarters.
Lastly, talking of this initial six week launch timeframe, the percentage of patients receiving free drug under our Patient Assistance Program was lower than our estimate of approximately 20% to 30%. However, as we communicated previously, this percentage can vary quarter-to-quarter. And moving forward, we continue to expect approximately 20% to 30% of patients to receive free drug as part of this program.
Before turning the call over to Matt, I would like to provide an update regarding our experience navigating the unprecedented challenges of the coronavirus pandemic, and our expectations regarding potential impact moving forward. As I reviewed on previous calls, the cross functional launch team has worked extremely hard to adapt their launch strategy tactics to a virtual model. This includes developing and deploying, remote detailing capabilities and increasing our investment in digital and other non-personal marketing channels. Our early experience is that while virtual details can be effective, accessing and coordinating the activities of physicians, pharmacists and other critical stakeholders, within large complex healthcare institutions can be quite challenging and can take longer than usual when required to do so remotely. Additionally, our recent market research with GIST prescribers indicate that GIST patient volume remains below pre-COVID-19 levels, and that some GIST treators may consider delaying treatment switches for advanced shift patients due to COVID-19 related concerns.
Lastly, it remains to be seen what impacts millions of people who are newly uninsured due to pandemic related job losses will have on the proportion of patients eligible to receive free drug under our Patient Assistance Program. Therefore, while we are very pleased with GIST treators initial response to QINLOCK, we also recognized the potential of the continued spread of COVID-19 to impact physician access, GIST patient treatment and the rate of uptake for QINLOCK in the near term.
I will now turn the call over to Matt to discuss the progress of our ongoing clinical programs. Matt?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thank you, Dan. As Dicephera enters transition into a commercial stage company, we've remained deeply committed to [Indecipherable] benefit patients beyond our initial approval in fourth-line GIST and advancing our additional ongoing clinical stage programs to create new medicines for patients with significant unmet medical needs. While our commercial team executes a successful launch, our medical team continues to support the potential of QINLOCK and GIST with a robust publication plan and lifecycle management strategy which includes the potential to treat second line and beyond GIST patients.
In June, results from the pivotal INVICTUS study were published in The Lancet Oncology highlighting QINLOCK significant improvement in progression free survival or PFS compared to placebo as well as it's clinically meaningful improvement in overall survival, along with a well-tolerated safety profile. We also presented additional QINLOCK data from the INVICTUS study, demonstrating positive patient reported outcome results at the ASCO Virtual Scientific program in May and additional clinical benefit for crossover patients at the ESMO World Congress of Gastrointestinal Cancer 2020 on 20th of July.
At the upcoming ESMO Virtual Congress in September, we look forward to presenting additional data from the ongoing Phase 1 studies of QINLOCK and [Indecipherable] study important presentation. The first presentation is titled ripretinib intra-patient dose escalation, following disease progression, provides clinically meaningful progression free survival in gastrointestinal stromal tumor in the Phase 1 study. This presentation focuses on the GIST patients who were enrolled in dose escalation and expansion phases across second, third and fourth line treatment, who received QINLOCK 150 milligrams QD. Patients in the Phase 1 study had the option to be dose escalated to 150 milligrams BID. We will report at the meeting the initial Progression Free Survival or PFS-1 and the subsequent Progression Free Survival or PFS-2 from the date of dose escalation to second disease progression or death from this subgroup of patients who dose escalated to 150 milligrams BID.
The second presentation is titled, Clinical benefit with ripretinib as fourth line or greater treatment and patients with advanced GIST update from the Phase 3 INVICTUS study. This presentation will highlight updated PFS by blinded independence central review, overall survival and safety with a new data cut-off of March 9, 2020, which is an additional nine months of follow up from the data presented at ESMO last year.
Our team at Deciphera continues to be encouraged by the potential for QINLOCK to meaningfully alter the treatment landscape for the spectrum of patients across multiple lines of therapy. While QINLOCK has been well received by fourth-line GIST patients and the treating physicians, we look forward to advancing QINLOCK for the treatment of patients with the second-line GIST, where we believe that could also provide meaningful benefit. To that end, we are pleased to report today that we are on track to complete the target enrollment in the fourth quarter of this year in our ongoing Phase 3 study of QINLOCK, compared to the current standard of ripretinib in patients with second-line GIST. Currently there are 122 sites in 22 countries that have been activated in the INTRIGUE study.
We also continue to rapidly advance our next wave of novel switch control kinase inhibitors. First, turning to DCC-3014, our opponent selective inhibitor, CSF1R, we are on track to select the Phase 2 dose level for treatment of tenosynovial giant cell tumor or TGCT and initiate the expansion collected in this year. We expect to present data from additional patients from the dose escalation portion of the Phase I study at the Medical meeting in the fourth quarter. As you recall, we presented initial clinical proof-of-concept data in three TGCT patients at the Connected Patient Oncology Society or CPOS Annual Meeting last year. And we look forward to sharing additional data later this year.
Turning to Rebastinib, our potent in selective TIE2 inhibitor. We are conducting two clinical phase 1b/2 studies in combination with chemotherapy. One with Paclitaxel and one with Carboplatin. At the ASCO 2020 Virtual meeting in May, we were highly encouraged by the preliminary data presented from the endometrial cancer cohort of Part 2 of the ongoing paclitaxel study, which showed an objective response rate at 29%, and the clinical benefit rate at 72% at eight weeks.
As we announced during ourearnings calllast quarter, we have also observed more than four responses in the ovarian cancer cohort, which has now advanced to the second stage of Simon Two-stage design. We look forward to presenting the data in the poster presentation from the ovarian cancer cohort from Part 2 of the study at the ESMO Virtual Congress in September. In addition, we announced today, that we will be presenting data from part one of the study of Rebastinib in combination with Carboplatin at the ESMO Virtual Congress. We're also happy to confirm that we are on track to file an IND for 3160, our potential first in class Autophagy Inhibitor, designed to treat mutant RAS cancers in the fourth quarter of this year.
Finally, I wanted to say a few words on the ongoing COVID-19 pandemic. Our studies remain open for a moment and patients continue to receive Investigational Drug as well as appropriate follow. We are committed to supporting our clinical studies sites and contract research organizations to help ensure patients receive care in a safe manner consistent with regulatory guidance.
I will now turn the call over to Tucker Kelly, our Chief Financial Officer to review the financial results. Tucker?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Thanks, Matt. I'd like to review the highlights from our second quarter financial results, which includes our first partial quarter of QINLOCK product sales. Total net revenues for the second quarter of 2020 were $7.1 million, which includes $4.8 million of net product sales of QINLOCK and $2.3 million of collaboration revenue. We recognized product revenue upon delivery of QINLOCK to our specialty pharmacy and distribution partners, and the second quarter revenue includes net product sales from our first shipments in May following FDA approval. The gross to net adjustment in Q2 was slightly lower than our prior guidance. Please keep in mind the growth to net can vary quarter-to-quarter, and we continue to expect the rate to be approximately 50% going forward. In addition, we recognized $2.3 million in collaboration revenue under our agreement with Zai Lab, including a $2 million milestone payment due upon their submission of a new drug application to the China National Medical Products Administration for ripretinib, for the treatment of adult patients with advanced gastrointestinal stromal tumor.
Cost of sales for the three months ended June 30, 2020 was immaterial. As the majority of the manufacturing costs related to the second quarter of QINLOCK sales were incurred prior to FDA approval, and thus were recorded as R&D expense. Cost of sales will not be significant until the initial pre-launch inventory is depleted, and additional inventory is manufactured and sold.
In the second quarter of 2020, our total operating expenses excluding cost of sales were $76 million, which remain consistent with expenses of $75.3 million in the first quarter of 2020. As we support our commercial launch of QINLOCK, as well as advance the clinical development activities across the pipeline. Research and development expenses were approximately $46.1 million and selling general and administrative expenses were approximately $29.9 million for the second quarter of 2020. We expect our operating expenses will increase in the second half of the year compared to the first half of this year, as we continue to support clinical development of our pipeline and the commercial launch of QINLOCK.
We ended the second quarter in a strong financial position and remain well capitalized to execute in the launch of QINLOCK in US and to fund the development of our exciting pipeline of novel switch control inhibitors. We ended the second quarter with cash, cash equivalents and marketable securities of approximately $632 million, which we expect will be sufficient to fund our operations into the second half of 2022.
With that, I'll now turn the call back over to Steve.
Steven L. Hoerter -- President & Chief Executive Officer
Thank you, Tucker. Before we open the call for Q&A, I'd like to take a moment and thank the entire team here at Deciphera for their impressive focus and hard work over this past quarter. Looking forward, I'm confident, we are well positioned to continue to execute together successfully both in our QINLOCK commercial launch, building on the momentum of our first partial quarter of launch that we reported today, and our remaining promising development programs.
With that operator, I'd like to open the call for questions.
Questions and Answers:
Operator
Thank you. [Operator instructions] And your first question from the line of Chris Raymond from Piper Sandler. Your line is now open.
Chris Raymond -- Piper Sandler -- Analyst
Thanks for taking the question. Congrats on the great number right out of the gate. Just a couple questions. On the QINLOCK revenue number, I think I heard you say that some of that was stocking, but I don't think I heard you guys quantify that. So, I'm just kind of curious if you could provide us some sense of end user demand?
Steven L. Hoerter -- President & Chief Executive Officer
Sure, Chris. So, this is Steve. So I'd be happy to take that. So, yes, we're really pleased with this initial partial quarter of launch that we've reported today and the strong revenues out of the gate. As Dan mentioned in his prepared remarks, which you may have been able to hear, I know there have been some technical issues on the line there. But we did note that one of the contributing factors in addition to strong demand was the usual and customary inventory build that we saw in this first partial quarter of launch. So, we haven't quantified that but we have said that we ended the quarter with what we expected to see in terms of days on hand for inventory.
Chris Raymond -- Piper Sandler -- Analyst
Okay, and maybe just another question here. I think I've seen in previous slides and the way you guys have described the mix of prescribers between community and academic has been sort of 70% academic, 30% community. But I think I heard you mentioned that 50% of prescribers were community based. So, I guess, on that, I mean, a, I guess is that a surprise to you guys especially given that the label is fourth line, and one would expect that to be maybe even more skewed toward academic? But maybe a second part of that is, are you getting a sense that there's some use an earlier lines in the community?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Chris. That's a great question. So, I'll ask Dan Martin, to take both of those questions for you.
Daniel C. Martin -- Chief Commercial Officer
Yes. And I hope you're able to hear me OK? How's the audio? All right. Okay?
Chris Raymond -- Piper Sandler -- Analyst
Yes.
Daniel C. Martin -- Chief Commercial Officer
So, apologies for any audio challenges previously. So, just to clarify the first part of your question, academic versus community. So, what we said previously, is that overall, about 70% of GIST treatment happens in the community setting, about 30% in the academic setting. Now to your point, when you look at fourth line, the later you go in the line of therapy that switches a bit as you might expect, as patient's treatment options dwindle, and you get more referrals in the academic setting. However, we've always thought in the fourth line still probably anywhere from 30% to 40% of GIST treatment was happening in the community setting. And so consistent with that, what we just shared in my prepared remarks was that about 40% of our QINLOCK treated patient volume is coming from the community, about 50% of the prescribers which you can do the math and the patient's per prescriber is a little bit heavier in the academic setting, as one would guess. So, really pretty consistent with what we expected.
With regard to your second part of your question, earlier lines of therapy. It's a good question. We're really pleased with the way the first partial quarter has gone. Of course, all of our focus is on optimizing the launch of QINLOCK in the fourth line. So all of our promotional efforts, all of our materials, etc, are all consistent with our FDA approved indication. That said, we recognized that some physicians may have an interest in using QINLOCK in earlier lines of therapy. It's really challenging to estimate the proportion of patients who may be receiving treatment in earlier lines, that the data sources that are available are imperfect, and often don't provide a very clear or reliable picture. So, at this time, I'm still very early on launch, it's really difficult for us to determine how much use if any, was off label.
Chris Raymond -- Piper Sandler -- Analyst
Okay. Thanks very much.
Operator
Thank you. Your next question is from the line of Eun Yang from Jefferies. Your line is now open.
Eun Yang -- Jefferies -- Analyst
Thanks very much. So, I just want to ask you again about the second quarter sales. So, the consensus was less than 1 million. And then you came at 4.8. So, can you talk about how much of your sales actually benefited from inventory as well as, do they expand, are the patient switching to commercial?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Eun, it's Steve here. So, Dan covered some of that in his prepared remarks, but Dan maybe you could provide Eun with a little bit more color in terms of factors that contributed to the strong performance in this first partial quarter.
Daniel C. Martin -- Chief Commercial Officer
Yes, absolutely. Thanks, Steve. Good question. So, again, it's really important, I think. I want to reiterate that. There were a number of factors that we think contributed to our initial strong result and primarily, that's strong physician demand for QINLOCK also really encouraging prescriber breadth and diversity. And importantly, very rapid gains toward broad patient access so those are the primary drivers. Additionally, just to provide some additional color. We outlined in my prepared remarks that there was some contribution to the Q2 revenue from conversion of US patients from our Expanded Access Program to commercial product. We have not given specific details on our EAP. What I can say is that program in the US is now closed, as is typical upon FDA approval.
And then as it relates to inventory build, what we can share is that, it's typical for any oral oncology launch in our first partial quarter to have some contribution of revenues tied to an initial inventory build. However, as Steve mentioned in his answer to a prior question, the teams did a great job managing inventory throughout the quarter. And the inventory held by our channel partners was very consistent with our days on hand targets. And we would expect the contribution or the impact of that initial inventory build to diminish in subsequent quarters.
Eun Yang -- Jefferies -- Analyst
Thank you. And have you actually seen QINLOCK usage in earlier lines -- earlier lines than fourth line?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Dan, would you like to address that question?
Daniel C. Martin -- Chief Commercial Officer
Sure, we know this is certainly an area of interest, but as I mentioned to the prior question, in my answer to the prior question. First and foremost, we are focused on the fourth line launch and all of our promotional efforts are toward that. We've recognized some physicians may have interest in using QINLOCK in earlier lines of therapy. The fact remains it's challenging to estimate, especially this early on and launch what proportion of patients may be receiving treatment in earlier lines, if any, because the data sources are just imperfect to do that and often don't provide a clear or reliable picture. So at this time, it's just difficult for us to determine how much use if any is in earlier lines of therapy.
Eun Yang -- Jefferies -- Analyst
Okay. And I have a last question, so in ripretinib in the past you are looking at other solid tumors, key driven tumors in the expansion cohort. So is there any update on what types of tumors you may pursue?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Eun it's Steve, thanks for the question. So Matt referenced in his prepared remarks that we're really pleased to see some of the Phase 1 data be accepted as a mini oral presentation coming up at ESMO. So this is the GIST cohorts from the Phase 1. As you noted, there are a number of other expansion cohorts, signal seeking cohorts that we had as part of the Phase 1. And we don't have a further update for you at this time on today's call.
Eun Yang -- Jefferies -- Analyst
Thank you.
Operator
Next question, from the line of Peter Lawson from Barclays. Your line is now open.
Peter Lawson -- Barclays -- Analyst
Hi. Thanks for taking my questions. Just on the TGCT data in 4Q. I mean, what should we expect to see a number of patients, any metrics we should be thinking about for that data?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Hi, Peter, it's Steve. So maybe I'll start off answering that and then Matt, please feel free to add some additional color to that. So as Matt noted in his prepared remarks, we have a couple of milestones, important milestones coming up for the 3014 program for the balance of the year. One of those is to declare a recommended phase two dose. The other is to open an expansion cohort in patients with TGCT. And then as Matt noted, we also intend to provide data from the Phase 1 at a medical meeting coming up in the fourth quarter of the year. So I think, we haven't guided specifically to a number of patients that you can expect to see data on. As you know, at CTOS last year, we reported initial clinical proof-of-concept in the first three patients that we had treated. So we'll have data updates on some of those patients and, of course, additional patients. But tough for us to specify at this time exactly what number to expect. But, of course, what we're going to be looking for as we go through the data and accumulate the data is what is the optimal dose going forward? How does that compare an early data with what we see from the other approved agent pexidartinib for this disease for TGCT. So stay tuned for more to come at the end of the year. Thanks, Peter.
Peter Lawson -- Barclays -- Analyst
Perfect. Thank you so much. And then, just an update on how things are moving for ASM and when we could see the next data, just any updated thoughts around Systemic Mastocytosis?
Steven L. Hoerter -- President & Chief Executive Officer
Sure. So I'm happy to address that. So its somewhat similar, I think, to Eun's question, earlier. Matt noted in his prepared remarks that we will have data at ESMO from the GIST expansion cohorts from the Phase 1. So for the first time, we're going to be reporting on the subset of patients that dose escalated to 150 BID in that study. So we'll be reporting on the PFS 1, so the initial interval of progression free survival for those patients. And then upon dose escalation, we then capture PFS 2. So we'll then also report for that subset, the PFS 2 data. So, on today's call I don't have any further update in terms of the other expansion cohorts from the Phase 1.
Peter Lawson -- Barclays -- Analyst
Okay. Thank you so much. Thanks for taking the questions.
Operator
Thank you. Your next question from the line of Michael Schmidt from Guggenheim. Your line is now open.
Michael Schmidt -- Guggenheim -- Analyst
Hey, guys. Thanks for taking my questions and congrats on the launch as well from me. Maybe a question around competitive dynamics and just QINLOCK obviously benefits from a broad label that doesn't specify a certain genotype, but there is obviously overlap to some degree with A bucket. I was just wondering if you could comment on, what do you see in terms of PDGFR alpha for to the positive patients that might have been treated with QINLOCK in the second quarter and how you see the competitive dynamics evolving there?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, thanks Michael. So it's Steve, maybe I'll start off and then turn it over to Dan as well, who can comment on what we've seen in the second quarter and also what we've seen in the extensive market research that we've done. But maybe just to tee that up a little bit. We've talked for a number of months now, probably starting back at the JP Morgan conference in January about the market research that we've done based on the INVICTUS data and with that target product profile, getting reactions from physicians to the profile as they evaluate the treatment options for their patients with gastrointestinal stromal tumor.
And what we've heard very consistently is with those randomized data in a broad spectrum of patients. So irrespective of mutational status, that physicians really value, a, the fact that we have randomized data. But b, the fact that we -- the drug offers based on INVICTUS, such as striking benefit in terms of progression free survival and also a clinically meaningful improvement in overall survival. And all of that against the backdrop of what is a very well tolerated drug.
So our expectation based on the data is that QINLOCK or ripretinib really has the potential to be best-in-class for this disease based on the INVICTUS data. Now, as you point out, in a competitive marketplace where there's one other recently approved agent with avapritinib with a narrow label, as you point out, for the exon 18 driven part of the disease, I think what physicians are now internalizing is that the negative VOYAGER trial that reported out a couple of months ago and what that means for them as they think about options for patients certainly puts the data from INVICTUS in context. But, Dan, maybe you want to comment further on what we're seeing and hearing in terms of this subset of patients that has exon 18 driven disease?
Daniel C. Martin -- Chief Commercial Officer
Sure. Just a couple of thoughts on both parts of the question, I mean, the only thing that I would add to Steve's answer as it relates to the profiles. We continue to do research and we've been doing research now that were launched and what comes back consistently is just very, very strong positives for the QINLOCK profile. And, one of the things that I've been pleased to see is that GIST traders are increasingly understanding how QINLOCK is differentiated from other products in this space, including avapritinib's much more narrow profile, as Steve just pointed to.
As it relates to PDGFR alpha, one of the things that we're really fortunate to have is a very broad indication. And so all of the payer policies that we're seeing going into place, they are agonistic to mutation and so we don't -- there's no reason for us to really collect or track data on the mutation profile of QINLOCK treated patients, because it's not commerce drug. So we've always viewed QINLOCK as Steve mentioned best-in-class and potentially standard-of-care product in the post-imatinib setting. And that it's inclusive of patients of all mutation types, including wild type for that matter.
Michael Schmidt -- Guggenheim -- Analyst
Okay, great. Thanks. And then a question on DCC-3014, I know you talked about the Phase 1 update later this year. I was just wondering how we should think about the potential development path forward longer term in TGCT? Should we think about maybe a single arm approval strategy here based on the Phase 1B dose expansion cohort? And I guess what would the regulatory bar be here? Do you need to exceed pexidartinib for example? Or what level of efficacy would you get confidence for example, that you could win in a randomized controlled studies? Maybe just some high level thoughts on the path to market here longer term?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Michael. So that's a good question. Matt, would you like to take that?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. Thanks, Steve and this is Matt. Thanks, Michael. Can you hear me? Okay, I just want to make sure the audio is coming through clearly. There was some trouble earlier with the storm passing overhead. So it's very, very good question. Let me just start with saying, we look forward to the updates at the end of this year, as we said, we'll be able to talk about the recommended Phase 2 dose, the initiation of an expansion cohort, and also to update folks at a medical meeting in the fourth quarter of this year for further data in the TGCT patients in the ongoing Phase 1 study.So if we think about further development, we can use as the benchmark the pexidartinib development when it was approved last year, in August by the FDA. And at that time, they conducted a 120 patient study randomized one-to-one to placebo. And based on objective response rate every 25% of 38%, 39% were able to receive full approval, despite also having a pretty significant safety profile with a blackbox warning on the label and the requirement for REMS program for patient enrollment on to treatment. So, using that sort of as a benchmark for development we think that safer drug potentially at 3014 has the ability on preapproval on TGCT patients. It also should be noted that the CHMP had a negative opinion for pexidartinib in the EU. So again, speaks to the safety profile that was shown with the pexi.
Michael Schmidt -- Guggenheim -- Analyst
Okay. Great. Well, thanks for taking my questions and congrats on the launch again.
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Michael.
Operator
Thank you. Your next question is from the line of Robyn Karnauskas, SunTrust. Your line is now open.
Nicole -- SunTrust Robinson Humphrey -- Analyst
Hi, this is Nicole [Phonetic] on for Robyn, SunTrust Securities. Thanks for taking our questions. So really quickly, can you remind us what's in the profile and what the overlap is in KIT & PDGFR alpha mutants between ripretinib and sunitinib? And then also, I'm not sure if I missed this, but how many prescriptions were filled or how many patients received drug in the second quarter?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Hi, Nicole. It's Steve. Thanks for the question. So maybe I'll take the second question first, and then I'll just ask Matt, if he'd like to briefly outline the spectrum of activity of ripretinib relative to sunitinib based on what we've previously published in cancer cell, for example, last year. But specifically for this question about number of scripts and number of patients, so we haven't disclosed that on today's call. That's not one of the launch metrics that we'll be sharing externally on a quarterly basis.
But as Dan said in his prepared remarks, and then in response to the questions that have come up so far, certainly we're very, very pleased with the launch. It's a reflection of strong demand, which spans not only physicians and patients being treated in the academic setting, but also very importantly, we believe the use of the drug in the community setting it's a real indicator that we're following very closely. And we're very pleased to see the breadth of utilization so far. So Matt, do you want to take that first question?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. So the question as I understand is speaking about the activity of ripretinib in the second line setting compared to the historical data for sunitinib, which is approved now for the second line. So, we did present at the triple meeting last year, the data from the Phase 1 study where we looked across 142 patients in second line, third line and fourth line patients. And so, going down on the second line patients, we had a progression free survival of 10.7 months in that study with a 19% objective response rate. And while it's across study comparison, sunitinib in its pivotal study had about a 5.6 month progression free survival with a 7% objective response rate. So that gave us the reason to believe for initiating the INTRIGUE study. As you know the INTRIGUE study is our randomized Phase 3 study comparing reprinted to sunitinib. And as we highlighted today as well too, our INTRIGUE is completing enrollment of that study by the end of this year.
Nicole -- SunTrust Robinson Humphrey -- Analyst
Okay. Great. Thanks so much.
Steven L. Hoerter -- President & Chief Executive Officer
Thanks Nicole.
Operator
Thank you. Your next question from the line of Ren Benjamin from JMP securities. Your line is now open.
Reni Benjamin -- JMP Securities -- Analyst
Hey, good afternoon guys. Thanks for taking the questions and congratulations on a great start to a launch. Maybe my first question a little bit having to do with a broad kind of ex-US strategy. Steve, you've got approvals in several kind of distributor based sort of delivery in those countries. You now have China the NDA being accepted. Can you just kind of take us through your latest thoughts on how the timing of when you think these revenues from the ex-US launch may start contributing to your P&L and how you see that unfolding?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Ren it's Steve. Thanks for the question. You broke up a little bit, but I think I got the guess of the question in terms of ex-US strategy and timing for any future potential revenues. So first, maybe we can just broad strokes kind of talk about where we are globally in terms of our regulatory strategy. Obviously approved here in the US, excited about the early days of the launch and looking forward to continuing to get out and educate physicians about QINLOCK or ripretinib as we drive further utilization of the brand here in the US.
As we've noted previously, we now have of course approval in Canada and in Australia. This was part of Project ORBIS. As you know Ren, and as we've talked about previously, our strategy in those two territories specifically is very likely to be a distributor approach, where we retain rights to the products but we partner with a local distributor that's able to help navigate the pricing and reimbursement process. And then of course, get the product to patients physically and also engage with physicians and share with physicians the data to support the product. Both of those territories for both Australia and Canada, there can be a somewhat lengthy pricing and reimbursement process. So these are territories that are very different from what we experienced here in the US where we price a product and then launch it immediately, of course, educating and working with insurance companies. But in these other single payer markets, there's quite a bit of negotiation of work that has to be done in submitting data to HTA bodies and then getting a price approval. So difficult from where we are now Ren, to project when we might see revenues from those territories. It's certainly at some point further off in the future.
Now with respect to China. As we noted today, the application submitted by Zai Lab, who is our partner for Greater China, they anticipate they receive priority review as we discussed today, and as they disclosed this morning. And they believe that the timeline for a potential approval could be about 12 months. I think that was their experience with Zejula. Unlike the system here in the US, there isn't a prescribed action date by which time the NMPA has to take action on the application. So there is some uncertainty in terms of when they may take action. And then when of course, Zai then would be able to start commercializing can lock in China specifically.
Now, as Matt also noted, and we noted in the press release, the next significant regulatory milestone for us is going to be filing the marketing authorization application to the European Medicines Agency. And we further refined our guidance today to say that we'll be making that filing in quarter four. So one of the things we haven't disclosed yet is what our go-to-market strategy is going to be for Europe. And so, as we get closer to that filing and at the right time then we'll disclose exactly what our go-to-market approach is going to be for the European Union.
Reni Benjamin -- JMP Securities -- Analyst
Got it. That's very helpful. And then just maybe switching gears to 3116. I know you'll be filing the IND. But can you maybe just give us a little bit more color on how we should be thinking about this asset and how we should be thinking about the development of this asset going forward? Should we be focusing on particular tumors [Technical Issues] model or any sort of color you could share?
Steven L. Hoerter -- President & Chief Executive Officer
Sure. So maybe I'll start off and then I'll turn it over to Matt. So, we're really excited about 3116. This is our potential first in class ULK inhibitor targeting the autophagy pathway, which we know is an escape pathway for mutant RAS cancers. And as you know, we plan to file an IND before the end of the year for that program, making it the next program coming out of our research organization. But Matt maybe you want to offer some additional color on how you're viewing the potential development path for 3116?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thanks, Steve. So, as we indicated today, we are very excited about the opportunity to develop 3116 as ULK inhibitor, first-in-class inhibitor of autophagy. The development path of this, as we indicated would be in the concerning of mutant RAS cancers. Mutant RAS cancers represent proximately 30% of all human cancers, and particularly represented in pancreatic cancers are fairly intractable cancer by many targeted therapies, as well as significant number of patients with the lung cancer and additional patients with colorectal cancer. So, if you think about the development, there would be potentially those indications. And we look forward to sharing more details once we've further -- once we move further along with the IND filing.
Reni Benjamin -- JMP Securities -- Analyst
Perfect. Thanks for taking the questions and congratulations.
Steven L. Hoerter -- President & Chief Executive Officer
Thanks, Ren.
Operator
Thank you. So, your next question from the line is Andrew Berens from SVB Leerink. Your line is now open.
Andrew Berens -- SVB Leerink -- Analyst
Hi, thanks. Congrats on the results for the quarter. So, if I ask some of the topics you already addressed with a power outage I had to dial back-in. I was wondering if you guys are getting patients that have failed sutin, but not gotten [Indecipherable] yet. And then also just wanted to get a color on whether or not you're seeing a warehouse of patients that were awaiting a novel GIST drug?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Andy. Both are really good questions. I'll ask Dan Martin, if he'd like to address those?
Daniel C. Martin -- Chief Commercial Officer
Yes, absolutely. Thanks, Andy. Appreciate the questions. So, first question was about earlier line patient. So, we are laser focused, of course, on promoting the drug and optimizing the launch in fourth line. So, all of our efforts and materials and messaging and whatnot are, of course, on label with the fourth line indication. That being said, we do appreciate that there may be some physicians who may have some interest in using QINLOCK in earlier lines of therapy. However, it's really challenging to estimate the proportion of patients who may be receiving treatment in earlier lines. The data source is available, just they're imperfect and often don't provide a clear or reliable picture. So, it's still certainly early days and at this time, it's difficult for us to determine how much use if any, is off label.
Regarding your question about whether or not there was sort of a bolus of prevalent patients. Another good question. We've communicated previously that we did not expect there to be a significant bolus of prevalent patients in this setting given how late line the setting is, how sick some of these patients are? And frankly, again, being quite early days, tough to assess. What I would say is that we are thrilled with the early experience of QINLOCK in the marketplace, the prescriber demand and breadth and diversity of prescribers. So, really pleased with that. And we did mention also, I don't know if you've heard it before, given the power outage experience, but we did also mention that a couple other factors contributed to the Q2 revenue. One was a modest impact of conversion of US patients in our Expanded Access Program to our commercial drug. Another was consistent with any oral oncology launch, particularly one with a partial first quarter inventory -- initial inventory build, so impact of initial inventory build. And then, thirdly, a lower than anticipated utilization of our Patient Assistance Program. We have previously estimated 20% to 30% came in bit lower than that, but we continue to expect that estimate to hold true moving forward.
Andrew Berens -- SVB Leerink -- Analyst
Okay, I appreciate all the color and then I think Peter asked you guys about the SM data that on the Q1 call, you said they are presented by year end? Are you still planning to present that, I wasn't really clear on your answer to that?
Steven L. Hoerter -- President & Chief Executive Officer
Sure. Thanks for the question, Andy. So, what I noted in my response to Peter's question is that we have some data from the Phase 1. As Matt noted, from the GIST cohorts that has been accepted as a mini oral presentation at ESMO. So, this is looking at the patient's who dose escalated to 150 BID and looking at PFS 1, as well as PFS 2 for that cohort. So, we don't have on today's call any further update with respect to other cohorts from the Phase 1.
Andrew Berens -- SVB Leerink -- Analyst
Okay. Is that SM cohorts still enrolling or what is the status of it?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. We don't have any further update at this time on the cohort. As we've talked about, previously, this has been a cohort for us that has been really challenging to enroll. As you know, from last year, we talked about how we had amended the protocol to start to treat patients at 150 BID. But it's been a tough going for us. So, we don't have any -- at this time any further update for you on that cohort.
Andrew Berens -- SVB Leerink -- Analyst
Okay. All right. Thanks for the questions. Appreciate and congrats again.
Steven L. Hoerter -- President & Chief Executive Officer
Thank you. Thanks, Andy.
Operator
Thank you. Your next question from the line of Ben Chan [Phonetic] from Canaccord. Your line is now open.
Ben Chan -- Cannacord Genuity -- Analyst
Hi. Thanks for taking my question and congratulations on launch this quarter. A couple of companies have remarked that the virtual formats of some of these medical meetings like ASCO has made it hard for the company to get the word out for product launches. And I'm just wondering if you agree with that, and maybe if you could rank order, some of the challenges that you might see out there that might be headwinds toward getting the launch trajectory up and going? Thanks.
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Ben. It's a great question. We started talking about the potential impact of COVID-19 on the Q1 call. And now that we're of course in the middle of the launch, Dan would be in a good position to offer some additional color. He had some in the prepared remarks, but I'm sure he can share some additional color in terms of what we're seeing, what our experience has been so far and what the challenges may be ahead in terms of being able to engage with physicians in a promotional discussion given COVID-19. Dan?
Daniel C. Martin -- Chief Commercial Officer
Sure, absolutely. As it relates to virtual details, what our experience has told us so far is that virtual details can be -- they can be very effective. The challenge is when you're trying to coordinate the activities of many diverse stakeholders via physicians, pharmacists and other key stakeholders in these large complex healthcare institutions, doing that when you're able to walk in live and spend the day in the facility is one thing. But when you have to coordinate all of that remotely with often one-off virtual engagements, it can be challenging. And it can frankly, it's not that it can't be done, it can and we are but sometimes it can take a bit longer than normal. So, it's just something to keep in mind as it relates to consideration for ramp trajectory, that sort of thing. But, we've been -- I really want to underscore again, how pleased we've been with physician, GIST prescribers reaction to QINLOCK, to the profile to the all the data into the FDA label.
So, when we are able to get in front of the right folks via the virtual means, it's been a very effective means. It just does create some challenges beyond that. I pointed to in the prepared remarks that someone we've done extensive launch market research and with GIST prescribers and some of that we've asked questions about expectations for COVID moving forward or the impact of COVID moving forward, and some of them have noted that overall patient volume as a result of COVID, GIST patient volume is still somewhat below pre-COVID-19 levels. And that some physicians would even consider delaying some late line switches as a result of COVID related concerns. So, those are some of the things that we've got our eye on and we'll continue to monitor as it relates to COVID-19 challenges.
Ben Chan -- Cannacord Genuity -- Analyst
Okay, great, I wish you the best of luck in tackling those. I just have another quick follow-up or two. Can you comment on the amount of inventory that flowed into prepaid from R&D prior to approval? Is that where it's going to be coming out of going forward until you actually start incurring cost of goods?
Daniel C. Martin -- Chief Commercial Officer
That's right, I can take that one. Up until the time of approval, all of the materials that we use for commercial products are expensed through R&D. Once we reached approval, we would then start to capitalize that so you'll see some initial capitalization inventory on the balance sheet now, but it will be quite some time before we start to have a higher and more normalized rate of cost of goods, given the expense prior to approval.
Ben Chan -- Cannacord Genuity -- Analyst
Okay. So that's going to be guess a tricky modeling item going forward. The last question I had is, I think you remarked that, it could take as long as 12 months for Zai to get approval in China? Can you refresh and remind us about what the financial milestones would be upon approval and thereafter?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Tucker, you want to -- would you like to take that question?
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Sure. So we haven't specifically provided the breakdown of the individual milestones. We've talked about the aggregate for a commercial and development based milestones. We did announce obviously today that these filing itself has a $2 million milestone payment, which we recognized in the second quarter, but we haven't given specifics on what a future milestone for a commercial approval might be.
Ben Chan -- Cannacord Genuity -- Analyst
Okay, fair enough. Thanks very much. And good luck to you guys.
Steven L. Hoerter -- President & Chief Executive Officer
Thank you.
Operator
Thank you. Your next question from the line of Eun Yang from Jefferies. Your line is now open.
Eun Yang -- Jefferies -- Analyst
Thank you for the follow-up question. So the Phase 3 INTRIGUE study patient enrollment completion in fourth quarter, do you have any expectation for the timeline for the data? Looking at clinicaltrials.gov you still missed primary completion date of the June 2021, so I just want to ask you if that is still in line with your expectation? Thank you.
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Hi, Eun, it's Steve. Thanks for the question. You're right, that time to study completion that you referenced in clinicaltrials.gov of June of 2021 was what we had put up on clinicaltrials.gov when we first loaded the study up. So what we said, as Matt noted in his prepared remarks is that, we're pleased with the pace of enrollment. We're pleased of course, with the site openings that we've seen and we intend to complete enrollment in the study at the end of the year. And when we achieve that milestone of getting to target enrollment, we'll then provide some additional color on when we might expect to see data from the study. I think we'll have additional information that will give us a better read on what the timeline could be for a read out. Of course, it's an endpoint in the study, that's in the time to event analysis to PFS endpoint. So you have to wait, of course, for the events to accumulate based in part on the pace of enrollment overtime and the like. But we'll provide that update when we get to completion of target enrollment here by the end of the year.
Eun Yang -- Jefferies -- Analyst
Thank you.
Operator
And we don't have any further questions over the phone. Let me turn call over back to Steve.
Steven L. Hoerter -- President & Chief Executive Officer
Great. Thanks Michelle and thanks to everybody for joining us on the call today and thank you for your continued support. We look forward to keeping all of you updated on our continued progress with our first commercial launch of QINLOCK as well as the balance of our development programs. Hope you all have a great evening. Thank you. Take care.
Operator
[Operator Closing Remarks]
Duration: 61 minutes
Call participants:
Jen Robinson -- Vice President, Investor Relations
Steven L. Hoerter -- President & Chief Executive Officer
Daniel C. Martin -- Chief Commercial Officer
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Chris Raymond -- Piper Sandler -- Analyst
Eun Yang -- Jefferies -- Analyst
Peter Lawson -- Barclays -- Analyst
Michael Schmidt -- Guggenheim -- Analyst
Nicole -- SunTrust Robinson Humphrey -- Analyst
Reni Benjamin -- JMP Securities -- Analyst
Andrew Berens -- SVB Leerink -- Analyst
Ben Chan -- Cannacord Genuity -- Analyst
More DCPH analysis
All earnings call transcripts
{%sfr%}
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 61 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Daniel C. Martin -- Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Chris Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Peter Lawson -- Barclays -- Analyst Michael Schmidt -- Guggenheim -- Analyst Nicole -- SunTrust Robinson Humphrey -- Analyst Reni Benjamin -- JMP Securities -- Analyst Andrew Berens -- SVB Leerink -- Analyst Ben Chan -- Cannacord Genuity -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. The FDA approval and launch of QINLOCK is an important milestone for the thousands of people in the United States facing a GIST diagnosis, and also serves as validation of Deciphers novel approach to designing switch control kinase inhibitors.
|
Operator [Operator Closing Remarks] Duration: 61 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Daniel C. Martin -- Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Chris Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Peter Lawson -- Barclays -- Analyst Michael Schmidt -- Guggenheim -- Analyst Nicole -- SunTrust Robinson Humphrey -- Analyst Reni Benjamin -- JMP Securities -- Analyst Andrew Berens -- SVB Leerink -- Analyst Ben Chan -- Cannacord Genuity -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 61 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Daniel C. Martin -- Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Chris Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Peter Lawson -- Barclays -- Analyst Michael Schmidt -- Guggenheim -- Analyst Nicole -- SunTrust Robinson Humphrey -- Analyst Reni Benjamin -- JMP Securities -- Analyst Andrew Berens -- SVB Leerink -- Analyst Ben Chan -- Cannacord Genuity -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 61 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Daniel C. Martin -- Chief Commercial Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Chris Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Peter Lawson -- Barclays -- Analyst Michael Schmidt -- Guggenheim -- Analyst Nicole -- SunTrust Robinson Humphrey -- Analyst Reni Benjamin -- JMP Securities -- Analyst Andrew Berens -- SVB Leerink -- Analyst Ben Chan -- Cannacord Genuity -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020, 4:30 p.m. I'll now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss the exciting results for the first partial quarter of our QINLOCK commercial launch.
|
c1f65541-50be-48c0-a30c-39f4adfdf047
|
715520.0
|
2020-07-14 00:00:00 UTC
|
Notable Two Hundred Day Moving Average Cross - DCPH
|
DCPH
|
https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-dcph-2020-07-14
|
nan
|
nan
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $51.98, changing hands as low as $50.37 per share. Deciphera Pharmaceuticals Inc shares are currently trading off about 1.4% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $51.37.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $51.98, changing hands as low as $50.37 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $51.37. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $51.98, changing hands as low as $50.37 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $51.37. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $51.98, changing hands as low as $50.37 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $51.37. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $51.98, changing hands as low as $50.37 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $51.37. Deciphera Pharmaceuticals Inc shares are currently trading off about 1.4% on the day.
|
36584b97-9dbb-4aca-829b-82cfaab9d4a9
|
715521.0
|
2020-07-06 00:00:00 UTC
|
Noteworthy Monday Option Activity: CIEN, UBER, DCPH
|
DCPH
|
https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-cien-uber-dcph-2020-07-06
|
nan
|
nan
|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ciena Corp (Symbol: CIEN), where a total volume of 13,147 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.9% of CIEN's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $48.50 strike put option expiring August 07, 2020, with 1,650 contracts trading so far today, representing approximately 165,000 underlying shares of CIEN. Below is a chart showing CIEN's trailing twelve month trading history, with the $48.50 strike highlighted in orange:
Uber Technologies Inc (Symbol: UBER) options are showing a volume of 169,760 contracts thus far today. That number of contracts represents approximately 17.0 million underlying shares, working out to a sizeable 69% of UBER's average daily trading volume over the past month, of 24.6 million shares. Especially high volume was seen for the $33 strike call option expiring July 10, 2020, with 10,644 contracts trading so far today, representing approximately 1.1 million underlying shares of UBER. Below is a chart showing UBER's trailing twelve month trading history, with the $33 strike highlighted in orange:
And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 4,017 contracts thus far today. That number of contracts represents approximately 401,700 underlying shares, working out to a sizeable 63.7% of DCPH's average daily trading volume over the past month, of 630,250 shares. Especially high volume was seen for the $75 strike call option expiring January 15, 2021, with 1,444 contracts trading so far today, representing approximately 144,400 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $75 strike highlighted in orange:
For the various different available expirations for CIEN options, UBER options, or DCPH options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Especially high volume was seen for the $75 strike call option expiring January 15, 2021, with 1,444 contracts trading so far today, representing approximately 144,400 underlying shares of DCPH. Below is a chart showing UBER's trailing twelve month trading history, with the $33 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 4,017 contracts thus far today. That number of contracts represents approximately 401,700 underlying shares, working out to a sizeable 63.7% of DCPH's average daily trading volume over the past month, of 630,250 shares.
|
That number of contracts represents approximately 401,700 underlying shares, working out to a sizeable 63.7% of DCPH's average daily trading volume over the past month, of 630,250 shares. Below is a chart showing UBER's trailing twelve month trading history, with the $33 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 4,017 contracts thus far today. Especially high volume was seen for the $75 strike call option expiring January 15, 2021, with 1,444 contracts trading so far today, representing approximately 144,400 underlying shares of DCPH.
|
Below is a chart showing UBER's trailing twelve month trading history, with the $33 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 4,017 contracts thus far today. That number of contracts represents approximately 401,700 underlying shares, working out to a sizeable 63.7% of DCPH's average daily trading volume over the past month, of 630,250 shares. Especially high volume was seen for the $75 strike call option expiring January 15, 2021, with 1,444 contracts trading so far today, representing approximately 144,400 underlying shares of DCPH.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $75 strike highlighted in orange: For the various different available expirations for CIEN options, UBER options, or DCPH options, visit StockOptionsChannel.com. Below is a chart showing UBER's trailing twelve month trading history, with the $33 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 4,017 contracts thus far today. That number of contracts represents approximately 401,700 underlying shares, working out to a sizeable 63.7% of DCPH's average daily trading volume over the past month, of 630,250 shares.
|
019b9caa-43b3-4fce-abbf-6b961d348457
|
715522.0
|
2020-06-17 00:00:00 UTC
|
3 “Strong Buy” Healthcare Stocks That Should Remain Healthy
|
DCPH
|
https://www.nasdaq.com/articles/3-strong-buy-healthcare-stocks-that-should-remain-healthy-2020-06-17
|
nan
|
nan
|
For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of COVID-19. This week, however, U.S. stocks recovered some lost ground thanks to strong retail sales data. There's a lot going on in the markets, and the only certainty is uncertainty.
Against this backdrop, we turned our attention to defensive stocks in the healthcare sector. In general, these stocks provide stable earnings regardless of the stock market’s state due to the constant demand for their products or services.
With this in mind, we used TipRanks’ database to identify three defensive healthcare stocks with upside potential north of 20%. Not to mention each of these companies has earned a “Strong Buy” consensus rating from the analyst community.
Deciphera Pharmaceuticals (DCPH)
We will start with Deciphera, a biopharmaceutical company which develops cancer medications. On May 15, the company received FDA approval for its QINLOCK™ therapy. The drug is used for the treatment of fourth-line gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.
The good news didn’t end there. On June 8, Deciphera announced that The Lancet Oncology (a medical journal) published positive results from the INVICTUS Phase 3 study of QINLOCK, which featured patients who have been previously treated with anticancer therapies. Data from the study showed a statistically significant improvement in the progression free survival in patients randomized to QINLOCK, compared with patients receiving a placebo.
5-star analyst Christopher Raymond, of Piper Sandler, expressed enthusiasm for QINLOCK. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.”
As a result, Raymond rates DCPH an Outperform (i.e. Buy). The analyst believes the stock has more room to run, as he maintains a $75 price target. This implies upside potential of 21% from current levels. (To watch Raymond’s track record, click here)
Like Raymond, other analysts are also bullish on the stock. The 11 ratings on the stock include 9 Buys, only 2 Holds and no Sells, adding up to a Strong Buy consensus rating. The average price target of $71.20 represents a possible 15% increase from the share price of $59.50. (See Deciphera stock analysis on TipRanks)
Laboratory Corporation of America (LH)
Up next is Laboratory Corporation of America, which operates two divisions, LabCorp Diagnostics (LCD) and Covance Drug Development. LCD provides clinical laboratory services such as blood, urine, and COVID-19 tests, while Covance offers services that help clients manage the drug development process.
The company’s sales were only slightly affected by the COVID-19 pandemic. Revenue for the first quarter of 2020 was $2.8 billion, an increase of 1.2% from the prior-year quarter. The increase in revenue was due to acquisitions, partially offset by the negative impact from COVID-19. However, earnings took a bigger hit thanks to the public health crisis, as the operating loss for the quarter was $193 million, compared to operating income of $318 million in the first quarter of 2019.
J.P. Morgan analyst Lisa Gill believes Laboratory is better positioned than the competition because of its income diversity, with it also less exposed to upcoming Medicare cuts. To provide additional support for her bullish thesis, the 5-star analyst cites improving trends in the company’s core business.
To this end, Gill rates LH an Overweight (i.e. Buy), while raising her price target from $118 to $223. The new figure implies upside potential of 31% from current levels. (To watch Gill’s track record, click here)
Turning now to the rest of the Street, most other analysts are on the same page. Laboratory has a Strong Buy analyst consensus rating comprised of 10 Buys, 3 Holds and no Sell ratings. The average price target on the stock is $213.27, which suggests 25% upside potential. (See LH stock analysis on TipRanks)
ACADIA Pharmaceuticals (ACAD)
Last on our list is ACADIA, a biopharmaceutical company that designs medications for central nervous system disorders. ACADIA has developed the only approved therapy for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, NUPLAZID.
Despite COVID-19, sales of NUPLAZID increased 43% to reach $90.1 million for the three months ended March 31, 2020, compared to $63 million in the first quarter of 2019.
In addition, management announced it completed a pre-sNDA meeting (a meeting between a company and the FDA to ensure the submission of a well-organized NDA), and is on-track to submit a supplemental NDA this summer for NUPLAZID as a potential breakthrough therapy for DRP (drug related problems) and MDD (major depressive disorder).
5-star analyst Charles Duncan, representing Cantor Fitzgerald, viewed management’s announcement positively. In a recent research note, he cited the company’s positive outlook as a major component of his bullish thesis. “Pipeline driven potential is more than additive to our view that NUPLAZID is continuing to gain traction on volume growth by increasing penetration and persistence,” he stated.
To this end, Duncan has an Overweight (i.e. Buy) rating on the stock. Along with his rating, the analyst gave the price target a lift, from $58 to $63, implying 34% upside potential. (To watch Duncan’s track record, click here).
Other analysts on the Street agree with Duncan and also have high expectations for the stock, with 9 Buys and 1 Hold resulting in a Strong Buy consensus rating. The average price target is $60.30, which implies upside potential of 27%. (See ACADIA stock-price forecast on TipRanks)
To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.” As a result, Raymond rates DCPH an Outperform (i.e. Buy). Deciphera Pharmaceuticals (DCPH) We will start with Deciphera, a biopharmaceutical company which develops cancer medications. On June 8, Deciphera announced that The Lancet Oncology (a medical journal) published positive results from the INVICTUS Phase 3 study of QINLOCK, which featured patients who have been previously treated with anticancer therapies.
|
Deciphera Pharmaceuticals (DCPH) We will start with Deciphera, a biopharmaceutical company which develops cancer medications. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.” As a result, Raymond rates DCPH an Outperform (i.e. Buy). (See Deciphera stock analysis on TipRanks) Laboratory Corporation of America (LH) Up next is Laboratory Corporation of America, which operates two divisions, LabCorp Diagnostics (LCD) and Covance Drug Development.
|
Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.” As a result, Raymond rates DCPH an Outperform (i.e. Buy). Deciphera Pharmaceuticals (DCPH) We will start with Deciphera, a biopharmaceutical company which develops cancer medications. Laboratory has a Strong Buy analyst consensus rating comprised of 10 Buys, 3 Holds and no Sell ratings.
|
Deciphera Pharmaceuticals (DCPH) We will start with Deciphera, a biopharmaceutical company which develops cancer medications. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.” As a result, Raymond rates DCPH an Outperform (i.e. Buy). To this end, Gill rates LH an Overweight (i.e. Buy), while raising her price target from $118 to $223.
|
315f05be-9f64-40cd-8949-a5a2784381e6
|
715523.0
|
2020-06-03 00:00:00 UTC
|
The Debate Is Over: This Cancer Stock Is Winning the GIST Race
|
DCPH
|
https://www.nasdaq.com/articles/the-debate-is-over%3A-this-cancer-stock-is-winning-the-gist-race-2020-06-03
|
nan
|
nan
|
In the last decade alone, scientists have made notable progress understanding cancer progression and developing targeted treatments that significantly improve outcomes. One of the best examples is gastrointestinal stromal tumors (GIST).
As recently as the late 1990s, doctors knew relatively little about the solid tumors, which meant GIST was often misdiagnosed as other cancers. Today, there are a handful of approved drugs targeting specific genetic mutations common in GIST. That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer.
While Wall Street had anointed Blueprint Medicines as the front-runner in the GIST race for the last several years, it's now clear that a drug from Deciphera Pharmaceuticals will provide the most benefit to patients. Here's the latest breakdown of the competitive landscape and what investors need to watch for these two healthcare stocks.
Image source: Getty Images.
What is GIST?
An estimated 4,000 to 6,000 individuals are diagnosed with GIST in the United States each year, according to the American Cancer Society. That represents only 0.3% of all cancer diagnoses in the country each year. The rarity has contributed to a lack of knowledge and targeted treatment options, although that's slowly changing.
In 2001, the U.S. Food and Drug Administration (FDA) approved imatinib (Gleevac) from Novartis as a first-line treatment option. It remains the standard treatment option for advanced GIST today: 65% of individuals achieve a partial response, roughly 15% achieve stable disease, and the median duration of response (DOR) exceeds 24 months. The outcomes can be even greater in less advanced cases and those with specific genetic mutations.
While imatinib is a highly effective first-line treatment option, there's a severe lack of treatment options available for patients who progress on the drug. Consider the steep drop-off in median progression-free survival (PFS) and median overall survival (OS) from first-line to second-line and above treatment options. (A second-line treatment option means the individual has received at least one prior treatment, and so on.)
DRUG (U.S. BRAND NAME)
TREATMENT OPTION
MEDIAN PFS
MEDIAN OS
Imatinib (Gleevac)
First-line
19 months
57.0 months
Sunitinib (Sutent)
Second-line
5.6 months
17.0 months
Regorafenib (Stivarga)
Third-line
4.8 months
17.4 months
Ripretinib (Qinlock)
Fourth-line
6.3 months
15.1 months
Data source: Deciphera Pharmaceuticals presentation, Blueprint Medicines presentation, Novartis.
The lack of second-line and greater treatment options is where the competition between Blueprint Medicines and Deciphera Pharmaceuticals began. Both were developing drug candidates aimed at the post-imatinib patient population, although recent developments hand Deciphera Pharmaceuticals the clear edge.
Image source: Getty Images.
Is this the next major GIST treatment?
Blueprint Medicines was developing avapritinib as a treatment for third- and fourth-line GIST. In April 2020, the company announced disappointing results in a phase 3 trial that pitted the drug candidate against the current standard third-line treatment option, regorafenib. That prompted the company to discontinue development of avapritinib in GIST, although the drug is approved to treat a small population of patients whose tumors harbor a specific genetic mutation.
Shortly thereafter, Deciphera Pharmaceuticals announced that the FDA had approved its drug candidate, ripretinib, as a fourth-line treatment option for GIST. It was the first drug to be approved for use in individuals who had failed at least three prior treatments, but the company has more ambitious plans.
Deciphera Pharmaceuticals is currently conducting a phase 3 trial pitting ripretinib against the current standard second-line treatment option, sunitinib. Investors and analysts are cautiously optimistic about the trial's outcome. In an earlier study, ripretinib achieved a median PFS of 10.6 months as a second-line treatment option. That's far better than the median PFS of 5.6 months sunitinib achieved to earn regulatory approval.
The fate of the drug depends on the ongoing phase 3 trial. If ripretinib emerges as the superior second-line treatment option for GIST, then SVB Leerink analyst Andrew Berens estimates the drug could generate peak annual sales of $1.6 billion in the United States and European Union. Considering Deciphera Pharmaceuticals is valued at $3.4 billion, a successful trial result could send the stock higher.
The GIST race is over, but these stocks are still worth watching
Despite the high-profile failure of avapritinib in third-line GIST, investors cannot write-off Blueprint Medicines. The company has two other clinical-stage assets in development targeting specific genetic mutations in multiple other cancers, while another three assets are in preclinical development. In other words, the business lost out on the near-term opportunity to generate revenue from a next-generation GIST treatment, but it has other shots on goal -- they're just earlier-stage assets.
The near-term future is potentially much brighter for Deciphera Pharmaceuticals. Investors and analysts are cautiously optimistic ripretinib can deliver a successful outcome in the ongoing phase 3 trial evaluating its potential as a second-line treatment option for GIST, which could allow the company to capture the post-imatinib market. That would significantly de-risk the development of the company's remaining two clinical assets and likely allow the stock to generate above-average returns in the next several years.
Of course, nothing is guaranteed for ripretinib, so investors need to remain cautious heading into the release of preliminary study results.
10 stocks we like better than Blueprint Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer. That prompted the company to discontinue development of avapritinib in GIST, although the drug is approved to treat a small population of patients whose tumors harbor a specific genetic mutation. If ripretinib emerges as the superior second-line treatment option for GIST, then SVB Leerink analyst Andrew Berens estimates the drug could generate peak annual sales of $1.6 billion in the United States and European Union.
|
That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer. Imatinib (Gleevac) First-line 19 months 57.0 months Sunitinib (Sutent) Second-line 5.6 months 17.0 months Regorafenib (Stivarga) Third-line 4.8 months 17.4 months Ripretinib (Qinlock) Fourth-line 6.3 months 15.1 months Data source: Deciphera Pharmaceuticals presentation, Blueprint Medicines presentation, Novartis. In April 2020, the company announced disappointing results in a phase 3 trial that pitted the drug candidate against the current standard third-line treatment option, regorafenib.
|
That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer. Imatinib (Gleevac) First-line 19 months 57.0 months Sunitinib (Sutent) Second-line 5.6 months 17.0 months Regorafenib (Stivarga) Third-line 4.8 months 17.4 months Ripretinib (Qinlock) Fourth-line 6.3 months 15.1 months Data source: Deciphera Pharmaceuticals presentation, Blueprint Medicines presentation, Novartis. Shortly thereafter, Deciphera Pharmaceuticals announced that the FDA had approved its drug candidate, ripretinib, as a fourth-line treatment option for GIST.
|
That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer. What is GIST? The lack of second-line and greater treatment options is where the competition between Blueprint Medicines and Deciphera Pharmaceuticals began.
|
2089758d-539f-466e-9042-6d0e96ddd5bf
|
715524.0
|
2020-05-23 00:00:00 UTC
|
FDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals
|
DCPH
|
https://www.nasdaq.com/articles/fda-approval-could-be-a-game-changer-for-deciphera-pharmaceuticals-2020-05-23
|
nan
|
nan
|
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since.
As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -- about a 15% jump, thanks to good news from the U.S. Food and Drug Administration (FDA) regarding its drug ripretinib, marketed under the name Qinlock.
IMAGE SOURCE: GETTY IMAGES.
First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status. That news came shortly after the FDA knocked down one of Deciphera's competitors in the process, issuing a complete response letter denying GIST therapy candidate avapritinib, from Blueprint Medicines (NASDAQ: BPMC).
No sense in waiting
Deciphera is moving to launch Qinlock this week. Analysts predict it could be worth as much as $1.6 billion in revenue this year.
As of March 31, Deciphera already had $691.5 million in cash, cash equivalents, and marketable securities, which the company said was enough to fund operating and capital expenditures through the second half of 2022. With Qinlock on the way and several other drugs in its pipeline, the company will have no difficulty getting more funding. For the present, Qinlock will be used only on fourth-line patients, whose cancers have proven resistant to other treatments. In the future, the company sees Qinlock being approved for second-line treatment and taking market share from sunitinib, which is marketed as Sutent by Pfizer (NYSE: PFE).
"With [Qinlock's] phase 1 looking better than sunitinib, it has a good chance of replacing sunitinib as the standard of care," Deciphera chief business officer Chris Morl said in January.
Another promising drug the company is developing is rebastinib. In one phase 1b/2 clinical study, it's being combined with paclitaxel to treat solid tumors in breast, ovarian, and endometrial cancer. In another 1b/2 clinical study, it's being combined with carboplatin to reduce solid tumors from mesothelioma, as well as ovarian and breast cancer.
A third drug, DCC-3014, is in phase 1 trials against advanced malignancies and tenosynovial giant cell tumors (a rare kind of tumor that forms in the joints).
Slowing down to take a look at the risks
From a pure bottom-line standpoint, Deciphera is still losing money. It reported a net loss of $72.8 million, or $1.36 per share, in the first quarter, compared with a net loss of $47.4 million, or $1.25 a share, in the same quarter in 2019. That will quickly change, however, as the company is already marketing Qinlock.
Analysts seem pretty bullish on the stock, with a typical target of $70. That leaves a lot of room from its current price in the high $50s.
That's because the biggest risk, that Qinlock would not be approved, has already been eliminated. The types of GIST cancers that it would be used on are rare, and while the incidence of GIST is low -- affecting as few as 1% of all people who develop gastrointestinal tumors -- the company would likely be able to charge $30,000 or more for a month's supply. There are few competitors, and the price point for targeted oncology drugs is high.
Still, like any clinical-stage biopharma, it's riskier than buying stock in an established mainline pharmaceutical stock. A lot is riding on Qinlock, with not much to fall back on if the drug doesn't succeed in the market.
On the plus side, Deciphera is all about growth. If you're willing to take the risk, there may be a huge upside.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Jim Halley owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status. That news came shortly after the FDA knocked down one of Deciphera's competitors in the process, issuing a complete response letter denying GIST therapy candidate avapritinib, from Blueprint Medicines (NASDAQ: BPMC).
|
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status. In the future, the company sees Qinlock being approved for second-line treatment and taking market share from sunitinib, which is marketed as Sutent by Pfizer (NYSE: PFE).
|
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -- about a 15% jump, thanks to good news from the U.S. Food and Drug Administration (FDA) regarding its drug ripretinib, marketed under the name Qinlock. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status. With Qinlock on the way and several other drugs in its pipeline, the company will have no difficulty getting more funding.
|
c6a0e41c-9980-4247-833c-06b0cc32aa00
|
715525.0
|
2020-05-18 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Oasis Midstream, L Brands, Diffusion Pharma
|
DCPH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oasis-midstream-l-brands-diffusion-pharma-2020-05-18
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks surged on Monday, with the S&P 500 hitting a 10-week high, as encouraging early data from a potential coronavirus vaccine trial boosted sentiment, with investors also hoping for stimulus to cushion the economic blow from the pandemic..N
At 13:46 ET, the Dow Jones Industrial Average .DJI was up 3.74% at 24,572.32. The S&P 500 .SPX was up 3.23% at 2,956.13 and the Nasdaq Composite .IXIC was up 2.53% at 9,243.01. The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 22.5% ** United Airlines Holdings Inc , up 20.1% ** Royal Caribbean Cruises Ltd , up 19.7% The top three S&P 500 .PL.INX percentage losers: ** Citrix Systems Inc , down 4.3% ** Campbell Soup Co , down 3.2 % ** Dominos Pizza , down 3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis INc , up 58.6% ** Direxion Daily Mid Cap Bull 3x Shares , up 34.5% ** Direxion Daily S&P 500 High Beta Bull 3X Shares , up 28.8% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 41.2% ** Velocityshares 3X Inverse Natural Gas ETN , down 29.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 28.4% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 80.9% ** Vir Biotechnology Inc , up 30.7% ** Liberty Tripadvisor Holdings Inc , up 30.7% The top three Nasdaq .PL.O percentage losers: ** Forescout Technologies Inc , down 23.6% ** Repro-Med Systems, Inc , down 16% ** Aptevo Therapeutics Inc , down 14.1% ** Meritage Homes Corp MTH.N: up 12.3%
BUZZ-Jumps after positive May outlook ** Heron Therapeutics Inc HRTX.O: up 6.7%
BUZZ-Up after co starts study for pain drug ** Inspired Entertainment Inc INSE.O: up 11.8%
BUZZ-Eyes best day in May on higher quarterly revenue ** NuCana Plc NCNA.O: up 3.3%
BUZZ-Up after co resumes clinical studies halted for COVID-19 ** International Game Technology Plc IGT.N: up 11.4%
BUZZ-Up on profit beat at a time when COVID-19 wreaked gambling ** Oasis Midstream Partners LP OMP.O: up 80.9%
BUZZ-Soars on capex curbs, qtrly dividend ** L Brands Inc LB.N: up 18.0%
BUZZ-Surges as brokerages raise PTs ahead of first-quarter results ** Gilead Sciences Inc GILD.O: down 1.5%
BUZZ-Weakness in Gilead's stock an opportunity to buy - RBC ** Ford Motor Co F.N: up 8.2% ** General Motors Co GM.N: up 10.4% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 8.7%
BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 2.4%
BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 23.6%
BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 20.0%
BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 18.4%
BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.3%
BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 2.3%
BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.4% ** Baxter International Inc BAX.N: up 0.3% ** Johnson & Johnson JNJ.N: up 0.4% ** Edwards Lifesciences Corp EW.N: up 2.4% ** Stryker Corp SYK.N: up 6.5% ** Boston Scientific Corp BSX.N: up 4.6% ** Zimmer Biomet Holdings ZBH.N: up 9.9% ** Medtronic Plc MDT.N: up 5.8%
BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 10.9%
BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 2.9%
BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 4.6% ** Citigroup Inc C.N: up 8.1% ** Wells Fargo & Co WFC.N: up 8.2% ** Bank of America Corp BAC.N: up 6.3% ** Morgan Stanley MS.N: up 8.2% ** Goldman Sachs Group Inc GS.N: up 4.7% BUZZ-U.S. big banks rise on easing lockdowns, COVID-19 vaccine trial data ** Chevron Corp CVX.N: up 5.4% ** Exxon Mobil Corp XOM.N: up 7.4% ** Apache Corp APA.N: up 14.1% ** Devon Energy Corp DVN.N: up 10.6% ** Hess Corp HES.N: up 11.5% ** Occidental Petroleum Corp OXY.N: up 9.2% ** Cimarex Energy Co XEC.N: up 11.0% ** EOG Resources EOG.N: up 7.8% ** TechnipFMC Plc FTI.N: up 14.2% ** Helmerich and Payne Inc HP.N: up 8.6% ** ONEOK Inc OKE.N: up 9.1% ** Kinder Morgan Inc KMI.N: up 4.4% ** HollyFrontier Corp HFC.N: up 14.2% ** Marathon Petroleum Corp MPC.N: up 15.1% ** Phillips 66 PSX.N: up 8.2% ** Valero Energy Corp VLO.N: up 10.1% ** Schlumberger NV SLB.N: up 10.0% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.9% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 5.4% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.2% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** VistaGen Therapeutics Inc VTGN.O: up 20.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 56.9% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 4.3% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 10.5% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.1% BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 14.6% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 24.3% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4%
BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.6%
BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 1.2%
BUZZ-RBC sees dampening subscription growth for Workday, cuts PT
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 2.23%
Consumer Discretionary
.SPLRCD
up 3.38%
Consumer Staples
.SPLRCS
up 1.41%
Energy
.SPNY
up 7.22%
Financial
.SPSY
up 5.12%
Health
.SPXHC
up 1.39%
Industrial
.SPLRCI
up 6.36%
Information Technology
.SPLRCT
up 2.79%
Materials
.SPLRCM
up 4.63%
Real Estate
.SPLRCR
up 4.81%
Utilities
.SPLRCU
up 3.70%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 22.5% ** United Airlines Holdings Inc , up 20.1% ** Royal Caribbean Cruises Ltd , up 19.7% The top three S&P 500 .PL.INX percentage losers: ** Citrix Systems Inc , down 4.3% ** Campbell Soup Co , down 3.2 % ** Dominos Pizza , down 3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis INc , up 58.6% ** Direxion Daily Mid Cap Bull 3x Shares , up 34.5% ** Direxion Daily S&P 500 High Beta Bull 3X Shares , up 28.8% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 41.2% ** Velocityshares 3X Inverse Natural Gas ETN , down 29.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 28.4% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 80.9% ** Vir Biotechnology Inc , up 30.7% ** Liberty Tripadvisor Holdings Inc , up 30.7% The top three Nasdaq .PL.O percentage losers: ** Forescout Technologies Inc , down 23.6% ** Repro-Med Systems, Inc , down 16% ** Aptevo Therapeutics Inc , down 14.1% ** Meritage Homes Corp MTH.N: up 12.3% BUZZ-Jumps after positive May outlook ** Heron Therapeutics Inc HRTX.O: up 6.7% BUZZ-Up after co starts study for pain drug ** Inspired Entertainment Inc INSE.O: up 11.8% BUZZ-Eyes best day in May on higher quarterly revenue ** NuCana Plc NCNA.O: up 3.3% BUZZ-Up after co resumes clinical studies halted for COVID-19 ** International Game Technology Plc IGT.N: up 11.4% BUZZ-Up on profit beat at a time when COVID-19 wreaked gambling ** Oasis Midstream Partners LP OMP.O: up 80.9% BUZZ-Soars on capex curbs, qtrly dividend ** L Brands Inc LB.N: up 18.0% BUZZ-Surges as brokerages raise PTs ahead of first-quarter results ** Gilead Sciences Inc GILD.O: down 1.5% BUZZ-Weakness in Gilead's stock an opportunity to buy - RBC ** Ford Motor Co F.N: up 8.2% ** General Motors Co GM.N: up 10.4% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 8.7% BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 2.4% BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 23.6% BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 20.0% BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 18.4% BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.3% BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 2.3% BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.4% ** Baxter International Inc BAX.N: up 0.3% ** Johnson & Johnson JNJ.N: up 0.4% ** Edwards Lifesciences Corp EW.N: up 2.4% ** Stryker Corp SYK.N: up 6.5% ** Boston Scientific Corp BSX.N: up 4.6% ** Zimmer Biomet Holdings ZBH.N: up 9.9% ** Medtronic Plc MDT.N: up 5.8% BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 10.9% BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 2.9% BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 4.6% ** Citigroup Inc C.N: up 8.1% ** Wells Fargo & Co WFC.N: up 8.2% ** Bank of America Corp BAC.N: up 6.3% ** Morgan Stanley MS.N: up 8.2% ** Goldman Sachs Group Inc GS.N: up 4.7% BUZZ-U.S. big banks rise on easing lockdowns, COVID-19 vaccine trial data ** Chevron Corp CVX.N: up 5.4% ** Exxon Mobil Corp XOM.N: up 7.4% ** Apache Corp APA.N: up 14.1% ** Devon Energy Corp DVN.N: up 10.6% ** Hess Corp HES.N: up 11.5% ** Occidental Petroleum Corp OXY.N: up 9.2% ** Cimarex Energy Co XEC.N: up 11.0% ** EOG Resources EOG.N: up 7.8% ** TechnipFMC Plc FTI.N: up 14.2% ** Helmerich and Payne Inc HP.N: up 8.6% ** ONEOK Inc OKE.N: up 9.1% ** Kinder Morgan Inc KMI.N: up 4.4% ** HollyFrontier Corp HFC.N: up 14.2% ** Marathon Petroleum Corp MPC.N: up 15.1% ** Phillips 66 PSX.N: up 8.2% ** Valero Energy Corp VLO.N: up 10.1% ** Schlumberger NV SLB.N: up 10.0% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.9% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 5.4% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.2% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** VistaGen Therapeutics Inc VTGN.O: up 20.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 56.9% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 4.3% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 10.5% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.1% BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 14.6% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 24.3% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.6% BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 1.2% BUZZ-RBC sees dampening subscription growth for Workday, cuts PT The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks surged on Monday, with the S&P 500 hitting a 10-week high, as encouraging early data from a potential coronavirus vaccine trial boosted sentiment, with investors also hoping for stimulus to cushion the economic blow from the pandemic..N At 13:46 ET, the Dow Jones Industrial Average .DJI was up 3.74% at 24,572.32. up 3.70% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 22.5% ** United Airlines Holdings Inc , up 20.1% ** Royal Caribbean Cruises Ltd , up 19.7% The top three S&P 500 .PL.INX percentage losers: ** Citrix Systems Inc , down 4.3% ** Campbell Soup Co , down 3.2 % ** Dominos Pizza , down 3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis INc , up 58.6% ** Direxion Daily Mid Cap Bull 3x Shares , up 34.5% ** Direxion Daily S&P 500 High Beta Bull 3X Shares , up 28.8% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 41.2% ** Velocityshares 3X Inverse Natural Gas ETN , down 29.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 28.4% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 80.9% ** Vir Biotechnology Inc , up 30.7% ** Liberty Tripadvisor Holdings Inc , up 30.7% The top three Nasdaq .PL.O percentage losers: ** Forescout Technologies Inc , down 23.6% ** Repro-Med Systems, Inc , down 16% ** Aptevo Therapeutics Inc , down 14.1% ** Meritage Homes Corp MTH.N: up 12.3% BUZZ-Jumps after positive May outlook ** Heron Therapeutics Inc HRTX.O: up 6.7% BUZZ-Up after co starts study for pain drug ** Inspired Entertainment Inc INSE.O: up 11.8% BUZZ-Eyes best day in May on higher quarterly revenue ** NuCana Plc NCNA.O: up 3.3% BUZZ-Up after co resumes clinical studies halted for COVID-19 ** International Game Technology Plc IGT.N: up 11.4% BUZZ-Up on profit beat at a time when COVID-19 wreaked gambling ** Oasis Midstream Partners LP OMP.O: up 80.9% BUZZ-Soars on capex curbs, qtrly dividend ** L Brands Inc LB.N: up 18.0% BUZZ-Surges as brokerages raise PTs ahead of first-quarter results ** Gilead Sciences Inc GILD.O: down 1.5% BUZZ-Weakness in Gilead's stock an opportunity to buy - RBC ** Ford Motor Co F.N: up 8.2% ** General Motors Co GM.N: up 10.4% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 8.7% BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 2.4% BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 23.6% BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 20.0% BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 18.4% BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.3% BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 2.3% BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.4% ** Baxter International Inc BAX.N: up 0.3% ** Johnson & Johnson JNJ.N: up 0.4% ** Edwards Lifesciences Corp EW.N: up 2.4% ** Stryker Corp SYK.N: up 6.5% ** Boston Scientific Corp BSX.N: up 4.6% ** Zimmer Biomet Holdings ZBH.N: up 9.9% ** Medtronic Plc MDT.N: up 5.8% BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 10.9% BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 2.9% BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 4.6% ** Citigroup Inc C.N: up 8.1% ** Wells Fargo & Co WFC.N: up 8.2% ** Bank of America Corp BAC.N: up 6.3% ** Morgan Stanley MS.N: up 8.2% ** Goldman Sachs Group Inc GS.N: up 4.7% BUZZ-U.S. big banks rise on easing lockdowns, COVID-19 vaccine trial data ** Chevron Corp CVX.N: up 5.4% ** Exxon Mobil Corp XOM.N: up 7.4% ** Apache Corp APA.N: up 14.1% ** Devon Energy Corp DVN.N: up 10.6% ** Hess Corp HES.N: up 11.5% ** Occidental Petroleum Corp OXY.N: up 9.2% ** Cimarex Energy Co XEC.N: up 11.0% ** EOG Resources EOG.N: up 7.8% ** TechnipFMC Plc FTI.N: up 14.2% ** Helmerich and Payne Inc HP.N: up 8.6% ** ONEOK Inc OKE.N: up 9.1% ** Kinder Morgan Inc KMI.N: up 4.4% ** HollyFrontier Corp HFC.N: up 14.2% ** Marathon Petroleum Corp MPC.N: up 15.1% ** Phillips 66 PSX.N: up 8.2% ** Valero Energy Corp VLO.N: up 10.1% ** Schlumberger NV SLB.N: up 10.0% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.9% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 5.4% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.2% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** VistaGen Therapeutics Inc VTGN.O: up 20.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 56.9% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 4.3% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 10.5% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.1% BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 14.6% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 24.3% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.6% BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 1.2% BUZZ-RBC sees dampening subscription growth for Workday, cuts PT The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks surged on Monday, with the S&P 500 hitting a 10-week high, as encouraging early data from a potential coronavirus vaccine trial boosted sentiment, with investors also hoping for stimulus to cushion the economic blow from the pandemic..N At 13:46 ET, the Dow Jones Industrial Average .DJI was up 3.74% at 24,572.32. up 3.70% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 22.5% ** United Airlines Holdings Inc , up 20.1% ** Royal Caribbean Cruises Ltd , up 19.7% The top three S&P 500 .PL.INX percentage losers: ** Citrix Systems Inc , down 4.3% ** Campbell Soup Co , down 3.2 % ** Dominos Pizza , down 3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis INc , up 58.6% ** Direxion Daily Mid Cap Bull 3x Shares , up 34.5% ** Direxion Daily S&P 500 High Beta Bull 3X Shares , up 28.8% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 41.2% ** Velocityshares 3X Inverse Natural Gas ETN , down 29.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 28.4% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 80.9% ** Vir Biotechnology Inc , up 30.7% ** Liberty Tripadvisor Holdings Inc , up 30.7% The top three Nasdaq .PL.O percentage losers: ** Forescout Technologies Inc , down 23.6% ** Repro-Med Systems, Inc , down 16% ** Aptevo Therapeutics Inc , down 14.1% ** Meritage Homes Corp MTH.N: up 12.3% BUZZ-Jumps after positive May outlook ** Heron Therapeutics Inc HRTX.O: up 6.7% BUZZ-Up after co starts study for pain drug ** Inspired Entertainment Inc INSE.O: up 11.8% BUZZ-Eyes best day in May on higher quarterly revenue ** NuCana Plc NCNA.O: up 3.3% BUZZ-Up after co resumes clinical studies halted for COVID-19 ** International Game Technology Plc IGT.N: up 11.4% BUZZ-Up on profit beat at a time when COVID-19 wreaked gambling ** Oasis Midstream Partners LP OMP.O: up 80.9% BUZZ-Soars on capex curbs, qtrly dividend ** L Brands Inc LB.N: up 18.0% BUZZ-Surges as brokerages raise PTs ahead of first-quarter results ** Gilead Sciences Inc GILD.O: down 1.5% BUZZ-Weakness in Gilead's stock an opportunity to buy - RBC ** Ford Motor Co F.N: up 8.2% ** General Motors Co GM.N: up 10.4% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 8.7% BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 2.4% BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 23.6% BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 20.0% BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 18.4% BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.3% BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 2.3% BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.4% ** Baxter International Inc BAX.N: up 0.3% ** Johnson & Johnson JNJ.N: up 0.4% ** Edwards Lifesciences Corp EW.N: up 2.4% ** Stryker Corp SYK.N: up 6.5% ** Boston Scientific Corp BSX.N: up 4.6% ** Zimmer Biomet Holdings ZBH.N: up 9.9% ** Medtronic Plc MDT.N: up 5.8% BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 10.9% BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 2.9% BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 4.6% ** Citigroup Inc C.N: up 8.1% ** Wells Fargo & Co WFC.N: up 8.2% ** Bank of America Corp BAC.N: up 6.3% ** Morgan Stanley MS.N: up 8.2% ** Goldman Sachs Group Inc GS.N: up 4.7% BUZZ-U.S. big banks rise on easing lockdowns, COVID-19 vaccine trial data ** Chevron Corp CVX.N: up 5.4% ** Exxon Mobil Corp XOM.N: up 7.4% ** Apache Corp APA.N: up 14.1% ** Devon Energy Corp DVN.N: up 10.6% ** Hess Corp HES.N: up 11.5% ** Occidental Petroleum Corp OXY.N: up 9.2% ** Cimarex Energy Co XEC.N: up 11.0% ** EOG Resources EOG.N: up 7.8% ** TechnipFMC Plc FTI.N: up 14.2% ** Helmerich and Payne Inc HP.N: up 8.6% ** ONEOK Inc OKE.N: up 9.1% ** Kinder Morgan Inc KMI.N: up 4.4% ** HollyFrontier Corp HFC.N: up 14.2% ** Marathon Petroleum Corp MPC.N: up 15.1% ** Phillips 66 PSX.N: up 8.2% ** Valero Energy Corp VLO.N: up 10.1% ** Schlumberger NV SLB.N: up 10.0% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.9% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 5.4% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.2% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** VistaGen Therapeutics Inc VTGN.O: up 20.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 56.9% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 4.3% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 10.5% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.1% BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 14.6% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 24.3% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.6% BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 1.2% BUZZ-RBC sees dampening subscription growth for Workday, cuts PT The 11 major S&P 500 sectors: Communication Services up 2.23% Consumer Discretionary up 3.38% Consumer Staples
|
The top three S&P 500 .PG.INX percentage gainers: ** Norwegian Cruise Line Holdings Ltd , up 22.5% ** United Airlines Holdings Inc , up 20.1% ** Royal Caribbean Cruises Ltd , up 19.7% The top three S&P 500 .PL.INX percentage losers: ** Citrix Systems Inc , down 4.3% ** Campbell Soup Co , down 3.2 % ** Dominos Pizza , down 3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis INc , up 58.6% ** Direxion Daily Mid Cap Bull 3x Shares , up 34.5% ** Direxion Daily S&P 500 High Beta Bull 3X Shares , up 28.8% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 41.2% ** Velocityshares 3X Inverse Natural Gas ETN , down 29.3% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 28.4% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 80.9% ** Vir Biotechnology Inc , up 30.7% ** Liberty Tripadvisor Holdings Inc , up 30.7% The top three Nasdaq .PL.O percentage losers: ** Forescout Technologies Inc , down 23.6% ** Repro-Med Systems, Inc , down 16% ** Aptevo Therapeutics Inc , down 14.1% ** Meritage Homes Corp MTH.N: up 12.3% BUZZ-Jumps after positive May outlook ** Heron Therapeutics Inc HRTX.O: up 6.7% BUZZ-Up after co starts study for pain drug ** Inspired Entertainment Inc INSE.O: up 11.8% BUZZ-Eyes best day in May on higher quarterly revenue ** NuCana Plc NCNA.O: up 3.3% BUZZ-Up after co resumes clinical studies halted for COVID-19 ** International Game Technology Plc IGT.N: up 11.4% BUZZ-Up on profit beat at a time when COVID-19 wreaked gambling ** Oasis Midstream Partners LP OMP.O: up 80.9% BUZZ-Soars on capex curbs, qtrly dividend ** L Brands Inc LB.N: up 18.0% BUZZ-Surges as brokerages raise PTs ahead of first-quarter results ** Gilead Sciences Inc GILD.O: down 1.5% BUZZ-Weakness in Gilead's stock an opportunity to buy - RBC ** Ford Motor Co F.N: up 8.2% ** General Motors Co GM.N: up 10.4% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 8.7% BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 2.4% BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 23.6% BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 20.0% BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 18.4% BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.3% BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 2.3% BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.4% ** Baxter International Inc BAX.N: up 0.3% ** Johnson & Johnson JNJ.N: up 0.4% ** Edwards Lifesciences Corp EW.N: up 2.4% ** Stryker Corp SYK.N: up 6.5% ** Boston Scientific Corp BSX.N: up 4.6% ** Zimmer Biomet Holdings ZBH.N: up 9.9% ** Medtronic Plc MDT.N: up 5.8% BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 10.9% BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 2.9% BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 4.6% ** Citigroup Inc C.N: up 8.1% ** Wells Fargo & Co WFC.N: up 8.2% ** Bank of America Corp BAC.N: up 6.3% ** Morgan Stanley MS.N: up 8.2% ** Goldman Sachs Group Inc GS.N: up 4.7% BUZZ-U.S. big banks rise on easing lockdowns, COVID-19 vaccine trial data ** Chevron Corp CVX.N: up 5.4% ** Exxon Mobil Corp XOM.N: up 7.4% ** Apache Corp APA.N: up 14.1% ** Devon Energy Corp DVN.N: up 10.6% ** Hess Corp HES.N: up 11.5% ** Occidental Petroleum Corp OXY.N: up 9.2% ** Cimarex Energy Co XEC.N: up 11.0% ** EOG Resources EOG.N: up 7.8% ** TechnipFMC Plc FTI.N: up 14.2% ** Helmerich and Payne Inc HP.N: up 8.6% ** ONEOK Inc OKE.N: up 9.1% ** Kinder Morgan Inc KMI.N: up 4.4% ** HollyFrontier Corp HFC.N: up 14.2% ** Marathon Petroleum Corp MPC.N: up 15.1% ** Phillips 66 PSX.N: up 8.2% ** Valero Energy Corp VLO.N: up 10.1% ** Schlumberger NV SLB.N: up 10.0% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.9% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 5.4% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.2% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** VistaGen Therapeutics Inc VTGN.O: up 20.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 56.9% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 4.3% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 10.5% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.1% BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 14.6% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 24.3% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.6% BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 1.2% BUZZ-RBC sees dampening subscription growth for Workday, cuts PT The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks surged on Monday, with the S&P 500 hitting a 10-week high, as encouraging early data from a potential coronavirus vaccine trial boosted sentiment, with investors also hoping for stimulus to cushion the economic blow from the pandemic..N At 13:46 ET, the Dow Jones Industrial Average .DJI was up 3.74% at 24,572.32. The S&P 500 .SPX was up 3.23% at 2,956.13 and the Nasdaq Composite .IXIC was up 2.53% at 9,243.01.
|
2a505444-c9d5-4b64-8b31-3b8ab5b4ab64
|
715526.0
|
2020-05-18 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Centric Brands, Fulgent Genetics, Moderna
|
DCPH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-centric-brands-fulgent-genetics-moderna-2020-05-18-0
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock indexes were set to open sharply higher on Monday on optimism fueled by encouraging data from a potential COVID-19 vaccine trial, with investors also counting on more stimulus to rescue the economy from a deep economic slump..N
At 8:58 ET, Dow e-minis 1YMc1 were up 3.25% at 24,281. S&P 500 e-minis ESc1 were up 2.91% at 2,929.25, while Nasdaq 100 e-minis NQc1 were up 2.03% at 9,281.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc , up 25% ** Chesapeake Energy Corp , up 24.2% ** Aurora Cannabis Inc , up 24.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** M/I Homes Inc , down 18.8% ** GSX Techedu Inc , down 12.5% ** Select Asst Inc , down 11.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Outlook Therapeutics Equity Warrants , up 229.7% ** Plus Therapeutics Equity Warrants , up 76.5% ** ALJ Regional Holdings Inc , up 46.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Centric Brands Inc , down 49% ** Pieris Pharmaceuticals Inc , down 22.1% ** Forescout Technologies Inc , down 20.4% ** JPMorgan Chase & Co JPM.N: up 3.9% premarket ** Citigroup Inc C.N: up 4.6% premarket ** Wells Fargo & Co WFC.N: up 5.1% premarket ** Bank of America Corp BAC.N: up 4.6% premarket ** Morgan Stanley MS.N: up 3.8% premarket ** Goldman Sachs Group Inc GS.N: up 3.4% premarket BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Bluebird bio Inc BLUE.O: down 2% premarket BUZZ-Drops on planned $400 mln stock offering ** Baker Hughes Co BKR.N: up 6.1% premarket ** Schlumberger NV SLB.N: up 5.8% premarket ** DMC Global Inc BOOM.O: up 3.7% premarket ** Oil States International Inc OIS.N: up 6.3% premarket Headline of story OR Buzz OR Brief USN ** Under Armour Inc UAA.N: up 6.4% premarket BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 6.3% premarket BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 8.7% premarket BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.3% premarket BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 16.8% premarket BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 49% premarket BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 31.2% premarket BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Clovis Oncology Inc CLVS.O: up 3.2% premarket BUZZ-Rises on FDA approval of prostate cancer drug ** Best Buy Co Inc BBY.N: up 4.3% premarket BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 4.6% premarket BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% premarket BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 10% premarket BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 34.7% premarket BUZZ-Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% premarket
BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 2.4% premarket
BUZZ-Best positioned to benefit from work-from-home trend - Brokerage
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc , up 25% ** Chesapeake Energy Corp , up 24.2% ** Aurora Cannabis Inc , up 24.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** M/I Homes Inc , down 18.8% ** GSX Techedu Inc , down 12.5% ** Select Asst Inc , down 11.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Outlook Therapeutics Equity Warrants , up 229.7% ** Plus Therapeutics Equity Warrants , up 76.5% ** ALJ Regional Holdings Inc , up 46.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Centric Brands Inc , down 49% ** Pieris Pharmaceuticals Inc , down 22.1% ** Forescout Technologies Inc , down 20.4% ** JPMorgan Chase & Co JPM.N: up 3.9% premarket ** Citigroup Inc C.N: up 4.6% premarket ** Wells Fargo & Co WFC.N: up 5.1% premarket ** Bank of America Corp BAC.N: up 4.6% premarket ** Morgan Stanley MS.N: up 3.8% premarket ** Goldman Sachs Group Inc GS.N: up 3.4% premarket BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Bluebird bio Inc BLUE.O: down 2% premarket BUZZ-Drops on planned $400 mln stock offering ** Baker Hughes Co BKR.N: up 6.1% premarket ** Schlumberger NV SLB.N: up 5.8% premarket ** DMC Global Inc BOOM.O: up 3.7% premarket ** Oil States International Inc OIS.N: up 6.3% premarket Headline of story OR Buzz OR Brief USN ** Under Armour Inc UAA.N: up 6.4% premarket BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 6.3% premarket BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 8.7% premarket BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.3% premarket BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 16.8% premarket BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 49% premarket BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 31.2% premarket BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Clovis Oncology Inc CLVS.O: up 3.2% premarket BUZZ-Rises on FDA approval of prostate cancer drug ** Best Buy Co Inc BBY.N: up 4.3% premarket BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 4.6% premarket BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% premarket BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 10% premarket BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 34.7% premarket BUZZ-Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% premarket BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 2.4% premarket BUZZ-Best positioned to benefit from work-from-home trend - Brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes were set to open sharply higher on Monday on optimism fueled by encouraging data from a potential COVID-19 vaccine trial, with investors also counting on more stimulus to rescue the economy from a deep economic slump..N At 8:58 ET, Dow e-minis 1YMc1 were up 3.25% at 24,281. S&P 500 e-minis ESc1 were up 2.91% at 2,929.25, while Nasdaq 100 e-minis NQc1 were up 2.03% at 9,281.25.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc , up 25% ** Chesapeake Energy Corp , up 24.2% ** Aurora Cannabis Inc , up 24.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** M/I Homes Inc , down 18.8% ** GSX Techedu Inc , down 12.5% ** Select Asst Inc , down 11.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Outlook Therapeutics Equity Warrants , up 229.7% ** Plus Therapeutics Equity Warrants , up 76.5% ** ALJ Regional Holdings Inc , up 46.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Centric Brands Inc , down 49% ** Pieris Pharmaceuticals Inc , down 22.1% ** Forescout Technologies Inc , down 20.4% ** JPMorgan Chase & Co JPM.N: up 3.9% premarket ** Citigroup Inc C.N: up 4.6% premarket ** Wells Fargo & Co WFC.N: up 5.1% premarket ** Bank of America Corp BAC.N: up 4.6% premarket ** Morgan Stanley MS.N: up 3.8% premarket ** Goldman Sachs Group Inc GS.N: up 3.4% premarket BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Bluebird bio Inc BLUE.O: down 2% premarket BUZZ-Drops on planned $400 mln stock offering ** Baker Hughes Co BKR.N: up 6.1% premarket ** Schlumberger NV SLB.N: up 5.8% premarket ** DMC Global Inc BOOM.O: up 3.7% premarket ** Oil States International Inc OIS.N: up 6.3% premarket Headline of story OR Buzz OR Brief USN ** Under Armour Inc UAA.N: up 6.4% premarket BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 6.3% premarket BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 8.7% premarket BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.3% premarket BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 16.8% premarket BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 49% premarket BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 31.2% premarket BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Clovis Oncology Inc CLVS.O: up 3.2% premarket BUZZ-Rises on FDA approval of prostate cancer drug ** Best Buy Co Inc BBY.N: up 4.3% premarket BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 4.6% premarket BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% premarket BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 10% premarket BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 34.7% premarket BUZZ-Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% premarket BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 2.4% premarket BUZZ-Best positioned to benefit from work-from-home trend - Brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes were set to open sharply higher on Monday on optimism fueled by encouraging data from a potential COVID-19 vaccine trial, with investors also counting on more stimulus to rescue the economy from a deep economic slump..N At 8:58 ET, Dow e-minis 1YMc1 were up 3.25% at 24,281. S&P 500 e-minis ESc1 were up 2.91% at 2,929.25, while Nasdaq 100 e-minis NQc1 were up 2.03% at 9,281.25.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc , up 25% ** Chesapeake Energy Corp , up 24.2% ** Aurora Cannabis Inc , up 24.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** M/I Homes Inc , down 18.8% ** GSX Techedu Inc , down 12.5% ** Select Asst Inc , down 11.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Outlook Therapeutics Equity Warrants , up 229.7% ** Plus Therapeutics Equity Warrants , up 76.5% ** ALJ Regional Holdings Inc , up 46.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Centric Brands Inc , down 49% ** Pieris Pharmaceuticals Inc , down 22.1% ** Forescout Technologies Inc , down 20.4% ** JPMorgan Chase & Co JPM.N: up 3.9% premarket ** Citigroup Inc C.N: up 4.6% premarket ** Wells Fargo & Co WFC.N: up 5.1% premarket ** Bank of America Corp BAC.N: up 4.6% premarket ** Morgan Stanley MS.N: up 3.8% premarket ** Goldman Sachs Group Inc GS.N: up 3.4% premarket BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Bluebird bio Inc BLUE.O: down 2% premarket BUZZ-Drops on planned $400 mln stock offering ** Baker Hughes Co BKR.N: up 6.1% premarket ** Schlumberger NV SLB.N: up 5.8% premarket ** DMC Global Inc BOOM.O: up 3.7% premarket ** Oil States International Inc OIS.N: up 6.3% premarket Headline of story OR Buzz OR Brief USN ** Under Armour Inc UAA.N: up 6.4% premarket BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 6.3% premarket BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 8.7% premarket BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.3% premarket BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 16.8% premarket BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 49% premarket BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 31.2% premarket BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Clovis Oncology Inc CLVS.O: up 3.2% premarket BUZZ-Rises on FDA approval of prostate cancer drug ** Best Buy Co Inc BBY.N: up 4.3% premarket BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 4.6% premarket BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% premarket BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 10% premarket BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 34.7% premarket BUZZ-Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% premarket BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 2.4% premarket BUZZ-Best positioned to benefit from work-from-home trend - Brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes were set to open sharply higher on Monday on optimism fueled by encouraging data from a potential COVID-19 vaccine trial, with investors also counting on more stimulus to rescue the economy from a deep economic slump..N At 8:58 ET, Dow e-minis 1YMc1 were up 3.25% at 24,281. S&P 500 e-minis ESc1 were up 2.91% at 2,929.25, while Nasdaq 100 e-minis NQc1 were up 2.03% at 9,281.25.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** Quintana Energy Services Inc , up 25% ** Chesapeake Energy Corp , up 24.2% ** Aurora Cannabis Inc , up 24.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** M/I Homes Inc , down 18.8% ** GSX Techedu Inc , down 12.5% ** Select Asst Inc , down 11.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Outlook Therapeutics Equity Warrants , up 229.7% ** Plus Therapeutics Equity Warrants , up 76.5% ** ALJ Regional Holdings Inc , up 46.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Centric Brands Inc , down 49% ** Pieris Pharmaceuticals Inc , down 22.1% ** Forescout Technologies Inc , down 20.4% ** JPMorgan Chase & Co JPM.N: up 3.9% premarket ** Citigroup Inc C.N: up 4.6% premarket ** Wells Fargo & Co WFC.N: up 5.1% premarket ** Bank of America Corp BAC.N: up 4.6% premarket ** Morgan Stanley MS.N: up 3.8% premarket ** Goldman Sachs Group Inc GS.N: up 3.4% premarket BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Bluebird bio Inc BLUE.O: down 2% premarket BUZZ-Drops on planned $400 mln stock offering ** Baker Hughes Co BKR.N: up 6.1% premarket ** Schlumberger NV SLB.N: up 5.8% premarket ** DMC Global Inc BOOM.O: up 3.7% premarket ** Oil States International Inc OIS.N: up 6.3% premarket Headline of story OR Buzz OR Brief USN ** Under Armour Inc UAA.N: up 6.4% premarket BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 6.3% premarket BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 8.7% premarket BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.3% premarket BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 16.8% premarket BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 49% premarket BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 31.2% premarket BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Clovis Oncology Inc CLVS.O: up 3.2% premarket BUZZ-Rises on FDA approval of prostate cancer drug ** Best Buy Co Inc BBY.N: up 4.3% premarket BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 4.6% premarket BUZZ-Rises after wildfire victims support reorganization plan[BUZZ-PG&E Corp rises after wildfire victims support reorganization plan] ** Teva Pharmaceutical TEVA.N: up 4.4% premarket BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 10% premarket BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 34.7% premarket BUZZ-Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.4% premarket BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 2.4% premarket BUZZ-Best positioned to benefit from work-from-home trend - Brokerage (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes were set to open sharply higher on Monday on optimism fueled by encouraging data from a potential COVID-19 vaccine trial, with investors also counting on more stimulus to rescue the economy from a deep economic slump..N At 8:58 ET, Dow e-minis 1YMc1 were up 3.25% at 24,281. S&P 500 e-minis ESc1 were up 2.91% at 2,929.25, while Nasdaq 100 e-minis NQc1 were up 2.03% at 9,281.25.
|
06517392-3dd7-4088-8af5-2f5d66150155
|
715527.0
|
2020-05-06 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2020 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-q1-2020-earnings-call-transcript-2020-05-06
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Q1 2020 Earnings Call
May 5, 2020, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone, and welcome to the Deciphera Pharmaceuticals First Quarter 2020 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Robinson, Vice President, Investor Relations. Thank you, Jen. Go ahead.
Jen Robinson -- Vice President, Investor Relations
Thank you. Frederica. Welcome and thank you for joining us today to discuss Deciphera's first quarter 2020 financial results. I'm Jen Robinson, Vice President, Investor Relations at Deciphera. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include the status of, and our expected timelines for, our preclinical and clinical studies, the impact of COVID-19, 2020 guidance, review and status of our NDA submission and preparations for our potential commercial launch.
Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include the impact of COVID-19, the execution of clinical trials, the timing of study data, the actions of regulatory agencies and those set forth in our most recent quarterly report on Form 10-Q as well as other -- our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call a replay will be available on the company's website www.deciphera.com.
With that I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of the Deciphera. Steve?
Steven L. Hoerter -- President & Chief Executive Officer
Thank you Jen. Good afternoon everyone and thank you for joining us on this call to discuss our first quarter 2020 financial results. In addition to providing our financial results and regular quarterly business update, today we are also reaffirming the timing of our clinical and commercial milestones and providing an update on the potential for COVID-19 to affect the business. Given the uncertainties that the COVID-19 pandemic presents, I want to emphasize that the outlook presented today is based on the assumption and the hope that the most severe impacts are of a short-term nature over the next few months, rather than a prolonged and sustained disruption to everyday life. At Deciphera, our first concern is maintaining the safety and security of our employees as well as the patients and physicians participating in our ongoing clinical trials, and this principle has guided the actions we've taken to date.
In early March, we adopted a work-from-home policy for our employees with limited exceptions for certain business-critical activities including ongoing laboratory research activities. For these activities, we have implemented appropriate safety measures designed to comply with federal, state and local guidelines. While adapting to our new work environment has presented its challenges, I have been continually impressed by the team's ability to adjust, while steadfastly maintaining our corporate values and executing on our company's mission. As the COVID-19 pandemic is spread around the world, the Deciphera team has worked to ensure the safety and well-being of patients enrolled in our clinical studies and our clinical teams. We are focused on advancing our ongoing clinical studies and are actively monitoring risks associated with potential interruptions to our programs. We are in frequent communication with our clinical study sites and contract research organizations around the world.
As you may be aware, some clinical trial sites are restricting site visits by sponsors and CROs, and imposing restrictions on the initiation of new trials, new patient enrollment and patient visits to protect both site staff and patients from possible COVID-19 exposure. While our studies remain open for enrollment, we have provided guidance that new patients enrollment may occur at sites where resources allow these patients to be safely enrolled and closely monitored. In some sites and our studies have temporarily paused enrollment of new patients. Importantly patients already enrolled in all of our clinical studies continue to receive investigational drug, and we are focused on supporting sites and providing ongoing care for these patients. We are also actively implementing remote and local procedures per recent FDA guidance and working with investigators to help ensure patients receive care in a safe manner consistent with agency guidelines.
As of this time, while there has been a slowdown in patient enrollment in the current environment, we currently expect to achieve our previously stated clinical milestones in the second half of this year, including full enrollment in INTRIGUE, our Phase III study in second-line GIST. Updated clinical data for DCC-3014 from the dose escalation portion of the study in tenosynovial giant cell tumor patients, selection of a Phase II dose for DCC-3014 and opening the expansion portion of the study in TGCT patients, and updated clinical data from both of the Phase 1b studies of rebastinib. In addition, our discovery research for clinic -- preclinical efforts in early development activities are currently on track and we expect to file the IND for DCC-3116, our ULK kinase inhibitor in the second half of 2020.
In terms of drug supply, Deciphera has commercial drug supply sufficient to support the potential launch of ripretinib in the fourth-line GIST. Based on current inventories and supply plan, the company does not anticipate any COVID-19 related supply interruptions to its clinical programs at this time.
With respect to our new drug application or NDA for ripretinib in patients with fourth-line GIST, we continue to work very collaboratively with the FDA as they review the submission, which has a PDUFA target action date of August 13 this year. We continue to build our commercial and medical affairs organizations to be ready to launch for ripretinib in the US upon the potential approval. The ripretinib NDA is also part of Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among participating International Health Authorities. Under this program, we have received priority review for a new drug submission with Health Canada and a market authorization application with the Therapeutic Goods Administration in Australia for ripretinib in advanced GIST. In addition, we plan to submit a marketing authorization application to the European Medicines Agency in the second half of this year. Given the evolving landscape, our commercial team has been preparing for a potential launch of ripretinib in a healthcare environment limited to no physical and promotional activities. And therefore, has been working intensively on effect of commercial launch using a virtual interaction model if necessary.
Lastly, we are in a strong position from a cash flow perspective, which we expect to last us into the second half of 2022. Despite the challenges we face, we expect this to be an exciting year for Deciphera, in particular, we look forward to a successful and impactful first commercial launch of ripretinib in fourth-line GIST if approved, and to achieving full enrollment in INTRUGUE, and we remain confident about ripretinib's potential to alter the treatment landscape for patients in the post-imatinib setting. Beyond ripretinib, we believe that our earlier stage programs can each deliver significant value creating events with additional clinical data for DCC-3014 and rebastinib and the filing of an IND for DCC-3116 later this year.
To review progress on our clinical programs, I'll now turn the call over to Matt Sherman, our Chief Medical Officer. Matt?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thank you, Steve. First, I would like to review our progress with ripretinib our investigational broad spectrum kit and PDGFR alpha kinase inhibitor. As Steve mentioned, the NDA for approval of ripretinib patients with fourth-line GIST is currently under priority review by the FDA with a PDUFA date of August 13 this year. The NDA submission is supported by highly significant and clinically meaningfully positive results from our INVICTUS pivotal Phase III study of ripretinib in patients with fourth line and fourth line plus GIST. Today we also announced that the two posters containing additional data from the INVICTUS study will be featured in ASCO [Phonetic] Annual Meeting which is being held virtually this year from May 29 through May 31. The first poster will focus on quality of life outcomes with ripretinib in the fourth line and fourth line plus treatment settings, while the second poster will focus on the safety profile for ripretinib including the impact of adverse events on patient reported outcomes. We look forward to reporting these data later this month.
As we work toward the potential approval and launch of ripretinib in patients with advanced GIST, who have received prior treatment with imatnib, sunitinib and regorafenib, we continue to explore other possible uses of ripretinib including in second line GIST patients. INTRIGUE is our ongoing randomized Phase III study of ripretinib in patients with second line GIST, compared to the current standard-of-care sunitinib. We have now finalized the amendment for INTRIGUE and the sample size will be 426 patients. We have approximately 118 sites activated in 22 countries. The global diversity and number of sites have been beneficial in helping us continue to enroll patients as we target full enrollment in the second half of this year. Additionally, as Steve mentioned, our clinical team has been closed correspondence with study sites to implement remote and local procedures per the recent FDA guidance to ensure the appropriate care of patients.
In addition, we expect to present data from at least one of the expansion cohorts of our ongoing Phase 1 study of ripretinib in the second half of this year. Beyond ripretinib, we are focused on the development of DCC-3014, our selective inhibitor of CSF1R for patients with Tenosynovial Giant Cell Tumor or TGCT. We believe 3014 has the potential to fulfill the unmet medical need for an effective treatment with a favorable safety profile for these patients. The only approved systemic therapy for patients with TGCT is pexidartinib, a small molecule inhibitor of a number of different kinases including CSF1R, which was approved in August of last year with a box warning for hepatotoxicity and is subject to a Risk Evaluation and Mitigation Strategy or REMS program.
We are continuing to enroll TGCT patients in the ongoing dose escalation portion of the Phase 1 study. In the second quarter due to the COVID-19 pandemic, and given that this is not a life threatening disease, we are seeing a slower than expected enrollment trend. Despite this, we are still currently expecting to present data from additional patients in the study, select to Phase II dose and open the Phase II expansion portion of the study in TGCT patients in the second half of this year.
Turning now to -- turning now to rebastinib our potent and selective TIE2 inhibitor, we are conducting two clinical studies in combination with chemotherapy. One with paclitaxel and one with carboplatin. Part one of each study was designed to select the combination dose of rebastinib with each chemotherapeutic agent and part two of each study was designed as a Simon 2 stage design. In the first stage the combinations are being evaluated in multiple solid tumor cohorts in up to 18 patients each. If there are more than four responses in a given cohort, then that cohort is expanded in the second stage to enroll up to a total of 33 patients.
Last year we presented preliminary data from Part 1 of the study of rebastinib in combination with paclitaxel. We saw encouraging preliminary activity with objective responses in patients who have previously received paclitaxel therapy across multiple solid tumor types. This afternoon, we announced that in Part 2 of the paclitaxel combination study, we have observed the required number of responses in both the endometrial and ovarian cancer cohorts, triggering the expansion in enrollment in these cohorts. We also announced today that we will present initial data from the endometrial cohort in Part 2 of the study at the ASCO meeting this year. In addition, we have added a new carcinosarcoma cohort in Part 2 of the study based on the encouraging anti-tumor activity from Part 1 presented at the triple meeting last year that showed partial responses in both patients with carcinosarcoma who were enrolled in the trial.
In our Phase 1b/2 study with rebastinib, in combination with carboplatin, we are continuing to enroll patients with breast cancer, ovarian cancer and mesothelioma in Part 2 of the study at the recommended Phase 2 dose of 50 milligrams BID, which was reduced from 100 milligrams BID based on the observed frequency of the muscular weakness and preliminary data from the ongoing Part 2 portion of the study. We expect to present data from Part 1 of the study in the second half of this year.
Finally, our discovery research engine continues to generate new product candidates for novel targets, and we disclosed last year that the next target will be pursuing as the ULK kinase, the initiating factor in autophagy pathway, namely DCC-3116 is our potential first-in-class ULK kinase inhibitor and we intend to develop for the treatment of mutant RAS cancers. And we continue to expect to file the IND for this program later this year.
Deciphera is a company founded on deep insights into kinase biology and inspired by the prospect of developing important new medicines for the treatment of cancer. Thus far this year, we have demonstrated our ability to remain focused on discovering and developing novel drug candidates based on our proprietary research, despite the significant challenges that for Deciphera in the biotechnology community as a whole faces from the ongoing COVID-19 pandemic. I look forward to updating you on the progress with our clinical and preclinical programs throughout the year.
I will now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss our commercial preparations for a potential launch of ripretinib in the US. Dan?
Daniel C. Martin -- Chief Commercial Officer
Thank you, Matt. Since its founding, Deciphera has been steadfast in its mission to discover and develop innovative therapies to improve the lives of patients with cancer worldwide. Now as we prepare for the potential commercial launch of ripretinib, the entire organization is lazer-focused on ensuring we optimize our ability to bring this important therapy to patients in need, despite the challenges of coronavirus pandemic may pose. Although this is uncharted territory and things continue to evolve, I want to provide updates on several topics including what we are hearing from market research regarding the impact of COVID-19 on providers and patients, how we are adapting our launch planning and our current thinking on how the potential launch of ripretinib could be impacted.
Results from various industry survey suggests that patient visits across many specialties, including oncology have decreased compared to pre-pandemic levels. Despite this, initial data suggest in oncology, the impact to both new patient starts and overall patient treatment volume may be less than in other specialties. It remains to be seen if the resilience we are seeing oncology continues as the data mature to more fully reflect the impact of the pandemic. Not surprisingly in-person interactions between oncologists and sales representatives have declined dramatically. However oncologists appear to be increasingly open to virtual engagement through various technology enabled platforms. To meet the unique challenges posed by the pandemic, the cross-functional launch team has done an outstanding job adapting our launch preparations and go-to-market strategies to ensure we optimize our ability to bring ripretinib to patients in need pending FDA approval.
We've hired a very talented commercial team including approximately 40 sales representatives with extensive oral oncology launch experience. Given our work-from-home policy, we have converted our entire training program including our launch meeting to virtual platforms. We have modified key go-to-market strategies in core elements of our plan tactical mix. This includes developing comprehensive remote detailing capabilities and increasing our investment in digital and other non-personnel marketing channels. The team is devised and implemented these changes to our launch plans without losing focus on the importance of providing disease education to providers and patients prior to approval.
In addition to our previously launched provider-oriented website, rethinkgist.com, we recently launched our patient site gisttogether.com, which provides important education and resources to support patients and caregivers during their treatment journey. We look forward to providing more updates on our launch preparations and core initiatives to support providers, patients and caregivers and their fight against GIST.
Our discussions with GIST KOLs confirm that despite the challenges of COVID-19, things that have not changed include the high unmet need in fourth-line GIST, their excitement for ripretinib and their dedication to providing optimal care for their GIST patients. As a result, our view of ripretinib's practice-changing potential for the treatment of GIST has not changed, nor has our expectation for ripretinib's mid and long-term commercial potential. That said, while we are confident in our revised launch plans, we also recognize that in the short term, the challenges from COVID-19 may slow the rate of uptake. Additionally, it's likely that the increased unemployment rate caused by the pandemic will increase the number of uninsured or underinsured patients, which, in turn, could drive increased utilization of our patient assistance program. As an organization, we are tremendously excited to potentially launch Deciphera's first drug this year and are extremely focused on bringing this important treatment option to patients in need. I look forward to updating you on our progress in the coming months.
I will now turn the call over to Tucker Kelly, our Chief Financial Officer, to review the financial results.
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Thanks, Dan. Let me take just a minute to discuss a few highlights from our first quarter financial results. Importantly, in the current market environment, we remain well capitalized to fund our business as we prepare to potentially launch ripretinib this year. We ended the first quarter with cash, cash equivalents and marketable securities of approximately $691.5 million. Based on our current plans, we expect that our cash will be sufficient to fund our operations and capex into the second half of 2022.
In the first quarter of 2020, our total operating expenses increased to approximately $75.3 million from $49 million in the first quarter of last year based on increased investments to support our potential commercial launch of ripretinib as well as increased clinical development activities across the pipeline. Research and development expenses were approximately $51.4 million, and selling, general and administration expenses were approximately $23.9 million for the first quarter of 2020. We expect our expenses to continue to grow modestly over the coming quarters as we continue to invest in our commercial and clinical activities.
And with that, I'll now turn the call back over to Steve.
Steven L. Hoerter -- President & Chief Executive Officer
Thank you, Tucker. I'd like to take a moment to thank the entire team here at Deciphera for their continued dedication to our mission in the face of adversity as we adapt to these rapidly changing conditions presented by COVID-19. Because of our focus and determination, 2020 will be a transformational year for the company as we await the potential approval and launch of ripretinib in the US later this year. We look forward to keeping you all updated as we continue to progress throughout the year.
And with that, Frederica, I'd like to open the call for questions.
Questions and Answers:
Operator
Sure. Your first question comes from the line of Jessica Fye with JP Morgan.
Yuko Oku -- JP Morgan -- Analyst
Hi. This is Yuko on the call for Jessica. Thank you for taking our question. Do you expect a pre-approval inspection will still be required prior to an FDA decision of ripretinib? Has this taken place yet?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Hi Yuko, it's Steve. Thanks very much for the question. So we haven't provided any additional color in terms of the granularity that you mentioned down to the level of PAIs and the like. What I can say is that we continue our very collaborative dialogue with the agency. We're very pleased with the progress, and we look forward to the agency taking action on the application by the PDUFA date, which, as you know, is August 13.
Yuko Oku -- JP Morgan -- Analyst
Great. And as of my second question, I have -- have patients enrolled in INTRIGUE been able to get their scans within the defined windows in the study protocol despite the pandemic?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks for the question. We've been working very closely, as Matt mentioned in his prepared remarks, with clinical trial sites across all of the trials, including INTRIGUE. Matt, would you like to provide a little bit more color about the nature of the work that we've been doing with respect to INTRIGUE specifically?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. Thanks, Steven. Thanks for the question. So as we indicated, due to the pandemic, the FDA has issued guidance about pharmaceutical sponsoring companies to be able to monitor patients, both centrally as traditionally done as well as locally. So we're able to implement those procedures at sites and feel very confident with the data that's being collected through the pandemic.
Yuko Oku -- JP Morgan -- Analyst
Thank you.
Operator
And your next question comes from the line of Chris Raymond with Piper Sandler.
Christopher Raymond -- Piper Sandler -- Analyst
Hey, thanks. Just two questions. I guess, first, it's more of a general sort of commercial question. I know you guys have talked about launch prep, and I would imagine you're not interested in giving us too much detail. But the VOYAGER miss, I think, was a pretty big deal in that you now have this market essentially to yourself in terms of KIT inhibitors. So I guess, can you give any more color about how this changes your commercial picture? Obviously, having one less competitor is good. But can you talk a little bit about how you are sort of structuring the field force differently, if at all, and sort of the go-to-market approach? I mean, obviously, you've got to get the KIT out there for a small subset, but just in terms of the broader population. And then maybe secondly, just in terms of the entry study, can you just remind us what's the bar for success in that study? I think you've talked about two to three months increase over Sutent. Can you sort of just reaffirm that and just sort of talk about what we should be looking for? Thanks.
Steven L. Hoerter -- President & Chief Executive Officer
Hi, Chris, it's Steve. So let me take the second part of your question first, and then I'll start off addressing your other question about VOYAGER and then turn it over to Dan Martin to offer some additional color on -- from a commercial point of view. So first, with respect to INTRIGUE, you're right, in terms of the study versus Sutent, we would expect Sutent to offer about six months of PFS. And that's consistent, I think, whether you look at the drug label or whether you look at other public studies with sunitinib or Sutent. And so we would expect that a two to three month improvement in progression-free survival over sunitinib would be a favorable study. And we haven't provided any additional detail in terms of powering assumptions and the like.
With respect to your first question around VOYAGER, I mean, I think, first, it's certainly disappointing news, I think, for the GIST community to have a negative study in this disease. As you know, this is a group of patients and a community that's really been waiting for new options for patients. And I think the data that we saw from VOYAGER certainly puts in context the potential for ripretinib and the INVICTUS study that we presented last year, where, as you know, we've showed, for the primary end point, an 85% reduction in the risk of progression or death. So I think it does show that the ripretinib has the real potential to be best-in-class in this disease. So now I'll turn it over to Dan Martin. Dan, do you want to offer any additional comments in terms of commercial context?
Daniel C. Martin -- Chief Commercial Officer
Sure. I think you framed it really well, Steve. I was just going to say that I really think that the VOYAGER outcome serves to really validate our long-held view of really the core value proposition -- the core clinical value proposition for ripretinib in GIST. GIST is a very heterogeneic disease from a mutational perspective and I think this really underscores the need for a broad spectrum inhibitor like ripretinib. It's really been the strategy all along and why this drug was designed specifically for GIST. So we've always knew ripretinib as really the drug with real practice changing potential, certainly in the fourth line and hopefully down the road beyond that. So in terms of your question about is it leading us to change our sales force size or structure, that sort of thing, VOYAGER result is not -- we don't view that as a rationale to change our strategy. So full steam ahead.
Christopher Raymond -- Piper Sandler -- Analyst
Okay. One more follow-up, if I can. So just another general question. But if you look at analogs of FDA's approval cycle for other RTOR designated oncology compounds, one would assume that your August PDUFA date might be outside the norm of what they generally approve. If it comes earlier, including much earlier, are you ready regardless to launch?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Chris, it's Steve. So it's a good question, and you're right. When you look at the analogs, whether if you look at drugs that have received breakthrough therapy designation as ripretinib has or you look at the handful of drugs that have been reviewed under RTOR, you're right. I think generally speaking, those reviews tend to conclude earlier than the PDUFA date. And so our team internally has been working really hard to be ready for what we would view as a reasonably accelerated time frame, recognizing, of course, that it's up to the FDA in terms of the time line in which they choose to act on the application up to the point of the PDUFA date. But we're really comfortable with our level of preparedness. As I mentioned in the prepared remarks, from a commercial supply perspective, we feel like we're in good shape there. And Dan and his team and Matt on the medical affairs side, I think they've done a really nice job, building superb teams, but also doing all of the heavy lifting to be ready for a potential early approval should that come.
Christopher Raymond -- Piper Sandler -- Analyst
Great. Thanks a lot.
Operator
And your next question comes from the line of Eun Yang with Jefferies.
Eun Yang -- Jefferies -- Analyst
Thank you. So Steve, as you pointed out, the pandemic impact is uncertain and it's so fluid, yet you are maintaining your clinical time lines including Phase III INTRIGUE study. So my question to you is, is there something that you are seeing giving you such a confidence? Or it is purely based on your expectation of short-term impacts such that you can catch up later?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Eun, it's Steve. Thanks for the question. It's a good question and we've been getting questions similar to this, as you can imagine, from investors over the course of the last month or two. So as you point out, the impact of the pandemic is inherently uncertain. So we're not -- we don't have any additional insight aside from what we shared in the prepared remarks, which is we believe and our guidance is predicated on this having a shorter term impact as opposed to a longer term fully disruptive impact. But based on the number of clinical trial sites that we have opened, based on the number of countries now in which we're operating with INTRIGUE and based on what we see in terms of enrollment in the study, that all gave us comfort in reiterating our guidance to have INTRIGUE enrolled by the end of the year. And so to the extent we need to change that guidance, we, of course, will, and we'll update investors at that time. But based on what's in view at the moment, we're comfortable with the reiteration of our guidance as to the INTRIGUE enrollment.
Eun Yang -- Jefferies -- Analyst
Okay. And then in terms of the 19% increase in total number of patients to be enrolled in INTRIGUE Phase III, has that been signed off by the FDA?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. So we've heard -- thanks, Eun, for the question. So we're comfortable now announcing what that N is as we did, as Matt did in his prepared remarks, N of 426 in INTRIGUE. So we formally have initiated the amendment process for the study and getting that information pushed out to clinical trial sites. So yes, so with that as the new N for the INTRIGUE study, and we're looking forward, as I noted, to getting the study fully enrolled by year-end and then reporting that out when the time is right.
Eun Yang -- Jefferies -- Analyst
Thanks. And then my last question is on ULK kinase inhibitor. So IND filing is on track for second half of this year. So obviously, it's very early, but given the target, is it reasonable to assume that the cancer type that you may go after are like a pancreatic, lung and colorectal cancer with a high frequency of RAS mutation?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Eun, I think that's right. So yes. You noted the tumor types that have a high frequency of mutant RAS, and so those would be obvious tumor types for us to consider pursuing. We haven't yet disclosed what tumor types we will pursue. We'll get to that later as we get the drug into the clinic and are able to articulate further what the development path may be and specifically what tumor types we might select. But certainly, we, of course, would consider moving into tumor types where there's a high frequency of mutant RAS.
Eun Yang -- Jefferies -- Analyst
Thank you very much.
Steven L. Hoerter -- President & Chief Executive Officer
Thanks Eun.
Operator
And your next question comes from the line of Peter Lawson with Barclays.
Waleed -- Barclays -- Analyst
Hey guys. This is Waleed [Phonetic] on for Peter. Thanks for taking our question. Just had a question, sort of a follow-up as to an earlier question on your market strategy in advance. Just wanted to ask whether your thoughts have changed on pricing now, especially after the VOYAGER failure, and how you're thinking about that going forward?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks for the question. So I'll start off, and then I'll turn it over to Dan to offer some additional color. I guess what I'd say is that this -- it's premature for us to talk about potential price for ripretinib. So we would do that upon a potential approval of the drug and we'd be in a position to talk about it then. I will offer that we've done a considerable amount of market research with payers to get their reaction and to understand their perspective on the profile of ripretinib based on the INVICTUS data. And Dan, perhaps you'd want to offer some additional color in terms of what we hear from both physicians, but also from payers?
Daniel C. Martin -- Chief Commercial Officer
Sure. Thanks, Steve. So good question. We -- the research that we've done with a number of stakeholders, obviously, payers being central to that, has really very clearly shown us the payers appreciate not only the unmet need in GIST, but the potentially best-in-class profile for ripretinib. And so we -- the methodology used in those studies, as you may know, certainly, we review the approved therapies and the class and their prices and their profiles as well as our profile and what continues to come back is just that payers really appreciate how this drug may be able to help patients. So as you said, it's premature for us to comment on pricing and we'll be doing so in due time upon approval.
Waleed -- Barclays -- Analyst
Got it. Thank you so much. That's really helpful. And just a question on your program in TGCT. Maybe if you can provide us some color on your differentiation between your drug and pexidartinib. And as we look to the data in second half, what would be the bar there and what you would consider to be a win?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks for the question on 3014. So maybe I'll start off and then Matt can add some additional color if he'd like to. So when we look at 3014 relative to the other approved agent to treat this disease, I think the things that come to mind for us in terms of distinctions between the two programs are the 3014 is highly selective for the target. So this is a very potent and selective CSF1R inhibitor. And pexidartinib, we know, as Matt referenced in his prepared remarks, is a multi-kinase inhibitor that hits a variety of targets, including C-KIT, including FLT3. And this is also a drug that upon review, as you know, may recall, it was referred to an ODAC for a discussion about risk-benefit, and the drug was ultimately approved, but with the REMS and a black box warning for hepatotoxicity. And it's a dose of the drug that is at a relatively high drug load, in the range of 800 milligrams daily for patients. So we believe that there's room in this disease setting for a more potent and selective agent that has an attractive efficacy as well as safety profile for these patients. And we're looking forward to continuing to generate additional data with 3014 in patients with TGCT. Matt, do you want to comment a little bit on that or on additional data that may be coming in the second half of this year?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Yes. No. So again, clearly, the distinction between the safety profiles may be a very important aspects of treating this disease because as we recognize, this is -- it's a locally aggressive disease, but it's not a malignant disease, so not generally life threatening, certainly can be associated with very severe morbidity, pain, swelling, limitations of activities. So a tolerable drug is really probably one of the most important characteristics along with an efficacious drug and the pexidartinib REMS warning certainly restricts its use under the FDA program.
So just referring back to the data that we did present for the first three patients, we're able to show that not only did we have a good safety profile in the data we presented at the CTOS meeting last year, but the first three patients that we enrolled all had reductions -- initial reductions in their tumor volume. And the first patient who's on the longest had a 48% reduction after two cycles and then after nine cycles of therapy, had an 84% reduction in their tumor size. So again, important early data that we believe can differentiate us from pexidartinib. And as we also said in our prepared remarks today, we continue -- we plan to have data to be able to update folks by the end of this year from the ongoing Phase I/II study.
Waleed -- Barclays -- Analyst
Thank you. And do you have any clarity on the potential regulatory path forward for 3014?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Yes. No, I think it's -- for us, specifically, it's probably too early to talk about a regulatory path forward for 3014. But clearly, the development of pexidartinib to establish at least the FDA's perspective on what they were looking for in terms of response rate. Importantly, also, functional outcomes or PROs were also a big part of the ODAC discussion for the approval of pexidartinib. So certainly it's something that we should be -- that we'll be considering for our development program.
Waleed -- Barclays -- Analyst
Got it. Thank you so much for taking the questions.
Operator
And your next question comes from the line of Michael Schmidt with Guggenheim.
Charles Zhu -- Guggenheim Partners -- Analyst
Hey guys. This is Charles Zhu on for Michael Schmidt. Thanks for taking the questions and congrats on all this progress. One quick one, swinging back to ripretinib. What are your high level plans? Or how has your thinking for commercializing ripretinib evolve with respect to ex-US as well as outside of Greater China? And if you decide to go and partner out this drug, how should we think of economics for Deciphera given that the Zai Lab collaboration was signed before INVICTUS and now you obviously have much more data?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Hi, Charles, it's Steve. Thanks for the question. So as you know, we've said that one of our key milestones for the year is filing the marketing authorization application with the European Medicines Agency in the second half of this year. So we're looking forward to engaging with the European regulator on the package for ripretinib and getting that review process started. We haven't provided any greater detail in terms of what our path might be to commercialization in Europe, what our go-to-market strategy might be in Europe. What I have said is there are two different options that we are evaluating. One is the potential for us to go at it alone in Europe and to build a capital-efficient structure to commercialize ripretinib on our own. And the alternative to that, of course, would be to pursue a potential licensing transaction.
Charles Zhu -- Guggenheim Partners -- Analyst
Got it. Okay. And shifting over to rebastinib. As you evaluate type 2 inhibition in conjunction with either paclitaxel or carboplatin, is there any reason to believe that the drug may perform differently between these two combinations, either from a drug mechanistic perspective or a disease biology perspective given their -- they may go into different tumor types?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. It's a good question, Charles. I'll ask Matt to take that question. Matt?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thanks for the question. So there's been a fair amount of preclinical data that's been done to look at the combination. And actually, there's been different combination partners up in the study with rebastinib, the type 2 kinase inhibitor. And what we've shown that with different combinations, we are able to have this inhibitory effect. I think the distinction may come from the tumor indications that will be developed because paclitaxel [Technical Issues] perhaps differently for different indications. So selection of particular tumor -- the selection of particular combination would be applicable to which tumor will be targeted.
Charles Zhu -- Guggenheim Partners -- Analyst
Got it. Thanks for taking the questions.
Steven L. Hoerter -- President & Chief Executive Officer
You bet. Thanks Charles.
Operator
And your next question comes from the line of Robyn Karnauskas with SunTrust.
Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst
Hi guys. Thanks for taking my question. Two of them. One, I'm sure you've heard a lot, but I think we just -- we need to go through it again. On big picture. So you have a competitor out of the way that presumably means you'll get more revenue. What does that mean for your company? That's more of a bull scenario maybe than you originally contemplated. So how do you put that money to work in the long run? And then second, just a question, I'm sure you hear all the time, let's deal with it. Obviously, we've seen other drugs do better in the real market than they do in their clinical trials. So does Sutent do better after a few years in the market, so would Sutent data look better today than it did when it launched? So that goes to the power in which you said is a two to three months difference from Sutent in second-line of PFS? And would that be enough to get stats today? I think that's a concern the investors have?
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Robyn, thanks. It's Steve. Let me take those two. So I'll start with the second question first with respect to sunitinib. So as you know, when you look at the sunitinib label and the data that was generated, that was the basis for approval. The PFS seen with Sutent was shy of six months in that pivotal study. And when you look at the literature, you, of course, see a range of different PFS estimates depending on the study, and there's some very small studies, some larger studies that have been done. But they tend to coalesce generally around the six month PFS range. And in fact, this, as you can imagine, was an important input for us when we were designing the INTRIGUE study, to try to understand how Sutent might perform in the current environment versus in the time when the original study was done. And from our discussions with thought leaders from around the world, very consistently, the group of thought leaders that manage patients with this disease came back and said that, yes, six months is the right sort of expectation in terms of how sunitinib might perform in the present day, in the second-line setting. So we feel very comfortable with that estimate.
And then as you know, our Phase I study, where we have a second line cohort of patients, so at the recommended dose of 150 milligrams once daily, which is an N of 31, we have seen a PFS in that patient population of about 10.6, 10.7 months. So that -- with the data, of course, now that's been generated with INVICTUS in the fourth line population gives us great confidence in the potential for ripretinib to perform in the INTRIGUE study versus sunitinib and to establish a new standard of care in that line of therapy.
So with respect to your first question, and this is coming on the heels now of the VOYAGER study failure where avapritinib underperformed regorafenib in that study. And as I mentioned earlier in the Q&A, while it's certainly disappointing news for the GIST community that has been waiting for new options for patients, I think it does help -- it does put in context, of course, the data that we've generated with INVICTUS and I believe firmly signals and establishes that ripretinib has the potential to be best-in-class in this setting and to be a new standard of care. And so we look forward to engaging with physicians upon a potential approval, sharing the data with them for those physicians that aren't already familiar with the INVICTUS data, and hopefully benefiting patients with ripretinib who are in need of additional options.
Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst
On my first question about your competitor's gone. I mean obviously, this has to change, like how you think about strategy of the company, how to be a good day, give you more flexibility to do other things that you want to do. Any thoughts on that?
Steven L. Hoerter -- President & Chief Executive Officer
Well, I think, Robyn, certainly, it's a clearing event, and I think that's how investors view it as well with the failure of the VOYAGER study. From our point of view, we designed ripretinib specifically to address the spectrum of mutations that drive this disease and our ingoing assumption all along has been that ripretinib would prove to be best-in-class in this setting in this disease. And so at some level, of course, while you're -- it's helpful to see final data, that data confirms what our ingoing set of assumptions were in terms of how ripretinib is truly best-in-class here. So we look forward to continuing to explore the role of ripretinib in other settings and just to see where ripretinib may be able to benefit patients beyond the INTRIGUE study in the second line. So that includes looking at the frontline setting, whether it be in monotherapy or in combination with other agents. But we certainly think there are additional places that we can go with ripretinib in GIST, and we look forward to exploring that further and initiating additional studies potentially in the future.
Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst
Okay. Thank you.
Operator
And your next question comes from the line of Christopher Marai with Nomura Instinet.
Jackson Harvey -- Nomura Instinet -- Analyst
Hello. This is Jackson Harvey on for Christopher Marai. My first question is when the ripretinib launch does get under way, what kinds of launch metrics do you plan on sharing? Will we be able to get any color on which line of therapy the patients are on?
Steven L. Hoerter -- President & Chief Executive Officer
Hey, Jackson, it's Steve. Thanks for the question. Yes, it's a little early for us to share what launch metrics would be for ripretinib. Once we get on the other side of a potential approval, we'll start to share how we're going to be tracking performance of ripretinib in the marketplace, and we'll share some of that information with investors.
Jackson Harvey -- Nomura Instinet -- Analyst
Got it. And my other question is on rebastinib around the muscular weakness side effects. So at the 50 milligram dose, are you able to dose through this side effect, meaning that the muscular weakness will get better with continued dosing? Or is it something that patients need to discontinue treatment for? Also, does that have any cardiac ramifications?
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Jackson. So I'll turn that over to Matt. If you'd like to answer that question, Matt?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Sure. So thanks for the question. So yes -- what we've reported previously in the paclitaxel/rebastinib combination study was the initial Phase I/II study was dose-ranging across 50 and 100 milligrams of rebastinib BID. And in that setting, we saw fairly equal and lower rates of muscular weakness in those two cohorts. When we started the expansion cohorts with 150 milligram BID, we did see some -- a few more cases at 100 milligrams BID. So we modified the dose down to 50 milligrams BID, which is what we just discussed today as well for the carboplatin combination study.When those patients are discontinued, they actually can recover fairly quickly from the muscle weakness. However, really, for longer term treatment, felt that the 50 milligram BID dose level is a more tolerable dose level. And this is really in the background, the fairly robust activity that we saw in the paclitaxel combination study with eight partial responses across those two dose levels. This is peripheral muscle weakness. It is not associated with cardiac -- any cardiac muscle effects.
Jackson Harvey -- Nomura Instinet -- Analyst
Got it. And is there a mechanistic basis to expect that cardiac muscle would not be affected?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
We haven't really talked about any specific mechanism that could be associated with this. So that would certainly be a conversation perhaps as we go forward with the development program. But there's no known target that we can identify that would make us believe that the cardiac muscle is involved.
Jackson Harvey -- Nomura Instinet -- Analyst
Great. Thanks for taking the questions.
Operator
And your last question comes from the line of Arlinda Lee with Cannacord. And your line is open Arlinda Lee.
Arlinda Lee -- Cannacord -- Analyst
Sorry I was on mute. I wanted to follow-up on the INTRIGUE population increase. You mentioned previously that it was due to early censoring. I'm wondering if given COVID and maybe some of the -- if you've put any other assumptions within that and how the pairing may or may not have changed? And then secondly, I was curious about your interactions with your thought leaders and sales with prescribers at how this might have been different now with COVID and following the avapritinib VOYAGER failure? Thank you.
Steven L. Hoerter -- President & Chief Executive Officer
Yes, Linda, it's Steve. Thanks for the two questions. So maybe what I'll do is ask Dan Martin to take the first question in terms of what we're hearing from thought leaders and from some of the secondary research that he referenced in the prepared remarks in the context of COVID-19. And then we can come back and I can answer the question with respect to INTRIGUE and Matt can offer some additional color. So Dan?
Daniel C. Martin -- Chief Commercial Officer
Sure. Thanks, Steve. So a couple of thoughts. We have been continuing to engage the thought leaders and the medical community, the GIST-prescribing community more broadly, very actively over the last several months as the COVID-19 situation has developed. We've continued to hold advisory boards. We've continued to have our one-on-one discussions. We do these through virtual platforms, of course, but we've had really great engagement that has helped inform our thinking not only on positioning for ripretinib in the market, but thoughts on strategies, tactics, that sort of thing.
A lot of the research that we've looked at, as I mentioned in my prepared remarks, would suggest that oncology has had some level of resilience just in terms of treatment volumes. But clearly, it's having an impact on patient visits, and it may ultimately have some impact on launch therapies -- launch drugs in terms of rate of uptake, and we'll just have to see. But beyond that, beyond what I shared in the prepared remarks, that's really what we're hearing.
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thanks, Dan. So Arlinda, hopefully, that answers that second question that you had. With respect to INTRIGUE, you're right, we disclosed today that the N for INTRIGUE is 426 subjects. So just wanted to be clear that the addition of these subjects to INTRIGUE has no impact on powering of the study. This is just about getting to the requisite number of events for the study to have those study readout in a timely fashion. And Matt, maybe you want to offer some additional commentary with respect to impact of COVID-19 and other considerations that may have been not taken into account as we got through this?
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Thanks, Steve. So yes, so as we have the early information about the number of patients that we're looking early in the study of who might have come off the study and didn't have central confirmation of progression, gave us a better estimate in terms of the overall sample size. But certainly, as Steve mentioned, this very modest increase in sample size will allow us to get to the required number of events, which does not change the statistical analysis of plan. This -- the implementation of the processes we put into place, again, we feel very comfortable during this particular unusual time with COVID-19 pandemic. And with the team being in close communication with investigators and the sites and able to implement local procedures as well, we still feel very comfortable about being able to collect the information that will be necessary to evaluate the effect of ripretinib in the second line setting.
Arlinda Lee -- Cannacord -- Analyst
Great. Thank you.
Steven L. Hoerter -- President & Chief Executive Officer
Thanks Arlinda.
Operator
And this concludes today's Q&A session. I would like to turn the call over to Steve Hoerter for closing remarks.
Steven L. Hoerter -- President & Chief Executive Officer
Yes. Thank you very much, Frederica, and thanks all of you for joining us on the call today. We look forward to continuing to update you on our progress as the rest of the year progresses. And we wish each of you safety and good health in these challenging times. Have a great night.
Operator
[Operator Closing Remarks]
Duration: 56 minutes
Call participants:
Jen Robinson -- Vice President, Investor Relations
Steven L. Hoerter -- President & Chief Executive Officer
Matthew L. Sherman -- Executive Vice President, Chief Medical Officer
Daniel C. Martin -- Chief Commercial Officer
Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer
Yuko Oku -- JP Morgan -- Analyst
Christopher Raymond -- Piper Sandler -- Analyst
Eun Yang -- Jefferies -- Analyst
Waleed -- Barclays -- Analyst
Charles Zhu -- Guggenheim Partners -- Analyst
Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst
Jackson Harvey -- Nomura Instinet -- Analyst
Arlinda Lee -- Cannacord -- Analyst
More DCPH analysis
All earnings call transcripts
{%sfr%}
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Daniel C. Martin -- Chief Commercial Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Yuko Oku -- JP Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Waleed -- Barclays -- Analyst Charles Zhu -- Guggenheim Partners -- Analyst Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Arlinda Lee -- Cannacord -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Such risks and uncertainties include the impact of COVID-19, the execution of clinical trials, the timing of study data, the actions of regulatory agencies and those set forth in our most recent quarterly report on Form 10-Q as well as other -- our other SEC filings.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Daniel C. Martin -- Chief Commercial Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Yuko Oku -- JP Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Waleed -- Barclays -- Analyst Charles Zhu -- Guggenheim Partners -- Analyst Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Arlinda Lee -- Cannacord -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Daniel C. Martin -- Chief Commercial Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Yuko Oku -- JP Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Waleed -- Barclays -- Analyst Charles Zhu -- Guggenheim Partners -- Analyst Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Arlinda Lee -- Cannacord -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 56 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steven L. Hoerter -- President & Chief Executive Officer Matthew L. Sherman -- Executive Vice President, Chief Medical Officer Daniel C. Martin -- Chief Commercial Officer Tucker Kelly -- Executive Vice President, Chief Financial Officer and Treasurer Yuko Oku -- JP Morgan -- Analyst Christopher Raymond -- Piper Sandler -- Analyst Eun Yang -- Jefferies -- Analyst Waleed -- Barclays -- Analyst Charles Zhu -- Guggenheim Partners -- Analyst Robyn Karnauskas -- SunTrust Robinson Humphrey -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Arlinda Lee -- Cannacord -- Analyst More DCPH analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020, 4:30 p.m. I will now turn the call over to Dan Martin, our Chief Commercial Officer, to discuss our commercial preparations for a potential launch of ripretinib in the US.
|
fdc98283-c3a1-4189-a917-f31e7c3e0bf6
|
715528.0
|
2020-04-28 00:00:00 UTC
|
Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure
|
DCPH
|
https://www.nasdaq.com/articles/blueprint-medicines-tumbles-20.8-on-phase-3-study-failure-2020-04-28
|
nan
|
nan
|
What happened
Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free survival (PFS) compared to regorafenib in patients with third- or fourth-line GIST, meaning they had received two or three other treatments prior to the study.
The disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines or Deciphera Pharmaceuticals (NASDAQ: DCPH). The former has earned a narrow regulatory approval for a specific genetic mutation in GIST, but the latter has generated encouraging results in second-, third-, and fourth-line GIST.
As of 10:58 a.m. EDT, the pharma stock had settled to a 17.2% loss.
Image source: Getty Images.
So what
In the phase 3 trial conducted by Blueprint Medicines, 240 individuals received avapritinib and 236 individuals received regorafenib, which is approved as a third-line GIST treatment. The experimental therapy achieved a median PFS of 4.2 months, while the standard treatment achieved a median PFS of 5.6 months. The difference wasn't considered statistically significant.
The top-line results suggest avapritinib might not be competitive as a second-line treatment option, for which Blueprint Medicines is currently conducting clinical trials. While a second-line GIST drug would have a larger market opportunity than later-line treatments, the bar for success is also higher. Sunitinib, the standard treatment for second-line GIST, achieved a median PFS of 5.6 months in registrational trials.
It might not matter in the long run. Ripretinib, the lead drug candidate from Deciphera Pharmaceuticals, achieved a median PFS of 6.3 months in a clinical trial testing its potential in fourth-line or greater GIST. It achieved a median PFS of 10.6 months as a second-line GIST treatment in a small phase 1 study.
Now what
On the one hand, today's news is disappointing for investors. Blueprint Medicines was positioned to offer next-generation therapies for underserved patients with GIST. That ambitious vision just took a hit, especially once promising results from Deciphera Pharmaceuticals are factored into the competitive landscape.
On the other hand, Blueprint Medicines isn't completely dependent on avapritinib. The company is developing several other assets aimed at genetically defined cancers in research and clinical programs. The business also reported $548 million in cash at the end of 2019, which management believes is enough to fund operations into 2022.
That said, a market cap of $3.1 billion prices in a lot of success that has yet to materialize. Investors should consider this a high-risk stock.
10 stocks we like better than Blueprint Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines or Deciphera Pharmaceuticals (NASDAQ: DCPH). What happened Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free survival (PFS) compared to regorafenib in patients with third- or fourth-line GIST, meaning they had received two or three other treatments prior to the study.
|
The disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines or Deciphera Pharmaceuticals (NASDAQ: DCPH). So what In the phase 3 trial conducted by Blueprint Medicines, 240 individuals received avapritinib and 236 individuals received regorafenib, which is approved as a third-line GIST treatment. The experimental therapy achieved a median PFS of 4.2 months, while the standard treatment achieved a median PFS of 5.6 months.
|
The disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines or Deciphera Pharmaceuticals (NASDAQ: DCPH). 10 stocks we like better than Blueprint Medicines When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Maxx Chatsko has no position in any of the stocks mentioned.
|
The disappointing results might settle the debate among investors over which company is better positioned to succeed in GIST: Blueprint Medicines or Deciphera Pharmaceuticals (NASDAQ: DCPH). The experimental therapy didn't lead to an improvement in progression-free survival (PFS) compared to regorafenib in patients with third- or fourth-line GIST, meaning they had received two or three other treatments prior to the study. On the other hand, Blueprint Medicines isn't completely dependent on avapritinib.
|
03034039-6b38-4e21-828c-a51d262d8345
|
715529.0
|
2020-04-22 00:00:00 UTC
|
Is Deciphera Pharmaceuticals a Buy?
|
DCPH
|
https://www.nasdaq.com/articles/is-deciphera-pharmaceuticals-a-buy-2020-04-22
|
nan
|
nan
|
There are plenty of intriguing biotech stocks on the market right now, and many of them are trading at a steep discount due to the coronavirus pandemic. However, no matter how exciting a company's prospects might be, investors still need to do their due diligence before choosing to invest in any biotech stock.
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Its lead drug candidate, ripretinib, is awaiting regulatory approval from the U.S. Food and Drug Administration (FDA) later this year. There's a lot of anticipation surrounding this decision; does this mean that now's a good time to buy this stock, or should you stay away from this company altogether?
Image source: Getty Images.
Understanding Deciphera's business
Deciphera has a few separate drug candidates in its pipeline right now; a couple of them are still in preclinical research, while others are just beginning phase 1 or 2 clinical trials. The most exciting part of Deciphera's pipeline is ripretinib, which treats a type of tumor that occurs in the stomach and small intestines known as a gastrointestinal stromal tumor (GIST). The drug works by targeting certain types of proteins (known as kinases) that are specifically involved in regulating the body's immune response. These types of drugs, also known as checkpoint inhibitors, end up amplifying the immune system's ability to attack cancerous cells in the body.
Overall, GIST is a pretty rare type of cancer, with only 5,000 patients or so being diagnosed in the U.S. each year. However, when you consider that some patients don't show major symptoms at all if their tumors are small enough, this figure may be much higher.
Shares of Deciphera almost doubled back in August when the company announced positive phase 3 trials for ripretinib. The trial in question, which compared the drug against a placebo, tested 129 patients with advanced GIST who had already tried previous cancer therapies. Ripretinib ended up meeting both its primary and secondary endpoints in improving patient survival times in comparison to the placebo.
Deciphera's New Drug Application (NDA) for ripretinib is currently undergoing a priority review by the FDA, with the decision scheduled to be announced by Aug. 13. Considering how positive the clinical data has been for ripretinib so far, the odds seem to be pretty good that the drug will be approved, although you can never be 100% certain how the FDA will rule on a decision.
What about the competition?
Eight different drugs have been approved by the FDA for use in treating GIST. One of the more notable ones is Gleevec, a cancer treatment produced by Novartis that received approval to treat GIST back in 2002. However, the drug has since lost its patent protection and has been losing market share at a significant rate.
Newer GIST treatments include Blueprint Medicine's Ayvakit, a GIST treatment that was approved in January. A 30-day supply of this drug carries a price tag of $32,000, and it wouldn't be surprising if Deciphera charges similarly for ripretinib.
GIST is a rare type of cancer, and there are already a significant number of other cancer treatments approved for the condition. Although Deciphera's new drug could capture a significant chunk of the market, it's uncertain just how commercially successful ripretinib will be in comparison with some of its newer competitors.
Image source: Getty Images.
What else does Deciphera have up its sleeve?
Putting aside GIST, ripretinib also is undergoing a separate phase 1 clinical trial to treat systemic mastocytosis, a condition where the body produces too many mast cells. These cells, which are involved in fighting off infections and allergic reactions, end up multiplying out of control in patients who have this condition. Systemic mastocytosis ends up becoming cancerous in up to 30% of all adult cases. However, it too is a fairly rare condition, affecting just 1 in 10,000 adults around the world.
Another drug Deciphera is working on is rebastinib, a tumor treatment meant to be used in combination with other cancer drugs. Rebastinib is currently undergoing two phase 2 trials involving tumors in breast, ovarian, and endometrial (a type of uterine) cancer. A second tumor drug, DCC-3014, is currently undergoing phase 1 trials as well.
Looking at the financials
Evaluating clinical-stage biotech stocks is a little different from evaluating most other companies. Because these companies have little in the way of revenue, potential investors should pay close attention tothe pipeline. Additionally, they should decide whether the company has enough cash on hand to finance its operations until any of its drug candidates get approved.
Deciphera has no revenue to speak of -- at all. Net losses for the fourth quarter of 2019 came in at $67.2 million, significantly worse than Q4 2018's net losses of $32.3 million. However, that's par for the course considering its main drug candidate went through two phase 3 trials, which tend to be quite expensive for smaller biotech stocks.
The good news is that Deciphera has more than enough cash to finance itself until ripretinib receives regulatory approval. The company has $120.3 million in cash and cash equivalents, alongside an extra $459.3 million in marketable securities if necessary. That comes to $579.6 million in total, which would be enough to last the company a couple of years at its current rate of cash expenditure.
Should you buy Deciphera right now?
The question really comes down to whether or not you think ripretinib will receive FDA approval this August. If that happens, which seems likely, then buying Deciphera's stock on that basis now could be a good idea.
However, there's a lot riding on this approval, and on the off chance that the FDA doesn't approve ripretinib, you can expect shares of Deciphera to tank. At the same time, there's still a fair bit of competition in the GIST arena, an already small market given how rare this type of cancer is.
Overall, if you're a high-risk, high-growth investor, I would be OK recommending picking up some shares of Deciphera right now in anticipation of the FDA's ruling. However, make sure to keep your position relatively small, especially since this is still a clinical-stage biotech stock with no revenue.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Although Deciphera's new drug could capture a significant chunk of the market, it's uncertain just how commercially successful ripretinib will be in comparison with some of its newer competitors. Putting aside GIST, ripretinib also is undergoing a separate phase 1 clinical trial to treat systemic mastocytosis, a condition where the body produces too many mast cells.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Shares of Deciphera almost doubled back in August when the company announced positive phase 3 trials for ripretinib. One of the more notable ones is Gleevec, a cancer treatment produced by Novartis that received approval to treat GIST back in 2002.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Its lead drug candidate, ripretinib, is awaiting regulatory approval from the U.S. Food and Drug Administration (FDA) later this year. Understanding Deciphera's business Deciphera has a few separate drug candidates in its pipeline right now; a couple of them are still in preclinical research, while others are just beginning phase 1 or 2 clinical trials.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one company on sale. Eight different drugs have been approved by the FDA for use in treating GIST. GIST is a rare type of cancer, and there are already a significant number of other cancer treatments approved for the condition.
|
3dca2b0b-4e32-4e20-9b95-6ecd3f62205e
|
715530.0
|
2020-04-07 00:00:00 UTC
|
DCPH Crosses Above Key Moving Average Level
|
DCPH
|
https://www.nasdaq.com/articles/dcph-crosses-above-key-moving-average-level-2020-04-07
|
nan
|
nan
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $43.38, changing hands as high as $46.41 per share. Deciphera Pharmaceuticals Inc shares are currently trading up about 9% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.08.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $43.38, changing hands as high as $46.41 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.08. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $43.38, changing hands as high as $46.41 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.08. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $43.38, changing hands as high as $46.41 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.08. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Tuesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $43.38, changing hands as high as $46.41 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $46.08. Deciphera Pharmaceuticals Inc shares are currently trading up about 9% on the day.
|
063e3370-fa54-4599-92e2-3ddea23eb04d
|
715531.0
|
2020-04-06 00:00:00 UTC
|
Here's Why Deciphera Pharmaceuticals Lost 22.7% in March
|
DCPH
|
https://www.nasdaq.com/articles/heres-why-deciphera-pharmaceuticals-lost-22.7-in-march-2020-04-07
|
nan
|
nan
|
What happened
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. Investors are concerned that the company's long-awaited transition to commercial operations will be delayed by the coronavirus pandemic. It's not an unreasonable concern.
The company's lead drug candidate, ripretinib, is widely expected to earn marketing approval from the U.S. Food and Drug Administration (FDA) in advanced gastrointestinal stromal tumors (GIST). But the previously stated regulatory decision deadline of mid-August could be pushed back in light of the current situation. That realization has weighed on the pharma stock.
Image source: Getty Images.
So what
Deciphera Pharmaceuticals has announced promising results from multiple clinical trials studying ripretinib in GIST. In one phase 3 trial, individuals taking the drug candidate as a fourth-line treatment (meaning they had been treated unsuccessfully with at least three other treatments) achieved a progression-free survival (PFS) of 6.3 months and a median overall survival (OS) of 15.1 months. By contrast, individuals taking a placebo achieved a PFS of one month and a median OS of 6.6 months.
There are currently no approved fourth-line treatment options for GIST, which prompted the FDA to accept the new drug application (NDA) for ripretinib for priority review. Regulators expected to make a decision on the NDA by Aug. 13, but investors are now concerned that the coronavirus pandemic will lead to a delay.
It's still possible for the FDA to stick to the original deadline, but the unfolding health crisis has obviously shifted priorities and disrupted day-to-day operations for the regulator. Many drug companies have also decided to pause clinical trials to protect patients, which has probably affected development activities at Deciphera Pharmaceuticals, too.
Now what
Investors with a long-term mindset might not be too concerned with potential delays for the company's commercialization timeline. Deciphera Pharmaceuticals is very likely to earn marketing approval for ripretinib in advanced GIST -- it just might take a little longer than previously expected for the NDA to be processed. Similarly, the drug candidate has shown promising potential as a second-line treatment option in GIST, which suggests delayed clinical trials will only be a short-term setback for the drug candidate's expansion.
10 stocks we like better than Deciphera Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. There are currently no approved fourth-line treatment options for GIST, which prompted the FDA to accept the new drug application (NDA) for ripretinib for priority review. Many drug companies have also decided to pause clinical trials to protect patients, which has probably affected development activities at Deciphera Pharmaceuticals, too.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. The company's lead drug candidate, ripretinib, is widely expected to earn marketing approval from the U.S. Food and Drug Administration (FDA) in advanced gastrointestinal stromal tumors (GIST). In one phase 3 trial, individuals taking the drug candidate as a fourth-line treatment (meaning they had been treated unsuccessfully with at least three other treatments) achieved a progression-free survival (PFS) of 6.3 months and a median overall survival (OS) of 15.1 months.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. The company's lead drug candidate, ripretinib, is widely expected to earn marketing approval from the U.S. Food and Drug Administration (FDA) in advanced gastrointestinal stromal tumors (GIST). 10 stocks we like better than Deciphera Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence. There are currently no approved fourth-line treatment options for GIST, which prompted the FDA to accept the new drug application (NDA) for ripretinib for priority review. Similarly, the drug candidate has shown promising potential as a second-line treatment option in GIST, which suggests delayed clinical trials will only be a short-term setback for the drug candidate's expansion.
|
5cd9ed04-ec2e-459f-b41b-a1bf6c52a316
|
715532.0
|
2020-03-12 00:00:00 UTC
|
Notable Two Hundred Day Moving Average Cross - DCPH
|
DCPH
|
https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-dcph-2020-03-12
|
nan
|
nan
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $41.93, changing hands as low as $39.47 per share. Deciphera Pharmaceuticals Inc shares are currently trading down about 10.7% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $39.53.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $41.93, changing hands as low as $39.47 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $39.53. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $41.93, changing hands as low as $39.47 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $39.53. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $41.93, changing hands as low as $39.47 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $39.53. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $41.93, changing hands as low as $39.47 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $19.88 per share, with $71.11 as the 52 week high point — that compares with a last trade of $39.53. Deciphera Pharmaceuticals Inc shares are currently trading down about 10.7% on the day.
|
36ec3441-1ea4-4780-a6be-be7f2f5368b4
|
715533.0
|
2020-02-14 00:00:00 UTC
|
Health Care Sector Update for 02/14/2020: DCPH,DXCM,IMGN,PLSE
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-02-14-2020%3A-dcphdxcmimgnplse-2020-02-14
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.45%
PFE -1.27%
ABT -0.06%
MRK +0.24%
AMGN -0.48%
Health care stocks were mostly lower, with the NYSE Health Care Index declining 0.3% on Friday while the shares of health care companies in the S&P 500 also were down 0.1% as a group. The Nasdaq Biotechnology index was climbing 0.4%.
Among health care stocks moving on news:
(-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. Net proceeds will be used to fund more research and development of its drug candidates, clinical trials and commercialization efforts and other general corporate purposes.
In other sector news:
(+) ImmunoGen (IMGN) climbed 29% to its best share price since October 2018 at $7.07 apiece after the biotechnology company reported a surprise Q4 profit and a more than three-fold increase in revenue compared with year-ago levels, also exceeding Wall Street estimates. Looking forward, it sees FY20 revenue in a range of $60 million to $65 million, topping the $44.7 million analyst mean.
(+) DexCom (DXCM) rose 13% after the medical device company late Thursday reported non-GAAP Q4 net income and revenue topping year-ago levels, earning $1.15 per share during the three months ended Dec. 31, more than doubling its $0.56 per share adjusted profit last year while revenue rose 36.9% to $462.8 million. Analysts, on average, had been looking for a $0.72 per share profit, excluding one-time items, on $457.1 million in revenue.
(-) Pulse Biosciences (PLSE) fell over 42% soon after Friday's opening bell, dropping to a three-year low of $7.00 a share after the US Food and Drug Administration said the company has not demonstrated its CellFX non-thermal cellular dermatology treatment was substantially equivalent to its predicate device. Pulse said it was prepared to provide the agency with more clinical data to obtain 510(k) market clearance for the device.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. Net proceeds will be used to fund more research and development of its drug candidates, clinical trials and commercialization efforts and other general corporate purposes. In other sector news: (+) ImmunoGen (IMGN) climbed 29% to its best share price since October 2018 at $7.07 apiece after the biotechnology company reported a surprise Q4 profit and a more than three-fold increase in revenue compared with year-ago levels, also exceeding Wall Street estimates.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. Top Health Care Stocks Health care stocks were mostly lower, with the NYSE Health Care Index declining 0.3% on Friday while the shares of health care companies in the S&P 500 also were down 0.1% as a group.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. Health care stocks were mostly lower, with the NYSE Health Care Index declining 0.3% on Friday while the shares of health care companies in the S&P 500 also were down 0.1% as a group. (+) DexCom (DXCM) rose 13% after the medical device company late Thursday reported non-GAAP Q4 net income and revenue topping year-ago levels, earning $1.15 per share during the three months ended Dec. 31, more than doubling its $0.56 per share adjusted profit last year while revenue rose 36.9% to $462.8 million.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) dropped 3.8% after the specialty drugmaker late Thursday priced a $175 million public offering of slightly more than 3.18 million common at $55 apiece, representing a 5.9% discount to its last closing price. The Nasdaq Biotechnology index was climbing 0.4%. Looking forward, it sees FY20 revenue in a range of $60 million to $65 million, topping the $44.7 million analyst mean.
|
63332c3e-4c1d-4f4e-9986-1d2c95ba8475
|
715534.0
|
2020-02-14 00:00:00 UTC
|
Noteworthy Friday Option Activity: TRUP, DIS, DCPH
|
DCPH
|
https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-trup-dis-dcph-2020-02-14
|
nan
|
nan
|
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Trupanion Inc (Symbol: TRUP), where a total of 2,085 contracts have traded so far, representing approximately 208,500 underlying shares. That amounts to about 86.3% of TRUP's average daily trading volume over the past month of 241,620 shares. Especially high volume was seen for the $30 strike call option expiring February 21, 2020, with 973 contracts trading so far today, representing approximately 97,300 underlying shares of TRUP. Below is a chart showing TRUP's trailing twelve month trading history, with the $30 strike highlighted in orange:
Walt Disney Co. (Symbol: DIS) options are showing a volume of 97,977 contracts thus far today. That number of contracts represents approximately 9.8 million underlying shares, working out to a sizeable 83.7% of DIS's average daily trading volume over the past month, of 11.7 million shares. Especially high volume was seen for the $145 strike call option expiring February 21, 2020, with 7,133 contracts trading so far today, representing approximately 713,300 underlying shares of DIS. Below is a chart showing DIS's trailing twelve month trading history, with the $145 strike highlighted in orange:
And Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 3,340 contracts, representing approximately 334,000 underlying shares or approximately 82.7% of DCPH's average daily trading volume over the past month, of 404,010 shares. Especially high volume was seen for the $70 strike put option expiring February 21, 2020, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $70 strike highlighted in orange:
For the various different available expirations for TRUP options, DIS options, or DCPH options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Especially high volume was seen for the $70 strike put option expiring February 21, 2020, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of DCPH. Below is a chart showing DIS's trailing twelve month trading history, with the $145 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 3,340 contracts, representing approximately 334,000 underlying shares or approximately 82.7% of DCPH's average daily trading volume over the past month, of 404,010 shares. Below is a chart showing DCPH's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for TRUP options, DIS options, or DCPH options, visit StockOptionsChannel.com.
|
Below is a chart showing DIS's trailing twelve month trading history, with the $145 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 3,340 contracts, representing approximately 334,000 underlying shares or approximately 82.7% of DCPH's average daily trading volume over the past month, of 404,010 shares. Especially high volume was seen for the $70 strike put option expiring February 21, 2020, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for TRUP options, DIS options, or DCPH options, visit StockOptionsChannel.com.
|
Below is a chart showing DIS's trailing twelve month trading history, with the $145 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 3,340 contracts, representing approximately 334,000 underlying shares or approximately 82.7% of DCPH's average daily trading volume over the past month, of 404,010 shares. Especially high volume was seen for the $70 strike put option expiring February 21, 2020, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for TRUP options, DIS options, or DCPH options, visit StockOptionsChannel.com.
|
Below is a chart showing DIS's trailing twelve month trading history, with the $145 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 3,340 contracts, representing approximately 334,000 underlying shares or approximately 82.7% of DCPH's average daily trading volume over the past month, of 404,010 shares. Especially high volume was seen for the $70 strike put option expiring February 21, 2020, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $70 strike highlighted in orange: For the various different available expirations for TRUP options, DIS options, or DCPH options, visit StockOptionsChannel.com.
|
96a937ca-cf9a-4a63-b2bb-2013cd251168
|
715535.0
|
2020-02-14 00:00:00 UTC
|
About to Buy Penny Stocks? Look at These 2 Companies First
|
DCPH
|
https://www.nasdaq.com/articles/about-to-buy-penny-stocks-look-at-these-2-companies-first-2020-02-14
|
nan
|
nan
|
Penny stocks might seem like a good investment because you can purchase many shares for a relatively small amount of money. But most of them represent businesses with questionable prospects at best, and owning thousands of shares of a worthless venture means your hard-earned money could vaporize before your eyes. To be blunt, penny stocks aren't worth it.
That's not to say individual investors have to maintain a boring wealth-building strategy. While high-risk, high-reward stocks shouldn't comprise a significant share of your portfolio, the world won't end if you reserve a small amount of your funds for riskier stocks. Why not have a little fun?
If you want to swear off penny stocks but still add some excitement to your portfolio, then consider gene-editing pioneer Precision BioSciences (NASDAQ: DTIL) and checkpoint-inhibitor developer Deciphera Pharmaceuticals (NASDAQ: DCPH).
Image source: Getty Images.
A novel gene editing platform
Investors must keep up with a growing list of gene editing tools these days. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are developing drug candidates based on first-generation CRISPR tools. Newcomers such as Beam Therapeutics and Prime Medicine are developing platforms based on CRISPR base editing and CRISPR prime editing, respectively.
Making matters more complicated, all CRISPR-based tools share intellectual property held by just a handful of major research institutions and universities. It might be best to avoid the tangled web of potential conflicts of interest altogether, but that doesn't mean investors have to avoid gene editing.
Precision BioSciences is developing a gene editing platform based on ARCUS nucleases. This approach has several potential technical advantages over CRISPR-based tools, but it's off to a mixed start.
The company's lead drug candidate, PBCAR0191, is a chimeric antigen receptor T cell (CAR-T) therapy engineered with ARCUS gene editing to treat advanced blood cancers. In a phase 1/2a clinical trial, the experimental cellular medicine triggered a response in 66% of patients with advanced non-Hodgkin's lymphoma (NHL) and 33% of patients with advanced B-cell precursor acute lymphoblastic leukemia (B-ALL).
But those objective response rates are based on just six and three patients, respectively, and only represent responses maintained through the first 28 days of treatment. Investors cheered the initial update in the fourth quarter of 2019, only to grow more cautious when expanded results were presented weeks later.
On the one hand, there were some treatment-related adverse events, and two individuals who initially demonstrated a response to treatment relapsed after 14 days. The individual who achieved the longest response (nearly six months) also relapsed. On the other hand, all individuals enrolled in the study had advanced disease. One individual remained in complete response (no evidence of disease) as of early December.
Investors appear to be waiting for Precision BioSciences to report the next data update from a third dose cohort, the highest dose studied to date, in the first quarter of 2020. If the results suggest higher doses of PBCAR0191 provide more durable responses and a manageable safety profile, then the gene editing stock could climb higher. If results aren't as clear cut, the stock might be mired in uncertainty for the foreseeable future.
Given the early stage nature of the ARCUS platform and gene edited cellular medicines, it's not too surprising that researchers are still learning optimal dosing strategies for PBCAR0191. But there will be more shots on goal soon, since Precision BioSciences expects to advance its second drug candidate into clinical trials in 2020. That should help the company's scientists to more quickly determine dosing strategies for its candidates.
Additionally, because Precision BioSciences owns all of the intellectual property for its platform, it can venture beyond healthcare applications of gene editing. The company's early stage agricultural biotech pipeline is intriguing, even if it doesn't factor into the company's valuation just yet. It could even become a supplier of plant-based proteins in the back half of the 2020s.
Simply put, Precision BioSciences is a risky stock, but one with undeniable potential -- and way better than a penny stock.
Image source: Getty Images.
Will this drug set the standard in GIST?
Deciphera Pharmaceuticals is developing five small-molecule inhibitors aimed at solid-tumor cancers, but all eyes are on the company's lead drug candidate, ripretinib. The compound inhibits the KIT and PDGFR-alpha proteins that play a pivotal role in the progression and development of drug resistance in certain cancers. Clinical results collected to date suggest ripretinib is poised to significantly improve treatment for gastrointestinal stromal tumors (GIST).
The drug candidate was pitted against placebo in a phase 3 trial investigating its potential as a fourth-line or greater treatment (meaning individuals have been unsuccessfully treated with at least three prior treatments) for GIST. Individuals who received ripretinib achieved a median progression-free survival (PFS) of 6.3 months and a median overall survival (OS) of 15.1 months, compared with only one month and 6.6 months, respectively, for those who received placebo. The drug candidate drove an 85% reduction of disease progression or death compared with placebo.
There are currently no approved fourth-line treatment options for GIST, which suggests the drug candidate has a relatively easy path to marketing approval. The Food and Drug Administration is scheduled to make a decision by Aug. 13.
The impressive results in advanced GIST also suggest ripretinib could significantly improve outcomes in less advanced cases of the cancer. Deciphera Pharmaceuticals is testing the drug candidate as a second- and third-line treatment option, and the early indications are promising.
In a phase 1 clinical trial, ripretinib achieved a median PFS of 46 weeks as a second-line treatment option for GIST. That compares with a median PFS of 24 weeks achieved by Sutent from Pfizer in the same indication. Deciphera Pharmaceuticals is now conducting a larger phase 3 trial to generate results to support a supplemental new drug application (sNDA).
Considering analysts expect ripretinib to achieve peak annual sales of over $1 billion in a best-case scenario, investors with a long-term mindset might be willing to give the pharma stock a closer look. But there could be some bumps in the road. Deciphera Pharmaceuticals is valued at $3 billion today, which prices in a decent amount of future success that has yet to be delivered. That could create volatility if market launch or the ramp-up of sales for ripretinib doesn't quite go as planned, or if a competing next-generation GIST treatment from Blueprint Medicines creates any roadblocks.
In other words, the stock is risky because of its early success and market valuation, but it certainly has long-term potential.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Editas Medicine. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If you want to swear off penny stocks but still add some excitement to your portfolio, then consider gene-editing pioneer Precision BioSciences (NASDAQ: DTIL) and checkpoint-inhibitor developer Deciphera Pharmaceuticals (NASDAQ: DCPH). The company's lead drug candidate, PBCAR0191, is a chimeric antigen receptor T cell (CAR-T) therapy engineered with ARCUS gene editing to treat advanced blood cancers. Given the early stage nature of the ARCUS platform and gene edited cellular medicines, it's not too surprising that researchers are still learning optimal dosing strategies for PBCAR0191.
|
If you want to swear off penny stocks but still add some excitement to your portfolio, then consider gene-editing pioneer Precision BioSciences (NASDAQ: DTIL) and checkpoint-inhibitor developer Deciphera Pharmaceuticals (NASDAQ: DCPH). CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are developing drug candidates based on first-generation CRISPR tools. Newcomers such as Beam Therapeutics and Prime Medicine are developing platforms based on CRISPR base editing and CRISPR prime editing, respectively.
|
If you want to swear off penny stocks but still add some excitement to your portfolio, then consider gene-editing pioneer Precision BioSciences (NASDAQ: DTIL) and checkpoint-inhibitor developer Deciphera Pharmaceuticals (NASDAQ: DCPH). While high-risk, high-reward stocks shouldn't comprise a significant share of your portfolio, the world won't end if you reserve a small amount of your funds for riskier stocks. The drug candidate was pitted against placebo in a phase 3 trial investigating its potential as a fourth-line or greater treatment (meaning individuals have been unsuccessfully treated with at least three prior treatments) for GIST.
|
If you want to swear off penny stocks but still add some excitement to your portfolio, then consider gene-editing pioneer Precision BioSciences (NASDAQ: DTIL) and checkpoint-inhibitor developer Deciphera Pharmaceuticals (NASDAQ: DCPH). A novel gene editing platform Investors must keep up with a growing list of gene editing tools these days. In a phase 1 clinical trial, ripretinib achieved a median PFS of 46 weeks as a second-line treatment option for GIST.
|
58109e6b-ab55-4ea5-b52d-c5db8c776537
|
715536.0
|
2020-02-13 00:00:00 UTC
|
Here's Why Deciphera Pharmaceuticals Tumbled Today
|
DCPH
|
https://www.nasdaq.com/articles/heres-why-deciphera-pharmaceuticals-tumbled-today-2020-02-13
|
nan
|
nan
|
What happened
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. The pre-revenue pharmaceutical company intends to raise gross proceeds of up to $287.5 million, although the number of shares offered won't be known until the pricing is announced.
The new funds will pad a balance sheet that sported $634 million in cash, cash equivalents, and marketable securities at the end of September. Although it may seem unnecessary, Deciphera Pharmaceuticals is preparing for a busy year. The company is expanding its pipeline, conducting an important late-stage trial for its lead drug candidate, and preparing for the potential market launch of the same experimental therapy in the second half of 2020.
As of 12:31 p.m. EST, the pharma stock had settled to a 14.9% loss.
Image source: Getty Images.
So what
The fundraising announcement comes on the heels of news that the U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for the company's lead drug candidate, ripretinib, as a fourth-line treatment option for gastrointestinal stromal tumors (GIST). The FDA is expected to make a decision by Aug. 13, 2020, which means the drug candidate could launch in the second half of 2020.
Ripretinib is widely expected to receive marketing approval. In a phase 3 clinical trial, the drug candidate achieved a median progression-free survival (PFS) of 6.3 months, compared to only one month for placebo. It achieved an 85% reduction in risk of disease progression or death compared to placebo. There are currently no approved fourth-line treatment options for GIST, which gives investors confidence that approval is imminent.
The strong showing in advanced GIST has also made investors confident that the drug candidate can significantly improve outcomes in less advanced cases of the illness. By the second half of 2020, Deciphera Pharmaceuticals expects to complete enrollment in a phase 3 study evaluating ripretinib as a second-line treatment option for GIST. In a best-case scenario, analysts expect the drug candidate to achieve peak annual sales of $1 billion or more.
Now what
Investors shouldn't be surprised by the proposed public offering of common stock. Deciphera Pharmaceuticals expects to have a busy -- and expensive -- year of operations in 2020. It's wise to stay ahead of an accelerating cash burn and to take advantage of a soaring stock price. All eyes will be on the next formal update from management: the fourth-quarter and full-year 2019earnings conference callin the coming weeks.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. The pre-revenue pharmaceutical company intends to raise gross proceeds of up to $287.5 million, although the number of shares offered won't be known until the pricing is announced. The company is expanding its pipeline, conducting an important late-stage trial for its lead drug candidate, and preparing for the potential market launch of the same experimental therapy in the second half of 2020.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. So what The fundraising announcement comes on the heels of news that the U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for the company's lead drug candidate, ripretinib, as a fourth-line treatment option for gastrointestinal stromal tumors (GIST). There are currently no approved fourth-line treatment options for GIST, which gives investors confidence that approval is imminent.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. So what The fundraising announcement comes on the heels of news that the U.S. Food and Drug Administration (FDA) accepted the new drug application (NDA) for the company's lead drug candidate, ripretinib, as a fourth-line treatment option for gastrointestinal stromal tumors (GIST). See the 10 stocks *Stock Advisor returns as of December 1, 2019 Maxx Chatsko has no position in any of the stocks mentioned.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell as much as 16.1% today after the company announced a proposed public offering of common stock. By the second half of 2020, Deciphera Pharmaceuticals expects to complete enrollment in a phase 3 study evaluating ripretinib as a second-line treatment option for GIST. 10 stocks we like better than Deciphera Pharmaceuticals, Inc.
|
3f346faa-5b49-4dcd-bfcf-7e24b356f263
|
715537.0
|
2020-02-12 00:00:00 UTC
|
ADXS, TROV On Watch, NRBO Soars 95%, DCPH To Face FDA In Aug.
|
DCPH
|
https://www.nasdaq.com/articles/adxs-trov-on-watch-nrbo-soars-95-dcph-to-face-fda-in-aug.-2020-02-12
|
nan
|
nan
|
(RTTNews) - Today's Daily Dose brings you news about Advaxis' upcoming presentation; Deciphera's date with FDA and Trovagene's update on its phase II study of Onvansertib in metastatic castrate-resistant prostate cancer.
Read on…
Advaxis Inc. (ADXS) is slated to present data from a Phase 1/2 clinical trial of ADXS-PSA as a standalone, or monotherapy, and in combination with Keytruda in people with previously treated metastatic castration-resistant prostate cancer, dubbed KEYNOTE-046, on February 13, 2020.
ADXS closed Wednesday's trading at $1.09, up 0.93%. In after-hours, the stock was up 2.75% at $1.12.
Deciphera Pharmaceuticals Inc.'s (DCPH) New Drug Application seeking approval for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors has been accepted for priority review by the FDA, with a decision date set for August 13, 2020.
The Company has sought approval for Ripretinib for the above proposed indication in Canada and Australia too.
In other news, Deciphera announced that it has commenced a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its common stock.
DCPH closed Wednesday's trading at $69.39, up 0.80%.
NeuroBo Pharmaceuticals Inc. (NRBO) soared more than 95% on Wednesday on no news.
The present NeuroBo Pharmaceuticals is the result of the reverse merger between privately-held NeuroBo Pharmaceuticals Inc and NASDAQ-listed Gemphire Therapeutics. The combined company began trading on the Nasdaq exchange under the ticker "NRBO" on December 31, 2019.
The pipeline includes:
-- NB-01 for the treatment of Painful Diabetic Neuropathy, which is expected to enter phase III trial in the first half of this year. -- NB-02 for Alzheimer's disease and other dementias, which has completed IND-enabling toxicology studies. -- Gemcabene for the treatment of dyslipidemia, which has been on partial clinical hold since 2004. The Company expects to submit a request to the FDA in the first half of this year, seeking lifting of the partial clinical hold for Gemcabene.
The combined cash as of June 30, 2019, was $28.2 million.
NRBO closed Wednesday's trading at $30.00, up 95.19%. In after-hours, the stock was down 11.67% at $26.50.
Trovagene Inc. (TROV) is scheduled to present new data from its phase II study of Onvansertib in metastatic castrate-resistant prostate cancer on Thursday, February 13th, 2020 at the American Society for Clinical Oncology 2020 Genitourinary Cancers Symposium in San Francisco.
Last month, the Company had announced positive data from an ongoing Phase 1b/2 clinical trial of Onvansertib plus FOLFIRI and Avastin for second-line treatment of KRAS-mutated metastatic colorectal cancer.
According to Trovagene, all colorectal cancer patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks - with clinical benefit having been achieved in 100% of patients.
TROV closed Wednesday's trading at $2.18, up 1.87%. In after-hours, the stock gained 2.75% and was at $2.24.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals Inc.'s (DCPH) New Drug Application seeking approval for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors has been accepted for priority review by the FDA, with a decision date set for August 13, 2020. DCPH closed Wednesday's trading at $69.39, up 0.80%. (RTTNews) - Today's Daily Dose brings you news about Advaxis' upcoming presentation; Deciphera's date with FDA and Trovagene's update on its phase II study of Onvansertib in metastatic castrate-resistant prostate cancer.
|
Deciphera Pharmaceuticals Inc.'s (DCPH) New Drug Application seeking approval for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors has been accepted for priority review by the FDA, with a decision date set for August 13, 2020. DCPH closed Wednesday's trading at $69.39, up 0.80%. (RTTNews) - Today's Daily Dose brings you news about Advaxis' upcoming presentation; Deciphera's date with FDA and Trovagene's update on its phase II study of Onvansertib in metastatic castrate-resistant prostate cancer.
|
Deciphera Pharmaceuticals Inc.'s (DCPH) New Drug Application seeking approval for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors has been accepted for priority review by the FDA, with a decision date set for August 13, 2020. DCPH closed Wednesday's trading at $69.39, up 0.80%. (RTTNews) - Today's Daily Dose brings you news about Advaxis' upcoming presentation; Deciphera's date with FDA and Trovagene's update on its phase II study of Onvansertib in metastatic castrate-resistant prostate cancer.
|
Deciphera Pharmaceuticals Inc.'s (DCPH) New Drug Application seeking approval for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors has been accepted for priority review by the FDA, with a decision date set for August 13, 2020. DCPH closed Wednesday's trading at $69.39, up 0.80%. NeuroBo Pharmaceuticals Inc. (NRBO) soared more than 95% on Wednesday on no news.
|
73f1c9b1-78e7-4706-adc4-e344078c730b
|
715538.0
|
2020-01-16 00:00:00 UTC
|
Notable Thursday Option Activity: AAL, HLF, DCPH
|
DCPH
|
https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-aal-hlf-dcph-2020-01-16
|
nan
|
nan
|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in American Airlines Group Inc (Symbol: AAL), where a total volume of 36,192 contracts has been traded thus far today, a contract volume which is representative of approximately 3.6 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 51% of AAL's average daily trading volume over the past month, of 7.1 million shares. Particularly high volume was seen for the $28 strike call option expiring January 17, 2020, with 3,865 contracts trading so far today, representing approximately 386,500 underlying shares of AAL. Below is a chart showing AAL's trailing twelve month trading history, with the $28 strike highlighted in orange:
Herbalife Nutrition Ltd (Symbol: HLF) options are showing a volume of 4,754 contracts thus far today. That number of contracts represents approximately 475,400 underlying shares, working out to a sizeable 50.5% of HLF's average daily trading volume over the past month, of 941,420 shares. Particularly high volume was seen for the $37.50 strike call option expiring January 17, 2020, with 629 contracts trading so far today, representing approximately 62,900 underlying shares of HLF. Below is a chart showing HLF's trailing twelve month trading history, with the $37.50 strike highlighted in orange:
And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 3,151 contracts thus far today. That number of contracts represents approximately 315,100 underlying shares, working out to a sizeable 47.9% of DCPH's average daily trading volume over the past month, of 658,060 shares. Particularly high volume was seen for the $60 strike put option expiring February 21, 2020, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $60 strike highlighted in orange:
For the various different available expirations for AAL options, HLF options, or DCPH options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Particularly high volume was seen for the $60 strike put option expiring February 21, 2020, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of DCPH. Below is a chart showing HLF's trailing twelve month trading history, with the $37.50 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 3,151 contracts thus far today. That number of contracts represents approximately 315,100 underlying shares, working out to a sizeable 47.9% of DCPH's average daily trading volume over the past month, of 658,060 shares.
|
That number of contracts represents approximately 315,100 underlying shares, working out to a sizeable 47.9% of DCPH's average daily trading volume over the past month, of 658,060 shares. Below is a chart showing HLF's trailing twelve month trading history, with the $37.50 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 3,151 contracts thus far today. Particularly high volume was seen for the $60 strike put option expiring February 21, 2020, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of DCPH.
|
Below is a chart showing HLF's trailing twelve month trading history, with the $37.50 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 3,151 contracts thus far today. That number of contracts represents approximately 315,100 underlying shares, working out to a sizeable 47.9% of DCPH's average daily trading volume over the past month, of 658,060 shares. Particularly high volume was seen for the $60 strike put option expiring February 21, 2020, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of DCPH.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $60 strike highlighted in orange: For the various different available expirations for AAL options, HLF options, or DCPH options, visit StockOptionsChannel.com. Below is a chart showing HLF's trailing twelve month trading history, with the $37.50 strike highlighted in orange: And Deciphera Pharmaceuticals Inc (Symbol: DCPH) options are showing a volume of 3,151 contracts thus far today. That number of contracts represents approximately 315,100 underlying shares, working out to a sizeable 47.9% of DCPH's average daily trading volume over the past month, of 658,060 shares.
|
d81f390e-1d41-4dd4-aca9-10f170211154
|
715539.0
|
2020-01-16 00:00:00 UTC
|
Deciphera Pharmaceuticals Reaches Analyst Target Price
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-reaches-analyst-target-price-2020-01-16
|
nan
|
nan
|
In recent trading, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) have crossed above the average analyst 12-month target price of $62.80, changing hands for $65.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 10 different analyst targets contributing to that average for Deciphera Pharmaceuticals Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $48.00. And then on the other side of the spectrum one analyst has a target as high as $77.00. The standard deviation is $10.496.
But the whole reason to look at the average DCPH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DCPH crossing above that average target price of $62.80/share, investors in DCPH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $62.80 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Deciphera Pharmaceuticals Inc:
RECENT DCPH ANALYST RATINGS BREAKDOWN
» Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 9 8 8 7
Buy ratings: 0 0 0 0
Hold ratings: 1 1 1 0
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 1
Average rating: 1.2 1.22 1.22 1.5
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on DCPH — FREE.
The Top 25 Broker Analyst Picks of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In recent trading, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) have crossed above the average analyst 12-month target price of $62.80, changing hands for $65.38/share. But the whole reason to look at the average DCPH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DCPH crossing above that average target price of $62.80/share, investors in DCPH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $62.80 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?
|
In recent trading, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) have crossed above the average analyst 12-month target price of $62.80, changing hands for $65.38/share. But the whole reason to look at the average DCPH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DCPH crossing above that average target price of $62.80/share, investors in DCPH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $62.80 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?
|
And so with DCPH crossing above that average target price of $62.80/share, investors in DCPH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $62.80 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) have crossed above the average analyst 12-month target price of $62.80, changing hands for $65.38/share. But the whole reason to look at the average DCPH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.
|
In recent trading, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) have crossed above the average analyst 12-month target price of $62.80, changing hands for $65.38/share. But the whole reason to look at the average DCPH price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DCPH crossing above that average target price of $62.80/share, investors in DCPH have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $62.80 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?
|
d3645bec-e602-41c4-b6be-da63e137dca3
|
715540.0
|
2020-01-06 00:00:00 UTC
|
Here's Why Deciphera Pharmaceuticals Rose 31.6% in December
|
DCPH
|
https://www.nasdaq.com/articles/heres-why-deciphera-pharmaceuticals-rose-31.6-in-december-2020-01-06
|
nan
|
nan
|
What happened
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. The monthly run-up topped 45% at one point before shares cooled off in the final days of the decade. Despite that, the stock erupted for a 196% gain in 2019.
There wasn't any company-specific news to send the pharma stock soaring, but investors have kept Deciphera Pharmaceuticals near the top of the list for potential buyout candidates. As such, when merger and acquisition activity picks up in the industry, shares are likely to become a little volatile. The speculation isn't entirely unwarranted.
Image source: Getty Images.
So what
Deciphera Pharmaceuticals boasts a pipeline of checkpoint inhibitors that have delivered impressive results in clinical trials. They're also wholly owned, which could attract a potential suitor now or later, especially if late-stage clinical trials continue to back up results from smaller studies.
The lead drug candidate, ripretinib, is an inhibitor of KIT and PDGFR-alpha proteins that are common in solid tumors. In the phase 3 Invictus study in gastrointestinal stromal tumors (GIST), ripretinib reduced the risk of disease progression or death by 85% compared with individuals who received a placebo. The experimental therapy achieved a median progression free survival of 6.3 months, compared with one month for placebo. All patients in the clinical trial had advanced stages of disease and had received three prior treatments.
Those solid results earned ripretinib the coveted Breakthrough Therapy designation from the U.S. Food and Drug Administration. Deciphera Pharmaceuticals expected to file a new drug application for the drug candidate in the first quarter of 2020, but submitted the paperwork in mid-December. That, together with Breakthrough Therapy label, should help it get to market even more quickly than investors had been expecting.
Now what
The market for advanced GIST isn't very large, but Deciphera Pharmaceuticals is studying ripretinib as a second-line and above treatment for GIST. If the drug candidate eventually earns a supplemental approval as an earlier-line treatment option, then it could earn peak annual sales of over $1 billion, according to Nomura Instinet analyst Christopher Marai. That optimism explains how the pre-revenue business boasts a current market cap of $2.9 billion.
10 stocks we like better than Deciphera Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Deciphera Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. There wasn't any company-specific news to send the pharma stock soaring, but investors have kept Deciphera Pharmaceuticals near the top of the list for potential buyout candidates. They're also wholly owned, which could attract a potential suitor now or later, especially if late-stage clinical trials continue to back up results from smaller studies.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. Those solid results earned ripretinib the coveted Breakthrough Therapy designation from the U.S. Food and Drug Administration. Now what The market for advanced GIST isn't very large, but Deciphera Pharmaceuticals is studying ripretinib as a second-line and above treatment for GIST.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. There wasn't any company-specific news to send the pharma stock soaring, but investors have kept Deciphera Pharmaceuticals near the top of the list for potential buyout candidates. 10 stocks we like better than Deciphera Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. All patients in the clinical trial had advanced stages of disease and had received three prior treatments. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Deciphera Pharmaceuticals wasn't one of them!
|
c39bd807-d4eb-496f-b1e2-a00c6d4ccf71
|
715541.0
|
2019-12-27 00:00:00 UTC
|
Health Care Sector Update for 12/27/2019: DCPH,MBOT,FLXN,MLNT
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-12-27-2019%3A-dcphmbotflxnmlnt-2019-12-27
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.14%
PFE -0.23%
ABT +0.22%
MRK +0.04%
AMGN -0.00%
Health care stocks eased somewhat Friday afternoon, with the NYSE Health Care Index climbing nearly 0.2% while the shares of health care companies in the S&P 500 also were up less than 0.1% as a group. The Nasdaq Biotechnology index was falling more than 0.8%.
Among health care stocks moving on news:
(-) Deciphera Pharmaceuticals (DCPH) fell almost 5% on Friday after a new regulatory filing showed the drugmaker's chief financial officer this week pocketed a more than $2.65 million profit when he exercised a quarterly option to buy and then sell 40,000 shares of the company's stock. Thomas Kelly Monday paid $1.89 for each of the shares and sold them at a weighted average of $68.21 per share. Kelly, who joined Deciphera from privately held molecular diagnostics company AdvanDx in February 2015, does not directly own any of the company's shares but holds additional options to buy up to 83,008 shares, according to a Form 4 filing late Thursday.
In other sector news:
(+) Flexion Therapeutics (FLXN) rose over 8% after the US Food and Drug Administration approved a supplemental new-drug application revising the product label for its Zilretta medication for osteoarthritis knee pain. The updated label removes current language stating Zilretta was not intended for repeat administration and now says the "efficacy and safety of repeat administration of Zilretta have not been demonstrated."
(-) Microbot Medical (MBOT) slid more than 20% after pricing a direct offering of 912,858 common shares at $10.50 apiece, representing a 25% discount to its most recent closing price. Net proceeds will be used to fund development of the company's self-cleaning shunt for the treatment of hydrocephalus and its Liberty disposal robotic system for use in neurovascular, cardiovascular and peripheral vascular surgeries.
(-) Melinta Therapeutics (MLNT) tumbled 74% to a worst-ever 39 cents a share after the drugmaker Friday announced a restructuring proposal with Deerfield Management, which will acquire 100% of the stock issued by the reorganized company in exchange for canceling $140 million in secured claims. Melinta will continue its normal operations and will evaluate any competing bids received during the court-supervised Chapter 11 bankruptcy process.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) fell almost 5% on Friday after a new regulatory filing showed the drugmaker's chief financial officer this week pocketed a more than $2.65 million profit when he exercised a quarterly option to buy and then sell 40,000 shares of the company's stock. In other sector news: (+) Flexion Therapeutics (FLXN) rose over 8% after the US Food and Drug Administration approved a supplemental new-drug application revising the product label for its Zilretta medication for osteoarthritis knee pain. Net proceeds will be used to fund development of the company's self-cleaning shunt for the treatment of hydrocephalus and its Liberty disposal robotic system for use in neurovascular, cardiovascular and peripheral vascular surgeries.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) fell almost 5% on Friday after a new regulatory filing showed the drugmaker's chief financial officer this week pocketed a more than $2.65 million profit when he exercised a quarterly option to buy and then sell 40,000 shares of the company's stock. Top Health Care Stocks Health care stocks eased somewhat Friday afternoon, with the NYSE Health Care Index climbing nearly 0.2% while the shares of health care companies in the S&P 500 also were up less than 0.1% as a group.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) fell almost 5% on Friday after a new regulatory filing showed the drugmaker's chief financial officer this week pocketed a more than $2.65 million profit when he exercised a quarterly option to buy and then sell 40,000 shares of the company's stock. Health care stocks eased somewhat Friday afternoon, with the NYSE Health Care Index climbing nearly 0.2% while the shares of health care companies in the S&P 500 also were up less than 0.1% as a group. Kelly, who joined Deciphera from privately held molecular diagnostics company AdvanDx in February 2015, does not directly own any of the company's shares but holds additional options to buy up to 83,008 shares, according to a Form 4 filing late Thursday.
|
Among health care stocks moving on news: (-) Deciphera Pharmaceuticals (DCPH) fell almost 5% on Friday after a new regulatory filing showed the drugmaker's chief financial officer this week pocketed a more than $2.65 million profit when he exercised a quarterly option to buy and then sell 40,000 shares of the company's stock. The Nasdaq Biotechnology index was falling more than 0.8%. Thomas Kelly Monday paid $1.89 for each of the shares and sold them at a weighted average of $68.21 per share.
|
ce5bdec8-b9ce-42d3-83d1-1665df00559a
|
715542.0
|
2019-12-11 00:00:00 UTC
|
3 Stocks That Could Be the Next Biotech Buyouts
|
DCPH
|
https://www.nasdaq.com/articles/3-stocks-that-could-be-the-next-biotech-buyouts-2019-12-11
|
nan
|
nan
|
Biotech investors are on the edge of their seats this holiday season thanks to a recent string of juicy buyout offers. Despite a busy year for acquisitions, big pharmaceutical companies with pipelines to fill and money to spend have been jumping over each other to acquire smaller biotechs at steep premiums.
Which of today's smaller biotechs will be the next one that inspires pharmaceutical giants to open their checkbooks wide? Arrowhead Pharmaceuticals (NASDAQ: ARWR), Blueprint Medicines (NASDAQ: BPMC), and Deciphera Pharmaceuticals (NASDAQ: DCPH) are on big pharma's Christmas list. Here's why.
Image source: Getty Images.
1. Arrowhead Pharmaceuticals
A recent $9.7 billion buyout offer for The Medicines Company from Novartis bodes well for Arrowhead. The only asset The Medicines Company had to offer was inclisiran, a new drug candidate that interferes with RNA (RNAi) to dramatically lower cholesterol.
Arrowhead Pharmaceuticals has a whole pipeline full of RNAi drugs aimed at treating inherited disorders. The furthest along the development timeline, JNJ-3989, could be the first highly effective treatment for chronic hepatitis B infections.
Arrowhead is developing JNJ-3989 in partnership with Johnson & Johnson and is entitled to a royalty percentage of potential sales and significant milestone payments. There are also three wholly owned clinical-stage RNAi drugs in its pipeline that could bring deep-pocketed drugmakers to the deal table.
2. Blueprint Medicines
Many of the most aggressive cancers are driven by known mutations to proteins that play a role in cell growth and proliferation. Blueprint Medicines is developing potential new small-molecule drugs that aim for those mutated proteins, and little else.
Small-molecule drugs that selectively inhibit mutated proteins so they can't promote tumor growth are all the rage lately. Earlier this year, Eli Lilly shelled out $8 billion for Loxo Oncology and Pfizer paid $11.4 billion for Array BioPharma. Both companies were developing highly targeted kinase inhibitors for the treatment of patients with cancer driven by very specific mutations.
An application for Blueprint's lead candidate, avapritinib, is under review for the treatment of people with a common mutation associated with gastrointestinal stromal tumors (GIST). In the first quarter of 2020, the company expects to submit an application for what could be its second new drug, pralsetinib. This potential new treatment is aimed at lung cancer driven by RET-fusion mutations.
3. Deciphera Pharmaceuticals
Blueprint's not the only company that can entice large pharma companies with small-molecule drug candidates. Deciphera Pharmaceuticals is developing a drug similar to pralsetinib called ripretinib for the treatment of patients with advanced GIST who relapsed following three other therapies.
Deciphera already completed a successful pivotal trial with fourth-line GIST patients and expects to have a new drug application ready for the FDA in the first quarter of 2020. Ripretinib lowered the risk of death by 64% compared to a placebo, which is probably enough to earn a stamp of approval.
Image source: Getty Images.
Who's the prettiest?
Wondering which one of these businesses is the most likely to be acquired at a steep premium? With a $7.1 billion market cap, there are only so many drugmakers capable of paying a premium for Arrowhead.
It's also important to remember that Arrowhead's employing a gene-silencing technique that hasn't yet proven itself in the commercial setting. If sales of recently approved RNAi drugs from Alnylam didn't rise much further in the fourth quarter, Arrowhead could lose its spot on this list.
With a market cap of just $2.9 billion, Deciphera's the least expensive of the three, but it probably doesn't offer as much bang for a potential buyer's buck as Blueprint Medicines. Deciphera's pipeline beyond ripretinib involves candidates with targets that aren't as well understood as the candidate next in line at Blueprint.
Around 2% of lung cancer patients have RET-fusion positive tumors that could make them eligible for treatment with Blueprint's pralsetinib. That might not sound like much, but lung cancer claims more lives than any other malignancy and treating just a sliver of this population could lead to significant sales.
Before the end of 2020, Blueprint could have a second drug in its product lineup with higher sales potential than its first.
Good enough for everyday investors?
These three biotechs have what it takes to attract attention from potential acquirers, but are they good enough for your portfolio? That all depends on how large of a position you intend to take and how soon you'd like to retire.
These stocks are too risky to form a cornerstone of anyone's stock portfolio. If you want to hold smaller positions as part of a diversified portfolio, though, all three could provide market-beating gains over the long run.
10 stocks we like better than Arrowhead Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Arrowhead Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Arrowhead Pharmaceuticals (NASDAQ: ARWR), Blueprint Medicines (NASDAQ: BPMC), and Deciphera Pharmaceuticals (NASDAQ: DCPH) are on big pharma's Christmas list. Despite a busy year for acquisitions, big pharmaceutical companies with pipelines to fill and money to spend have been jumping over each other to acquire smaller biotechs at steep premiums. Deciphera already completed a successful pivotal trial with fourth-line GIST patients and expects to have a new drug application ready for the FDA in the first quarter of 2020.
|
Arrowhead Pharmaceuticals (NASDAQ: ARWR), Blueprint Medicines (NASDAQ: BPMC), and Deciphera Pharmaceuticals (NASDAQ: DCPH) are on big pharma's Christmas list. Arrowhead Pharmaceuticals A recent $9.7 billion buyout offer for The Medicines Company from Novartis bodes well for Arrowhead. Deciphera Pharmaceuticals Blueprint's not the only company that can entice large pharma companies with small-molecule drug candidates.
|
Arrowhead Pharmaceuticals (NASDAQ: ARWR), Blueprint Medicines (NASDAQ: BPMC), and Deciphera Pharmaceuticals (NASDAQ: DCPH) are on big pharma's Christmas list. Arrowhead Pharmaceuticals A recent $9.7 billion buyout offer for The Medicines Company from Novartis bodes well for Arrowhead. Deciphera Pharmaceuticals Blueprint's not the only company that can entice large pharma companies with small-molecule drug candidates.
|
Arrowhead Pharmaceuticals (NASDAQ: ARWR), Blueprint Medicines (NASDAQ: BPMC), and Deciphera Pharmaceuticals (NASDAQ: DCPH) are on big pharma's Christmas list. Arrowhead Pharmaceuticals A recent $9.7 billion buyout offer for The Medicines Company from Novartis bodes well for Arrowhead. Blueprint Medicines is developing potential new small-molecule drugs that aim for those mutated proteins, and little else.
|
96346faa-ceb1-4cf2-8b20-2abe42a5a284
|
715543.0
|
2019-11-04 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2019 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-q3-2019-earnings-call-transcript-2019-11-05
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Q3 2019 Earnings Call
Nov 4, 2019, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good day, everyone, and welcome to the Deciphera Pharmaceuticals Third Quarter 2019 Financial Results Conference Call.
[Operator Instructions]
At this time, I would like to turn the call over to Jen Robinson, Vice President and Investor Relations. Jen?
Jennifer H. Robinson -- Vice President of Investor Relations
Thank you, Bill. Welcome and thank you to those of you joining us today to discuss the Deciphera's Third Quarter 2019 Financial Results. I'm Jen Robinson, Vice President, Investor Relations, at Deciphera. With me this afternoon to discuss the quarter's results and provide a general corporate update is Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management, made pursuant to Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include the status of and our expected timelines for our preclinical and clinical studies and preparations for a potential NDA submission.
Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include the execution of clinical trials, the timing of data, the actions of regulatory agencies and those set forth in our most recent quarterly report on Form 10-Q, as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the Company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Thank you, Jen, and good afternoon to everyone who is listening on the call and joining via the webcast. I'd like to welcome all of you to our first conference call to provide a general corporate update and financial results.
We have made significant progress across the entire pipeline over the last quarter. Most importantly, we announced positive results from our INVICTUS Pivotal Phase 3 Study of ripretinib for the treatment of advanced gastrointestinal stromal tumors or GIST. These data mark a transformative milestone for Deciphera representing our first registration enabling data set and importantly strong clinical validation of our proprietary kinase switch control inhibitor platform and the potential for our product candidates to improve the lives of people with cancer. For people living with GIST, whose disease has progressed after treatment with the currently approved drugs, there is an urgent unmet need for new therapies that can deliver effective disease control. We believe ripretinib has demonstrated the potential to transform the GIST treatment landscape and serve as an effective therapy for this heavily pre-treated patient population.
Today, we announced that the FDA has granted ripretinib Breakthrough Therapy Designation for the treatment of patients with advanced GIST who have received prior treatment with imatinib, sunitinib and regorafenib. We look forward to our continued very collaborative dialog with the agency, as we work toward our submission of a New Drug Application or NDA for ripretinib, which we continue to expect to submit in the first quarter of 2020. As we ready ourselves for the potential transition from a development stage to a commercial stage company, we are focused on building out our commercial and medical affairs capabilities. We are committed to ensuring that we're well positioned to support the planned launch of ripretinib in the United States, if approved, and we look forward to updating you on these efforts in the coming months.
Beyond ripretinib, we have a diverse and exciting pipeline of wholly owned oral product candidates spanning all stages of development and all generated from our proprietary kinase switch control inhibitor platform. These include DCC-3014, rebastinib and DCC-3116. At the AACR-NCI-EORTC or so called triple meeting, last week in Boston, we presented updated data from all of our pipeline programs.
To review these programs in greater detail, I'd now like to introduce Matt Sherman, our recently appointed Chief Medical Officer. Matt brings over 25 years of experience as a physician scientist in clinical drug development in oncology and hematology, most recently as Chief Medical Officer of Acceleron. In just a short period of time, Matt has already made important contributions to Deciphera and I look forward to working alongside him and the rest of the team here as we advance our pipeline.
I'll now turn the call over to Matt for an overview of recent program updates. Matt?
Matthew L. Sherman -- Chief Medical Officer
Thank you, Steve. This is truly an honor to have joined Deciphera at this exciting time. Deciphera's proprietary kinase switch control platform has generated a robust pipeline of novel kinase inhibitors spending late stage to preclinical development, all of which are designed to address unmet need in difficult-to-treat cancers. I'm grateful for the opportunity to help advance and shape these programs to deliver much needed novel therapies to patients and look forward to working alongside such as deeply knowledgeable and impressive team.
I would now like to give an overview and provide an update on our pipeline programs starting with ripretinib. Before we get into the data, it is important to put the GIST population into perspective. KIT mutations comprised approximately 8% of both primary and secondary mutations; an estimated 4,000 to 6,000 new patients are diagnosed with GIST in the US each year, the majority of which receive imatinib in the frontline setting; resistance develops, which was generally due to the emergence of secondary mutations in the KIT gene. After imatinib, patients move to treatment with sunitinib in the second-line and regorafenib in the third-line setting. There are currently no approved therapies for patients who have received prior treatment with these three drugs. We believe the ripretinib data from INVICTUS study and the ongoing Phase 1 study demonstrates potential for ripretinib to transform the post-imatinib treatment landscape.
The INVICTUS study achieved its primary endpoint of improved progression-free survival or PFS with a median PFS of 6.3 months in a ripretinib arm compared to one month in the placebo arm, with a p-value of less than 0.0001. Ripretinib significantly reduce the risk of disease progression or death by 85% with a hazard ratio of 0.15. For the key secondary endpoint of objective response rate or ORR, ripretinib showed the rate of 9.4% compared with 0% for placebo with a p-value of 0.0504, which was not statistically significant. Ripretinib also showed a clinically meaningful improvement of overall survival or OS versus placebo, with a median OS of 15.1 months versus 6.6 months for placebo, a hazard ratio of 0.36 and nominal p-value of 0.0004.
This was not formally tested do the hierarchy of the statistical plan. Additionally ripretinib was generally well tolerated and the adverse events in INVICTUS study were consistent with data from presented Phase 1 results. Grade three or four treatment-emergent adverse events in greater than 5% of patients in the ripretinib arm were anemia, abdominal pain and hypertension and in the placebo arm, anemia. We believe these efficacy and safety data are highly impressive particularly the magnitude of benefit observed for overall survival and suggest that ripretinib's approach of targeting the broad spectrum of mutations known to drive GIST can improve outcomes in the most heavily pre-treated patients. We expect to submit an NDA to the FDA in the first quarter of 2020 for ripretinib for the treatment of patients with advanced GIST. We look forward to actively working with the agency on our goal to deliver this potential treatment option to patients.
Turning to the triple meeting that took place last week, we reported positive updated results from the ongoing Phase 1 study of ripretinib in GIST patients, with the starting dose of 150 milligrams daily. We are very pleased with how the results have matured and with an additional five months of data across all lines of therapy in all measures of clinical activity as assessed by the investigator. In particular, I would like to highlight the data from the cohort 31 patients with second line GIST, which is the same patient population, there is the subject of our ongoing second randomized Phase 3 trial INTRIGUE. Median PFS increased to 46 weeks and confirmed ORR was 19% with a median duration of response of 18 weeks. As you will recall, published data from centrally read pivotal trials for sunitinib, the standard of care in second-line GIST, demonstrated the median PFS of 24.1 weeks and with a confirmed ORR of 6.8%. In addition, the mean treatment duration, which includes patients that were dose escalating, increased across all lines of treatment with the longest treatment duration of 142 weeks. Ripretinib was generally well tolerated and the updated adverse events were consistent with previously presented Phase 1 data in patients with GIST. Grade three or four treatment-emergent adverse events in more than 5% of patients were an increase in lipase level, anemia and abdominal pain.
We believe these data along with the INVICTUS data continue to support the ongoing INTRIGUE Phase 3 pivotal study in second-line GIST. We're making great progress activating sites and enrolling patients in this study and we currently have 92 sites opened in 18 countries.
I'd like to spend some time now working through our other programs beyond ripretinib in GIST. First DCC-3014 is our orally administered, potent and highly selective inhibitor of CSF1 receptor or CSF1R. 3014 was designed to selectively bind to the CSF1R switch pocket and has a greater than 100 fold selectivity for CSF1R over the closely related kinases and has an even greater selectivity for CSF1R over approximately 300 other human kinases. 3014 is currently being evaluated in a multi-center open label Phase 1 clinical study in patients with advanced solid tumors including patients with tenosynovial giant cell tumors or TGCT. Our initial focus with 3014 is on TGCT. This disease is driven by genetic mutation in certain cells within the tumor causing an over-production of CSF-1, the ligand for CSF1R. TGCT is a locally aggressive tumor of the synovial, bursa or tendon sheath that has significant morbidity for patients. The only approved systemic therapy is pexidartinib, a small molecule inhibitor CSF1R, which was approved in August and is subject to a REMS program due to hepatotoxicity. We believe that 3014 has the potential to fulfill the unmet medical need for a more effective treatment with a favorable safety profile for TGCT patients.
Last week at the triple meeting, we presented Phase 1 data of 3014 from seven dose cohorts across 36 patients with advanced solid malignancies. The data demonstrated those proportional exposure for 3014 that was associated with an increase in plasma, CSF-1 and IL 34 levels, a rapid and sustained reduction of CD16 positive monocytes in peripheral blood and in substantial decreases in CD163 positive macrophages in tumor. 3014 has been generally well-tolerated and most treatment-emergent adverse events were grade one or two. The most common treatment related adverse events greater than or equal to 10% were fatigue, diarrhea and nausea. Grade three or four treatment-related adverse events occurred in four patients, which were an increase in AST, an increase in lipase, an increase in amylase, and colitis. There were no related serious adverse events.
Dose escalation evaluation is ongoing to determine the recommended Phase 2 dose for advanced solid tumors and TGCT. Currently, we have not reached the maximum tolerated dose for 3014. We look forward to presenting preliminary Phase I data from a small group of initial TGCT patients at the upcoming connective tissue oncology society or CTOS Annual Meeting in Tokyo, Japan.
Turning now to rebastinib, our potent small molecule designed to inhibit type two kinase expressing macrophages or TEMs. TEMs are known to promote tumor angiogenesis, invasiveness, metastasis and immuno-tolerance. Rebastinib is currently being evaluated in the Phase 1b 2 study in combination with paclitaxel and also in the Phase 1b 2 study in combination with carboplatin. The Phase 1b 2 study of rebastinib and combination paclitaxel in patients with advanced and metastatic solid tumors is an open label multicenter study designed to evaluate the safety, tolerability and pharmacokinetics.
Data reported that the triple meeting was from Part 1 of the study, which enrolled 43 patients, including 24 patients from the rebastinib 50 milligram BID cohort and 19 patients from the 100 milligram BID cohort. Exposure to rebastinib was dose proportional and given in the combination with paclitaxel and mean circulating angiopoietin-2 levels increased with exposure to higher doses of rebastinib indicating TIE2 inhibition.
Importantly, the Phase 1 data demonstrated encouraging preliminary anti-tumor activity in both dose cohorts, with objective responses seen across the heavily pre-treated patient population, including patients with prior exposure to paclitaxel. Most patients receive more than three prior treatments and the median number of prior therapies was 4.5. Confirmed and unconfirmed responses were seeing in eight patients, including three ovarian, two breast, two carcinosarcoma and one peritoneal mesothelioma; five of these responses were in the 15 milligram BID dose cohort and three were in the 100 milligram BID cohort. Seven of these eight responding patients had prior therapy with paclitaxel or docetaxel.
Rebastinib in combination with paclitaxel was generally well tolerated with similar the frequency of treatment-emergent adverse events between the two dose cohorts. Most treatment-emergent adverse events were consistent with the first-in-human study of rebastinib are known to be associated with paclitaxel treatment.
Part two of this study is ongoing and is a Simon two-Stage Design with four expansion cohorts in triple-negative breast cancer, inflammatory breast cancer, ovarian cancer and endometrial cancer. So recommended Phase 2 dose of 50 milligrams BID, we are encouraged by the early signs of activity in the study and look forward to providing additional updates in the future.
Finally, earlier this year, we announced the addition of DCC-3116 to our pipeline. 3116 is potential first-in-class small molecule designed to inhibit autophagy by selectively targeting the ULK1 and 2 kinases. This family of kinases initiates autophagy and provides the potential for targeted approach by selective inhibiting autophagy in RAS mutant cancers. Autophagy is a cellular pathway that has been shown to be up-regulated in mutant RAS cancers and mediates resistance to inhibitors that are RAS signaling pathway.
Preclinical data presented last week at the triple meeting showed that 3116 is a potent, selective and tight-binding inhibitor of the ULK kinase. Subject to favorable investigational new drug enabling studies and submission and activation of an IND application with submission expected in the middle of 2020, we intend to develop 3116 for the potential treatment of mutant RAS cancers in combination with Nab [Phonetic] kinase inhibitors.
In summary, we have to say, we are excited to have an extensive pipeline of potentially paradigm shifting molecules spanning across various stages of development. While we are proud of the progress we've made with ripretinib, as we near the expected NDA submission for the treatment of advanced GIST. We remain focused on the opportunities at had with 3014, rebastinib and 3116, as well as other discovery programs that we have not yet disclosed.
I will now turn the call over to Tucker to review the financial results from this quarter.
Tucker Kelly, J.D -- Chief Financial Officer and Treasurer
Thanks, Matt. Let me take testament to discuss a few highlights from our third quarter 2019 financial results. First, following the positive top line results of INVICTUS, in August, we completed a very successful follow-on public offering that raised approximately $432 million in net proceeds, money which will help us fund our expected transition to a commercial company and support the continued development of our expanding pipeline of novel switch control inhibitors. With the net proceeds of the public offering, we had cash, cash equivalents and marketable securities, approximately $635 million as of September 30, 2019, which we expect will be sufficient to fund our operations and capex requirements into 2020. In the third quarter of 2019, our total operating expenses were $58.4 million, an increase of $10.4 million from the second quarter of 2019. Research and development expenses were $40.4 million, and general and administrative expenses were $18 million in the third quarter. We expect our expenses to continue to grow over the coming quarters as we continue to build our commercial organization and expand our clinical development activities.
With that, I'll now turn the call back over to Steve.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Thank you, Tucker. We made significant progress across the company and across the pipeline over the last few months, and are preparing for what will be an exciting year ahead. We remain on track to submit the ripretinib NDA in the first quarter of next year for the treatment of patients with advanced GIST and we continue to drive forward with rapid site opening and patient enrollment for our INTRIGUE study where we're comparing ripretinib to sunitinib and patients with GIST who have received prior treatment with imatinib. The rest of our clinical stage pipeline is now coming into view and we look forward to advancing these programs and providing additional meaningful updates in the year ahead.
Before opening the call for questions, I'd like to thank the patients, their caregivers, and the physicians who have participated in our clinical trials and the amazing team here at Deciphera for their hard work and dedication to making a difference for patients.
With that operator, I'd like to open the call for questions.
Questions and Answers:
Operator
(Operator Instructions) Your first question comes from the line of Jessica Fye from JPMorgan. Your line is open.
Jessica Fye -- JPMorgan -- Analyst
Hey guys, good afternoon, and thanks for taking my questions. I had a couple, first, are there any remaining deliverables on the factoring side that are gating for the filing of ripretinib and if so can you talk about what they are? And then second for Tucker, you mentioned that OpEx would continue to grow, can you think -- can you help us think about how do you -- we had a project that kind of help us think about the magnitude of growth, I'm assuming most of its R&D driven?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Hi, Jess, it's Steve. I'll take the first part of the question and then turn it over to Tucker to address the other question that you asked. There is a lot of work ongoing across the company really as we prepare for the NDA and that's really across each and every one of the modules, including CMC. So there is not anything specific that I would call out on CMC, they would stick out as a gating item is really work across all of the modules that the team is preparing for that filing to go in Q1 of 2020.
Tucker Kelly, J.D -- Chief Financial Officer and Treasurer
So, hey, Jess, this is Tucker. On the financial side what I say is that the third quarter obviously included both the completion of INVICTUS, as well as the ramping up on entry, which is a larger study than INVICTUS. So those clinical costs will carry over, particularly an entry into the next few quarters in 2020, as well as the continued development of the other pipeline assets, so rebastinib and 3014 will have increased expenses particularly rebastinib as we move through part one and into the part two of those combination studies with paclitaxel and carboplatin.
So you're right that a lot of the increase in spend going forward will be on the R&D side. In addition, we are scaling up to meet the potential commercial requirements of having a sales force and commercial infrastructure, so those will hit on the G&A side, and we'll be judicious but ready in terms of hiring sales force at the appropriate time.
Jessica Fye -- JPMorgan -- Analyst
Okay, great. And then just a last one on the Expanded Access Program. Will that be open to patients who have seen any number of prior therapies for GIST or just those who have seen three prior lines of therapy? And I'm wondering if you can talk about how many centers you plan to include in the Expanded Access?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, thanks, Jess, for the question on the EAP. So we're excited to get that open. So we expect that we'll have over 150 patients globally on that EAP ,that's what we're planning for. In terms of sites, we would expect in the US, somewhere in the range of 20 sites and we're planning on globally around 20 -- over 20 different countries that would participate in that EAP. In terms of eligibility for the EAP, patients of course need to have a locally advanced unresectable or metastatic GIST and have received prior treatment with at least two prior FDA approved therapies.
Jessica Fye -- JPMorgan -- Analyst
Great, thank you.
Operator
Your next question comes from the line of Chris Raymond from Piper Jaffray. Your line is open.
Christopher Raymond -- Piper Jaffray -- Analyst
Hey, thanks. I just wanted to clarify on one of the questions you just answered from the last question. Question about, just on Breakthrough Designation status for ripretinib. So I think I heard you say, Steve, that you're going to submit all of modules at the same time. o, I think last time I heard you guys talking about it, there was an option for doing a rolling submission. So should we assume that you're not going to do that; it will be a regular submission?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Hi, Chris. So thanks for the question. So you're right with Fast Track designation, which we disclosed earlier in the year that provided us with an option of initiating a rolling submission and so on the call today, we're not changing our guidance, are providing any additional color around that. We will work with the FDA, now with Breakthrough Therapy Designation for ripretinib to get the file in as expeditiously as possible and our guidance remains that we would have that file completed in quarter one of 2020.
Christopher Raymond -- Piper Jaffray -- Analyst
Okay. So it could still be a rolling submission. Is that correct?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, we're not providing any further detail in terms of whether it would be a rolling submission or not a rolling submission.
Christopher Raymond -- Piper Jaffray -- Analyst
Got it, OK. And then just on the INTRIGUE study, so we just recently learned that your competitor, avapritinib second-line COMPASS trial was pushed back pretty meaningfully; I know it's early days, but I'm just curious, have you got any early sort of feedback from your enrolling physicians with respect to potential dynamics there? I mean when should assume that that's perhaps a plus in terms of enrollment dynamics, but just kind of curious if you got any early feedback.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. So we've been really pleased with the pace of getting INTRIGUE up and running. As you know, we haven't had any competitive trial dynamic up until now, and as you pointed out, it looks like we won't have a competitive trial for the foreseeable future. As Matt, mentioned in the prepared remarks, we have 92 sites now open, we expect to open over 100 sites for that study, we're active in 18 countries and we're really pleased with the pace both of how we're opening sites and also the pace of enrolling patients on the study.
As you would expect and we would expect based on the very positive INVICTUS results that we've released in August of this year, there is a considerable amount of enthusiasm for the data in that fourth-line, fourth-line plus setting and we believe that will translate meaningfully into enthusiasm for both patients, as well as investigators thinking about the INTRIGUE study as an option in the second-line setting. This is still a little early to tell what that pace of enrollment is going to look like, but as you point out by virtue of the fact that we were ahead anyway of Blueprint and getting a second-line study up and now the fact that they won't have a second line study. It's smooth sailing ahead for us at least in our view in terms of getting that study enrolled, generating the data and then reporting results.
Christopher Raymond -- Piper Jaffray -- Analyst
Okay. Thanks very much.
Operator
Your next question comes from the line of Michael Schmidt from Guggenheim Securities. Your line is open.
Charles Zhu -- Guggenheim Securities -- Analyst
Hey guys, this is Charles Zhu on for Michael Schmidt. Thanks for taking the questions and congrats on all the progress. First one on INTRIGUE, I see on clinicaltrials.gov that PFS is the primary endpoint with ORR and OS as secondary, so I'm wondering the degree to which plans for INTRIGUE's OS assessment is similar or different than that of INVICTUS, as well as the potential for a complication given patients coming up Sutent could effectively crossover by accessing commercial and off-trial ripretinib in later lines of therapy?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Hi, Charles, it's Steve, thanks for the question, which is a good one. You're right, of course, PFS is the primary endpoint. It's not a study in which we allow crossover given that there is an approved therapy currently in the second line setting. And I think you're also right in suggesting that it would be challenging in the second line setting given the availability of subsequent therapies for ripretinib in that setting to demonstrate an overall survival benefit. But nonetheless, OS is a secondary endpoint in the study. We look forward certainly getting patients on study and enrolling the study, generating the data and then we'll report the data when they're available.
Charles Zhu -- Guggenheim Securities -- Analyst
Okay, great. And correct me if I'm wrong, but I also think INTRIGUE does not allow for dose escalation on BID upon progression. And with that in mind, how might physicians feel about potential dose escalation in second line just assuming INTRIGUE is successful given INTRIGUE doesn't explicitly study it, but you'll have data for it in the Phase 1 as well as, I guess kind of from INVICTUS in fourth line?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Thanks, Charles for the question on dose escalation. So you're right in the Phase 1 study and we just provided the update that Matt described in his prepared remarks at the triple meeting in Boston last week and of course you're familiar with the INVICTUS data where dose escalation was also allowed for patients. It's still in the early days for us in terms of our analysis of those data and what the potential implication might be for help physicians ultimately might want to use this drug, assuming it's approved, whether it'd be in the fourth line setting or the second line setting.
So I think this is really just the beginning of that drug development journey for us with this product. Clearly, a highly active drug in GIST in the fourth line setting. I think the Phase 1 study across second, third and fourth line also clearly shows the drug is highly active in those lines of therapy and I think the challenge ahead for us and for the clinical community is going to be to determine going forward how will this drug and what setting and at what dose meaning does dose escalation demonstrated a prolonged benefit for patients. We will have to sort through that I think in the coming years ahead as we continue to expand our understanding of the use of this drug in GIST.
Charles Zhu -- Guggenheim Securities -- Analyst
All right. It makes sense. And last one from me. What's your view on the potential -- your view as well as any feedback you've gotten from KOLs, your investigators, for the potential of ripretinib rechallenge in fourth line GIST if a patient has already received it in earlier line especially if such patient weren't previously dose escalated.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Thanks, Charles. Good question. In this setting in GIST certainly physicians are quite familiar and used to rechallenge with imatinib as an example. And given the broad spectrum inhibitory profile of ripretinib really addressing all of these relevant mutations that drive this disease. I suppose it's not outside of the kind of the realm of possibility that we may be able to pursue a similar path -- generate the data of course but pursue a similar path with ripretinib and explore the potential for patients to benefit with the drug upon rechallenge or retreatment.
We still need to of course understand that better generate data in that context and see what sort of benefit the drug might offer. So still a little bit early, as I said we view this is as the initial set of steps and developing this drug in this disease and we think there are future opportunity certainly for us to explore whether it be related to dose escalation or whether it be related to retreatment as you point out.
Charles Zhu -- Guggenheim Securities -- Analyst
Great. Thanks for taking the questions, and congrats again on all the progress.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Thanks, Charles.
Operator
Your next question comes from the line of Eun Yang from Jefferies. Your line is open.
Eun Yang -- Jefferies -- Analyst
Thank you. Question on second-line GIST for ripretinib. So Sutent Phase 3 show the PFS of about 24 weeks, but some other published papers show PFS of about 36 weeks, which is still lower than what you have recently shown 46 weeks for ripretinib. So when I ask you what your powering assumptions for sunitinib in a Phase 3 INTRIGUE?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, thanks, Eun, it's Steve, I'll take that question. So we of course have spent a lot of time over the last couple of years, working with expert thought leaders in the field to understand how the disease is treated and to understand a contemporary review of sunitinib and what one might expect in terms of progression-free survival in the second line setting.
You're right. We often point to of course what's in the label, the FDA approved label for sunitinib, which is the 24 weeks of PFS that you referenced, and there are also some smaller studies out there that have of course different PFS rates and so as we've explored this and discuss the topic with the experts to treat the disease, the very consistent feedback that we've received is that yes, 24 weeks is still the relevant mark, in terms of what one would expect with Sutent in the second line setting and this disease.
You've also noted, of course the Phase 1, which we updated last week at the triple meeting in Boston, where we showed in the cohort second line patients, now a PFS of 46 weeks, which is an improvement -- a substantial improvement actually over the last data disclosure with ripretinib in that setting. So we've remained very confident in our design and the underlying powering for the INTRIGUE study. As I noted earlier, we are looking forward to continuing to enroll patients and then to generate the data and reported out once we have that data generated, but I don't have any additional set of powering assumptions that I can share with you at this time beyond what we've already disclosed.
Eun Yang -- Jefferies -- Analyst
Okay. And then 3014, so [Indecipherable] number of patients with the TGCT. In that study -- in that data, would you be able to see response rate there could it be a comparable to what [Indecipherable] shown 38%.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, thanks, Eun for the question on 3014. So, as you point out, what we reported last week at the triple meeting was the Phase 1 in the solid tumor patient population. And so we're looking forward at the CTOS meeting, the Connective Tissue Oncology Society Meeting, in Tokyo, which is coming up already next week, we'll be reporting for the first time data with 3014 in a small number of patients with tenosynovial giant cell tumor. And so included in that data set will be patients who of course are evaluable for safety, but also patients who are evaluable for efficacy. I'll just point out that this is an initial small number of patients we of course look forward to enrolling the expansion cohort that's open for that study in generating even more data in additional patients with 3014 and we hope to report out on a more complete full dataset over the course of 2020. But yes, next week you can look forward data that would include response evaluable patients.
Eun Yang -- Jefferies -- Analyst
Okay. Last question is on rebastinib. So at the triple meeting you showed about 21% response rate at 50 milligram BID recommended Phase 2 dose, but is there any kind of response rate that you have in mind that could determine go- no-go decision for the program?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. So we have certainly for rebastinib, we have these four expansion cohorts that we are enrolling and we outline those in the posture that we presented last week, and maybe what I'll do is turn it to Matt, he can provide some additional color on those expansion cohorts and the decision that will make then for further expansion of the expansion cohorts assuming certain criteria are met.
Matthew L. Sherman -- Chief Medical Officer
Yes. So again, thanks for the question. So, as we indicated, we will be moving forward into the part two of the study with the four expansion cohorts as I mentioned in triple-negative breast cancer and inflammatory breast cancer, ovarian cancer and endometrial cancer, and in those patient populations, it's a Simon Two-Stage Design, where we will be enrolling the first group of 18 patients, and if there is more than four responses in the group of 18 patients, we then move into the second stage of the Simon Two-Stage design to roll up to 33 patients and so it's based on those numbers that will have a point estimate for the response rate in those four different indications.
Eun Yang -- Jefferies -- Analyst
Okay.
Steven L. Hoerter -- President, Chief Executive Officer, Director
And I would add to that, we're certainly encouraged by the early signs of efficacy with the combination and look forward to generating more data and more homogeneous patient populations in those expansion cohorts that Matt referred to.
Eun Yang -- Jefferies -- Analyst
That's helpful. Thank you.
Operator
Your next question comes from the line of Christopher Marai from Nomura Instinet. Your line is open.
Jackson Harvey -- Nomura Instinet -- Analyst
Hi, this is Jackson Harvey on for Christopher. Thanks for taking my question. I was just curious about 3014, could you provide some more color around the AST elevations. Did they have anything in common with pexidartinib as far as you can tell?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Jackson. And it's, Steve. Thanks for the question on 3014 in AST elevations. I'll turn it over to Matt to address that.
Matthew L. Sherman -- Chief Medical Officer
Hi. Jackson, so again thanks for the question. And as you noted, with this class of agents, one can see elevations in certain liver enzyme, so particularly AST and ALT can be elevated and in part that's due to decreased clearance of these enzymes within the liver due to the targeted nature of the of the products against the CSF-1 receptor. Now, in pexidartinib's case, there was a number of patients who went on to in addition to having elevations of liver function enzymes those [Indecipherable] hepatotoxicity that was reported in their Phase 3 ENLIVEN study in across their program as well too. So that may be represents a different type of toxicity beyond the benign elevations of liver function test.
Jackson Harvey -- Nomura Instinet -- Analyst
Great. Got it. And as you think about possible registration studies, do you anticipate having to do head-to-head studies with pexidartinib?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, thanks, Jackson for the question. Too early for us to tell really exactly what the design of a registration study might be, whether it could be a single-arm study, whether it could be a randomized study like the ENLIVEN study versus placebo or a head-to-head versus pex. It's not clear to us that we would need to do a head-to-head versus pexidartinib, but still a little early for us to comment on what future development past might be, we look forward to presenting the data next week and then to generating further data and additional patients with TGCT.
Jackson Harvey -- Nomura Instinet -- Analyst
Great. Thanks for addressing my questions.
Steven L. Hoerter -- President, Chief Executive Officer, Director
You bet.
Operator
Your next question comes from the line of Reni Benjamin from JMP Securities. Your line is open.
Reni Benjamin -- JMP Securities -- Analyst
Hey, thanks guys for taking the questions and congrats on all the progress. I guess, beyond GIST, can you talk a little bit about your strategy for SM, do you anticipate initiating an ISM trial, how are you making the decisions there. And I guess related to that, when might we see an update from the SM cohort of the gliomas and non-small cell lung cohorts of ripretinib?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Hi, Reni, It's Steve. Thanks for the question and on SM specifically. So, as you know, this was an expansion cohort, is an expansion cohort in the Phase 1 study and we've been working really hard to get patients on study. It's not to be frank, not been the easiest cohort for us to enroll. We think we've made some good progress recently and we would hope and expect to have a data update during the course of 2020 once we have a critical mass of patients enrolled and they've been on therapy for at the necessary period of time to evaluate for response. So look for data in 2020, we don't have any further comment or guidance at this time, until we generate those data on what a further development path might look like.
Reni Benjamin -- JMP Securities -- Analyst
Got it. And then just regarding ripretinib, what are your thoughts regarding combinations studies in GIST, It seems like mechanistically that it should work out perfectly, but maybe the side effect profile is overlapping, just any sort of thoughts you might have regarding that going forward.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, thanks, Reni. So for ripretinib specifically in thinking about combination therapies, recall that we never reached an MTD with this drug in the Phase 1 study. And as we talked about earlier on the call, we have a number of patients who in fact of dose escalated to 150 mg BID and the drug appears to be very well tolerated in that context as well. So we think in fact that ripretinib is uniquely positioned as an agent that has a really good therapeutic index and may well be a good combination partner with other agents whether targeted or non-targeted agents, and so we're not ready at this time to talk about what potential combinations might look like, but certainly it's something that's on our radar. I referenced earlier that this is the beginning of what we think is going to be a very lengthy and productive journey as we explore the potential role for this drug in the treatment of GIST and potentially other tumor types, and whether that be as monotherapy or combination, we're committed to exploring all of those avenues and seeing how this drug may be able to most optimally benefit patients across a variety of different lines of therapy and in different settings.
Reni Benjamin -- JMP Securities -- Analyst
Great and just one final one, regarding the commercial sales force, can you just give us your kind of latest thoughts on how big it should be, will you be ready to start selling as soon as you get approval and kind of where you are right now in the hiring process?
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. So we've been really pleased with the team that we've been able to attract to Deciphera to fill all of the roles across the commercial organization and the medical affairs organization. These are folks that have a deep oncology experience, many of them have deep experience launching oral oncolytics in the US market and so we're really thrilled with the quality of the team. We're doing a lot of work right now to think through and finalize what our go-to-market strategy is going to be specifically for the field sales organization. And so it would be premature for me to comment specifically on what a final number might be. I can give you a range, we would expect to see somewhere in the range of 40 to 60 sales representatives in the US on the medical affairs side, we have now filled the entire MSL team and again absolute absolutely fantastic group of folks that we have in the MSL organization and that team has already trained and prepared and out speaking with the physicians about GIST, about the disease and management of the disease.
So the team is working really hard across all functions to make sure that we are prepared, as I've mentioned in my prepared remarks for a potential approval next year and we're committed to doing everything in our power to have all the right people hired and trained and ready to go, so that when the FDA acts on the application and assuming approval, we're ready to get this drug out to the broader group of patients who are in need of it.
Reni Benjamin -- JMP Securities -- Analyst
Perfect. Thanks for taking the questions. And congrats again.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah. Thanks, Reni.
Operator
[Operator Instructions] Your next question comes from the line of Soumit Roy from Jones Trading. Your line is open. Mr. Roy, your line is open.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Okay. Operator, maybe we should go to the next caller unless Soumit maybe is on mute or had to step away.
Operator
Thank you. One moment. Your next question comes from the line of Arlinda Lee from Canaccord. Your line is open.
Arlinda Lee -- Canaccord -- Analyst
Hi guys, thanks for taking my questions and congrats on the Breakthrough Designation. I had a question about any data that you might have been able to glean from the PDGFR patients from the GIST study and if that might give you any read through to the efficacy? Thank you.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, Linda, it's Steve. Thanks for the question. With respect to the PDGFR offers, are you referring specifically to the patients in the INVICTUS study?
Arlinda Lee -- Canaccord -- Analyst
Yes.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Yeah, so as you know, looking at the patient demographics, we had relatively few patients PDGFR alpha patients enrolled, we only had I think it was three a handful, a handful of them really and the ripretinib arm and none in the placebo arm. So we don't have any real conclusions that we can draw from those data. We haven't yet broken out data by subgroup, so really doesn't offer us any help or guidance. I think with respect to SM, the key question will be generating data in that specific population. As I noted earlier, we're committed to enrolling that cohort and generating the data and presenting those data in 2020. So I'd say stay tuned on SM, let us get some patients on study generate some data in those patients and then we look forward to presenting at next year.
Operator
I'm showing no questions at this time, I would now like to turn the conference back to Steve Hoerter, President and CEO. Please go ahead, sir.
Steven L. Hoerter -- President, Chief Executive Officer, Director
Great, thanks. I'd like to thank all of you for joining us today on the call. Thanks for your interest and continued support. We're looking forward to an exciting close to the year this year and then in 2020 generating additional data from our pipeline and preparing for the launch potentially of our first therapy ripretinib. Thank you and have a great afternoon.
Operator
[Operator Closing Remarks]
Duration: 47 minutes
Call participants:
Jennifer H. Robinson -- Vice President of Investor Relations
Steven L. Hoerter -- President, Chief Executive Officer, Director
Matthew L. Sherman -- Chief Medical Officer
Tucker Kelly, J.D -- Chief Financial Officer and Treasurer
Jessica Fye -- JPMorgan -- Analyst
Christopher Raymond -- Piper Jaffray -- Analyst
Charles Zhu -- Guggenheim Securities -- Analyst
Eun Yang -- Jefferies -- Analyst
Jackson Harvey -- Nomura Instinet -- Analyst
Reni Benjamin -- JMP Securities -- Analyst
Arlinda Lee -- Canaccord -- Analyst
More DCPH analysis
All earnings call transcripts
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 1, 2019
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 47 minutes Call participants: Jennifer H. Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President, Chief Executive Officer, Director Matthew L. Sherman -- Chief Medical Officer Tucker Kelly, J.D -- Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Christopher Raymond -- Piper Jaffray -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Reni Benjamin -- JMP Securities -- Analyst Arlinda Lee -- Canaccord -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. We believe these efficacy and safety data are highly impressive particularly the magnitude of benefit observed for overall survival and suggest that ripretinib's approach of targeting the broad spectrum of mutations known to drive GIST can improve outcomes in the most heavily pre-treated patients.
|
Operator [Operator Closing Remarks] Duration: 47 minutes Call participants: Jennifer H. Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President, Chief Executive Officer, Director Matthew L. Sherman -- Chief Medical Officer Tucker Kelly, J.D -- Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Christopher Raymond -- Piper Jaffray -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Reni Benjamin -- JMP Securities -- Analyst Arlinda Lee -- Canaccord -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019, 4:30 p.m. With me this afternoon to discuss the quarter's results and provide a general corporate update is Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 47 minutes Call participants: Jennifer H. Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President, Chief Executive Officer, Director Matthew L. Sherman -- Chief Medical Officer Tucker Kelly, J.D -- Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Christopher Raymond -- Piper Jaffray -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Reni Benjamin -- JMP Securities -- Analyst Arlinda Lee -- Canaccord -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019, 4:30 p.m. We remain on track to submit the ripretinib NDA in the first quarter of next year for the treatment of patients with advanced GIST and we continue to drive forward with rapid site opening and patient enrollment for our INTRIGUE study where we're comparing ripretinib to sunitinib and patients with GIST who have received prior treatment with imatinib.
|
Operator [Operator Closing Remarks] Duration: 47 minutes Call participants: Jennifer H. Robinson -- Vice President of Investor Relations Steven L. Hoerter -- President, Chief Executive Officer, Director Matthew L. Sherman -- Chief Medical Officer Tucker Kelly, J.D -- Chief Financial Officer and Treasurer Jessica Fye -- JPMorgan -- Analyst Christopher Raymond -- Piper Jaffray -- Analyst Charles Zhu -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Jackson Harvey -- Nomura Instinet -- Analyst Reni Benjamin -- JMP Securities -- Analyst Arlinda Lee -- Canaccord -- Analyst More DCPH analysis All earnings call transcripts 10 stocks we like better than Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019, 4:30 p.m. We remain on track to submit the ripretinib NDA in the first quarter of next year for the treatment of patients with advanced GIST and we continue to drive forward with rapid site opening and patient enrollment for our INTRIGUE study where we're comparing ripretinib to sunitinib and patients with GIST who have received prior treatment with imatinib.
|
a589e8ee-bd1e-4368-8159-4d8f4b30f9ee
|
715544.0
|
2019-11-01 00:00:00 UTC
|
3 ‘Strong Buy’ Stocks Jefferies Thinks Are Set to Rip Higher
|
DCPH
|
https://www.nasdaq.com/articles/3-strong-buy-stocks-jefferies-thinks-are-set-to-rip-higher-2019-11-01
|
nan
|
nan
|
Given the market’s latest rally, is it smooth sailing from here? Judging by recent trading activity, some investors are optimistic that this is in fact the case.
Jefferies analyst Steven DeSanctis told clients that funds containing stocks from the cyclical sector have seen a $1.5 billion influx since October 4. Stocks in this space can include consumer discretionary, energy as well as information technology names, and tend to perform well when the market is prospering. He added that investors have shifted away from bond proxies, which are seen as a go-to when the economy trends downward.
“Although fund flows were muted this past week, under the surface we are seeing some significant changes,” DeSanctis stated.
We’ve used TipRanks’ Stock Screener tool to further sort Jefferies' list of stocks to watch for the coming year. These names have earned the rest of the Street’s support as each sports a “Strong Buy” consensus rating. This is based on the calls published by all of the other analysts covering the stock over the last three months. Let’s jump right in.
Deciphera (DCPH)
Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development.
Coming on the heels of promising trial data, Jefferies analyst Eun Yang believes this biotech is well positioned for strong long-term growth.
Based on the findings from the Phase 3 INVICTUS trial for ripretinib, the drug was able to cut the risk of disease progression or death by 85% compared to the placebo. Not to mention it more than doubled median overall survival. Yang noted that these results substantially reduce the risks of the drug and give ripretinib the potential to “be the best-in-class therapy”.
If that isn’t enough, the analyst predicts peak revenue of $830 million given the potential for an even larger ripretinib market opportunity based on the Phase 3 INTRIGUE trial. That being said, data from this trial isn’t expected until the end of 2020.
With its additional candidates also standing to drive upside once further proof-of-concept is available, Yang is convinced that now is the time to buy. This conclusion prompted the 5-star analyst to initiate coverage as well as set a $47 price target. (To watch Yang’s track record, click here)
Similarly, other Wall Street analysts like what they’re seeing. With 11 Buy ratings vs 1 Hold received in the last three months, the stock earns a ‘Strong Buy’ Street consensus. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH. (See Deciphera stock analysis on TipRanks)
LPL Financial (LPLA)
LPL Financial offers financial services as well as customer service to independent financial advisors. Despite the fact that interest rates pose a threat to the company, several analysts argue that its business strategy has put it on the path towards future gains.
Jefferies’ Gerald O’Hara cites both the fee-based advisory segment and the independent employee channel as representing key points of strength. Cerulli estimates point to the U.S. retail investment market increasing from its current value of $27 trillion to reach or surpass $32 trillion by 2022, with 75% of this being advice driven. This lends itself to O’Hara’s conclusion that “LPLA is positioned to take share within the $5 trillion fee-based segment (~2% market share) and $4 trillion independent employee channel."
On top of this, management is looking to further expand its capabilities across the advice driven wealth management spectrum. “The expanded addressable market (Play 1) will enable LPLA to broaden its opportunity set from about 25% of the wealth management market, to over 60% as it looks to increase penetration on the fee-based businesses and enter a portion of the approximately $11 trillion traditional employee segment,” O’Hara commented.
With LPLA primed to see additional upside from higher fee portfolio construction and premium services in the next few years, the five-star analyst tells investors that the current discounted share price represents a unique buying opportunity. As a result, he initiated coverage with a Buy and set a $96 price target, suggesting 16% upside potential. (To watch O’Hara’s track record, click here)
In general, the rest of the Street is on the same page. 4 Buy ratings compared to 1 Hold assigned in the last three months give it a ‘Strong Buy’ analyst consensus. At the $97.20 average price target, shares could surge 18% over the next twelve months. (See LPL Financial stock analysis on TipRanks)
IGM Biosciences (IGMS)
Also fighting the good fight against cancer, IGM Biosciences is developing its treatments utilizing engineered IgM antibodies. As the company’s IgM-based therapeutics represent a unique approach with the potential to improve efficacy and safety, it’s no wonder Wall Street has this biotech under its microscope.
“IGM Biosciences has addressed many of these challenges, making advancements in IgM protein engineering, as well as antibody capture and purification. A key engineering advancement is the ability to convert IgM antibodies into T cell engagers and vehicles for targeted tumor delivery of cytokines and immunostimulatory agents,” explained Jefferies’ Biren Amin.
IGMS is especially noteworthy thanks to its lead product candidate, IGM-2323. The drug is a biospecific IgM T-cell engager, with preclinical data implying that it has a greater potency in killing Rituximab resistant cell lines as well as shows overall lower levels of cytokine release in cell lines and non-human primates. This means that the drug could produce greater clinical responses with an improved CRS profile compared to current IgG based biospecifics and CAR-T therapies.
Adding to the good news, IGMS is trying to target Dr5 to treat solid tumors and hematological malignancies. If the company can achieve this using its IgM antibody, the implications could be monumental as other attempts to target Dr5 have been unsuccessful.
Based on all of the above factors, Amin initiated coverage with a Buy. Along with this bullish call, the 5-star analyst gave IGMS a $25 price target. (To watch Amin’s track record, click here)
With only Buy recommendations issued over the last three months, the message is clear: IGMS is a ‘Strong Buy.’ The biotech also boasts 22% upside potential from the current share price. (See IGM Biosciences stock analysis on TipRanks)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera (DCPH) Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH.
|
Deciphera (DCPH) Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH.
|
Deciphera (DCPH) Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH.
|
Deciphera (DCPH) Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH.
|
0591faec-39ca-44dd-8fd2-6bf7ce3c8a91
|
715545.0
|
2019-10-29 00:00:00 UTC
|
Health Care Sector Update for 10/29/2019: DCPH,MRTX,NEO,MOR,GLPG
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-10-29-2019%3A-dcphmrtxneomorglpg-2019-10-29
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.07%
PFE +2.82%
ABT +1.03%
MRK +4.04%
AMGN +2.39%
Health care stocks were sharply higher in late trade, with the NYSE Health Care Index rising nearly 1.2% while the shares of health care companies in the S&P 500 also were up more than 1.2% as a group. The Nasdaq Biotechnology index also was climbing nearly 0.7%.
Among health care stocks moving on news:
(+) Deciphera Pharmaceuticals (DCPH) rose more than 3% after the immuno-oncology company Tuesday presented interim results from phase I testing of its ripretinib drug candidate in patients with gastrointestinal stromal tumors, saying the investigational tyrosine kinase switch control inhibitor produced an overall response rate in 19% of the patients with a second line form of the disease and 14% and 7% response rates in third- and fourth-line patients. Patients also demonstrated median responses of between 76 to 80 weeks, the company said this afternoon at an industry conference in Boston.
In other sector news:
(+) Mirati Therapeutics (MRTX) climbed over 16% after the oncology company lae Monday said its MRTX849 drug candidate demonstrated early efficacy in patients with solid tumors expressing KRAS G12C mutations during phase I/II testing. Dose-expansion is now underway to determine the maximum tolerated dose, the company said, adding it was continuing to enroll new patients.
(+) NeoGenomics (NEO) jumped nearly 12% higher on Tuesday after the genetic testing company earned $0.07 per share during the three months ended Sept. 30, excluding one-time items, improving on a $0.05 per share adjusted profit during the year-ago period and beating the Capital IQ consensus by $0.01 per share. Revenue grew 51.5% over the same quarter last year to $104.7 million, also topping the $99.4 million Street view.
(-) MorphoSys (MOR) turned 1% higher this afternoon, reversing a prior decline that followed the biotechnology company and Galapagos (GLPG) saying they were ending phase II testing of their MOR106 drug candidate after interim analysis indicated the prospective treatment for atopic dermatitis was unlikely to meet the primary endpoint of the trial. The company said it was exploring a future strategy for MOR106.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Among health care stocks moving on news: (+) Deciphera Pharmaceuticals (DCPH) rose more than 3% after the immuno-oncology company Tuesday presented interim results from phase I testing of its ripretinib drug candidate in patients with gastrointestinal stromal tumors, saying the investigational tyrosine kinase switch control inhibitor produced an overall response rate in 19% of the patients with a second line form of the disease and 14% and 7% response rates in third- and fourth-line patients. In other sector news: (+) Mirati Therapeutics (MRTX) climbed over 16% after the oncology company lae Monday said its MRTX849 drug candidate demonstrated early efficacy in patients with solid tumors expressing KRAS G12C mutations during phase I/II testing. Dose-expansion is now underway to determine the maximum tolerated dose, the company said, adding it was continuing to enroll new patients.
|
Among health care stocks moving on news: (+) Deciphera Pharmaceuticals (DCPH) rose more than 3% after the immuno-oncology company Tuesday presented interim results from phase I testing of its ripretinib drug candidate in patients with gastrointestinal stromal tumors, saying the investigational tyrosine kinase switch control inhibitor produced an overall response rate in 19% of the patients with a second line form of the disease and 14% and 7% response rates in third- and fourth-line patients. Top Health Care Stocks In other sector news: (+) Mirati Therapeutics (MRTX) climbed over 16% after the oncology company lae Monday said its MRTX849 drug candidate demonstrated early efficacy in patients with solid tumors expressing KRAS G12C mutations during phase I/II testing.
|
Among health care stocks moving on news: (+) Deciphera Pharmaceuticals (DCPH) rose more than 3% after the immuno-oncology company Tuesday presented interim results from phase I testing of its ripretinib drug candidate in patients with gastrointestinal stromal tumors, saying the investigational tyrosine kinase switch control inhibitor produced an overall response rate in 19% of the patients with a second line form of the disease and 14% and 7% response rates in third- and fourth-line patients. Health care stocks were sharply higher in late trade, with the NYSE Health Care Index rising nearly 1.2% while the shares of health care companies in the S&P 500 also were up more than 1.2% as a group. In other sector news: (+) Mirati Therapeutics (MRTX) climbed over 16% after the oncology company lae Monday said its MRTX849 drug candidate demonstrated early efficacy in patients with solid tumors expressing KRAS G12C mutations during phase I/II testing.
|
Among health care stocks moving on news: (+) Deciphera Pharmaceuticals (DCPH) rose more than 3% after the immuno-oncology company Tuesday presented interim results from phase I testing of its ripretinib drug candidate in patients with gastrointestinal stromal tumors, saying the investigational tyrosine kinase switch control inhibitor produced an overall response rate in 19% of the patients with a second line form of the disease and 14% and 7% response rates in third- and fourth-line patients. Health care stocks were sharply higher in late trade, with the NYSE Health Care Index rising nearly 1.2% while the shares of health care companies in the S&P 500 also were up more than 1.2% as a group. Dose-expansion is now underway to determine the maximum tolerated dose, the company said, adding it was continuing to enroll new patients.
|
674f4f33-0673-4695-99ad-d55b804edd70
|
715546.0
|
2019-10-22 00:00:00 UTC
|
Notable Tuesday Option Activity: DCPH, SSYS, XPO
|
DCPH
|
https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-dcph-ssys-xpo-2019-10-22
|
nan
|
nan
|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (Symbol: DCPH), where a total volume of 3,235 contracts has been traded thus far today, a contract volume which is representative of approximately 323,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 94.9% of DCPH's average daily trading volume over the past month, of 340,785 shares. Especially high volume was seen for the $35 strike put option expiring November 15, 2019, with 1,550 contracts trading so far today, representing approximately 155,000 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $35 strike highlighted in orange:
Stratasys, Ltd. (Symbol: SSYS) saw options trading volume of 3,869 contracts, representing approximately 386,900 underlying shares or approximately 90.5% of SSYS's average daily trading volume over the past month, of 427,405 shares. Especially high volume was seen for the $20 strike call option expiring November 08, 2019, with 500 contracts trading so far today, representing approximately 50,000 underlying shares of SSYS. Below is a chart showing SSYS's trailing twelve month trading history, with the $20 strike highlighted in orange:
And XPO Logistics, Inc. (Symbol: XPO) saw options trading volume of 6,278 contracts, representing approximately 627,800 underlying shares or approximately 86.4% of XPO's average daily trading volume over the past month, of 726,430 shares. Especially high volume was seen for the $85 strike call option expiring November 15, 2019, with 4,212 contracts trading so far today, representing approximately 421,200 underlying shares of XPO. Below is a chart showing XPO's trailing twelve month trading history, with the $85 strike highlighted in orange:
For the various different available expirations for DCPH options, SSYS options, or XPO options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Especially high volume was seen for the $35 strike put option expiring November 15, 2019, with 1,550 contracts trading so far today, representing approximately 155,000 underlying shares of DCPH. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (Symbol: DCPH), where a total volume of 3,235 contracts has been traded thus far today, a contract volume which is representative of approximately 323,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 94.9% of DCPH's average daily trading volume over the past month, of 340,785 shares.
|
Especially high volume was seen for the $35 strike put option expiring November 15, 2019, with 1,550 contracts trading so far today, representing approximately 155,000 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $35 strike highlighted in orange: Stratasys, Ltd. (Symbol: SSYS) saw options trading volume of 3,869 contracts, representing approximately 386,900 underlying shares or approximately 90.5% of SSYS's average daily trading volume over the past month, of 427,405 shares. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (Symbol: DCPH), where a total volume of 3,235 contracts has been traded thus far today, a contract volume which is representative of approximately 323,500 underlying shares (given that every 1 contract represents 100 underlying shares).
|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (Symbol: DCPH), where a total volume of 3,235 contracts has been traded thus far today, a contract volume which is representative of approximately 323,500 underlying shares (given that every 1 contract represents 100 underlying shares). Below is a chart showing DCPH's trailing twelve month trading history, with the $35 strike highlighted in orange: Stratasys, Ltd. (Symbol: SSYS) saw options trading volume of 3,869 contracts, representing approximately 386,900 underlying shares or approximately 90.5% of SSYS's average daily trading volume over the past month, of 427,405 shares. That number works out to 94.9% of DCPH's average daily trading volume over the past month, of 340,785 shares.
|
Especially high volume was seen for the $35 strike put option expiring November 15, 2019, with 1,550 contracts trading so far today, representing approximately 155,000 underlying shares of DCPH. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (Symbol: DCPH), where a total volume of 3,235 contracts has been traded thus far today, a contract volume which is representative of approximately 323,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 94.9% of DCPH's average daily trading volume over the past month, of 340,785 shares.
|
067bed7e-1b69-4d58-b5dd-05b4fc1d648d
|
715547.0
|
2019-08-20 00:00:00 UTC
|
Deciphera Pharmaceuticals: Buy at the High?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals%3A-buy-at-the-high-2019-08-20
|
nan
|
nan
|
One quick look at the stock chart of Deciphera Pharmaceuticals (NASDAQ: DCPH) shows a constant tension between optimism and pessimism. In the last two years, investors haven't been sure what to make of clinical updates from the clinical-stage pharma, especially in comparison to competitors. The latest results might make that decision a little easier.
Shares more than doubled in mid-August after the company reported solid results from a phase 3 trial investigating its lead drug candidate, ripretinib, as a treatment for advanced gastrointestinal stromal tumors (GIST). That gives the stock a one-year gain of just 6% after factoring in a massive $400 million public stock offering, but the results should be enough to earn marketing approval from the U.S. Food and Drug Administration (FDA). Is that enough to make Deciphera Pharmaceuticals stock a buy?
Image source: Getty Images.
A promising pipeline
Deciphera Pharmaceuticals is developing four small molecule drug candidates called checkpoint inhibitors. They're specifically designed to inhibit the function of enzymes called kinases that play a role in the growth, spread, and survival of cancer cells. According to Chemoth.com, "Of the 43 new drugs approved by the FDA for cancer from 2015 to 2018, 13 were kinase inhibitors."
That shows how active the research area has become, but there's one major issue with checkpoint inhibitors: resistance. While stopping certain parts of a cancer's metabolism can help patients to manage their disease initially, many cancers adapt by mutating the structure of the targeted kinase and rendering the treatment ineffective. It's one of the biggest obstacles facing cancer therapeutics today.
Deciphera Pharmaceuticals thinks it can delay the onset of tumor resistance by developing checkpoint inhibitors capable of targeting specific kinases and many or all of the possible mutants. That's a big claim, and one reason for the stock's volatility in the last two years, as the clinical update in October 2018 raised some important questions. But the latest results suggest the company's approach may yet elevate the standard in GIST.
Image source: Getty Images.
Solid clinical results
Ripretinib is a kinase inhibitor aimed at tyrosine-protein kinase KIT, or KIT for short, and platelet derived growth factor alpha (PDGFRA). Considering over 90% of patients with KIT-driven GIST have multiple mutations of KIT, it's a promising target for treating the rare cancer. The drug candidate shone in two recent clinical trials.
In a phase 3 trial evaluating patients with advanced GIST (fourth-line and above) who received at least three prior therapies, Deciphera Pharmaceuticals reported that ripretinib met its primary endpoint. Patients taking the drug candidate achieved a median progression-free survival (PFS) of 6.3 months, compared to just 1 month for individuals taking placebo, and saw their risk of disease progression or death decline by 85%.
That should be enough for the company to file a new drug application (NDA) with the FDA in the first quarter of 2020. Deciphera Pharmaceuticals thinks the drug candidate's potential extends far beyond treating late-stage patients who've failed other therapies, however. In a separate phase 3 trial, ripretinib is being compared directly to Sutent from Pfizer, which generates over $1 billion in global annual revenue, as a second-line treatment option.
Deciphera Pharmaceuticals also recently announced encouraging results from a broad phase 1 trial evaluating the drug candidate's potential in treating second-line and above GIST. Consider the clear relationships among objective response rates (ORR; whether a patient responds to treatment), disease control rates (DCR; how many patients don't see disease progression), and progression-free survival (PFS) based on the severity of GIST observed as of the end of March 2019.
Data source: Press release.
That may not seem like much, but existing second- and third-line GIST treatments achieve an ORR of just 7% and 4.5%, respectively. The question on the minds of investors is just how competitive ripretinib will be compared with other drug candidates barreling toward the market.
For instance, Blueprint Medicines (NASDAQ: BPMC) is developing its own kinase inhibitor, avapritinib, in second-line and above GIST. It also takes aim at KIT and PDGFRA. It's delivered impressive results to date with fewer side effects than ripretinib and existing treatments. And it's on track to earn marketing approval months before ripretinib. That's led several analysts to declare it the favorite in the race for the future of GIST treatments.
A deeper look reveals the matchup might be too close to call. While avapritinib achieved an ORR of 20% in fourth-line and later GIST, it achieved a four-month DCR of 40% and a median PFS of 3.7 months. Ripretinib achieved an ORR of just 8% in the same patient population, but reported a three-month DCR of 70% and a median PFS of 6 months. It's too early to tell which drug might prove superior, but investors should get a more concrete answer as second-line studies are wrapped up in the next two years.
Ready to hit the ground running
Deciphera Pharmaceuticals is well positioned to earn marketing approval for ripretinib in fourth-line and later GIST in late 2020. While that will lag months behind Blueprint Medicines, the clinical update from mid-August demonstrated that the smaller company shouldn't be written off just yet. Investors will now be eagerly awaiting study results from both companies in second-line and above GIST to determine how market share might get divided.
However that shakes out, Deciphera Pharmaceuticals should be able to hit the ground running. It exited June with $225 million in cash and raised another $400 million in gross proceeds in mid-August. That should be enough to fund ongoing clinical trials and get ripretinib launched, although more cash will likely be needed in late 2020 or early 2021.
So is Deciphera Pharmaceuticals a buy? There's no denying that a lot of success is priced into the current $1.3 billion valuation. Given the competition in GIST, investors would like to see competitive results as a second-line therapy and success in additional pipeline candidates. But investors with an appetite for risk may find it exciting to open a small position in the stock.
10 stocks we like better than Blueprint Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 1, 2019
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One quick look at the stock chart of Deciphera Pharmaceuticals (NASDAQ: DCPH) shows a constant tension between optimism and pessimism. Shares more than doubled in mid-August after the company reported solid results from a phase 3 trial investigating its lead drug candidate, ripretinib, as a treatment for advanced gastrointestinal stromal tumors (GIST). In a phase 3 trial evaluating patients with advanced GIST (fourth-line and above) who received at least three prior therapies, Deciphera Pharmaceuticals reported that ripretinib met its primary endpoint.
|
One quick look at the stock chart of Deciphera Pharmaceuticals (NASDAQ: DCPH) shows a constant tension between optimism and pessimism. A promising pipeline Deciphera Pharmaceuticals is developing four small molecule drug candidates called checkpoint inhibitors. Patients taking the drug candidate achieved a median progression-free survival (PFS) of 6.3 months, compared to just 1 month for individuals taking placebo, and saw their risk of disease progression or death decline by 85%.
|
One quick look at the stock chart of Deciphera Pharmaceuticals (NASDAQ: DCPH) shows a constant tension between optimism and pessimism. Shares more than doubled in mid-August after the company reported solid results from a phase 3 trial investigating its lead drug candidate, ripretinib, as a treatment for advanced gastrointestinal stromal tumors (GIST). That gives the stock a one-year gain of just 6% after factoring in a massive $400 million public stock offering, but the results should be enough to earn marketing approval from the U.S. Food and Drug Administration (FDA).
|
One quick look at the stock chart of Deciphera Pharmaceuticals (NASDAQ: DCPH) shows a constant tension between optimism and pessimism. Is that enough to make Deciphera Pharmaceuticals stock a buy? A promising pipeline Deciphera Pharmaceuticals is developing four small molecule drug candidates called checkpoint inhibitors.
|
ea15c30a-3dba-466f-96f2-900a2d6f5731
|
715548.0
|
2019-08-13 00:00:00 UTC
|
Health Care Sector Update for 08/13/2019: WMGI,DCPH,DRIO
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-08-13-2019%3A-wmgidcphdrio-2019-08-13
|
nan
|
nan
|
Top Health Care Stocks
JNJ +1.58%
PFE +1.12%
ABT +2.23%
MRK +0.68%
AMGN +0.35%
Health care stocks were rising in recent trade, with the NYSE Health Care Index climbing over 1.3% while the shares of health care companies in the S&P 500 also were up more than 1.5% as a group. The Nasdaq Biotechnology index was ahead about 1.2%.
Among health care stocks moving on news:
(+) Wright Medical Group (WMGI) was 2% higher this afternoon, giving up much of its 7.5% advance earlier Tuesday after a new regulatory filing showed Richard Wallman, a member of the medical device company's board of directors, purchased 23,000 shares at a volume-weighted average of $21.56 apiece. Wallman now owns a total of 156,291 Wright Medical shares.
In other sector news:
(+) Deciphera Pharmaceuticals (DCPH) climbed 115.5% to a 14-month high of $42.99 a share after saying its ripretinib drug candidate met its primary endpoint of significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors compared with a placebo during phase III testing. Ripretinib also produced positive results during a phase I trial in patients with second-line through fourth-line plus gastrointestinal stromal tumors.
(-) DarioHealth (DRIO) was down over 20% after the diabetes-diagnosis company turned in a GAAP Q2 net loss of $0.13 per share, more than halving its $0.32 per share net loss during the year-ago period but still missing the Capital IQ consensus by $0.01 per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In other sector news: (+) Deciphera Pharmaceuticals (DCPH) climbed 115.5% to a 14-month high of $42.99 a share after saying its ripretinib drug candidate met its primary endpoint of significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors compared with a placebo during phase III testing. Among health care stocks moving on news: (+) Wright Medical Group (WMGI) was 2% higher this afternoon, giving up much of its 7.5% advance earlier Tuesday after a new regulatory filing showed Richard Wallman, a member of the medical device company's board of directors, purchased 23,000 shares at a volume-weighted average of $21.56 apiece. Ripretinib also produced positive results during a phase I trial in patients with second-line through fourth-line plus gastrointestinal stromal tumors.
|
In other sector news: (+) Deciphera Pharmaceuticals (DCPH) climbed 115.5% to a 14-month high of $42.99 a share after saying its ripretinib drug candidate met its primary endpoint of significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors compared with a placebo during phase III testing. Health care stocks were rising in recent trade, with the NYSE Health Care Index climbing over 1.3% while the shares of health care companies in the S&P 500 also were up more than 1.5% as a group. Among health care stocks moving on news: (+) Wright Medical Group (WMGI) was 2% higher this afternoon, giving up much of its 7.5% advance earlier Tuesday after a new regulatory filing showed Richard Wallman, a member of the medical device company's board of directors, purchased 23,000 shares at a volume-weighted average of $21.56 apiece.
|
In other sector news: (+) Deciphera Pharmaceuticals (DCPH) climbed 115.5% to a 14-month high of $42.99 a share after saying its ripretinib drug candidate met its primary endpoint of significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors compared with a placebo during phase III testing. Health care stocks were rising in recent trade, with the NYSE Health Care Index climbing over 1.3% while the shares of health care companies in the S&P 500 also were up more than 1.5% as a group. Among health care stocks moving on news: (+) Wright Medical Group (WMGI) was 2% higher this afternoon, giving up much of its 7.5% advance earlier Tuesday after a new regulatory filing showed Richard Wallman, a member of the medical device company's board of directors, purchased 23,000 shares at a volume-weighted average of $21.56 apiece.
|
In other sector news: (+) Deciphera Pharmaceuticals (DCPH) climbed 115.5% to a 14-month high of $42.99 a share after saying its ripretinib drug candidate met its primary endpoint of significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors compared with a placebo during phase III testing. The Nasdaq Biotechnology index was ahead about 1.2%. Among health care stocks moving on news: (+) Wright Medical Group (WMGI) was 2% higher this afternoon, giving up much of its 7.5% advance earlier Tuesday after a new regulatory filing showed Richard Wallman, a member of the medical device company's board of directors, purchased 23,000 shares at a volume-weighted average of $21.56 apiece.
|
20191159-72dd-483a-8710-0ee122d5ff68
|
715549.0
|
2019-08-13 00:00:00 UTC
|
Health Care Sector Update for 08/13/2019: DCPH, DRIO, ELAN, JNJ, PFE, ABT, MRK, AMGN
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-08-13-2019%3A-dcph-drio-elan-jnj-pfe-abt-mrk-amgn-2019-08-13
|
nan
|
nan
|
Top Health Care Stocks:
JNJ: +0.01%
PFE: -0.03%
ABT: Flat
MRK: +0.67%
AMGN: -0.60%
Top health care stocks were mixed in Tuesday's pre-market trading.
Stocks moving on news include:
(+) Deciphera Pharmaceuticals (DCPH), which was surging by over 122% after saying its phase 3 INVICTUS study of ripretinib has met its primary endpoint, significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors.
(-) DarioHealth (DRIO) was declining by more than 6% as it reported Q2 net loss of $0.13 per share on a GAAP basis, compared with a net loss of $0.32 per share a year earlier. Analysts polled by Capital IQ had estimated a loss of $0.14 per share for the quarter.
(+) Elanco Animal Health (ELAN) was advancing by nearly 3% after posting Q2 adjusted earnings of $0.28 per share, up from $0.27 in the same period a year ago and exceeding the estimate of $0.26 from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Stocks moving on news include: (+) Deciphera Pharmaceuticals (DCPH), which was surging by over 122% after saying its phase 3 INVICTUS study of ripretinib has met its primary endpoint, significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors. Top health care stocks were mixed in Tuesday's pre-market trading. (+) Elanco Animal Health (ELAN) was advancing by nearly 3% after posting Q2 adjusted earnings of $0.28 per share, up from $0.27 in the same period a year ago and exceeding the estimate of $0.26 from analysts polled by Capital IQ.
|
Stocks moving on news include: (+) Deciphera Pharmaceuticals (DCPH), which was surging by over 122% after saying its phase 3 INVICTUS study of ripretinib has met its primary endpoint, significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors. Top Health Care Stocks: Top health care stocks were mixed in Tuesday's pre-market trading.
|
Stocks moving on news include: (+) Deciphera Pharmaceuticals (DCPH), which was surging by over 122% after saying its phase 3 INVICTUS study of ripretinib has met its primary endpoint, significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors. (-) DarioHealth (DRIO) was declining by more than 6% as it reported Q2 net loss of $0.13 per share on a GAAP basis, compared with a net loss of $0.32 per share a year earlier. (+) Elanco Animal Health (ELAN) was advancing by nearly 3% after posting Q2 adjusted earnings of $0.28 per share, up from $0.27 in the same period a year ago and exceeding the estimate of $0.26 from analysts polled by Capital IQ.
|
Stocks moving on news include: (+) Deciphera Pharmaceuticals (DCPH), which was surging by over 122% after saying its phase 3 INVICTUS study of ripretinib has met its primary endpoint, significantly improving progression-free survival in patients with advanced gastrointestinal stromal tumors. Top Health Care Stocks: ABT: Flat
|
7a7d2d4d-f994-40a1-8919-e228e3d0dc75
|
715550.0
|
2019-07-12 00:00:00 UTC
|
Noteworthy Friday Option Activity: GOOGL, DCPH, ONB
|
DCPH
|
https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-googl-dcph-onb-2019-07-12
|
nan
|
nan
|
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alphabet Inc (Symbol: GOOGL), where a total of 28,063 contracts have traded so far, representing approximately 2.8 million underlying shares. That amounts to about 198.5% of GOOGL's average daily trading volume over the past month of 1.4 million shares. Particularly high volume was seen for the $1145 strike call option expiring July 12, 2019, with 4,631 contracts trading so far today, representing approximately 463,100 underlying shares of GOOGL. Below is a chart showing GOOGL's trailing twelve month trading history, with the $1145 strike highlighted in orange:
Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 5,429 contracts, representing approximately 542,900 underlying shares or approximately 177.2% of DCPH's average daily trading volume over the past month, of 306,455 shares. Particularly high volume was seen for the $15 strike put option expiring July 19, 2019, with 2,932 contracts trading so far today, representing approximately 293,200 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $15 strike highlighted in orange:
And Old National Bancorp (Symbol: ONB) saw options trading volume of 12,003 contracts, representing approximately 1.2 million underlying shares or approximately 152.8% of ONB's average daily trading volume over the past month, of 785,580 shares. Especially high volume was seen for the $17.50 strike call option expiring July 19, 2019, with 5,001 contracts trading so far today, representing approximately 500,100 underlying shares of ONB. Below is a chart showing ONB's trailing twelve month trading history, with the $17.50 strike highlighted in orange:
For the various different available expirations for GOOGL options, DCPH options, or ONB options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Particularly high volume was seen for the $15 strike put option expiring July 19, 2019, with 2,932 contracts trading so far today, representing approximately 293,200 underlying shares of DCPH. Below is a chart showing GOOGL's trailing twelve month trading history, with the $1145 strike highlighted in orange: Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 5,429 contracts, representing approximately 542,900 underlying shares or approximately 177.2% of DCPH's average daily trading volume over the past month, of 306,455 shares. Below is a chart showing DCPH's trailing twelve month trading history, with the $15 strike highlighted in orange: And Old National Bancorp (Symbol: ONB) saw options trading volume of 12,003 contracts, representing approximately 1.2 million underlying shares or approximately 152.8% of ONB's average daily trading volume over the past month, of 785,580 shares.
|
Below is a chart showing GOOGL's trailing twelve month trading history, with the $1145 strike highlighted in orange: Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 5,429 contracts, representing approximately 542,900 underlying shares or approximately 177.2% of DCPH's average daily trading volume over the past month, of 306,455 shares. Below is a chart showing DCPH's trailing twelve month trading history, with the $15 strike highlighted in orange: And Old National Bancorp (Symbol: ONB) saw options trading volume of 12,003 contracts, representing approximately 1.2 million underlying shares or approximately 152.8% of ONB's average daily trading volume over the past month, of 785,580 shares. Particularly high volume was seen for the $15 strike put option expiring July 19, 2019, with 2,932 contracts trading so far today, representing approximately 293,200 underlying shares of DCPH.
|
Below is a chart showing GOOGL's trailing twelve month trading history, with the $1145 strike highlighted in orange: Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw options trading volume of 5,429 contracts, representing approximately 542,900 underlying shares or approximately 177.2% of DCPH's average daily trading volume over the past month, of 306,455 shares. Below is a chart showing DCPH's trailing twelve month trading history, with the $15 strike highlighted in orange: And Old National Bancorp (Symbol: ONB) saw options trading volume of 12,003 contracts, representing approximately 1.2 million underlying shares or approximately 152.8% of ONB's average daily trading volume over the past month, of 785,580 shares. Particularly high volume was seen for the $15 strike put option expiring July 19, 2019, with 2,932 contracts trading so far today, representing approximately 293,200 underlying shares of DCPH.
|
Particularly high volume was seen for the $15 strike put option expiring July 19, 2019, with 2,932 contracts trading so far today, representing approximately 293,200 underlying shares of DCPH. Below is a chart showing DCPH's trailing twelve month trading history, with the $15 strike highlighted in orange: And Old National Bancorp (Symbol: ONB) saw options trading volume of 12,003 contracts, representing approximately 1.2 million underlying shares or approximately 152.8% of ONB's average daily trading volume over the past month, of 785,580 shares. Below is a chart showing ONB's trailing twelve month trading history, with the $17.50 strike highlighted in orange: For the various different available expirations for GOOGL options, DCPH options, or ONB options, visit StockOptionsChannel.com.
|
7f7c59b7-334c-4681-a81c-9a17ee2f4579
|
715551.0
|
2019-01-07 00:00:00 UTC
|
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
|
DCPH
|
https://www.nasdaq.com/articles/why-array-biopharma-deciphera-pharmaceuticals-and-blueprint-medicines-are-double-digits
|
nan
|
nan
|
What happened
Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. All three companies' stocks settled down in the early afternoon but were still up at least 9% as of 3:30 p.m. EST. The price moves appear to be related to the news that fellow cancer-focused biopharma Loxo Oncology (NASDAQ: LOXO) has agreed to be purchased by Eli Lilly and Company (NYSE: LLY) .
Biotech stocks, in general, are having a great day. Shares of the SPDR S&P Biotech ETF (NYSEMKT: XBI) were up more than 5% in the early afternoon.
So what
News broke on Monday morning that Loxo Oncology had accepted an $8 billion buyout offer by Eli Lilly. The acquisition price translates into a 68% premium to Loxo's closing price on Friday, Jan. 4.
Lilly said that it agreed to offer such a huge premium to acquire Loxo because it wants to broaden its portfolio of oncology products to be used in the growing field of precision medicine . Buying Loxo was a natural fit as the company recently won approval for its first cancer drug, Vitrakvi , a TRK inhibitor that targets tumors with specific genetic abnormalities.
Traders appear to believe that this sizable financial move by Lilly could convince other big pharma companies to go on a shopping spree. If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own.
Array BioPharma has already reached the market with two cancer drugs, Braftovi and Mektovi. Sales for these drugs recently came in at $14 million last quarter , which is pretty good when considering that they only became available for sale in July 2018.
Deciphera Pharmaceuticals is still in the clinical stage, but its lead drug candidate, DCC-2618, holds a lot of promise . Deciphera released upbeat data in 2018 from a phase 1 trial of the drug as a potential treatment for gastrointestinal stromal tumors (GIST) with a specific genetic mutation. The results were so good that the company decided to move straight into a phase 3 trial.
Blueprint Medicines is another clinical-stage company whose stock has been red-hot for years. Blueprint has a number of products in development as potential treatments for specific types of liver cancer. Management recently announced that it has set a goal of having two of its products on the market by the end of 2020, and at least four other products in regulators' hands by the same time. That time frame suggests that the next few years will be an incredibly exciting period for investors.
Now what
Healthcare investors should expect that the next couple of days will be a highly volatile stretch for scores of individual stocks. The reason is that the annual J.P. Morgan Healthcare Conference is just getting underway. It's common for companies to give presentations at the conference in which they share market-moving information such as clinical or financial updates.
Array BioPharma and Blueprint Medicines both gave their investor presentations earlier in the day. Deciphera Pharmaceuticals is scheduled to provide investors with a detailed update on Tuesday.
If you're an investor in any of these businesses, then it will be worth your while to comb through their presentations to get the latest information.
10 stocks we like better than Array BioPharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Array BioPharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. Buying Loxo was a natural fit as the company recently won approval for its first cancer drug, Vitrakvi , a TRK inhibitor that targets tumors with specific genetic abnormalities. If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own.
|
What happened Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. The price moves appear to be related to the news that fellow cancer-focused biopharma Loxo Oncology (NASDAQ: LOXO) has agreed to be purchased by Eli Lilly and Company (NYSE: LLY) . If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own.
|
What happened Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. The price moves appear to be related to the news that fellow cancer-focused biopharma Loxo Oncology (NASDAQ: LOXO) has agreed to be purchased by Eli Lilly and Company (NYSE: LLY) . If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own.
|
What happened Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own. Array BioPharma and Blueprint Medicines both gave their investor presentations earlier in the day.
|
5a23a13c-a733-4c3a-b45f-dff0fda20dc6
|
715552.0
|
2018-11-15 00:00:00 UTC
|
Thursday's ETF Movers: XBI, ITB
|
DCPH
|
https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-itb-2018-11-15
|
nan
|
nan
|
In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.6% on the day. Components of that ETF showing particular strength include shares of Arena Pharmaceuticals, up about 22.1% and shares of Deciphera Pharmaceuticals, up about 17.8% on the day.
And underperforming other ETFs today is the iShares U.S. Home Construction ETF, down about 2.7% in Thursday afternoon trading. Among components of that ETF with the weakest showing on Thursday were shares of KB Home, lower by about 15.4%, and shares of Toll Brothers, lower by about 5.7% on the day.
VIDEO: Thursday's ETF Movers: XBI, ITB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Components of that ETF showing particular strength include shares of Arena Pharmaceuticals, up about 22.1% and shares of Deciphera Pharmaceuticals, up about 17.8% on the day. Among components of that ETF with the weakest showing on Thursday were shares of KB Home, lower by about 15.4%, and shares of Toll Brothers, lower by about 5.7% on the day. VIDEO: Thursday's ETF Movers: XBI, ITB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Among components of that ETF with the weakest showing on Thursday were shares of KB Home, lower by about 15.4%, and shares of Toll Brothers, lower by about 5.7% on the day. VIDEO: Thursday's ETF Movers: XBI, ITB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Components of that ETF showing particular strength include shares of Arena Pharmaceuticals, up about 22.1% and shares of Deciphera Pharmaceuticals, up about 17.8% on the day. Among components of that ETF with the weakest showing on Thursday were shares of KB Home, lower by about 15.4%, and shares of Toll Brothers, lower by about 5.7% on the day. VIDEO: Thursday's ETF Movers: XBI, ITB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.6% on the day. Components of that ETF showing particular strength include shares of Arena Pharmaceuticals, up about 22.1% and shares of Deciphera Pharmaceuticals, up about 17.8% on the day. And underperforming other ETFs today is the iShares U.S. Home Construction ETF, down about 2.7% in Thursday afternoon trading.
|
15cfe7c8-a418-44f7-abff-692a5e0b72c7
|
715553.0
|
2018-11-15 00:00:00 UTC
|
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-completes-enrollment-invictus-pivotal-phase-3-clinical-study-dcc
|
nan
|
nan
|
Deciphera Pharmaceuticals ( DCPH ), a clinical-stage biopharmaceutical company, said late Thursday that it has completed the enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients.
The INVICTUS pivotal Phase 3 study was initiated in January 2018.
The company said that it expects to report top-line data from this randomized, double-blind study in mid-2019 and, if successful, it believes the results would support a New Drug Application (NDA) for full approval in fourth-line and fourth-line-plus GIST patients.
In addition, Deciphera said it will be initiating later this year a second pivotal Phase 3 study, the INTRIGUE study, in second-line GIST patients who have progressed or are intolerant to front-line therapy with imatinib, including those with any KIT or PDGFRα mutation.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals ( DCPH ), a clinical-stage biopharmaceutical company, said late Thursday that it has completed the enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients. The company said that it expects to report top-line data from this randomized, double-blind study in mid-2019 and, if successful, it believes the results would support a New Drug Application (NDA) for full approval in fourth-line and fourth-line-plus GIST patients. In addition, Deciphera said it will be initiating later this year a second pivotal Phase 3 study, the INTRIGUE study, in second-line GIST patients who have progressed or are intolerant to front-line therapy with imatinib, including those with any KIT or PDGFRα mutation.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Deciphera Pharmaceuticals ( DCPH ), a clinical-stage biopharmaceutical company, said late Thursday that it has completed the enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients. The INVICTUS pivotal Phase 3 study was initiated in January 2018.
|
Deciphera Pharmaceuticals ( DCPH ), a clinical-stage biopharmaceutical company, said late Thursday that it has completed the enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients. In addition, Deciphera said it will be initiating later this year a second pivotal Phase 3 study, the INTRIGUE study, in second-line GIST patients who have progressed or are intolerant to front-line therapy with imatinib, including those with any KIT or PDGFRα mutation. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals ( DCPH ), a clinical-stage biopharmaceutical company, said late Thursday that it has completed the enrollment in the INVICTUS pivotal Phase 3 clinical study evaluating the safety and efficacy of DCC-2618, a broad-spectrum KIT and PDGFRα inhibitor, in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 MTNewswires.com.
|
9c01d42d-e41e-4bf7-98dd-26ee139e255f
|
715554.0
|
2018-10-03 00:00:00 UTC
|
Commit To Buy Deciphera Pharmaceuticals At $30, Earn 25.3% Annualized Using Options
|
DCPH
|
https://www.nasdaq.com/articles/commit-buy-deciphera-pharmaceuticals-30-earn-253-annualized-using-options-2018-10-03
|
nan
|
nan
|
Investors eyeing a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) stock, but cautious about paying the going market price of $34.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2019 put at the $30 strike, which has a bid at the time of this writing of $4.10. Collecting that bid as the premium represents a 13.7% return against the $30 commitment, or a 25.3% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $30 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Deciphera Pharmaceuticals Inc sees its shares decline 14.2% and the contract is exercised (resulting in a cost basis of $25.90 per share before broker commissions, subtracting the $4.10 from $30), the only upside to the put seller is from collecting that premium for the 25.3% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, and highlighting in green where the $30 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the April 2019 put at the $30 strike for the 25.3% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Deciphera Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $34.96) to be 76%. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors eyeing a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) stock, but cautious about paying the going market price of $34.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Investors eyeing a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) stock, but cautious about paying the going market price of $34.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Investors eyeing a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) stock, but cautious about paying the going market price of $34.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Investors eyeing a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) stock, but cautious about paying the going market price of $34.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com. Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised.
|
0669add3-9f52-47a5-9cce-17e373b72d98
|
715555.0
|
2018-08-02 00:00:00 UTC
|
What Blueprint Medicines Just Said About Its Future
|
DCPH
|
https://www.nasdaq.com/articles/what-blueprint-medicines-just-said-about-its-future-2018-08-02
|
nan
|
nan
|
After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ: BPMC) saw its shares rocket 17% yesterday. News that management is initiating new trials and potentially filing its first drug for FDA approval in 2019 helped spark investors' interest, but that wasn't the only thing management said about its future. Read on to learn more about this clinical-stage biotech stock and whether it's right for your portfolio.
Racing toward the finish line
Blueprint Medicines is in a race to develop next-generation, cancer-killing therapies that work in an entirely new way. Instead of targeting cancer based on the location of its origin, Blueprint Medicines is crafting therapies that address cancer in patients based on their genetic makeup.
Blueprint Medicines' most advanced clinical-stage therapy is avapritinib, an inhibitor of KIT and PDGFRA, two protein kinases that can become overly active in patients with gastrointestinal stromal tumors (GIST) and systemic mastocytosis because of genetic mutations.
The company enrolled the first patient in its phase 3 GIST clinical trial in June, and that trial will evaluate avapritinib head-to-head against the currently approved nine-figure cancer drug, Stivarga, in third-line and fourth-line patients with advanced disease. Management says updated data from Blueprint Medicines phase 1 trial in second-line or later GIST should be available later this year and that it's on track to file for FDA approval in fourth-line GIST in the first half of 2019. If the second-line data reads out positively, then management plans to begin enrolling patients in a second-line GIST phase 3 trial next year.
Blueprint Medicines presented phase 1 clinical data for avapritinib in advanced SM during Q2, including an 83% overall response rate, and management says it plans to start two registration-enabling phase 2 trials in advanced SM by the end of 2018. According to the company, avapritinib's addressable patient population in the EU, Europe, and Japan, including both GIST and SM patients, is north of 30,000 people.
The company's also continuing to add patients to the expansion part of its phase 1 trial of BLU-667, a RET (rearranged during transfection) fusion targeting therapy. In April, management said BLU-667 delivered a preliminary overall response rate of 50% in 14 patients with non-small-cell lung cancer (NSCLC) and 40% in 25 patients with medullary thyroid cancer (MTC).
Solid financial footing
The company's balance sheet got a bit better last quarter following the receipt of $40 million in upfront licensing money from CStone Pharmaceuticals, a Chinese biopharma company that's licensed the rights to develop and commercialize avapritinib, BLU-667, and a third drug, BLU-554, in mainland China.
Also, the company pocketed a $10 million milestone payment from Roche Holdings in the quarter tied to their 2016 collaboration agreement. As part of that deal, Roche secured options to up to five cancer immunotherapies in exchange for $45 million in upfront money and promises of up to $965 million in option fees and milestones tied to pre-clinical, clinical, regulatory and sales-based milestones.
The additional $55 million inflow of cash partially offset cash burn from research and development and general and administrative spending, allowing Blueprint Medicine to finish Q2 2018 with $617 million in cash on the books. Based on its current spending projections, management believes that's enough money to fund its operations into the back half of 2020.
Competition mounts
The business update, including the chance for an FDA filing early next year, has sparked investor interest, but Blueprint Medicines isn't the only one pursuing therapies that target these genetic mutations.
For instance, Loxo Oncology (NASDAQ: LOXO) is working on a RET-fusion drug, Loxo-292, and it reported data earlier this year that includes response rates of 77% in NSCLC patients and 45% in MTC patients. Also, Deciphera Pharmaceuticals (NASDAQ: DCPH) has a KIT and PDGFRA inhibitor, DCC-2618, in trials for late-line GIST. Earlier this year, it reported a 24% overall response rate in second-line and third-line GIST patients, and a phase 3 trial in second-line GIST is expected to begin this year.
Is it a buy?
The data reported so far is solid, but results from trials involving more patients are necessary before we can say for sure that targeting RET fusions and KIT and PDDGa mutations is effective and safe. It's also unclear if Blueprint Medicines will be able to outmaneuver its competitors.
Nevertheless, precision medicines such as those Blueprint Medicine is developing could revolutionize cancer treatment in the future, so owning a basket of companies, including Blueprint Medicine, in a diversified portfolio could be a smart bet.
10 stocks we like better than Blueprint Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Also, Deciphera Pharmaceuticals (NASDAQ: DCPH) has a KIT and PDGFRA inhibitor, DCC-2618, in trials for late-line GIST. After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ: BPMC) saw its shares rocket 17% yesterday. Blueprint Medicines' most advanced clinical-stage therapy is avapritinib, an inhibitor of KIT and PDGFRA, two protein kinases that can become overly active in patients with gastrointestinal stromal tumors (GIST) and systemic mastocytosis because of genetic mutations.
|
Also, Deciphera Pharmaceuticals (NASDAQ: DCPH) has a KIT and PDGFRA inhibitor, DCC-2618, in trials for late-line GIST. After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ: BPMC) saw its shares rocket 17% yesterday. If the second-line data reads out positively, then management plans to begin enrolling patients in a second-line GIST phase 3 trial next year.
|
Also, Deciphera Pharmaceuticals (NASDAQ: DCPH) has a KIT and PDGFRA inhibitor, DCC-2618, in trials for late-line GIST. The company enrolled the first patient in its phase 3 GIST clinical trial in June, and that trial will evaluate avapritinib head-to-head against the currently approved nine-figure cancer drug, Stivarga, in third-line and fourth-line patients with advanced disease. Management says updated data from Blueprint Medicines phase 1 trial in second-line or later GIST should be available later this year and that it's on track to file for FDA approval in fourth-line GIST in the first half of 2019.
|
Also, Deciphera Pharmaceuticals (NASDAQ: DCPH) has a KIT and PDGFRA inhibitor, DCC-2618, in trials for late-line GIST. The company enrolled the first patient in its phase 3 GIST clinical trial in June, and that trial will evaluate avapritinib head-to-head against the currently approved nine-figure cancer drug, Stivarga, in third-line and fourth-line patients with advanced disease. Management says updated data from Blueprint Medicines phase 1 trial in second-line or later GIST should be available later this year and that it's on track to file for FDA approval in fourth-line GIST in the first half of 2019.
|
acf696bc-9955-4500-8f09-e9c326c94308
|
715556.0
|
2018-07-15 00:00:00 UTC
|
3 Top Stocks That Aren't on Wall Street's Radar
|
DCPH
|
https://www.nasdaq.com/articles/3-top-stocks-arent-wall-streets-radar-2018-07-15
|
nan
|
nan
|
It may seem impossible for any stock to stay off Wall Street's radar in 2018. Between electronic filings, social media, and huge resources to invest in discovering the next big thing, no stock is truly hidden from Mr. Market. But there are still times when a stock isn't catching the market's interest, such as when it's just too small for the biggest investors to consider, or when its business is viewed as out of favor or in decline.
And sometimes that means potentially great companies can fall through the cracks, and individual investors can reap the rewards. Here are three that fit this description: NV5 Global Inc. (NASDAQ: NVEE) , Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) , and Beasley Broadcast Group Inc (NASDAQ: BBGI) .
These companies aren't getting much notice from Wall Street now, but if they continue to deliver solid results, that will certainly change. Read more on to learn why these stocks caught the attention of our Foolish investors, even while Wall Street looks in other places.
This upstart won't stay off Wall Street's radar forever
Jason Hall (NV5 Global) : With only four Wall Street analysts covering it, small civil engineering and infrastructure consultancy NV5 Global doesn't get much attention. This shouldn't be surprising, considering the company's total sales were $363 million the past 12 months and its market capitalization is less than $825 million. Microcap stocks rarely get much notice from the biggest investors until they've grown up and become much bigger companies.
But at its pace of growth since going public in 2013, it won't take that much longer before Mr. Market starts paying closer attention.
NVEE data by YCharts
And the growth looks on pace to continue: First-quarter revenue increased 47% and earnings per share jumped 86%. This surge in growth led management to raise full-year earnings guidance to $2.26-$2.54 per share, up from last year's $1.68 per share when adjusted to exclude a one-time impact from federal tax reform.
That means management expects profits to surge 35%-51% this year. Eventually, the market will catch on, but for now we little guys can buy shares of a fast-growing -- yet still below-the-radar -- company early in its growth phase.
NV5 isn't cheap, trading for between 29 and 33 times 2018 earnings guidance. But small companies growing at such a high rate rarely come cheap. If you can stomach the volatility -- the stock price fell over 20% at one point this year before rebounding to the current 37% gain -- investors willing to buy and hold before Wall Street joins the party could see enormous gains.
A promising biopharma on the rise
Maxx Chatsko (Deciphera Pharmaceuticals): A little over one year ago, Merck made history with a cancer drug called Keytruda, which the U.S. Food and Drug Administration approved to treat cancers based on the genetic profile of tumors, rather than where tumors reside in the body. Others have followed, and some of the early results have been spectacular.
Focusing on the new approach has put several companies on the map. For instance, development-stage company Loxo Oncology is now valued at $5.3 billion after several midstage drug candidates displayed impressive results. And although Deciphera Pharmaceuticals is up over 150% since its debut in late 2017, its earlier stage pipeline is still flying a little under Wall Street's radar.
The $1.6 billion company is planning a phase 3 trial for its lead drug candidate, DCC-2618, to become a second-line treatment for gastrointestinal stromal tumors (GIST) with a specific genetic mutation. Deciphera Pharmaceuticals reported promising results from a phase 1 trial at the recent 2018 American Society of Clinical Oncology's annual meeting, which supports the leap to a late-stage trial. Management even wisely took advantage of a soaring stock price to conduct a share offering that added about $200 million in cash to the balance sheet.
That will be needed to fund the development of DCC-2618 and two early-stage assets, rebastinib and DCC-3014, which could have more potential than the lead drug candidate. Both are designed to target specific pieces of cellular machinery harbored by a broad range of solid tumors, which could make them an important "add-on" platform for existing immunotherapies -- a tried and true approach to becoming a commercial success in biopharma.
Of course, it's important to stay grounded. Much of the pipeline is still in the earliest stages of development, so although the technical potential for the treatment approach is there on paper, clinical trials have to deliver results before Wall Street pays too much attention. Nonetheless, Deciphera Pharmaceuticals is a biopharma stock investors will want to keep an eye on.
An attractively priced and positioned company in a still solid industry
Chuck Saletta(Beasley Broadcast Group): Radio -- a communications medium older than television, and often considered one that's dying by the day -- still has some life left in it. According to Nielsen's second-quarter 2017 total audience report, the average adult American spends around 1 hour, 50 minutes a day listening to AM/FM radio, and rates have been fairly constant in recent years. Even young adults (aged 18-24) spend nearly 10 hours a week listening to radio, giving hope for radio's future.
A willingness to compete -- and drive consolidation -- in the radio industry is a key reason Beasley Broadcasting Group looks like an attractive potential investment opportunity. After all, when an industry is given up for dead, assets in that industry are often available more cheaply than they would be in a business line that's considered to be rapidly growing. That gives Beasley Broadcasting group the ability to buy productive stations that much more cheaply, thus fueling its own profitable growth.
BBGI data by YCharts
Through smart acquisitions, Beasley Broadcasting Group has grown to be one of the four largest radio groups in the country, and it is building its digital media presence as well. Yet it has done so largely under the radar of Wall Street's analysts -- with virtually nobody on Wall Street actively following its business. Its operations are profitable and its balance sheet is healthy, giving it plenty of opportunity to continue its growth through consolidation.
By playing in a space few others want to play, Beasley Broadcasting Group may very well be on to a winning strategy. By doing so without attracting much Wall Street attention, it can potentially grow to a decent size before institutional investors really catch on. And that combination -- along with its financial health -- makes it worthy of consideration among ordinary investors looking to buy in before the company hits Wall Street's radar.
10 stocks we like better than Beasly Broadcast Group
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Beasly Broadcast Group wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Chuck Saletta has no position in any of the stocks mentioned. Jason Hall owns shares of NV5 Global. Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of NV5 Global. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are three that fit this description: NV5 Global Inc. (NASDAQ: NVEE) , Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) , and Beasley Broadcast Group Inc (NASDAQ: BBGI) . Both are designed to target specific pieces of cellular machinery harbored by a broad range of solid tumors, which could make them an important "add-on" platform for existing immunotherapies -- a tried and true approach to becoming a commercial success in biopharma. An attractively priced and positioned company in a still solid industry Chuck Saletta(Beasley Broadcast Group): Radio -- a communications medium older than television, and often considered one that's dying by the day -- still has some life left in it.
|
Here are three that fit this description: NV5 Global Inc. (NASDAQ: NVEE) , Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) , and Beasley Broadcast Group Inc (NASDAQ: BBGI) . This upstart won't stay off Wall Street's radar forever Jason Hall (NV5 Global) : With only four Wall Street analysts covering it, small civil engineering and infrastructure consultancy NV5 Global doesn't get much attention. An attractively priced and positioned company in a still solid industry Chuck Saletta(Beasley Broadcast Group): Radio -- a communications medium older than television, and often considered one that's dying by the day -- still has some life left in it.
|
Here are three that fit this description: NV5 Global Inc. (NASDAQ: NVEE) , Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) , and Beasley Broadcast Group Inc (NASDAQ: BBGI) . This upstart won't stay off Wall Street's radar forever Jason Hall (NV5 Global) : With only four Wall Street analysts covering it, small civil engineering and infrastructure consultancy NV5 Global doesn't get much attention. If you can stomach the volatility -- the stock price fell over 20% at one point this year before rebounding to the current 37% gain -- investors willing to buy and hold before Wall Street joins the party could see enormous gains.
|
Here are three that fit this description: NV5 Global Inc. (NASDAQ: NVEE) , Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) , and Beasley Broadcast Group Inc (NASDAQ: BBGI) . But there are still times when a stock isn't catching the market's interest, such as when it's just too small for the biggest investors to consider, or when its business is viewed as out of favor or in decline. This upstart won't stay off Wall Street's radar forever Jason Hall (NV5 Global) : With only four Wall Street analysts covering it, small civil engineering and infrastructure consultancy NV5 Global doesn't get much attention.
|
3e23453c-8375-4ed4-98f1-25ec5975d706
|
715557.0
|
2018-06-09 00:00:00 UTC
|
3 Drug Stocks That Soared This Week: Are They Buys?
|
DCPH
|
https://www.nasdaq.com/articles/3-drug-stocks-soared-week-are-they-buys-2018-06-09
|
nan
|
nan
|
I recently checked the stocks I own to see how they're performing so far in 2018. Year-to-date gains of more than 20% for three of my stocks brought a smile to my face. That's not bad at all for less than halfway through the year, but it pales in comparison to the performance of three drug stocks in just the last five days.
Axovant Sciences (NASDAQ: AXON) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and TherapeuticsMD (NASDAQ: TXMD) stocks soared by 26% or more this week. What sent these drug stocks into orbit? And are they still buys? Here's the scoop behind the big gains and what could be next for the companies.
1. Axovant Sciences: A big deal and a big hire
Axovant Sciences was the biggest winner of the week with its stock skyrocketing 150%. That's a welcome change for Axovant shareholders, who had seen the stock lose more than 75% of its value in 2018 prior to this week.
The biggest news for Axovant was that the company signed an important deal with Oxford Biomedica to license experimental gene therapy OXB-102 and its predecessor product, ProSavin. Axovant paid $30 million upfront and agreed to pay Oxford Biomedical additional payments contingent on reaching development, regulatory, and commercial milestones that could top $832 million. Axovant plans to begin a phase 1/2 clinical study of OXB-102, which the company is renaming AXO-Lenti-PD, targeting treatment of Parkinson's disease by late 2018.
Axovant also announced other news on Wednesday. The company hired Fraser Wright as Chief Technology Officer (CTO) to lead its gene therapy program. Wright was a co-founder and CTO of Spark Therapeutics , where he directed the establishment of manufacturing processes for Luxturna, a gene therapy approved by the Food and Drug Administration (FDA) in December 2017 for treating a rare genetic disorder that can lead to blindness.
2. Deciphera Pharmaceuticals: An ASCO afterglow
Deciphera Pharmaceuticals stock jumped 36% higher this week. The gains could have been even higher except the biotech took advantage of the spike in its share price to raise cash through a stock offering.
It's easy to decipher why Deciphera is enjoying such great momentum. The company announced an update from its phase 1 clinical study of DCC-2618 in treating gastrointestinal stromal tumors (GIST) at the American Society of Clinical Oncology (ASCO) meeting on June 2. Deciphera's updated data shows promise for DCC-2168 to be more effective at treating GIST with a specific gene mutation than existing therapies Sutent and Stivarga.
This update gives investors more confidence about the prospects for DCC-2168 as it advances to further clinical trials. Deciphera plans to begin a phase 3 clinical study evaluating the drug as a second-line treatment for GIST later in 2018. The company also has three other phase 1 studies of DCC-2168 in progress targeting system mastocytosis -- a rare disease where mast cells accumulate in tissues and organs -- and other forms of cancer.
3. TherapeuticsMD: No stifling from Stifel
TherapeuticsMD stock vaulted nearly 27% higher over the last five days. Praise from a Wall Street analyst served as a big catalyst for the drug stock.
Investing website The Fly reported on Tuesday that Stifel Financial analyst Annabel Samimy had "high confidence" about TherapeuticsMD's prospects after attending the company's investor and analyst day held on June 4. Samimy reiterated a buy rating for the stock with a price target of $20, a level that represents a premium of 160% over the current share price.
TherapeuticsMD recently received FDA approval for Imvexxy in treating moderate-to-severe dyspareunia -- vaginal pain that's associated with sexual activity -- due to menopause. An FDA decision is expected by Oct. 28, 2018 for another of the company's drugs, TX-001HR, as a treatment for moderate-to-severe vasomotor symptoms due to menopause.
Are they buys?
I think it's too early to jump aboard the Axovant Sciences train. While it's great news that the company now has a clear strategy for moving forward, there's still a long way to go.
As for Deciphera, I suspect the company eventually could have a winner with DCC-2618. Still, I'd prefer to wait and see what happens with the drug in its late-stage clinical study.
That leaves TherapeuticsMD. After this week's nice gain, the company's market cap stands at close to $1.6 billion. Jefferies analyst Matthew Andrews thinks that Imvexxy could generate peak annual sales in the ballpark of $650 million. If approved, TX-001HR could get close to that level within five years.
So is TherapeuticsMD a slam-dunk pick? I wouldn't go that far. It could take Imvexxy over a decade to reach peak sales. TX-001HR might have challenges gaining reimbursement because it's a combination of two drugs that are already available in generic form.
I think there's a good chance that TherapeuticsMD stock will move a lot higher over the next few years. My take, though, is to see how the initial launches of Imvexxy and TX-001HR go -- assuming it wins approval.
10 stocks we like better than TherapeuticsMD, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TherapeuticsMD, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Axovant Sciences (NASDAQ: AXON) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and TherapeuticsMD (NASDAQ: TXMD) stocks soared by 26% or more this week. The biggest news for Axovant was that the company signed an important deal with Oxford Biomedica to license experimental gene therapy OXB-102 and its predecessor product, ProSavin. Wright was a co-founder and CTO of Spark Therapeutics , where he directed the establishment of manufacturing processes for Luxturna, a gene therapy approved by the Food and Drug Administration (FDA) in December 2017 for treating a rare genetic disorder that can lead to blindness.
|
Axovant Sciences (NASDAQ: AXON) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and TherapeuticsMD (NASDAQ: TXMD) stocks soared by 26% or more this week. Axovant Sciences: A big deal and a big hire Axovant Sciences was the biggest winner of the week with its stock skyrocketing 150%. Deciphera Pharmaceuticals: An ASCO afterglow Deciphera Pharmaceuticals stock jumped 36% higher this week.
|
Axovant Sciences (NASDAQ: AXON) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and TherapeuticsMD (NASDAQ: TXMD) stocks soared by 26% or more this week. Axovant Sciences: A big deal and a big hire Axovant Sciences was the biggest winner of the week with its stock skyrocketing 150%. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TherapeuticsMD, Inc. wasn't one of them!
|
Axovant Sciences (NASDAQ: AXON) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and TherapeuticsMD (NASDAQ: TXMD) stocks soared by 26% or more this week. Here's the scoop behind the big gains and what could be next for the companies. Axovant Sciences: A big deal and a big hire Axovant Sciences was the biggest winner of the week with its stock skyrocketing 150%.
|
be19ddd2-a94e-4efe-8469-e581a3eb9419
|
715558.0
|
2018-06-07 00:00:00 UTC
|
Here's Why Deciphera Pharmaceuticals Fell as Much as 11.9% Today
|
DCPH
|
https://www.nasdaq.com/articles/heres-why-deciphera-pharmaceuticals-fell-much-119-today-2018-06-07
|
nan
|
nan
|
What happened
Shares of early-stage biopharma Deciphera Pharmaceuticals (NASDAQ: DCPH) dropped nearly 12% today after the company announced the pricing of a share offering that was first disclosed two days ago. Surprisingly, the stock has fallen today even though the 4.3 million shares being offered will come at a price of $40 apiece -- above the current share price.
While it's unusual for a stock to slide when an offering is priced above current share prices, investors are likely contending with the fact that the offering will result in dilution, no matter the value of the shares involved. Does that properly account for a recent clinical update, though?
As of 3:28 p.m. EDT, the stock had settled to a 9.8% loss.
So what
The share offering is a wise move by management. That's because Deciphera Pharmaceuticals stock was trading near $25 per share just a few days ago. The company announced an impressive clinical update at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that lifted the company's valuation to its current healthy level. It may have been deserved.
The lead drug candidate, DCC-2618, is being evaluated in an ongoing phase 1 trial as a potential treatment for gastrointestinal stromal tumors (GIST) with a specific genetic mutation -- a common theme at this year's ASCO meeting. Deciphera Pharmaceuticals reported an overall response rate of 24% when the drug candidate was used as a second- or third-line treatment (in 25 and 29 patients, respectively) and 9% when used as a fourth-line or later treatment option (in 91 patients). That's well ahead of response rates for existing treatments, which sit at just 7% and 4.5%, respectively, for second- and third-line treatments.
Those results support the company's plan to initiate a phase 3 trial evaluating DCC-2618 as a second-line treatment option for GIST. That also supports the recent share offering, which could provide up to $197.8 million in gross proceeds.
Now what
Stock dilution is not ideal, but management is executing the share offering with exceptional timing (immediately following an impressive clinical update that lifted the stock price) and at an exceptional price (higher than the current price). The amount of the offering -- at nearly $200 million -- is also encouraging, as it could alleviate the need for frequent financing going forward. Long story short, Deciphera Pharmaceuticals may not be on many biopharma investors' radars, but it should be.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of early-stage biopharma Deciphera Pharmaceuticals (NASDAQ: DCPH) dropped nearly 12% today after the company announced the pricing of a share offering that was first disclosed two days ago. The lead drug candidate, DCC-2618, is being evaluated in an ongoing phase 1 trial as a potential treatment for gastrointestinal stromal tumors (GIST) with a specific genetic mutation -- a common theme at this year's ASCO meeting. Those results support the company's plan to initiate a phase 3 trial evaluating DCC-2618 as a second-line treatment option for GIST.
|
What happened Shares of early-stage biopharma Deciphera Pharmaceuticals (NASDAQ: DCPH) dropped nearly 12% today after the company announced the pricing of a share offering that was first disclosed two days ago. While it's unusual for a stock to slide when an offering is priced above current share prices, investors are likely contending with the fact that the offering will result in dilution, no matter the value of the shares involved. Now what Stock dilution is not ideal, but management is executing the share offering with exceptional timing (immediately following an impressive clinical update that lifted the stock price) and at an exceptional price (higher than the current price).
|
What happened Shares of early-stage biopharma Deciphera Pharmaceuticals (NASDAQ: DCPH) dropped nearly 12% today after the company announced the pricing of a share offering that was first disclosed two days ago. Surprisingly, the stock has fallen today even though the 4.3 million shares being offered will come at a price of $40 apiece -- above the current share price. While it's unusual for a stock to slide when an offering is priced above current share prices, investors are likely contending with the fact that the offering will result in dilution, no matter the value of the shares involved.
|
What happened Shares of early-stage biopharma Deciphera Pharmaceuticals (NASDAQ: DCPH) dropped nearly 12% today after the company announced the pricing of a share offering that was first disclosed two days ago. That also supports the recent share offering, which could provide up to $197.8 million in gross proceeds. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them!
|
ceac7dc4-b88c-4f5c-9bca-f9d26382152e
|
715559.0
|
2018-06-05 00:00:00 UTC
|
Company News For Jun 5, 2018
|
DCPH
|
https://www.nasdaq.com/articles/company-news-for-jun-5-2018-2018-06-05
|
nan
|
nan
|
Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25
Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker
Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy
Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Nektar Therapeutics (NKTR): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25 Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618 Want the latest recommendations from Zacks Investment Research? Click to get this free report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Click to get this free report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report To read this article on Zacks.com click here. Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25 Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618 Want the latest recommendations from Zacks Investment Research? Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25 Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618 Want the latest recommendations from Zacks Investment Research? Click to get this free report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25 Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618 Want the latest recommendations from Zacks Investment Research? Click to get this free report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days.
|
fda4f130-1d7c-4a3c-a9cd-e064a98cebc6
|
715560.0
|
2018-06-04 00:00:00 UTC
|
Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today
|
DCPH
|
https://www.nasdaq.com/articles/why-asco18-caused-blueprint-medicines-shares-tumble-16-today-2018-06-04
|
nan
|
nan
|
What happened
After clinical-stage competitor Loxo Oncology (NASDAQ: LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ: BPMC) tumbled by as much as 16% on Monday.
So what
In April, Blueprint Medicines reported solid efficacy from an early-stage study of BLU-667, a precision medicine targeting cancer in patients with RET ("rearranged during transfection") fusions.
In BLU-667's study, the preliminary overall response rates (ORR) were 50% in 14 patients with non-small cell lung cancer (NSCLC) and 40% in 25 patients with medullary thyroid cancer (MTC).
However, Loxo Oncology is also working on a RET-fusion drug, Loxo-292, and over the weekend, data was unveiled on it that investors are interpreting as better than Blueprint Medicines' BLU-667. Specifically, as of the data cutoff for the presentation, 77% of NSCLC patients and 45% of MTC patients responded to Loxo-292.
Separately, another competitor, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported a 24% ORR and 80% three-month disease control rate in combined second-line and third-line patients with gastrointestinal stromal tumors (GIST). Like Blueprint Medicines' avapritinib, Deciphera's drug, DCC-2618, targets mutations to kinase enzymes (KIT and PDDGa) that can contribute to cancer proliferation and survival.
Now what
Although you can't compare efficacy in separate trials, that's exactly what's happening today. Perhaps the biggest takeaway is that targeting RET fusions and KIT/PDDGa mutations is a successful strategy that may pay off for all of these clinical-stage companies.
The data from all these competing trials is from early-stage studies involving a relatively small number of people, so the data could change markedly for all of these companies as time passes and more people are enrolled.
Personally, I think precision medicines like those being developed by these companies represent the next big thing in how we treat cancer, so I'm inclined to buy Blueprint Medicine's shares on this drop, not sell them. This is especially true given that Blueprint Medicine plans to update industry watchers on data from its avapritinib GIST trial at the 23rd Congress of the European Hematology Association (EHA) on June 15.
10 stocks we like better than Blueprint Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Separately, another competitor, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported a 24% ORR and 80% three-month disease control rate in combined second-line and third-line patients with gastrointestinal stromal tumors (GIST). Like Blueprint Medicines' avapritinib, Deciphera's drug, DCC-2618, targets mutations to kinase enzymes (KIT and PDDGa) that can contribute to cancer proliferation and survival. This is especially true given that Blueprint Medicine plans to update industry watchers on data from its avapritinib GIST trial at the 23rd Congress of the European Hematology Association (EHA) on June 15.
|
Separately, another competitor, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported a 24% ORR and 80% three-month disease control rate in combined second-line and third-line patients with gastrointestinal stromal tumors (GIST). What happened After clinical-stage competitor Loxo Oncology (NASDAQ: LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ: BPMC) tumbled by as much as 16% on Monday. So what In April, Blueprint Medicines reported solid efficacy from an early-stage study of BLU-667, a precision medicine targeting cancer in patients with RET ("rearranged during transfection") fusions.
|
Separately, another competitor, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported a 24% ORR and 80% three-month disease control rate in combined second-line and third-line patients with gastrointestinal stromal tumors (GIST). What happened After clinical-stage competitor Loxo Oncology (NASDAQ: LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ: BPMC) tumbled by as much as 16% on Monday. So what In April, Blueprint Medicines reported solid efficacy from an early-stage study of BLU-667, a precision medicine targeting cancer in patients with RET ("rearranged during transfection") fusions.
|
Separately, another competitor, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported a 24% ORR and 80% three-month disease control rate in combined second-line and third-line patients with gastrointestinal stromal tumors (GIST). In BLU-667's study, the preliminary overall response rates (ORR) were 50% in 14 patients with non-small cell lung cancer (NSCLC) and 40% in 25 patients with medullary thyroid cancer (MTC). * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Blueprint Medicines wasn't one of them!
|
dbe30577-f1e8-4e04-b08d-f2a812cbffdf
|
715561.0
|
2017-12-22 00:00:00 UTC
|
Stocks Close Lower; Why A Logistics Firm Is Getting Attention From Amazon, Home Depot
|
DCPH
|
https://www.nasdaq.com/articles/stocks-close-lower-why-logistics-firm-getting-attention-amazon-home-depot-2017-12-22
|
nan
|
nan
|
Stock pared losses and had only minor dips at the close Friday, as Home Depot ( HD ) and Amazon.com ( AMZN ) found themselves in the middle of a potential buyout.
[ibd-display-video id=3037819 width=50 float=left autostart=true] The Dow Jones industrial average, Nasdaq and S&P 500 fell 0.1% in what was a typically quiet session ahead of a three-day weekend.
The Russell 2000 fell 0.2%. The indexes posted moderate gains of 0.3% to 0.4% for the week, but the small-cap Russell climbed more than 1% to outperform the other indexes.
All but the Russell made it five weeks up in a row as the market seemed intent on ending the year at or near new highs.
Volume fell sharply, based on early figures. That was expected because Wall Street slows down on the day before a long weekend. Markets will be closed Monday for Christmas.
The logistics industry group was Friday's best, up more than 3%. XPO Logistics ( XPO ) surged 14% after Recode.net reported that Home Depot has held talks to acquire the company . A deal would be aimed at keeping Amazon.com from buying the logistics company and its appliance-delivery services, the online publication said. Home Depot believes Amazon has been eyeing XPO.
Home Depot, a Dow component, rose modestly and remained near a new high. Amazon.com was down slightly. XPO shares are extended from a breakout past 62.94 in September. Other stocks in the group rose in sympathy.
Trucking stocks also were among the best in today's market, which is why the Dow transports outperformed with a 0.4% increase.
Biotechs also were leading as several stocks showed bullish action . AveXis ( AVXS ) edged past the 108.37 buy point of a cup without handle pattern. Deciphera Pharma ( DCPH ) surged about 8% and rose above the 21.92 buy point of a double-bottom base . But neither stock had impressive volume.
The weakest industry groups were in auto, consumer, machinery and retail although no particular sector drew more selling than others.
RELATED:
Christmas Comes A Little Early For These Biotechnology Stocks
Roche Buys Cancer Drug Maker Ignyta In A $1.7 Billion Deal
Top Large-Cap Companies: A Peek Inside IBD Big Cap 20
How To Find Outstanding Growth Stocks: Start With A Simple Routine
The Latest In Investor's Corner
Where Is The Market Headed Next Year? Read The Big Picture Each Day
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharma ( DCPH ) surged about 8% and rose above the 21.92 buy point of a double-bottom base . Stock pared losses and had only minor dips at the close Friday, as Home Depot ( HD ) and Amazon.com ( AMZN ) found themselves in the middle of a potential buyout. [ibd-display-video id=3037819 width=50 float=left autostart=true] The Dow Jones industrial average, Nasdaq and S&P 500 fell 0.1% in what was a typically quiet session ahead of a three-day weekend.
|
Deciphera Pharma ( DCPH ) surged about 8% and rose above the 21.92 buy point of a double-bottom base . XPO Logistics ( XPO ) surged 14% after Recode.net reported that Home Depot has held talks to acquire the company . Read The Big Picture Each Day The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharma ( DCPH ) surged about 8% and rose above the 21.92 buy point of a double-bottom base . Stock pared losses and had only minor dips at the close Friday, as Home Depot ( HD ) and Amazon.com ( AMZN ) found themselves in the middle of a potential buyout. XPO Logistics ( XPO ) surged 14% after Recode.net reported that Home Depot has held talks to acquire the company .
|
Deciphera Pharma ( DCPH ) surged about 8% and rose above the 21.92 buy point of a double-bottom base . The Russell 2000 fell 0.2%. The logistics industry group was Friday's best, up more than 3%.
|
f499703d-d81c-4532-9132-f0c957783a8e
|
715562.0
|
2017-10-12 00:00:00 UTC
|
Andreas Halvorsen Dives into Deciphera Pharma
|
DCPH
|
https://www.nasdaq.com/articles/andreas-halvorsen-dives-deciphera-pharma-2017-10-12
|
nan
|
nan
|
Andreas Halvorsen ( Trades , Portfolio ), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. ( DCPH ) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks .
The Massachusetts-based biopharmaceutical company launched an initial public offering of 7.5 million common stock shares at $17 per share in late September. JPMorgan Chase & Co. ( JPM ) and Piper Jaffray Cos. ( PJC ), the IPO's underwriters, exercised their option to purchase an additional 666,496 shares at $17 per share, bringing the total gross proceeds to approximately $138.83 million.
Company background
Deciphera, a clinical-stage biotech company, focuses on improving the lives of cancer patients through small drug molecules that target kinases, a family of enzymes that can potentially worsen various cancers. The company is developing drug candidate DCC-2618 for patients with gastronomical stromal tumors (GIST).
Company CEO Michael Taylor said the clinical activity from DCC-2618 "supports the planned evaluation of [the drug] in a placebo-controlled, randomized, pivotal Phase 3 trial" in GIST patients. Taylor emphasized that GIST currently does not have approved therapies and the company plans to initiate further trials in second-line and fourth-line GIST patients. Chief Medical Officer Oliver Rosen, M.D., amplified the CEO's comments by saying DCC-2618 "continues to demonstrate good tolerability and clinical activity in heavily pretreated patients with GIST."
See also
Halvorsen's investment in Deciphera represents the guru's third investment in health care companies since August. The Viking Global chief investment officer also took stakes in Abeona Therapeutics Inc. ( ABEO ) and aTyr Pharma Inc. ( LIFE ). Halvorsen currently has a 12.3% weight in health care companies.
You can view all guru trades within a sector through the Sector Picks page. Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B) CEO Warren Buffett (Trades, Portfolio) said to stay in your "circle of competence." According to the Health Care Sector Picks page, other gurus like Steven Cohen (Trades, Portfolio), Jerome Dodson (Trades, Portfolio) and Steven Romick (Trades, Portfolio) recently invested in health care companies.
Disclosure:
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Andreas Halvorsen ( Trades , Portfolio ), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. ( DCPH ) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks . Company CEO Michael Taylor said the clinical activity from DCC-2618 "supports the planned evaluation of [the drug] in a placebo-controlled, randomized, pivotal Phase 3 trial" in GIST patients. Chief Medical Officer Oliver Rosen, M.D., amplified the CEO's comments by saying DCC-2618 "continues to demonstrate good tolerability and clinical activity in heavily pretreated patients with GIST."
|
Andreas Halvorsen ( Trades , Portfolio ), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. ( DCPH ) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks . The Viking Global chief investment officer also took stakes in Abeona Therapeutics Inc. ( ABEO ) and aTyr Pharma Inc. ( LIFE ). According to the Health Care Sector Picks page, other gurus like Steven Cohen (Trades, Portfolio), Jerome Dodson (Trades, Portfolio) and Steven Romick (Trades, Portfolio) recently invested in health care companies.
|
Andreas Halvorsen ( Trades , Portfolio ), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. ( DCPH ) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks . Company background Deciphera, a clinical-stage biotech company, focuses on improving the lives of cancer patients through small drug molecules that target kinases, a family of enzymes that can potentially worsen various cancers. According to the Health Care Sector Picks page, other gurus like Steven Cohen (Trades, Portfolio), Jerome Dodson (Trades, Portfolio) and Steven Romick (Trades, Portfolio) recently invested in health care companies.
|
Andreas Halvorsen ( Trades , Portfolio ), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. ( DCPH ) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks . Company CEO Michael Taylor said the clinical activity from DCC-2618 "supports the planned evaluation of [the drug] in a placebo-controlled, randomized, pivotal Phase 3 trial" in GIST patients. According to the Health Care Sector Picks page, other gurus like Steven Cohen (Trades, Portfolio), Jerome Dodson (Trades, Portfolio) and Steven Romick (Trades, Portfolio) recently invested in health care companies.
|
5427c405-f392-444a-9102-a1934c305e10
|
715563.0
|
2023-11-13 00:00:00 UTC
|
Delcath Systems Inc. Q3 Loss Increases
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-q3-loss-increases
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its third quarter that increased from last year
The company's bottom line totaled -$20.34 million, or -$1.14 per share. This compares with -$8.88 million, or -$0.96 per share, in last year's third quarter.
The company's revenue for the quarter fell 52.7% to $0.43 million from $0.91 million last year.
Delcath Systems Inc. earnings at a glance (GAAP) :
-Earnings (Q3): -$20.34 Mln. vs. -$8.88 Mln. last year. -EPS (Q3): -$1.14 vs. -$0.96 last year. -Revenue (Q3): $0.43 Mln vs. $0.91 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its third quarter that increased from last year The company's bottom line totaled -$20.34 million, or -$1.14 per share. This compares with -$8.88 million, or -$0.96 per share, in last year's third quarter. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q3): -$20.34 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its third quarter that increased from last year The company's bottom line totaled -$20.34 million, or -$1.14 per share. The company's revenue for the quarter fell 52.7% to $0.43 million from $0.91 million last year. -Revenue (Q3): $0.43 Mln vs. $0.91 Mln last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its third quarter that increased from last year The company's bottom line totaled -$20.34 million, or -$1.14 per share. The company's revenue for the quarter fell 52.7% to $0.43 million from $0.91 million last year. -Revenue (Q3): $0.43 Mln vs. $0.91 Mln last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its third quarter that increased from last year The company's bottom line totaled -$20.34 million, or -$1.14 per share. This compares with -$8.88 million, or -$0.96 per share, in last year's third quarter. -Revenue (Q3): $0.43 Mln vs. $0.91 Mln last year.
|
e99af899-ee4a-418c-8c8a-76cd753febd1
|
715564.0
|
2023-10-18 00:00:00 UTC
|
Wednesday 10/18 Insider Buying Report: BYRN, DCTH
|
DCTH
|
https://www.nasdaq.com/articles/wednesday-10-18-insider-buying-report%3A-byrn-dcth
|
nan
|
nan
|
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At Byrna Technologies, a filing with the SEC revealed that on Monday, CEO Bryan Ganz purchased 17,000 shares of BYRN, at a cost of $3.19 each, for a total investment of $54,193. So far Ganz is in the green, up about 29.9% on their purchase based on today's trading high of $4.14. Byrna Technologies is trading off about 2.7% on the day Wednesday.
And on Friday, Chief Operating Officer John Purpura bought $49,897 worth of Delcath Systems, buying 14,505 shares at a cost of $3.44 a piece. Delcath Systems is trading up about 1% on the day Wednesday. Purpura was up about 14.0% on the buy at the high point of today's trading session, with DCTH trading as high as $3.92 at last check today.
VIDEO: Wednesday 10/18 Insider Buying Report: BYRN, DCTH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Purpura was up about 14.0% on the buy at the high point of today's trading session, with DCTH trading as high as $3.92 at last check today. VIDEO: Wednesday 10/18 Insider Buying Report: BYRN, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
|
Purpura was up about 14.0% on the buy at the high point of today's trading session, with DCTH trading as high as $3.92 at last check today. VIDEO: Wednesday 10/18 Insider Buying Report: BYRN, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And on Friday, Chief Operating Officer John Purpura bought $49,897 worth of Delcath Systems, buying 14,505 shares at a cost of $3.44 a piece.
|
Purpura was up about 14.0% on the buy at the high point of today's trading session, with DCTH trading as high as $3.92 at last check today. VIDEO: Wednesday 10/18 Insider Buying Report: BYRN, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
|
Purpura was up about 14.0% on the buy at the high point of today's trading session, with DCTH trading as high as $3.92 at last check today. VIDEO: Wednesday 10/18 Insider Buying Report: BYRN, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
|
3246554a-72bd-4557-b28b-d1a2eb39f5a8
|
715565.0
|
2023-09-14 00:00:00 UTC
|
These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say Analysts
|
DCTH
|
https://www.nasdaq.com/articles/these-2-strong-buy-penny-stocks-could-soar-to-%2417-or-higher-say-analysts
|
nan
|
nan
|
Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model.
Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid points when defending their stance. Sure, the price tag may look like a steal, but the fact that shares are trading at such low levels could reflect overwhelming headwinds or weak fundamentals.
That being said, the fans offer up a solid argument as well. Not only does the low price mean you get more shares for your money, but hefty returns are also on the table. Even seemingly insignificant share price appreciation can result in colossal percentage gains that other more well-known or expensive names aren’t as likely to deliver.
The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps?
To help with the due diligence process, we used TipRanks’ database to zero in on only the penny stocks that have received bullish support from the analyst community. We found two that are backed by enough analysts to earn a “Strong Buy” consensus rating. Not to mention each offers up massive upside potential and could climb to $17 or even higher.
AlloVir, Inc. (ALVR)
We'll start with AlloVir, a clinical-stage biopharma company working on new allogenic, virus-specific T cell therapies (VSTs) to target a range of dangerous viral diseases with high unmet medical needs. The company’s drug candidates are developed on a proprietary platform and are designed as off-the-shelf VSTs to restore patients’ immunity and act as treatments or preventative therapies.
The most advanced of AlloVir’s drug candidates has successfully completed its proof-of-concept trials and is now undergoing late-stage pivotal testing against multiple viruses. The candidate, posoleucel, targets six pathogens – adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and JC virus (JCV). Posoleucel is showing promise in its clinical trials and has the potential to radically transform the standard of care for patients undergoing organ transplants.
The company has released positive data from the Phase 2 trial of the drug in the treatment of BK disease in kidney transplant patients. This development was complemented by continuing enrollment in no fewer than three Phase 3 global registrational trials of posoleucel, for which data releases are expected in 2H24. These include the treatment of AdV infection, the treatment of vHC (virus-associated hemorrhagic cystitis), and the prevention of clinically significant infection or disease from AdV, BK, CMV, EBV, HHV-6, and JCV.
One of the company’s largest corporate shareholders, Gilead Sciences, apparently likes what it sees. The pharma giant made a large purchase, totaling ~2.93 million shares at the end of Q2. This brings Gilead’s total holding in ALVR to ~16.63 million shares, valued at more than $41 million at current prices.
With ALVR shares trading for $2.50, some analysts also think that now is the time to pull the trigger.
Among the bulls is Bank of America's Jason Zemansky who sees several reasons to back this name. The analyst writes, “Supported by solid phase 2 proof-of-concept data and given high unmet need, we think lead asset posoleucel has compelling and underappreciated upside (2030e BofA $1.5B vs. cons $1.3B) – with three ongoing pivotal studies capable of driving a near-term re-rating (data expected mid-24)... With limited downside risk at current levels in concert with a catalyst rich 18 mos that could see AlloVir transition into a commercial stage company, we see positive risk/reward for shares.”
In line with his bullish stance, Zemansky rates ALVR a Buy, and his $17 price target implies room for a stunning 577% upside potential in the next 12 months. (To watch Zemansky’s track record, click here)
While highly bullish, this is no outlier among the analyst views of AlloVir. The stock has 4 recent positive reviews, for a unanimous Strong Buy consensus rating. The stock has a $19.75 average price target, suggesting an impressive ~687% upside potential from the current share price. (See ALVR stock forecast)
Delcath Systems (DCTH)
The second penny stock we're looking at here is Delcath Systems, a biotech firm focused on interventional oncology. The company specializes in the development of minimally invasive surgical treatments designed to enhance the effectiveness of chemotherapies.
Delcath has developed two primary products, both proprietary. The first is the HEPZATO Kit, designed for melphalan hydrochloride for injection/hepatic delivery system. The second is the CHEMOSAT, a hepatic delivery system for melphalan percutaneous hepatic perfusion, or PHP. Both products are optimized to administer a high dose of chemotherapy drugs directly to the liver while also controlling the general systemic exposure and side effects that can accompany a PHP procedure.
For cutting-edge biotech companies, the 'Holy Grail' is regulatory approval or a positive step in that direction. Delcath has already achieved this feat, receiving FDA approval on August 15 for the use of the Hepzato Kit in the treatment of metastatic uveal melanoma—an eye cancer known for metastatic involvement of the liver. This regulatory approval makes Delcath's product the only FDA-approved liver-directed therapy for this cancer.
The regulatory approval caught the attention of BTIG analyst Marie Thibault, who wrote of Delcath: “We believe the company's percutaneous hepatic perfusion system offers a safe, effective treatment option for metastatic uveal melanoma (mUM). With FDA approval in hand, we view DCTH as a compelling investment that hinges on commercial execution and treatment adoption. We think the strong clinical data from the FOCUS trial can support gradual treatment adoption and believe peak annual sales in the U.S. can top $250M. In addition, DCTH has multiple indications in the pipeline that could offer a significantly larger market opportunity over the long term.”
Quantifying her bullish stance, Thibault gives the stock a Buy rating along with a $20 price target, implying a robust 328% upside potential on the one-year horizon. (To watch Thibault’s track record, click here)
Once again, we’re looking at a stock with a unanimously positive Strong Buy analyst consensus rating, based on 4 recent analyst reviews. DCTH is selling for $4.67, and its $17.75 average price target points toward a one-year gain of 285%. (See DCTH stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In addition, DCTH has multiple indications in the pipeline that could offer a significantly larger market opportunity over the long term.” Quantifying her bullish stance, Thibault gives the stock a Buy rating along with a $20 price target, implying a robust 328% upside potential on the one-year horizon. (See ALVR stock forecast) Delcath Systems (DCTH) The second penny stock we're looking at here is Delcath Systems, a biotech firm focused on interventional oncology. With FDA approval in hand, we view DCTH as a compelling investment that hinges on commercial execution and treatment adoption.
|
(See ALVR stock forecast) Delcath Systems (DCTH) The second penny stock we're looking at here is Delcath Systems, a biotech firm focused on interventional oncology. With FDA approval in hand, we view DCTH as a compelling investment that hinges on commercial execution and treatment adoption. In addition, DCTH has multiple indications in the pipeline that could offer a significantly larger market opportunity over the long term.” Quantifying her bullish stance, Thibault gives the stock a Buy rating along with a $20 price target, implying a robust 328% upside potential on the one-year horizon.
|
(See ALVR stock forecast) Delcath Systems (DCTH) The second penny stock we're looking at here is Delcath Systems, a biotech firm focused on interventional oncology. In addition, DCTH has multiple indications in the pipeline that could offer a significantly larger market opportunity over the long term.” Quantifying her bullish stance, Thibault gives the stock a Buy rating along with a $20 price target, implying a robust 328% upside potential on the one-year horizon. With FDA approval in hand, we view DCTH as a compelling investment that hinges on commercial execution and treatment adoption.
|
(See ALVR stock forecast) Delcath Systems (DCTH) The second penny stock we're looking at here is Delcath Systems, a biotech firm focused on interventional oncology. With FDA approval in hand, we view DCTH as a compelling investment that hinges on commercial execution and treatment adoption. In addition, DCTH has multiple indications in the pipeline that could offer a significantly larger market opportunity over the long term.” Quantifying her bullish stance, Thibault gives the stock a Buy rating along with a $20 price target, implying a robust 328% upside potential on the one-year horizon.
|
fa0261c2-ef9a-4fc2-852f-11e890dbbb7c
|
715566.0
|
2023-09-13 00:00:00 UTC
|
Delcath Systems To Participate At The H.C. Wainwright Investor Conference; Webcast At 11:00 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-to-participate-at-the-h.c.-wainwright-investor-conference-webcast-at-11%3A00
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will present at the H.C Wainwright 25th Annual Global Investor Conference.
The event is scheduled to begin at 11:00 AM ET on Sept. 13, 2023.
To access the live webcast, log on to https://delcath.com/investors/events-presentations/
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will present at the H.C Wainwright 25th Annual Global Investor Conference. The event is scheduled to begin at 11:00 AM ET on Sept. 13, 2023. To access the live webcast, log on to https://delcath.com/investors/events-presentations/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will present at the H.C Wainwright 25th Annual Global Investor Conference. The event is scheduled to begin at 11:00 AM ET on Sept. 13, 2023. To access the live webcast, log on to https://delcath.com/investors/events-presentations/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will present at the H.C Wainwright 25th Annual Global Investor Conference. The event is scheduled to begin at 11:00 AM ET on Sept. 13, 2023. To access the live webcast, log on to https://delcath.com/investors/events-presentations/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will present at the H.C Wainwright 25th Annual Global Investor Conference. The event is scheduled to begin at 11:00 AM ET on Sept. 13, 2023. To access the live webcast, log on to https://delcath.com/investors/events-presentations/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
b5f4d9d5-4378-4e23-a566-143cbc03bcfc
|
715567.0
|
2023-09-07 00:00:00 UTC
|
Canaccord Genuity Maintains Delcath Systems (DCTH) Buy Recommendation
|
DCTH
|
https://www.nasdaq.com/articles/canaccord-genuity-maintains-delcath-systems-dcth-buy-recommendation-0
|
nan
|
nan
|
Fintel reports that on September 7, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 294.14% Upside
As of August 31, 2023, the average one-year price target for Delcath Systems is 18.56. The forecasts range from a low of 13.13 to a high of $23.10. The average price target represents an increase of 294.14% from its latest reported closing price of 4.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 368.83%. The projected annual non-GAAP EPS is -2.13.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 50 funds or institutions reporting positions in Delcath Systems. This is an increase of 11 owner(s) or 28.21% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. Total shares owned by institutions increased in the last three months by 293.57% to 5,227K shares.
The put/call ratio of DCTH is 0.78, indicating a bullish outlook.
What are Other Shareholders Doing?
Vivo Capital holds 1,179K shares representing 7.72% ownership of the company.
Bvf holds 1,179K shares representing 7.72% ownership of the company.
Logos Global Management holds 1,179K shares representing 7.72% ownership of the company.
Stonepine Capital Management holds 379K shares representing 2.48% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 1.67% ownership of the company. No change in the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainti
JOINT FILING AGREEMENT
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on September 7, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.78, indicating a bullish outlook.
|
Fintel reports that on September 7, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.78, indicating a bullish outlook.
|
Fintel reports that on September 7, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.78, indicating a bullish outlook.
|
Fintel reports that on September 7, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.78, indicating a bullish outlook.
|
1101c736-84f9-4364-91df-4771f21a78bd
|
715568.0
|
2023-08-31 00:00:00 UTC
|
Delcath Systems (DCTH) Price Target Increased by 10.98% to 18.56
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-dcth-price-target-increased-by-10.98-to-18.56
|
nan
|
nan
|
The average one-year price target for Delcath Systems (NASDAQ:DCTH) has been revised to 18.56 / share. This is an increase of 10.98% from the prior estimate of 16.73 dated August 1, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 13.13 to a high of 23.10 / share. The average price target represents an increase of 285.95% from the latest reported closing price of 4.81 / share.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 50 funds or institutions reporting positions in Delcath Systems. This is an increase of 11 owner(s) or 28.21% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. Total shares owned by institutions increased in the last three months by 293.57% to 5,227K shares.
The put/call ratio of DCTH is 0.82, indicating a bullish outlook.
What are Other Shareholders Doing?
Vivo Capital holds 1,179K shares representing 7.72% ownership of the company.
Bvf holds 1,179K shares representing 7.72% ownership of the company.
Logos Global Management holds 1,179K shares representing 7.72% ownership of the company.
Stonepine Capital Management holds 379K shares representing 2.48% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 1.67% ownership of the company. No change in the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
JOINT FILING AGREEMENT
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to ce
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The average one-year price target for Delcath Systems (NASDAQ:DCTH) has been revised to 18.56 / share. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.82, indicating a bullish outlook.
|
The average one-year price target for Delcath Systems (NASDAQ:DCTH) has been revised to 18.56 / share. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.82, indicating a bullish outlook.
|
The average one-year price target for Delcath Systems (NASDAQ:DCTH) has been revised to 18.56 / share. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.82, indicating a bullish outlook.
|
The average one-year price target for Delcath Systems (NASDAQ:DCTH) has been revised to 18.56 / share. Average portfolio weight of all funds dedicated to DCTH is 0.47%, an increase of 1,475.57%. The put/call ratio of DCTH is 0.82, indicating a bullish outlook.
|
93b9f899-9def-4f8a-b366-4563e5c6c7ab
|
715569.0
|
2023-08-16 00:00:00 UTC
|
Roth MKM Maintains Delcath Systems (DCTH) Buy Recommendation
|
DCTH
|
https://www.nasdaq.com/articles/roth-mkm-maintains-delcath-systems-dcth-buy-recommendation
|
nan
|
nan
|
Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 195.03% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 195.03% from its latest reported closing price of 5.67.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 368.83%. The projected annual non-GAAP EPS is -2.13.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Delcath Systems. This is an increase of 7 owner(s) or 17.95% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. Total shares owned by institutions increased in the last three months by 156.93% to 3,412K shares.
The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,179K shares representing 7.72% ownership of the company.
Logos Global Management holds 1,179K shares representing 7.72% ownership of the company.
Stonepine Capital Management holds 379K shares representing 2.48% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 1.67% ownership of the company. No change in the last quarter.
Kent Lake Capital holds 219K shares representing 1.44% ownership of the company. No change in the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to ce
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
|
Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
|
Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
|
Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
|
4b095bbc-bdd8-4db1-b09b-2afdcb53e2ed
|
715570.0
|
2023-08-15 00:00:00 UTC
|
HC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy Recommendation
|
DCTH
|
https://www.nasdaq.com/articles/hc-wainwright-co.-maintains-delcath-systems-dcth-buy-recommendation
|
nan
|
nan
|
Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 436.15% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 368.83%. The projected annual non-GAAP EPS is -2.13.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Delcath Systems. This is an increase of 5 owner(s) or 12.20% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. Total shares owned by institutions increased in the last three months by 44.63% to 1,402K shares.
The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,179K shares representing 11.10% ownership of the company.
Logos Global Management holds 1,179K shares representing 11.10% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 2.40% ownership of the company. No change in the last quarter.
Kent Lake Capital holds 219K shares representing 2.07% ownership of the company. No change in the last quarter.
CIBC World Markets holds 125K shares representing 1.17% ownership of the company. In it's prior filing, the firm reported owning 103K shares, representing an increase of 17.55%. The firm increased its portfolio allocation in DCTH by 16.21% over the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to ce
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Joint Filing Agreement
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
The firm increased its portfolio allocation in DCTH by 16.21% over the last quarter. Fintel reports that on August 15, 2023, HC Wainwright & Co. maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%.
|
cd611f0e-7ec3-477a-81ee-103e41677e47
|
715571.0
|
2023-08-15 00:00:00 UTC
|
Canaccord Genuity Maintains Delcath Systems (DCTH) Buy Recommendation
|
DCTH
|
https://www.nasdaq.com/articles/canaccord-genuity-maintains-delcath-systems-dcth-buy-recommendation
|
nan
|
nan
|
Fintel reports that on August 15, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 436.15% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 436.15% from its latest reported closing price of 3.12.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 368.83%. The projected annual non-GAAP EPS is -2.13.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Delcath Systems. This is an increase of 5 owner(s) or 12.20% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. Total shares owned by institutions increased in the last three months by 44.63% to 1,402K shares.
The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,179K shares representing 11.10% ownership of the company.
Logos Global Management holds 1,179K shares representing 11.10% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 2.40% ownership of the company. No change in the last quarter.
Kent Lake Capital holds 219K shares representing 2.07% ownership of the company. No change in the last quarter.
CIBC World Markets holds 125K shares representing 1.17% ownership of the company. In it's prior filing, the firm reported owning 103K shares, representing an increase of 17.55%. The firm increased its portfolio allocation in DCTH by 16.21% over the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to ce
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Joint Filing Agreement
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on August 15, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
Fintel reports that on August 15, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
Fintel reports that on August 15, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%. The put/call ratio of DCTH is 0.40, indicating a bullish outlook.
|
The firm increased its portfolio allocation in DCTH by 16.21% over the last quarter. Fintel reports that on August 15, 2023, Canaccord Genuity maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 262.05%.
|
1141092b-0312-42ca-a3a4-a1794aa89012
|
715572.0
|
2023-08-15 00:00:00 UTC
|
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints
|
DCTH
|
https://www.nasdaq.com/articles/stock-index-futures-plunge-on-pressure-from-rising-bond-yields-china-data-disappoints
|
nan
|
nan
|
September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data.
In Monday’s trading session, Wall Street’s major averages closed higher. NVIDIA Corporation (NVDA) climbed over +7% and was the top percentage gainer on the tech-heavy Nasdaq 100 after Morgan Stanley said the recent decline in the stock is a “good entry point” ahead of its Q2 results next week. Also, United States Steel Corporation (X) surged more than +36% after the company rejected a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs and said it would initiate a formal review of its strategic options. In addition, Monday.Com Ltd (MNDY) rose over +8% after reporting upbeat Q2 results and raising its full-year revenue guidance. On the bearish side, Tesla Inc (TSLA) dropped more than -1% after the automaker said it had cut prices in China for Model Y Long Range and Performance versions. Regional bank stocks also retreated, with KeyCorp (KEY) plunging over -4% and Comerica Inc (CMA) falling more than -3%.
“It’s the first day in a while that tech has really significantly outperformed. I think that’s indicative of the fact that you have this blockbuster Nvidia report coming up, and that could support the tech market pretty substantially,” said Jay Hatfield, CEO of Infrastructure Capital Advisors.
Meanwhile, U.S. rate futures have priced in an 88.5% probability of no hike and an 11.5% chance of a 25 basis point rate increase at September’s monetary policy meeting.
On the earnings front, major companies like Home Depot (HD), Suncor Energy (SU), Alcon (ALC), and Agilent Technologies (A) are slated to release their quarterly results today.
Today, all eyes are focused on U.S. Retail Sales data in a couple of hours. Economists, on average, forecast that July Retail Sales will stand at +0.4% m/m, compared to the previous value of +0.2% m/m.
Also, investors will likely focus on U.S. Core Retail Sales data, which came in at +0.2% m/m in June. Economists foresee the new figure to be -0.3% m/m.
U.S. Export and Import Price Indexes for July will also be in focus today. Economists anticipate Export Price Index to be at +0.2% m/m and Import Price Index to stand at +0.2% m/m.
U.S. NY Empire State Manufacturing Index will be reported today as well. Economists foresee this figure to stand at -1.00 in August, compared to the previous number of +1.10.
In the bond markets, United States 10-Year rates are at 4.228%, up +1.02%.
The Euro Stoxx 50 futures are down -0.78% this morning as apprehensions about inflation have led to speculation that interest rates will remain elevated for an extended period. Bond yields surged across Europe, with U.K. gilts experiencing a notable spike after a record-high wage growth spurred worries about inflationary pressures. Real estate and insurance stocks underperformed on Tuesday, while retail stocks gained ground. In corporate news, Marks and Spencer Group Plc (MKS.LN) soared over +6% after the retailer lifted its profit forecast.
U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today.
U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%.
U.K. July Claimant Count Change stood at +29.0K, weaker than expectations of -7.3K.
U.K. June Employment Change 3M/3M came in at -66K, weaker than expectations of +75K.
U.K. June Unemployment Rate was at 4.2%, weaker than expectations of 4.0%.
The German August ZEW Economic Sentiment stood at -12.3, stronger than expectations of -14.7.
Eurozone August ZEW Economic Sentiment arrived at -5.5, stronger than expectations of -12.0.
Asian stock markets today closed mixed. China’s Shanghai Composite Index (SHCOMP) closed down -0.07%, and Japan’s Nikkei 225 Stock Index (NIK) closed up +0.56%.
China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. Data released by the National Bureau of Statistics showed on Tuesday that China’s industrial production and retail sales growth decelerated and fell short of expectations in July. The People’s Bank of China lowered the rate on 401 billion yuan worth of one-year medium-term lending facility loans to some financial institutions by 15 basis points to 2.50%. Also, the central bank conducted a 204 billion yuan injection through seven-day reverse repos while cutting borrowing costs by 10 basis points to 1.80%. Meanwhile, the yuan declined to the weakest level since November, and China’s government bonds experienced a rally following the central bank’s decision to lower interest rates.
“The weak dataset continues to paint a bearish picture of China after the Politburo meeting. Most investors are in wait-and-see mode, only willing to allocate tactically to China on expectations of stimulus,” said UBS analysts in a note.
The Chinese July Industrial Production stood at +3.7% y/y, weaker than expectations of +4.4% y/y.
The Chinese July Retail Sales came in at +2.5% y/y, weaker than expectations of +4.5% y/y.
The Chinese July Fixed Asset Investment arrived at +3.4% y/y, weaker than expectations of +3.8% y/y.
The Chinese July Unemployment Rate was at 5.3%, in line with expectations.
At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data. According to government data released on Tuesday, Japan’s economy expanded for a third consecutive quarter in April-June, as robust exports countered the impact of a decelerating post-COVID recovery in consumption. In corporate news, Japan Post Holdings climbed over +4% after the conglomerate of banks and insurance businesses revealed plans to repurchase up to 8.4% of its own shares, totaling 300 billion yen. At the same time, Dentsu Group plunged more than -7% after the advertising firm slashed its full-year net profit guidance. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed down -4.31% to 18.85.
The Japanese GDP has been reported at +1.5% q/q and +6.0% y/y in the second quarter, stronger than expectations of +0.8% q/q and +3.1% y/y.
The Japanese June Industrial Production came in at +2.4% m/m, stronger than expectations of +2.0% m/m.
Pre-Market U.S. Stock Movers
DR Horton Inc (DHI) and Lennar Corporation (LEN) climbed about +2% in pre-market trading after Warren Buffett’s Berkshire Hathaway revealed new positions in the stocks.
LL Flooring Holdings Inc (LL) surged over +12% in pre-market trading after the company announced that it had planned to explore strategic alternatives, including a potential sale of the company.
Arena Group Holdings Inc (AREN) soared about +18% in pre-market trading after the company signed a binding letter of intent with Simplify Inventions, LLC and its founder, Manoj Bhargava, to acquire certain assets of its subsidiary Bridge Media Networks.
Getty Images Holdings Inc (GETY) tumbled more than -18% in pre-market trading after the company reported downbeat Q2 results and cut its FY23 revenue guidance.
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma.
Caredx Inc (CDNA) rose over +5% in pre-market trading after Raymond James upgraded the stock to Outperform from Market Perform.
You can see more pre-market stock movers here
Today’s U.S. Earnings Spotlight: Tuesday - August 15th
Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR).
More Stock Market News from Barchart
Strength in Chip Stocks Lifts the Overall MarketGeneral Mills vs. Kraft Heinz: Which is the Better Consumer Defensive Stock?Should You Buy the Dip in Apple Stock?Why Is Warren Buffett Selling U.S. Stocks?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Tuesday - August 15th Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR).
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity.
|
5d31daf7-6a6d-4378-801b-e1361277b51d
|
715573.0
|
2023-08-15 00:00:00 UTC
|
Stock Index Futures Slip on Pressure from Rising Bond Yields, China Data Disappoints
|
DCTH
|
https://www.nasdaq.com/articles/stock-index-futures-slip-on-pressure-from-rising-bond-yields-china-data-disappoints
|
nan
|
nan
|
September S&P 500 futures (ESU23) are down -0.37%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.31% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data.
In Monday’s trading session, Wall Street’s major averages closed higher. NVIDIA Corporation (NVDA) climbed over +7% and was the top percentage gainer on the tech-heavy Nasdaq 100 after Morgan Stanley said the recent decline in the stock is a “good entry point” ahead of its Q2 results next week. Also, United States Steel Corporation (X) surged more than +36% after the company rejected a $7.25 billion cash and stock takeover offer from Cleveland-Cliffs and said it would initiate a formal review of its strategic options. In addition, Monday.Com Ltd (MNDY) rose over +8% after reporting upbeat Q2 results and raising its full-year revenue guidance. On the bearish side, Tesla Inc (TSLA) dropped more than -1% after the automaker said it had cut prices in China for Model Y Long Range and Performance versions. Regional bank stocks also retreated, with KeyCorp (KEY) plunging over -4% and Comerica Inc (CMA) falling more than -3%.
“It’s the first day in a while that tech has really significantly outperformed. I think that’s indicative of the fact that you have this blockbuster Nvidia report coming up, and that could support the tech market pretty substantially,” said Jay Hatfield, CEO of Infrastructure Capital Advisors.
Meanwhile, U.S. rate futures have priced in an 88.5% probability of no hike and an 11.5% chance of a 25 basis point rate increase at September’s monetary policy meeting.
On the earnings front, major companies like Home Depot (HD), Suncor Energy (SU), Alcon (ALC), and Agilent Technologies (A) are slated to release their quarterly results today.
Today, all eyes are focused on U.S. Retail Sales data in a couple of hours. Economists, on average, forecast that July Retail Sales will stand at +0.4% m/m, compared to the previous value of +0.2% m/m.
Also, investors will likely focus on U.S. Core Retail Sales data, which came in at +0.2% m/m in June. Economists foresee the new figure to be -0.3% m/m.
U.S. Export and Import Price Indexes for July will also be in focus today. Economists anticipate Export Price Index to be at +0.2% m/m and Import Price Index to stand at +0.2% m/m.
U.S. NY Empire State Manufacturing Index will be reported today as well. Economists foresee this figure to stand at -1.00 in August, compared to the previous number of +1.10.
In the bond markets, United States 10-Year rates are at 4.228%, up +1.02%.
The Euro Stoxx 50 futures are down -0.78% this morning as apprehensions about inflation have led to speculation that interest rates will remain elevated for an extended period. Bond yields surged across Europe, with U.K. gilts experiencing a notable spike after a record-high wage growth spurred worries about inflationary pressures. Real estate and insurance stocks underperformed on Tuesday, while retail stocks gained ground. In corporate news, Marks and Spencer Group Plc (MKS.LN) soared over +6% after the retailer lifted its profit forecast.
U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today.
U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%.
U.K. July Claimant Count Change stood at +29.0K, weaker than expectations of -7.3K.
U.K. June Employment Change 3M/3M came in at -66K, weaker than expectations of +75K.
U.K. June Unemployment Rate was at 4.2%, weaker than expectations of 4.0%.
The German August ZEW Economic Sentiment stood at -12.3, stronger than expectations of -14.7.
Eurozone August ZEW Economic Sentiment arrived at -5.5, stronger than expectations of -12.0.
Asian stock markets today closed mixed. China’s Shanghai Composite Index (SHCOMP) closed down -0.07%, and Japan’s Nikkei 225 Stock Index (NIK) closed up +0.56%.
China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. Data released by the National Bureau of Statistics showed on Tuesday that China’s industrial production and retail sales growth decelerated and fell short of expectations in July. The People’s Bank of China lowered the rate on 401 billion yuan worth of one-year medium-term lending facility loans to some financial institutions by 15 basis points to 2.50%. Also, the central bank conducted a 204 billion yuan injection through seven-day reverse repos while cutting borrowing costs by 10 basis points to 1.80%. Meanwhile, the yuan declined to the weakest level since November, and China’s government bonds experienced a rally following the central bank’s decision to lower interest rates.
“The weak dataset continues to paint a bearish picture of China after the Politburo meeting. Most investors are in wait-and-see mode, only willing to allocate tactically to China on expectations of stimulus,” said UBS analysts in a note.
The Chinese July Industrial Production stood at +3.7% y/y, weaker than expectations of +4.4% y/y.
The Chinese July Retail Sales came in at +2.5% y/y, weaker than expectations of +4.5% y/y.
The Chinese July Fixed Asset Investment arrived at +3.4% y/y, weaker than expectations of +3.8% y/y.
The Chinese July Unemployment Rate was at 5.3%, in line with expectations.
At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data. According to government data released on Tuesday, Japan’s economy expanded for a third consecutive quarter in April-June, as robust exports countered the impact of a decelerating post-COVID recovery in consumption. In corporate news, Japan Post Holdings climbed over +4% after the conglomerate of banks and insurance businesses revealed plans to repurchase up to 8.4% of its own shares, totaling 300 billion yen. At the same time, Dentsu Group plunged more than -7% after the advertising firm slashed its full-year net profit guidance. The Nikkei Volatility, which takes into account the implied volatility of Nikkei 225 options, closed down -4.31% to 18.85.
The Japanese GDP has been reported at +1.5% q/q and +6.0% y/y in the second quarter, stronger than expectations of +0.8% q/q and +3.1% y/y.
The Japanese June Industrial Production came in at +2.4% m/m, stronger than expectations of +2.0% m/m.
Pre-Market U.S. Stock Movers
DR Horton Inc (DHI) and Lennar Corporation (LEN) climbed about +2% in pre-market trading after Warren Buffett’s Berkshire Hathaway revealed new positions in the stocks.
LL Flooring Holdings Inc (LL) surged over +12% in pre-market trading after announcing that it planned to explore strategic alternatives, including a potential sale of the company.
Arena Group Holdings Inc (AREN) soared about +18% in pre-market trading after the company signed a binding letter of intent with Simplify Inventions, LLC and its founder, Manoj Bhargava, to acquire certain assets of its subsidiary Bridge Media Networks.
Getty Images Holdings Inc (GETY) tumbled more than -18% in pre-market trading after the company reported downbeat Q2 results.
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma.
Caredx Inc (CDNA) rose over +5% in pre-market trading after Raymond James upgraded the stock to Outperform from Market Perform.
You can see more pre-market stock movers here
Today’s U.S. Earnings Spotlight: Tuesday - August 15th
Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR).
More Stock Market News from Barchart
Strength in Chip Stocks Lifts the Overall MarketGeneral Mills vs. Kraft Heinz: Which is the Better Consumer Defensive Stock?Should You Buy the Dip in Apple Stock?Why Is Warren Buffett Selling U.S. Stocks?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. U.K.’s Average Earnings Index +Bonus, U.K.’s Claimant Count Change, U.K.’s Employment Change 3M/3M, U.K.’s Unemployment Rate, Germany’s ZEW Economic Sentiment, and Eurozone’s ZEW Economic Sentiment data were released today. At the same time, Japan’s Nikkei 225 Stock Index closed higher today, tracking Wall Street’s firm overnight finish, and market sentiment was additionally lifted by stronger-than-expected economic growth data.
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. September S&P 500 futures (ESU23) are down -0.37%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.31% this morning as market participants digested the latest U.K. employment data, which fueled concerns about inflationary pressures and consequently pushed U.S. Treasury yields higher, while disappointing economic data from China also weighed on sentiment ahead of crucial U.S. retail sales data. You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Tuesday - August 15th Home Depot (HD), Suncor Energy (SU), Alcon (ALC), Agilent Technologies (A), Nu Holdings (NU), Sea (SE), Cardinal Health (CAH), Legend Bio (LEGN), Jack Henry&Associates (JKHY), Tencent Music Entertainment Group (TME), Coherent (COHR), CAVA Group (CAVA), H&R Block (HRB), Dlocal (DLO), IHS Holding (IHS), Mercury (MRCY), Stride (LRN), Dada Nexus (DADA), Riskified (RSKD), HUYA (HUYA), Eagle Point Cred (ECC), Mondee Holdings (MOND), International General Insurance (IGIC), GigaCloud Technology (GCT), Terran Orbital (LLAP), Rekor Systems (REKR).
|
Delcath Systems Inc (DCTH) spiked about +66% in pre-market trading after announcing that the U.S. Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma. U.K. June Average Earnings Index +Bonus has been reported at 8.2%, stronger than expectations of 7.3%. China’s Shanghai Composite today closed lower even after the central bank unexpectedly cut a key interest rate to bolster growth, following the latest data indicating a further slowdown in the country’s economic activity.
|
0702bad2-b4cb-4004-bfa9-ecc0691a3573
|
715574.0
|
2023-08-14 00:00:00 UTC
|
Delcath Systems : FDA Approves HEPZATO KIT To Treat Metastatic Uveal Melanoma In Adults
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-%3A-fda-approves-hepzato-kit-to-treat-metastatic-uveal-melanoma-in-adults
|
nan
|
nan
|
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation, Delcath Systems Inc. (DCTH) said in a statement on Monday.
Metastatic uveal melanoma is a rare and aggressive form of metastatic cancer.
The company plans to have commercial product available in the fourth quarter, and patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation, Delcath Systems Inc. (DCTH) said in a statement on Monday. The company plans to have commercial product available in the fourth quarter, and patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites. For More Such Health News, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation, Delcath Systems Inc. (DCTH) said in a statement on Monday. Metastatic uveal melanoma is a rare and aggressive form of metastatic cancer. For More Such Health News, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation, Delcath Systems Inc. (DCTH) said in a statement on Monday. The company plans to have commercial product available in the fourth quarter, and patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites. For More Such Health News, visit rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation, Delcath Systems Inc. (DCTH) said in a statement on Monday. Metastatic uveal melanoma is a rare and aggressive form of metastatic cancer. The company plans to have commercial product available in the fourth quarter, and patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites.
|
bc1fa85d-457f-47f3-bbaf-a3d73f0290b5
|
715575.0
|
2023-08-09 00:00:00 UTC
|
Delcath Systems Inc. Q2 Loss Declines
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-q2-loss-declines
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for second quarter that decreased from last year
The company's earnings totaled -$7.20 million, or -$0.58 per share. This compares with -$10.16 million, or -$1.24 per share, in last year's second quarter.
The company's revenue for the quarter fell 37.5% to $0.50 million from $0.80 million last year.
Delcath Systems Inc. earnings at a glance (GAAP) :
-Earnings (Q2): -$7.20 Mln. vs. -$10.16 Mln. last year. -EPS (Q2): -$0.58 vs. -$1.24 last year. -Revenue (Q2): $0.50 Mln vs. $0.80 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for second quarter that decreased from last year The company's earnings totaled -$7.20 million, or -$0.58 per share. This compares with -$10.16 million, or -$1.24 per share, in last year's second quarter. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q2): -$7.20 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for second quarter that decreased from last year The company's earnings totaled -$7.20 million, or -$0.58 per share. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q2): -$7.20 Mln. -Revenue (Q2): $0.50 Mln vs. $0.80 Mln last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for second quarter that decreased from last year The company's earnings totaled -$7.20 million, or -$0.58 per share. The company's revenue for the quarter fell 37.5% to $0.50 million from $0.80 million last year. -Revenue (Q2): $0.50 Mln vs. $0.80 Mln last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for second quarter that decreased from last year The company's earnings totaled -$7.20 million, or -$0.58 per share. This compares with -$10.16 million, or -$1.24 per share, in last year's second quarter. -Revenue (Q2): $0.50 Mln vs. $0.80 Mln last year.
|
2979a69b-a300-493e-a94d-665fa4f2d865
|
715576.0
|
2023-08-02 00:00:00 UTC
|
Inari Medical, Inc. (NARI) Tops Q2 Earnings and Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/inari-medical-inc.-nari-tops-q2-earnings-and-revenue-estimates
|
nan
|
nan
|
Inari Medical, Inc. (NARI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 128.57%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.04, delivering a surprise of 82.61%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Inari Medical, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $119.01 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.34%. This compares to year-ago revenues of $92.74 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Inari Medical, Inc. Shares have lost about 11% since the beginning of the year versus the S&P 500's gain of 19.2%.
What's Next for Inari Medical, Inc.
While Inari Medical, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Inari Medical, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.10 on $120.97 million in revenues for the coming quarter and -$0.27 on $483.81 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended June 2023.
This company is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of +43.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.73 million, down 9.4% from the year-ago quarter.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended June 2023. Click to get this free report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended June 2023. Inari Medical, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $119.01 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.34%.
|
Click to get this free report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended June 2023. Inari Medical, Inc. (NARI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended June 2023. Click to get this free report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Inari Medical, Inc. (NARI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share.
|
b0585870-0219-4487-9f08-09ba236437ee
|
715577.0
|
2023-07-20 00:00:00 UTC
|
Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/intuitive-surgical-inc.-isrg-tops-q2-earnings-and-revenue-estimates
|
nan
|
nan
|
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 7.58%. A quarter ago, it was expected that this company would post earnings of $1.19 per share when it actually produced earnings of $1.23, delivering a surprise of 3.36%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Intuitive Surgical, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.76 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $1.52 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Intuitive Surgical, Inc. Shares have added about 31.8% since the beginning of the year versus the S&P 500's gain of 18.9%.
What's Next for Intuitive Surgical, Inc.
While Intuitive Surgical, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Intuitive Surgical, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.40 on $1.77 billion in revenues for the coming quarter and $5.47 on $7.12 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended June 2023.
This company is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of +43.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.73 million, down 9.4% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended June 2023. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended June 2023. Intuitive Surgical, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.76 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 1.35%.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended June 2023. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.32 per share.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended June 2023. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.32 per share.
|
e2ba5577-6711-4ab3-b8b2-02a08a586b78
|
715578.0
|
2023-05-24 00:00:00 UTC
|
HC Wainwright & Co. Reiterates Delcath Systems (DCTH) Buy Recommendation
|
DCTH
|
https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-delcath-systems-dcth-buy-recommendation
|
nan
|
nan
|
Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 133.63% Upside
As of May 11, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 133.63% from its latest reported closing price of 7.16.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 320.80%. The projected annual non-GAAP EPS is -2.13.
For more in-depth coverage of Delcath Systems, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 39 funds or institutions reporting positions in Delcath Systems. This is an increase of 1 owner(s) or 2.63% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.03%, an increase of 26.41%. Total shares owned by institutions increased in the last three months by 46.98% to 1,328K shares.
The put/call ratio of DCTH is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Ikarian Capital holds 361K shares representing 3.40% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 2.40% ownership of the company. No change in the last quarter.
Kent Lake Capital holds 219K shares representing 2.07% ownership of the company. No change in the last quarter.
CIBC World Markets holds 103K shares representing 0.97% ownership of the company. In it's prior filing, the firm reported owning 80K shares, representing an increase of 22.66%. The firm increased its portfolio allocation in DCTH by 96.91% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 93K shares representing 0.87% ownership of the company. In it's prior filing, the firm reported owning 92K shares, representing an increase of 0.18%. The firm increased its portfolio allocation in DCTH by 8.61% over the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Key filings for this company:
UNITED STATES SECURITIES AND EXCHA N GE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 ☐ Transition report pursuant to Sec
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.03%, an increase of 26.41%. The put/call ratio of DCTH is 0.02, indicating a bullish outlook.
|
Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.03%, an increase of 26.41%. The put/call ratio of DCTH is 0.02, indicating a bullish outlook.
|
Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCTH is 0.03%, an increase of 26.41%. The put/call ratio of DCTH is 0.02, indicating a bullish outlook.
|
The firm increased its portfolio allocation in DCTH by 96.91% over the last quarter. The firm increased its portfolio allocation in DCTH by 8.61% over the last quarter. Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
|
c56fe674-5e61-4f53-ab50-ffe60dbd8944
|
715579.0
|
2023-05-11 00:00:00 UTC
|
Pre-Market Earnings Report for May 12, 2023 : CPG, SPB, HUMA, SHCO, AIRS, ADAP, AUGX, CAAS, DCTH, ACXP, RGF, LGVN
|
DCTH
|
https://www.nasdaq.com/articles/pre-market-earnings-report-for-may-12-2023-%3A-cpg-spb-huma-shco-airs-adap-augx-caas-dcth
|
nan
|
nan
|
The following companies are expected to report earnings prior to market open on 05/12/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Crescent Point Energy Corporation (CPG)is reporting for the quarter ending March 31, 2023. The oil company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.27. This value represents a 15.63% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CPG is 6.03 vs. an industry ratio of 10.90.
Spectrum Brands Holdings, Inc. (SPB)is reporting for the quarter ending March 31, 2023. The consumer company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.23. This value represents a 156.10% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SPB is 53.01 vs. an industry ratio of 12.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Humacyte, Inc. (HUMA)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.22. This value represents a no change for the same quarter last year. The "days to cover" for this stock exceeds 45 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for HUMA is -5.23 vs. an industry ratio of -3.90.
Soho House & Co Inc. (SHCO)is reporting for the quarter ending March 31, 2023. The internet software company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.18. This value represents a 40.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SHCO is -15.78 vs. an industry ratio of -58.10, implying that they will have a higher earnings growth than their competitors in the same industry.
AirSculpt Technologies, Inc. (AIRS)is reporting for the quarter ending March 31, 2023. The technology services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.05. This value represents a 0.00% decrease compared to the same quarter last year. The "days to cover" for this stock exceeds 18 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AIRS is -50.40 vs. an industry ratio of -22.40.
Adaptimmune Therapeutics plc (ADAP)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.19. This value represents a 40.63% increase compared to the same quarter last year. ADAP missed the consensus earnings per share in the 1st calendar quarter of 2022 by -23.08%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ADAP is -2.22 vs. an industry ratio of -3.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Augmedix, Inc. (AUGX)is reporting for the quarter ending March 31, 2023. The medical information systems company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.15. This value represents a 6.25% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for AUGX is -7.31 vs. an industry ratio of 5.80.
China Automotive Systems, Inc. (CAAS)is reporting for the quarter ending March 31, 2023. The auto (truck) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.12. This value represents a 0.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CAAS is 9.65 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending March 31, 2023. The medical instruments company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.56. This value represents a 44.00% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 25 days.The days to cover, as reported in the 4/28/2023 short interest update, increased 280.31% from previous report on 4/14/2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is -3.82 vs. an industry ratio of -9.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Acurx Pharmaceuticals, Inc. (ACXP)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.34. This value represents a 30.77% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACXP is -3.02 vs. an industry ratio of -3.90, implying that they will have a higher earnings growth than their competitors in the same industry.
The Real Good Food Company, Inc. (RGF)is reporting for the quarter ending March 31, 2023. The food company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.24. This value represents a 242.86% decrease compared to the same quarter last year. RGF missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -168.42%. The days to cover, as reported in the 4/28/2023 short interest update, increased 155.47% from previous report on 4/14/2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for RGF is -8.58 vs. an industry ratio of 51.60.
Longeveron Inc. (LGVN)is reporting for the quarter ending March 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.19. This value represents a 11.76% decrease compared to the same quarter last year. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LGVN is -4.61 vs. an industry ratio of -3.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is -3.82 vs. an industry ratio of -9.80, implying that they will have a higher earnings growth than their competitors in the same industry. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.22.
|
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is -3.82 vs. an industry ratio of -9.80, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SPB is 53.01 vs. an industry ratio of 12.20, implying that they will have a higher earnings growth than their competitors in the same industry.
|
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is -3.82 vs. an industry ratio of -9.80, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for SHCO is -15.78 vs. an industry ratio of -58.10, implying that they will have a higher earnings growth than their competitors in the same industry.
|
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is -3.82 vs. an industry ratio of -9.80, implying that they will have a higher earnings growth than their competitors in the same industry. ADAP missed the consensus earnings per share in the 1st calendar quarter of 2022 by -23.08%.
|
1cbd4926-711e-43ff-89a4-308e9d7f4064
|
715580.0
|
2023-05-11 00:00:00 UTC
|
Dynatronics Corporation (DYNT) Reports Q3 Loss, Misses Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/dynatronics-corporation-dynt-reports-q3-loss-misses-revenue-estimates
|
nan
|
nan
|
Dynatronics Corporation (DYNT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -125%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.27, delivering a surprise of -80%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Dynatronics Corporation, which belongs to the Zacks Medical - Instruments industry, posted revenues of $9.24 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 11.17%. This compares to year-ago revenues of $10.32 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Dynatronics Corporation shares have lost about 27.2% since the beginning of the year versus the S&P 500's gain of 7.8%.
What's Next for Dynatronics Corporation?
While Dynatronics Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Dynatronics Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.07 on $12.81 million in revenues for the coming quarter and -$0.63 on $46.15 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. The results are expected to be released on May 12.
This company is expected to post quarterly loss of $0.57 per share in its upcoming report, which represents a year-over-year change of +43%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.73 million, up 90.8% from the year-ago quarter.
Free Report: Top EV Battery Stocks to Buy Now
Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to "insane levels," and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid.
Download free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dynatronics Corporation (DYNT) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report Dynatronics Corporation (DYNT) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Dynatronics Corporation (DYNT) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Dynatronics Corporation, which belongs to the Zacks Medical - Instruments industry, posted revenues of $9.24 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 11.17%.
|
Click to get this free report Dynatronics Corporation (DYNT) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Dynatronics Corporation (DYNT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.16.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report Dynatronics Corporation (DYNT) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates just once over the last four quarters.
|
70be42aa-fa19-4b73-9c75-7e36d72d7cd3
|
715581.0
|
2023-05-09 00:00:00 UTC
|
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/orthofix-ofix-reports-q1-loss-tops-revenue-estimates-0
|
nan
|
nan
|
Orthofix (OFIX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.37 per share when it actually produced earnings of $0.19, delivering a surprise of 151.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $175.2 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 3.79%. This compares to year-ago revenues of $106.42 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Orthofix shares have lost about 9.4% since the beginning of the year versus the S&P 500's gain of 7.8%.
What's Next for Orthofix?
While Orthofix has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Orthofix: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.36 on $187.4 million in revenues for the coming quarter and -$1.75 on $743.3 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. The results are expected to be released on May 12.
This company is expected to post quarterly loss of $0.57 per share in its upcoming report, which represents a year-over-year change of +43%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.73 million, up 90.8% from the year-ago quarter.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. A quarter ago, it was expected that this medical device maker would post a loss of $0.37 per share when it actually produced earnings of $0.19, delivering a surprise of 151.35%.
|
Click to get this free report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $175.2 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 3.79%.
|
Click to get this free report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $175.2 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 3.79%.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $175.2 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 3.79%.
|
56268ff8-40c8-4317-a56b-fe790e093c81
|
715582.0
|
2023-05-04 00:00:00 UTC
|
Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/globus-medical-gmed-surpasses-q1-earnings-and-revenue-estimates
|
nan
|
nan
|
Globus Medical (GMED) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.92%. A quarter ago, it was expected that this medical device company would post earnings of $0.55 per share when it actually produced earnings of $0.59, delivering a surprise of 7.27%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Globus Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $276.69 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 8.94%. This compares to year-ago revenues of $230.55 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Globus Medical shares have lost about 23.5% since the beginning of the year versus the S&P 500's gain of 6.5%.
What's Next for Globus Medical?
While Globus Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Globus Medical: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.61 on $283.12 million in revenues for the coming quarter and $2.30 on $1.1 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 49% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. The results are expected to be released on May 12.
This company is expected to post quarterly loss of $0.57 per share in its upcoming report, which represents a year-over-year change of +43%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.73 million, up 90.8% from the year-ago quarter.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Globus Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $276.69 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 8.94%.
|
Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Globus Medical (GMED) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.51 per share.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2023. Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Globus Medical (GMED) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.51 per share.
|
82ba806f-088c-4fc6-959d-08fe747f77b9
|
715583.0
|
2023-03-27 00:00:00 UTC
|
Delcath Systems Inc. Q4 Loss increases, misses estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-q4-loss-increases-misses-estimates
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) announced Loss for its fourth quarter that increased from last year and missed the Street estimates.
The company's bottom line came in at -$8.47 million, or -$0.86 per share. This compares with -$5.35 million, or -$0.69 per share, in last year's fourth quarter.
Analysts on average had expected the company to earn -$0.76 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 69.7% to $0.64 million from $2.11 million last year.
Delcath Systems Inc. earnings at a glance (GAAP) :
-Earnings (Q4): -$8.47 Mln. vs. -$5.35 Mln. last year. -EPS (Q4): -$0.86 vs. -$0.69 last year. -Analyst Estimate: -$0.76 -Revenue (Q4): $0.64 Mln vs. $2.11 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) announced Loss for its fourth quarter that increased from last year and missed the Street estimates. This compares with -$5.35 million, or -$0.69 per share, in last year's fourth quarter. Analysts on average had expected the company to earn -$0.76 per share, according to figures compiled by Thomson Reuters.
|
(RTTNews) - Delcath Systems Inc. (DCTH) announced Loss for its fourth quarter that increased from last year and missed the Street estimates. This compares with -$5.35 million, or -$0.69 per share, in last year's fourth quarter. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q4): -$8.47 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) announced Loss for its fourth quarter that increased from last year and missed the Street estimates. This compares with -$5.35 million, or -$0.69 per share, in last year's fourth quarter. The company's revenue for the quarter fell 69.7% to $0.64 million from $2.11 million last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) announced Loss for its fourth quarter that increased from last year and missed the Street estimates. This compares with -$5.35 million, or -$0.69 per share, in last year's fourth quarter. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q4): -$8.47 Mln.
|
ff599694-4876-463a-9146-a031f77608f5
|
715584.0
|
2023-03-03 00:00:00 UTC
|
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/rapid-micro-biosystems-inc.-rpid-reports-q4-loss-tops-revenue-estimates
|
nan
|
nan
|
Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -2.63%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.38, delivering a surprise of -2.70%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Rapid Micro Biosystems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $4.37 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.72%. This compares to year-ago revenues of $5.21 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Rapid Micro Biosystems, Inc. Shares have added about 3.5% since the beginning of the year versus the S&P 500's gain of 3.7%.
What's Next for Rapid Micro Biosystems, Inc.
While Rapid Micro Biosystems, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Rapid Micro Biosystems, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.30 on $4.8 million in revenues for the coming quarter and -$1.26 on $24.47 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended December 2022.
This company is expected to post quarterly loss of $0.68 per share in its upcoming report, which represents a year-over-year change of +1.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $1.97 million, down 6.9% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Rapid Micro Biosystems, Inc. (RPID) : Free Stock Analysis Report
Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended December 2022. Click to get this free report Rapid Micro Biosystems, Inc. (RPID) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Rapid Micro Biosystems, Inc. (RPID) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended December 2022. Rapid Micro Biosystems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $4.37 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.72%.
|
Click to get this free report Rapid Micro Biosystems, Inc. (RPID) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended December 2022. Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.38.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended December 2022. Click to get this free report Rapid Micro Biosystems, Inc. (RPID) : Free Stock Analysis Report Delcath Systems, Inc. (DCTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.38.
|
905c01e8-313c-454a-bd31-fb12c747a89c
|
715585.0
|
2023-02-16 00:00:00 UTC
|
Delcath Systems' Board Voted To Appoint John Sylvester As New Chairman
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-board-voted-to-appoint-john-sylvester-as-new-chairman
|
nan
|
nan
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units.
In addition, Sylvester served as BTG plc's Chief Commercial Officer, leading both their Interventional Oncology and Interventional Vascular businesses, as well as BTG's Chief Development Officer accountable for Strategy, M&A and Market access.
His role at BTG culminated with Boston Scientific's 2019 purchase of BTG for $4.2 billion. Sylvester also built Biocompatibles International plc's Interventional Oncology business, which BTG purchased in 2010.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In addition, Sylvester served as BTG plc's Chief Commercial Officer, leading both their Interventional Oncology and Interventional Vascular businesses, as well as BTG's Chief Development Officer accountable for Strategy, M&A and Market access.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In addition, Sylvester served as BTG plc's Chief Commercial Officer, leading both their Interventional Oncology and Interventional Vascular businesses, as well as BTG's Chief Development Officer accountable for Strategy, M&A and Market access.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In addition, Sylvester served as BTG plc's Chief Commercial Officer, leading both their Interventional Oncology and Interventional Vascular businesses, as well as BTG's Chief Development Officer accountable for Strategy, M&A and Market access.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester also built Biocompatibles International plc's Interventional Oncology business, which BTG purchased in 2010. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
0df5a41c-04f6-4a96-833d-67573e544e88
|
715586.0
|
2023-02-14 00:00:00 UTC
|
Delcath Systems Announces Resubmission Of NDA For Hepzato Kit
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-announces-resubmission-of-nda-for-hepzato-kit
|
nan
|
nan
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced on Tuesday that it submitted a new drug application or NDA to the US Food and Drug Administration for the Hepzato Kit for the treatment of unresectable hepatic-dominant metastatic ocular melanoma or mOM.
The company said FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for review within 30 days. The resubmission is in response to a September 12, 2013 Complete Response Letter from the FDA.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced on Tuesday that it submitted a new drug application or NDA to the US Food and Drug Administration for the Hepzato Kit for the treatment of unresectable hepatic-dominant metastatic ocular melanoma or mOM. The company said FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for review within 30 days. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced on Tuesday that it submitted a new drug application or NDA to the US Food and Drug Administration for the Hepzato Kit for the treatment of unresectable hepatic-dominant metastatic ocular melanoma or mOM. The company said FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for review within 30 days. The resubmission is in response to a September 12, 2013 Complete Response Letter from the FDA.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced on Tuesday that it submitted a new drug application or NDA to the US Food and Drug Administration for the Hepzato Kit for the treatment of unresectable hepatic-dominant metastatic ocular melanoma or mOM. The company said FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for review within 30 days. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced on Tuesday that it submitted a new drug application or NDA to the US Food and Drug Administration for the Hepzato Kit for the treatment of unresectable hepatic-dominant metastatic ocular melanoma or mOM. The company said FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for review within 30 days. The resubmission is in response to a September 12, 2013 Complete Response Letter from the FDA.
|
aaccb76e-7332-46fb-b471-0d88ba4fdc93
|
715587.0
|
2023-01-17 00:00:00 UTC
|
Delcath Systems Reports Updated Results From CHOPIN Phase 1b Trial
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-reports-updated-results-from-chopin-phase-1b-trial
|
nan
|
nan
|
(RTTNews) - Delcath Systems, Inc. (DCTH) published updated results from the Phase 1b CHOPIN Trial on the use of the Delcath CHEMOSAT Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. At the cut-off date of November 15, 2022, the median follow-up was 29.1 months, the median PFS was 29.1 months and the median duration of response was 27.1 months. All patients in the trial are still alive. Grade 1/2 adverse events were seen in all patients and 71.4% experienced grade 3/4 toxicities.
"If similar results are observed in the larger, randomized second phase of this trial, it would represent a meaningful improvement over current treatment options for this patient population," said Johnny John, Senior Vice President, Medical and Clinical Affairs.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) published updated results from the Phase 1b CHOPIN Trial on the use of the Delcath CHEMOSAT Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. "If similar results are observed in the larger, randomized second phase of this trial, it would represent a meaningful improvement over current treatment options for this patient population," said Johnny John, Senior Vice President, Medical and Clinical Affairs. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) published updated results from the Phase 1b CHOPIN Trial on the use of the Delcath CHEMOSAT Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. At the cut-off date of November 15, 2022, the median follow-up was 29.1 months, the median PFS was 29.1 months and the median duration of response was 27.1 months. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) published updated results from the Phase 1b CHOPIN Trial on the use of the Delcath CHEMOSAT Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. At the cut-off date of November 15, 2022, the median follow-up was 29.1 months, the median PFS was 29.1 months and the median duration of response was 27.1 months. "If similar results are observed in the larger, randomized second phase of this trial, it would represent a meaningful improvement over current treatment options for this patient population," said Johnny John, Senior Vice President, Medical and Clinical Affairs.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) published updated results from the Phase 1b CHOPIN Trial on the use of the Delcath CHEMOSAT Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. At the cut-off date of November 15, 2022, the median follow-up was 29.1 months, the median PFS was 29.1 months and the median duration of response was 27.1 months. All patients in the trial are still alive.
|
cde54854-7cd4-4349-a76d-890d3e49b48a
|
715588.0
|
2023-01-09 00:00:00 UTC
|
Vista Equity Partners To Acquire Duck Creek Technologies
|
DCTH
|
https://www.nasdaq.com/articles/vista-equity-partners-to-acquire-duck-creek-technologies
|
nan
|
nan
|
(RTTNews) - Duck Creek Technologies (DCT) has entered into a definitive agreement to be acquired by Vista Equity Partners for $19.00 per share, in an all-cash deal valued at approximately $2.6 billion. Upon completion, Duck Creek's common stock will no longer be publicly listed, and Duck Creek will become a privately held company. The agreement includes a go-shop period expiring on February 7, 2023.
Following the recommendation of the Special Committee, the Duck Creek Board approved the merger agreement with Vista Equity Partners. The deal is expected to close in the second calendar quarter of 2023.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Duck Creek Technologies (DCT) has entered into a definitive agreement to be acquired by Vista Equity Partners for $19.00 per share, in an all-cash deal valued at approximately $2.6 billion. The agreement includes a go-shop period expiring on February 7, 2023. Following the recommendation of the Special Committee, the Duck Creek Board approved the merger agreement with Vista Equity Partners.
|
(RTTNews) - Duck Creek Technologies (DCT) has entered into a definitive agreement to be acquired by Vista Equity Partners for $19.00 per share, in an all-cash deal valued at approximately $2.6 billion. Upon completion, Duck Creek's common stock will no longer be publicly listed, and Duck Creek will become a privately held company. Following the recommendation of the Special Committee, the Duck Creek Board approved the merger agreement with Vista Equity Partners.
|
(RTTNews) - Duck Creek Technologies (DCT) has entered into a definitive agreement to be acquired by Vista Equity Partners for $19.00 per share, in an all-cash deal valued at approximately $2.6 billion. Upon completion, Duck Creek's common stock will no longer be publicly listed, and Duck Creek will become a privately held company. Following the recommendation of the Special Committee, the Duck Creek Board approved the merger agreement with Vista Equity Partners.
|
(RTTNews) - Duck Creek Technologies (DCT) has entered into a definitive agreement to be acquired by Vista Equity Partners for $19.00 per share, in an all-cash deal valued at approximately $2.6 billion. Upon completion, Duck Creek's common stock will no longer be publicly listed, and Duck Creek will become a privately held company. The agreement includes a go-shop period expiring on February 7, 2023.
|
3b953b55-67a0-4015-be3c-f72746c6a205
|
715589.0
|
2022-11-08 00:00:00 UTC
|
Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-dcth-reports-q3-loss-tops-revenue-estimates
|
nan
|
nan
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 12.38%. A quarter ago, it was expected that this company would post a loss of $0.88 per share when it actually produced a loss of $1.18, delivering a surprise of -34.09%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.91 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 10.49%. This compares to year-ago revenues of $0.52 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Delcath Systems, Inc. Shares have lost about 61.3% since the beginning of the year versus the S&P 500's decline of -20.1%.
What's Next for Delcath Systems, Inc.
While Delcath Systems, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Delcath Systems, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.68 on $0.87 million in revenues for the coming quarter and -$3.86 on $2.86 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 47% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Stereotaxis Inc. (STXS), another stock in the same industry, has yet to report results for the quarter ended September 2022. The results are expected to be released on November 10.
This company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of +14.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stereotaxis Inc.'s revenues are expected to be $8.1 million, down 11.1% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
Stereotaxis Inc. (STXS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.05. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.05. Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.91 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 10.49%.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.05. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.91 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 10.49%.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.05. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report The company has topped consensus revenue estimates two times over the last four quarters.
|
9a0f291d-730d-4b83-b002-3c8f18f8e4ba
|
715590.0
|
2022-11-02 00:00:00 UTC
|
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
|
DCTH
|
https://www.nasdaq.com/articles/avanos-medical-avns-tops-q3-earnings-estimates
|
nan
|
nan
|
Avanos Medical (AVNS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this medical technology company would post earnings of $0.39 per share when it actually produced earnings of $0.41, delivering a surprise of 5.13%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Avanos Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $202.1 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 1.79%. This compares to year-ago revenues of $184.1 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Avanos Medical shares have lost about 35.3% since the beginning of the year versus the S&P 500's decline of -19.1%.
What's Next for Avanos Medical?
While Avanos Medical has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Avanos Medical: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.49 on $219.14 million in revenues for the coming quarter and $1.51 on $825.33 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. The results are expected to be released on November 8.
This company is expected to post quarterly loss of $1.05 per share in its upcoming report, which represents a year-over-year change of -11.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.82 million, up 57.7% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Avanos Medical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $202.1 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 1.79%.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Avanos Medical (AVNS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.36 per share.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Avanos Medical (AVNS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.36 per share.
|
169a9d40-2944-4047-99e4-ae9ed73ff41f
|
715591.0
|
2022-11-01 00:00:00 UTC
|
Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates
|
DCTH
|
https://www.nasdaq.com/articles/semler-scientific-inc.-smlr-q3-earnings-beat-estimates
|
nan
|
nan
|
Semler Scientific Inc. (SMLR) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 24.32%. A quarter ago, it was expected that this company would post earnings of $0.40 per share when it actually produced earnings of $0.51, delivering a surprise of 27.50%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Semler Scientific Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $14.05 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.60%. This compares to year-ago revenues of $13.99 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Semler Scientific Inc. Shares have lost about 54.2% since the beginning of the year versus the S&P 500's decline of -18.8%.
What's Next for Semler Scientific Inc.
While Semler Scientific Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Semler Scientific Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $15.08 million in revenues for the coming quarter and $1.58 on $58.96 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 47% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. The results are expected to be released on November 8.
This company is expected to post quarterly loss of $1.05 per share in its upcoming report, which represents a year-over-year change of -11.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.82 million, up 57.7% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Semler Scientific Inc. (SMLR): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Semler Scientific Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $14.05 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.60%.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Semler Scientific Inc. (SMLR) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.37 per share.
|
Delcath Systems, Inc. (DCTH), another stock in the same industry, has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Semler Scientific Inc. (SMLR) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.37 per share.
|
588060f9-cb94-4a7f-b357-e3b9dede1083
|
715592.0
|
2022-10-31 00:00:00 UTC
|
Acadia Healthcare (ACHC) Q3 Earnings Lag Estimates
|
DCTH
|
https://www.nasdaq.com/articles/acadia-healthcare-achc-q3-earnings-lag-estimates
|
nan
|
nan
|
Acadia Healthcare (ACHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -2.50%. A quarter ago, it was expected that this provider of inpatient behavioral health care services would post earnings of $0.77 per share when it actually produced earnings of $0.84, delivering a surprise of 9.09%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Acadia Healthcare, which belongs to the Zacks Medical - Hospital industry, posted revenues of $666.73 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 1.53%. This compares to year-ago revenues of $587.56 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia Healthcare shares have added about 36.8% since the beginning of the year versus the S&P 500's decline of -18.2%.
What's Next for Acadia Healthcare?
While Acadia Healthcare has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia Healthcare: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.78 on $664.76 million in revenues for the coming quarter and $3.08 on $2.59 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Medical sector, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended September 2022. The results are expected to be released on November 8.
This company is expected to post quarterly loss of $1.05 per share in its upcoming report, which represents a year-over-year change of -11.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $0.82 million, up 57.7% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the broader Zacks Medical sector, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Another stock from the broader Zacks Medical sector, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended September 2022. Acadia Healthcare, which belongs to the Zacks Medical - Hospital industry, posted revenues of $666.73 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 1.53%.
|
Another stock from the broader Zacks Medical sector, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Acadia Healthcare (ACHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.80 per share.
|
Another stock from the broader Zacks Medical sector, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended September 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Acadia Healthcare (ACHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.80 per share.
|
82d7b2b2-cd48-4a72-bb84-b541e0cbb45d
|
715593.0
|
2022-08-08 00:00:00 UTC
|
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-dcth-reports-q2-loss-lags-revenue-estimates
|
nan
|
nan
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $0.96 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -34.09%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $1, delivering a surprise of -19.05%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.8 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 36.49%. This compares to year-ago revenues of $0.54 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Delcath Systems, Inc. Shares have lost about 43.7% since the beginning of the year versus the S&P 500's decline of -13%.
What's Next for Delcath Systems, Inc.
While Delcath Systems, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Delcath Systems, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.75 on $1.28 million in revenues for the coming quarter and -$3.15 on $5.09 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Avinger (AVGR), another stock in the same industry, has yet to report results for the quarter ended June 2022.
This medical device maker is expected to post quarterly loss of $1.09 per share in its upcoming report, which represents a year-over-year change of -36.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Avinger's revenues are expected to be $2.38 million, down 15% from the year-ago quarter.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
Avinger, Inc. (AVGR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $0.88. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $0.88. Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.8 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 36.49%.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $0.88. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.8 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 36.49%.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $0.88. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.8 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 36.49%.
|
94889b19-07b5-4374-8b7a-031044768e04
|
715594.0
|
2022-08-08 00:00:00 UTC
|
Delcath Systems Inc. Q2 Loss increases, misses estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-q2-loss-increases-misses-estimates
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its second quarter that increased from last year and missed the Street estimates.
The company's earnings came in at -$9.66 million, or -$1.18 per share. This compares with -$6.43 million, or -$0.96 per share, in last year's second quarter.
Analysts on average had expected the company to earn -$0.95 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 100% to $0.80 million from $0.40 million last year.
Delcath Systems Inc. earnings at a glance (GAAP) :
-Earnings (Q2): -$9.66 Mln. vs. -$6.43 Mln. last year. -EPS (Q2): -$1.18 vs. -$0.96 last year. -Analyst Estimate: -$0.95 -Revenue (Q2): $0.80 Mln vs. $0.40 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its second quarter that increased from last year and missed the Street estimates. Analysts on average had expected the company to earn -$0.95 per share, according to figures compiled by Thomson Reuters. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q2): -$9.66 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its second quarter that increased from last year and missed the Street estimates. The company's revenue for the quarter rose 100% to $0.80 million from $0.40 million last year. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q2): -$9.66 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its second quarter that increased from last year and missed the Street estimates. This compares with -$6.43 million, or -$0.96 per share, in last year's second quarter. The company's revenue for the quarter rose 100% to $0.80 million from $0.40 million last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported Loss for its second quarter that increased from last year and missed the Street estimates. The company's earnings came in at -$9.66 million, or -$1.18 per share. This compares with -$6.43 million, or -$0.96 per share, in last year's second quarter.
|
533894cc-2559-4b7e-81de-befe5a5fb867
|
715595.0
|
2022-07-28 00:00:00 UTC
|
DexCom (DXCM) Matches Q2 Earnings Estimates
|
DCTH
|
https://www.nasdaq.com/articles/dexcom-dxcm-matches-q2-earnings-estimates
|
nan
|
nan
|
DexCom (DXCM) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this medical device company would post earnings of $0.13 per share when it actually produced earnings of $0.08, delivering a surprise of -38.46%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $696.2 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.12%. This compares to year-ago revenues of $595.1 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
DexCom shares have lost about 36.1% since the beginning of the year versus the S&P 500's decline of -15.6%.
What's Next for DexCom?
While DexCom has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for DexCom: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $761.56 million in revenues for the coming quarter and $0.82 on $2.92 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022.
This company is expected to post quarterly loss of $0.88 per share in its upcoming report, which represents a year-over-year change of +8.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $1.26 million, up 132.4% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022. DexCom, which belongs to the Zacks Medical - Instruments industry, posted revenues of $696.2 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.12%.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report DexCom (DXCM) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended June 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report DexCom (DXCM) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate.
|
d185a0cc-0ea2-4626-90c7-1cb047d792d2
|
715596.0
|
2022-07-21 00:00:00 UTC
|
Thursday 7/21 Insider Buying Report: KDP, DCTH
|
DCTH
|
https://www.nasdaq.com/articles/thursday-7-21-insider-buying-report%3A-kdp-dcth
|
nan
|
nan
|
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Keurig Dr Pepper, a filing with the SEC revealed that on Monday, Chief Supply Chain Officer Maurice Anthony Milikin bought 12,979 shares of KDP, for a cost of $36.36 each, for a total investment of $471,916. Keurig Dr Pepper is trading off about 0.7% on the day Thursday. Before this latest buy, Milikin purchased KDP at 3 other times during the past twelve months, for a total investment of $1.40M at an average of $35.96 per share.
And at Delcath Systems, there was insider buying on Wednesday, by Chief Executive Officer Gerard J. Michel who bought 62,814 shares for a cost of $3.98 each, for a total investment of $250,000. Before this latest buy, Michel bought DCTH at 3 other times during the past twelve months, for a total investment of $225,622 at an average of $8.29 per share. Delcath Systems is trading up about 10% on the day Thursday.
VIDEO: Thursday 7/21 Insider Buying Report: KDP, DCTH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Before this latest buy, Michel bought DCTH at 3 other times during the past twelve months, for a total investment of $225,622 at an average of $8.29 per share. VIDEO: Thursday 7/21 Insider Buying Report: KDP, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Keurig Dr Pepper, a filing with the SEC revealed that on Monday, Chief Supply Chain Officer Maurice Anthony Milikin bought 12,979 shares of KDP, for a cost of $36.36 each, for a total investment of $471,916.
|
Before this latest buy, Michel bought DCTH at 3 other times during the past twelve months, for a total investment of $225,622 at an average of $8.29 per share. VIDEO: Thursday 7/21 Insider Buying Report: KDP, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Before this latest buy, Milikin purchased KDP at 3 other times during the past twelve months, for a total investment of $1.40M at an average of $35.96 per share.
|
Before this latest buy, Michel bought DCTH at 3 other times during the past twelve months, for a total investment of $225,622 at an average of $8.29 per share. VIDEO: Thursday 7/21 Insider Buying Report: KDP, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Keurig Dr Pepper, a filing with the SEC revealed that on Monday, Chief Supply Chain Officer Maurice Anthony Milikin bought 12,979 shares of KDP, for a cost of $36.36 each, for a total investment of $471,916.
|
Before this latest buy, Michel bought DCTH at 3 other times during the past twelve months, for a total investment of $225,622 at an average of $8.29 per share. VIDEO: Thursday 7/21 Insider Buying Report: KDP, DCTH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.
|
177069af-20cd-4714-9557-ef62f5bfa385
|
715597.0
|
2022-05-10 00:00:00 UTC
|
Delcath Systems Inc. Q1 Loss misses estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-q1-loss-misses-estimates
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for first quarter that missed the Street estimates.
The company's bottom line came in at -$8.20 million, or -$1.00 per share. This compares with -$6.75 million, or -$1.04 per share, in last year's first quarter.
Analysts on average had expected the company to earn -$0.88 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 19.2% to $0.21 million from $0.26 million last year.
Delcath Systems Inc. earnings at a glance (GAAP) :
-Earnings (Q1): -$8.20 Mln. vs. -$6.75 Mln. last year. -EPS (Q1): -$1.00 vs. -$1.04 last year. -Analyst Estimates: -$0.88 -Revenue (Q1): $0.21 Mln vs. $0.26 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for first quarter that missed the Street estimates. Analysts on average had expected the company to earn -$0.88 per share, according to figures compiled by Thomson Reuters. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q1): -$8.20 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for first quarter that missed the Street estimates. The company's revenue for the quarter fell 19.2% to $0.21 million from $0.26 million last year. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q1): -$8.20 Mln.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for first quarter that missed the Street estimates. This compares with -$6.75 million, or -$1.04 per share, in last year's first quarter. The company's revenue for the quarter fell 19.2% to $0.21 million from $0.26 million last year.
|
(RTTNews) - Delcath Systems Inc. (DCTH) released Loss for first quarter that missed the Street estimates. This compares with -$6.75 million, or -$1.04 per share, in last year's first quarter. Delcath Systems Inc. earnings at a glance (GAAP) : -Earnings (Q1): -$8.20 Mln.
|
a29db9f3-9c33-4661-990b-e2986b0d67e9
|
715598.0
|
2022-05-10 00:00:00 UTC
|
Delcath Systems Q1 22 Earnings Conference Call At 8:30 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-q1-22-earnings-conference-call-at-8%3A30-am-et
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on May 10, 2022, to discuss Q1 22 earnings results.
To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/
To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Access Code: 633971.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on May 10, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Access Code: 633971. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on May 10, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Access Code: 633971. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on May 10, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Access Code: 633971. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on May 10, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Access Code: 633971. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
233dc0fa-2ae4-4d4e-b1ab-1fdfeba56b21
|
715599.0
|
2022-05-06 00:00:00 UTC
|
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/orthofix-ofix-reports-q1-loss-tops-revenue-estimates
|
nan
|
nan
|
Orthofix (OFIX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.18. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -155.56%. A quarter ago, it was expected that this medical device maker would post earnings of $0.13 per share when it actually produced earnings of $0.27, delivering a surprise of 107.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $106.42 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.64%. This compares to year-ago revenues of $105.59 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Orthofix shares have not added anything since the beginning of the year versus the S&P 500's decline of -13%.
What's Next for Orthofix?
While Orthofix has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Orthofix: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.24 on $121.4 million in revenues for the coming quarter and $0.66 on $487.9 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended March 2022. The results are expected to be released on May 10.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of +19.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $1.26 million, up 223.1% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $106.42 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.64%.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $106.42 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.64%.
|
Another stock from the same industry, Delcath Systems, Inc. (DCTH), has yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Orthofix, which belongs to the Zacks Medical - Instruments industry, posted revenues of $106.42 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.64%.
|
e4addf69-117d-4b78-8b1a-b2db4a51e480
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.